Encompass Health (EHC) 10-K 25 Feb 16 2015 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Billions	12 Months Ended
	Dec. 31, 2015	Feb. 16, 2016	Jun. 30, 2015
Document Information [Line Items]
Entity Registrant Name	HEALTHSOUTH CORP
Entity Central Index Key	785,161
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-K
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Common Stock, Shares Outstanding		89,777,044
Entity Public Float			$ 4

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Net operating revenues	$ 3,162.9	$ 2,405.9	$ 2,273.2
Less: Provision for doubtful accounts	(47.2)	(31.6)	(26)
Net operating revenues less provision for doubtful accounts	3,115.7	2,374.3	2,247.2
Operating expenses:
Salaries and benefits	1,670.8	1,161.7	1,089.7
Other operating expenses	432.1	351.6	323
Occupancy costs	53.9	41.6	47
Supplies	128.7	111.9	105.4
General and administrative expenses	133.3	124.8	119.1
Depreciation and amortization	139.7	107.7	94.7
Government, class action, and related settlements	7.5	(1.7)	(23.5)
Professional fees-accounting, tax, and legal	3	9.3	9.5
Total operating expenses	2,569	1,906.9	1,764.9
Loss on early extinguishment of debt	22.4	13.2	2.4
Interest expense and amortization of debt discounts and fees	142.9	109.2	100.4
Other income	(5.5)	(31.2)	(4.5)
Equity in net income of nonconsolidated affiliates	(8.7)	(10.7)	(11.2)
Income from continuing operations before income tax expense	395.6	386.9	395.2
Provision for income tax expense	141.9	110.7	12.7
Income from continuing operations	253.7	276.2	382.5
(Loss) income from discontinued operations, net of tax	(0.9)	5.5	(1.1)
Net income	252.8	281.7	381.4
Less: Net income attributable to noncontrolling interests	(69.7)	(59.7)	(57.8)
Net income attributable to HealthSouth	183.1	222	323.6
Less: Convertible perpetual preferred stock dividends	(1.6)	(6.3)	(21)
Less: Repurchase of convertible perpetual preferred stock	0	0	(71.6)
Net income attributable to HealthSouth common shareholders	$ 181.5	$ 215.7	$ 231
Weighted average common shares outstanding:
Basic	89.4	86.8	88.1
Diluted	101	100.7	102.1
Basic earnings per share attributable to HealthSouth common shareholders
Continuing operations	$ 2.03	$ 2.40	$ 2.59
Discontinued Operations	(0.01)	0.06	(0.01)
Net income	2.02	2.46	2.58
Diluted earnings per share attributable to HealthSouth common shareholders:
Continuing operations	1.92	2.24	2.59
Discontinued operations	(0.01)	0.05	(0.01)
Net income	1.91	2.29	2.58
Cash dividends per common share	$ 0.88	$ 0.78	$ 0.36
Amounts attributable to HealthSouth common shareholders:
Income from continuing operations	$ 184	$ 216.5	$ 324.7
(Loss) income from discontinued operations, net of tax	(0.9)	5.5	(1.1)
Net income attributable to HealthSouth	$ 183.1	$ 222	$ 323.6

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Net income	$ 252.8	$ 281.7	$ 381.4
Net change in unrealized loss on available-for-sale securities:
Unrealized net holding loss arising during the period	(0.1)	(0.2)	(0.7)
Reclassifications to net income	(1.2)	(0.5)	(0.9)
Other comprehensive loss before income taxes	(1.3)	(0.7)	(1.6)
Provision for income tax benefit related to other comprehensive loss items	0.6	0.3	0.1
Other comprehensive loss, net of tax:	(0.7)	(0.4)	(1.5)
Comprehensive income	252.1	281.3	379.9
Comprehensive income attributable to noncontrolling interests	(69.7)	(59.7)	(57.8)
Comprehensive income attributable to HealthSouth	$ 182.4	$ 221.6	$ 322.1

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 61.6	$ 66.7
Restricted Cash	45.9	45.6
Accounts receivable, net of allowance for doubtful accounts of $39.3 in 2015; $22.2 in 2014	410.5	323.2
Deferred income tax assets	0	188.4
Prepaid expenses and other current assets	80.7	62.7
Total current assets	598.7	686.6
Property and equipment, net	1,310.1	1,019.7
Goodwill	1,890.1	1,084
Intangible assets, net	419.4	306.1
Deferred income tax assets	190.8	129.4
Other long-term assets	197	162.5
Total assets	4,606.1	3,388.3
Current liabilities:
Current portion of long-term debt	36.8	20.8
Accounts payable	61.6	53.4
Accrued payroll	126.2	123.3
Accrued interest payable	29.7	21.2
Other current liabilities	172.1	145.6
Total current liabilities	426.4	364.3
Long-term debt, net of current portion	3,134.7	2,090.4
Self-insured risks	101.6	98.7
Other long-term liabilities	43	37.5
Total liabilities	$ 3,705.7	$ 2,590.9
Commitments and contingencies
Convertible perpetual preferred stock, $.10 par value; 1,500,000 shares authorized; zero shares issued in 2015 and 96,245 shares issued in 2014; liquidation preference of $1,000 per share	$ 0	$ 93.2
Redeemable noncontrolling interests	121.1	84.7
HealthSouth shareholders' equity:
Common stock, $.01 par value; 200,000,000 shares authorized; issued: 108,275,900 in 2015; 104,058,832 in 2014	1.1	1
Capital in excess of par value	2,834.9	2,810.5
Accumulated deficit	(1,696)	(1,879.1)
Accumulated other comprehensive loss	(1.2)	(0.5)
Treasury stock, at cost (18,145,822 shares in 2015 and 16,270,159 shares in 2014)	(527.4)	(458.7)
Total HealthSouth shareholders' equity	611.4	473.2
Noncontrolling interests	167.9	146.3
Total shareholders' equity	779.3	619.5
Total liabilities and shareholders' equity	$ 4,606.1	$ 3,388.3

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Assets
Allowance for doubtful accounts	$ 39.3	$ 22.2
Liabilities and Shareholders' Equity
Convertible perpetual preferred stock, par value	$ 0	$ 0.10
Convertible perpetual preferred stock, shares authorized	0	1,500,000
Convertible perpetual preferred stock, shares issued	0	96,245
Convertible perpetual preferred stock, liquidation preference	$ 0	$ 1,000
HealthSouth shareholders' equity:
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	108,275,900	104,058,832
Treasury stock, shares	18,145,822	16,270,159

Consolidated Statement of Share

Consolidated Statement of Shareholders' Equity - USD ($) shares in Thousands, $ in Millions	Total	Capital in Excess of Par Value	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)	Treasury Stock	Noncontrolling Interests	Common Stock [Member]
Balance at beginning of period at Dec. 31, 2012	$ 403.5	$ 2,876.6	$ (2,424.7)	$ 1.4	$ (163.3)	$ 112.5	$ 1
Balance at beginning of period, shares at Dec. 31, 2012							95,700
Net income	381.4		323.6
Net income attributable to nonredeemable noncontrolling interest	52					52
Net income, including portion attributable to nonredeemable noncontrolling interest	375.6
Receipt of treasury stock	(5.8)				(5.8)
Receipt of treasury stock, shares							(300)
Dividends declared on common stock	(32)	(32)
Dividends declared on convertible perpetual preferred stock	(21)	(21)
Stock-based compensation	24.8	24.8
Stock options exercised	8.2	8.2
Stock options exercised, Shares							300
Stock warrants exercised	15.3	15.3
Stock warrants exercised, Shares							500
Distributions declared	(40.4)					(40.4)
Repurchase of common stock	(234.1)				(234.1)
Repurchase of common stock, Shares							(9,100)
Repurchase of preferred stock through convertible exchange	(71.6)	(71.6)
Equity portion of convertible debt	71	71
Tax impact of equity portion of convertible debt	(28)	(28)
Other	3.2	6.1		(1.5)	(1.4)	0
Other, Shares							900
Balance at end of period at Dec. 31, 2013	468.7	2,849.4	(2,101.1)	(0.1)	(404.6)	124.1	$ 1
Balance at end of period, shares at Dec. 31, 2013							88,000
Net income	281.7		222
Net income attributable to nonredeemable noncontrolling interest	53.1					53.1
Net income, including portion attributable to nonredeemable noncontrolling interest	275.1
Receipt of treasury stock	(9.7)				(9.7)
Receipt of treasury stock, shares							(300)
Dividends declared on common stock	(69)	(69)
Dividends declared on convertible perpetual preferred stock	(6.3)	(6.3)
Stock-based compensation	23.9	23.9
Stock options exercised	7.4	7.5			(0.1)
Stock options exercised, Shares							300
Stock warrants exercised	6.3	6.3
Stock warrants exercised, Shares							200
Distributions declared	(44.9)					(44.9)
Repurchase of common stock	(43.1)				(43.1)
Repurchase of common stock, Shares							(1,300)
Consolidation of Hospital	14					14
Other	(2.9)	(1.3)		(0.4)	(1.2)	0
Other, Shares							900
Balance at end of period at Dec. 31, 2014	619.5	2,810.5	(1,879.1)	(0.5)	(458.7)	146.3	$ 1
Balance at end of period, shares at Dec. 31, 2014							87,800
Net income	252.8		183.1
Net income attributable to nonredeemable noncontrolling interest	55.9					55.9
Net income, including portion attributable to nonredeemable noncontrolling interest	239
Conversion of preferred stock, shares							3,300
Conversion of Preferred Stock	93.2	93.2
Receipt of treasury stock	(17.2)				(17.2)
Receipt of treasury stock, shares							(500)
Dividends declared on common stock	(79.9)	(79.9)
Dividends declared on convertible perpetual preferred stock	(1.6)	(1.6)
Stock-based compensation	22.4	22.4
Stock options exercised	$ 2.3	6.7			(4.4)
Stock options exercised, Shares	257						200
Distributions declared	$ (49)					(49)
Repurchase of common stock	(45.3)				(45.3)
Repurchase of common stock, Shares							(1,300)
Capital contributions from consolidated affiliates	14.8					14.8
Fair value adjustments to redeemable noncontrolling interests, net of tax	(18.2)	(18.2)
Other	(0.7)	1.8		(0.7)	(1.8)	(0.1)	$ 0.1
Other, Shares							600
Balance at end of period at Dec. 31, 2015	$ 779.3	$ 2,834.9	$ (1,696)	$ (1.2)	$ (527.4)	$ 167.9	$ 1.1
Balance at end of period, shares at Dec. 31, 2015							90,100

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities:
Net income	$ 252.8	$ 281.7	$ 381.4
Loss (income) from discontinued operations, net of tax	0.9	(5.5)	1.1
Adjustments to reconcile net income to net cash provided by operating activities-
Provision for doubtful accounts	47.2	31.6	26
Provision for government, class action, and related settlements	7.5	(1.7)	(23.5)
Depreciation and amortization	139.7	107.7	94.7
Amortization of debt-related items	14.3	12.7	5
Loss on early extinguishment of debt	22.4	13.2	2.4
Equity in net income of nonconsolidated affiliates	(8.7)	(10.7)	(11.2)
Distributions from nonconsolidated affiliates	7.7	12.6	11.4
Stock-based compensation	26.2	23.9	24.8
Deferred tax expense	127.1	97.4	6.4
Gain on consolidation of Fairlawn	0	(27.2)	0
Other	(0.6)	4.8	4.3
(Increase) decrease in assets, net of acquisitions-
Accounts receivable	(134.1)	(91.6)	(55.1)
Prepaid expenses and other assets	(9.6)	6.5	(4.8)
Increase (decrease) in liabilities, net of acquisitions-
Accounts payable	0.9	5.4	6.4
Other liabilities	(4.3)	(10.4)	4.6
Premium received on bond issuance	9.8	6.3	0
Premium paid on redemption of bonds	(13.7)	(10.6)	(1.7)
Net cash used in operating activities of discontinued operations	(0.7)	(1.2)	(1.9)
Total adjustments	231.1	168.7	87.8
Net cash provided by operating activities	484.8	444.9	470.3
Cash flows from investing activities:
Acquisition of businesses, net of cash acquired	(985.1)	(694.8)	(28.9)
Purchases of property and equipment	(128.4)	(170.9)	(195.2)
Capitalized software costs	(28.1)	(17)	(21.3)
Proceeds from sale of restricted investments	0.2	0.3	16.9
Proceeds from sale of Digital Hospital	0	0	10.8
Proceeds from sale of marketable securities	12.8	0	0
Purchases of restricted investments	(7.1)	(3.5)	(9.2)
Net change in restricted cash	2.7	6.8	(3.1)
Other	2.7	2.2	0.5
Net cash provided by investing activities of discontinued operations	0.5	0	3.3
Net cash used in investing activities	(1,129.8)	(876.9)	(226.2)
Cash flows from financing activities:
Principal borrowings on term loan facilities	250	450	0
Proceeds from bond issuance	1,400	175	0
Principal payments on debt, including pre-payments	(597.4)	(302.6)	(62.5)
Principal borrowings on notes	0	0	15.2
Borrowings on revolving credit facility	540	440	197
Payments on revolving credit facility	(735)	(160)	(152)
Principal payments under capital lease obligations	(11)	(6.1)	(10.1)
Debt amendment and issuance costs	(31.9)	(6.5)	(2.6)
Repurchase of common stock, including fees and expenses	(45.3)	(43.1)	(234.1)
Dividends paid on common stock	(77.2)	(65.8)	(15.7)
Dividends paid on convertible perpetual preferred stock	(3.1)	(6.3)	(23)
Distributions paid to noncontrolling interests of consolidated affiliates	(54.4)	(54.1)	(46.3)
Proceeds from exercising stock warrants	0	6.3	15.3
Other	5.2	7.4	6.4
Net cash provided by (used in) financing activities	639.9	434.2	(312.4)
(Decrease) increase in cash and cash equivalents	(5.1)	2.2	(68.3)
Cash and cash equivalents at beginning of year	66.7	64.5	132.8
Cash and cash equivalents at end of year	61.6	66.7	64.5
Cash (paid) received during the year for-
Interest	(121.4)	(100.6)	(99.4)
Income tax refunds	7.4	1.3	4.8
Income tax payments	(16.8)	(17.7)	(12.5)
Supplemental schedule of noncash investing and financing activities: [Abstract]
Convertible debt issued	0	0	320
Repurchase of preferred stock	0	0	(320)
Equity rollover from Encompass management	0	64.5	0
Preferred stock conversion	$ 93.2	$ 0	$ 0

Cash and Marketable Securities

Cash and Marketable Securities	12 Months Ended
	Dec. 31, 2015
Cash and Cash Equivalents [Abstract]
Cash and Marketable Securities	Cash and Marketable Securities : The components of our investments as of December 31, 2015 are as follows (in millions): Cash & Cash Equivalents Restricted Cash Restricted Marketable Securities Total Cash $ 61.6 $ 45.9 $ — $ 107.5 Equity securities — — 56.2 56.2 Total $ 61.6 $ 45.9 $ 56.2 $ 163.7 The components of our investments as of December 31, 2014 are as follows (in millions): Cash & Cash Equivalents Restricted Cash Restricted Marketable Securities Total Cash $ 66.7 $ 45.6 $ — $ 112.3 Equity securities — — 50.5 50.5 Total $ 66.7 $ 45.6 $ 50.5 $ 162.8 Restricted Cash— As of December 31, 2015 and 2014 , Restricted cash consisted of the following (in millions): As of December 31, 2015 2014 Affiliate cash $ 20.3 $ 13.1 Self-insured captive funds 25.6 32.4 Paid-loss deposit funds — 0.1 Total restricted cash $ 45.9 $ 45.6 Affiliate cash represents cash accounts maintained by joint ventures in which we participate where one or more of our external partners requested, and we agreed, that the joint venture’s cash not be commingled with other corporate cash accounts and be used only to fund the operations of those joint ventures. Self-insured captive funds represent cash held at our wholly owned insurance captive, HCS, Ltd., as discussed in Note 9, Self-Insured Risks . These funds are committed to pay third-party administrators for claims incurred and are restricted by insurance regulations and requirements. These funds cannot be used for purposes outside HCS without the permission of the Cayman Islands Monetary Authority. Paid-loss deposit funds represent cash held by third-party administrators to fund expenses and other payments related to claims. The classification of restricted cash held by HCS as current or noncurrent depends on the classification of the corresponding claims liability. As of December 31, 2015 and 2014 , all restricted cash was current. Marketable Securities— Restricted marketable securities at both balance sheet dates represent restricted assets held at HCS. HCS insures HealthSouth’s professional liability, workers’ compensation, and other insurance claims. These funds are committed for payment of claims incurred, and the classification of these marketable securities as current or noncurrent depends on the classification of the corresponding claims liability. As of December 31, 2015 and 2014 , $40.1 million and $45.9 million , respectively, of restricted marketable securities are included in Other long-term assets in our consolidated balance sheets. A summary of our restricted marketable securities as of December 31, 2015 is as follows (in millions): Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Equity securities $ 58.3 $ 0.3 $ (2.4 ) $ 56.2 A summary of our restricted marketable securities as of December 31, 2014 is as follows (in millions): Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Equity securities $ 51.3 $ 0.5 $ (1.3 ) $ 50.5 Cost in the above tables includes adjustments made to the cost basis of our equity securities for other-than-temporary impairments. During the years ended December 31, 2015 , 2014 , and 2013 , we did not record any impairment charges related to our restricted marketable securities. Investing information related to our restricted marketable securities is as follows (in millions): For the Year Ended December 31, 2015 2014 2013 Proceeds from sales of restricted available-for-sale securities $ — $ — $ 16.6 Proceeds from sales of nonrestricted available-for-sale securities $ 12.8 $ 2.7 $ — Gross realized gains $ 1.2 $ 0.5 $ 1.0 Gross realized losses $ — $ (0.1 ) $ (0.1 ) Our portfolio of marketable securities is comprised of investments in mutual funds that hold investments in a variety of industries and geographies. As discussed in Note 1, Summary of Significant Accounting Policies , “Marketable Securities,” when our portfolio includes marketable securities with unrealized losses that are not deemed to be other-than-temporarily impaired, we examine the severity and duration of the impairments in relation to the cost of the individual investments. We also consider the industry and geography in which each investment is held and the near-term prospects for a recovery in each.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies : Organization and Description of Business— HealthSouth Corporation, incorporated in Delaware in 1984 , including its subsidiaries, is one of the nation’s largest providers of post-acute healthcare services, offering both facility-based and home-based post-acute services in 34 states and Puerto Rico through our network of inpatient rehabilitation hospitals, home health agencies, and hospice agencies. As a result of the December 31, 2014 acquisition of Encompass Home Health and Hospice (“Encompass”), management changed the way it manages and operates the consolidated reporting entity and modified the reports used by its chief operating decision maker to assess performance and allocate resources. These changes required us to revise our segment reporting from our historic presentation of only one reportable segment. We now manage our operations and disclose financial information using two reportable segments: (1) inpatient rehabilitation and (2) home health and hospice. See Note 18 , Segment Reporting . Basis of Presentation and Consolidation— The accompanying consolidated financial statements of HealthSouth and its subsidiaries were prepared in accordance with generally accepted accounting principles in the United States of America and include the assets, liabilities, revenues, and expenses of all wholly-owned subsidiaries, majority-owned subsidiaries over which we exercise control, and, when applicable, entities in which we have a controlling financial interest. We use the equity method to account for our investments in entities we do not control, but where we have the ability to exercise significant influence over operating and financial policies. Consolidated Net income attributable to HealthSouth includes our share of the net earnings of these entities. The difference between consolidation and the equity method impacts certain of our financial ratios because of the presentation of the detailed line items reported in the consolidated financial statements for consolidated entities compared to a one line presentation of equity method investments. We use the cost method to account for our investments in entities we do not control and for which we do not have the ability to exercise significant influence over operating and financial policies. In accordance with the cost method, these investments are recorded at the lower of cost or fair value, as appropriate. We also consider the guidance for consolidating variable interest entities. We eliminate all significant intercompany accounts and transactions from our financial results. Use of Estimates and Assumptions— The preparation of our consolidated financial statements in conformity with GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions are used for, but not limited to: (1) allowance for contractual revenue adjustments; (2) allowance for doubtful accounts; (3) fair value of acquired assets and assumed liabilities in business combinations; (4) asset impairments, including goodwill; (5) depreciable lives of assets; (6) useful lives of intangible assets; (7) economic lives and fair value of leased assets; (8) income tax valuation allowances; (9) uncertain tax positions; (10) fair value of stock options and restricted stock containing a market condition; (11) fair value of redeemable noncontrolling interests; (12) reserves for self-insured healthcare plans; (13) reserves for professional, workers’ compensation, and comprehensive general insurance liability risks; and (14) contingency and litigation reserves. Future events and their effects cannot be predicted with certainty; accordingly, our accounting estimates require the exercise of judgment. The accounting estimates used in the preparation of our consolidated financial statements will change as new events occur, as more experience is acquired, as additional information is obtained, and as our operating environment changes. We evaluate and update our assumptions and estimates on an ongoing basis and may employ outside experts to assist in our evaluation, as considered necessary. Actual results could differ from those estimates. Risks and Uncertainties— As a healthcare provider, we are required to comply with extensive and complex laws and regulations at the federal, state, and local government levels. These laws and regulations relate to, among other things: • licensure, certification, and accreditation; • policies, either at the national or local level, delineating what conditions must be met to qualify for reimbursement under Medicare (also referred to as coverage requirements); • coding and billing for services; • requirements of the 60% compliance threshold under The Medicare, Medicaid and State Children’s Health Insurance Program (SCHIP) Extension Act of 2007; • relationships with physicians and other referral sources, including physician self-referral and anti-kickback laws; • quality of medical care; • use and maintenance of medical supplies and equipment; • maintenance and security of patient information and medical records; • acquisition and dispensing of pharmaceuticals and controlled substances; and • disposal of medical and hazardous waste. In the future, changes in these laws or regulations or the manner in which they are enforced could subject our current or past practices to allegations of impropriety or illegality or could require us to make changes in our hospitals, equipment, personnel, services, capital expenditure programs, operating procedures, contractual arrangements, and patient admittance practices, as well as the way in which we deliver home health and hospice services. If we fail to comply with applicable laws and regulations, we could be required to return portions of reimbursements deemed after the fact to have not been appropriate. We could also be subjected to liabilities, including (1) criminal penalties, (2) civil penalties, including monetary penalties and the loss of our licenses to operate one or more of our hospitals or agencies, and (3) exclusion or suspension of one or more of our hospitals from participation in the Medicare, Medicaid, and other federal and state healthcare programs which, if lengthy in duration and material to us, could potentially trigger a default under our credit agreement. Because Medicare comprises a significant portion of our Net operating revenues , it is important for us to remain compliant with the laws and regulations governing the Medicare program and related matters including anti-kickback and anti-fraud requirements. Reductions in reimbursements, substantial damages, and other remedies assessed against us could have a material adverse effect on our business, financial position, results of operation, and cash flows. Even the assertion of a violation, depending on its nature, could have a material adverse effect upon our stock price or reputation. Historically, the United States Congress and some state legislatures have periodically proposed significant changes in regulations governing the healthcare system. Many of these changes have resulted in limitations on the increases in and, in some cases, significant roll-backs or reductions in the levels of payments to healthcare providers for services under many government reimbursement programs. There can be no assurance that future governmental initiatives will not result in pricing roll-backs or freezes or reimbursement reductions. Because we receive a significant percentage of our revenues from Medicare, such changes in legislation might have a material adverse effect on our financial position, results of operations, and cash flows. Pursuant to legislative directives and authorizations from Congress, the United States Centers for Medicare and Medicaid Services (“CMS”) developed and instituted various Medicare audit programs. We undertake significant efforts through training and education to ensure compliance with coding and medical necessity coverage rules. Despite our belief that our coding and assessment of patients is accurate, audits may lead to assertions that we have been underpaid or overpaid by Medicare or submitted improper claims in some instances, require us to incur additional costs to respond to requests for records and defend the validity of payments and claims, and ultimately require us to refund any amounts determined to have been overpaid. We cannot predict when or how these programs will affect us. In addition, there are increasing pressures from many third-party payors to control healthcare costs and to reduce or limit increases in reimbursement rates for medical services. Our relationships with managed care and nongovernmental third-party payors are generally governed by negotiated agreements. These agreements set forth the amounts we are entitled to receive for our services. We could be adversely affected in some of the markets where we operate if we are unable to negotiate and maintain favorable agreements with third-party payors. Our third-party payors may also, from time to time, request audits of the amounts paid, or to be paid, to us. We could be adversely affected in some of the markets where we operate if the auditing payor alleges substantial overpayments were made to us due to coding errors or lack of documentation to support medical necessity determinations. As discussed in Note 17, Contingencies and Other Commitments , we are a party to a number of lawsuits. We cannot predict the outcome of litigation filed against us. Substantial damages or other monetary remedies assessed against us could have a material adverse effect on our business, financial position, results of operations, and cash flows. Net Operating Revenues— We derived consolidated Net operating revenues from the following payor sources: For the Year Ended December 31, 2015 2014 2013 Medicare 74.9 % 74.1 % 74.5 % Managed care and other discount plans, including Medicare Advantage 17.7 % 18.6 % 18.5 % Medicaid 3.0 % 1.8 % 1.2 % Other third-party payors 1.7 % 1.8 % 1.8 % Workers' compensation 0.9 % 1.2 % 1.2 % Patients 0.6 % 1.0 % 1.1 % Other income 1.2 % 1.5 % 1.7 % Total 100.0 % 100.0 % 100.0 % We record gross service charges in our accounting records on an accrual basis using our established rates for the type of service provided to the patient. We recognize an estimated contractual allowance and an estimate of potential subsequent adjustments that may arise from post-payment and other reviews to reduce gross patient charges to the amount we estimate we will actually realize for the service rendered based upon previously agreed to rates with a payor. Our accounting systems calculate contractual allowances on a patient-by-patient basis based on the rates in effect for each primary third-party payor. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms that result from contract renegotiations and renewals. Due to complexities involved in determining amounts ultimately due under reimbursement arrangements with third-party payors, which are often subject to interpretation, we may receive reimbursement for healthcare services authorized and provided that is different from our estimates, and such differences could be material. In addition, laws and regulations governing the Medicare and Medicaid programs are complex, subject to interpretation, and are routinely modified for provider reimbursement. All healthcare providers participating in the Medicare and Medicaid programs are required to meet certain financial reporting requirements. Federal regulations require submission of annual cost reports covering medical costs and expenses associated with the services provided under each hospital, home health, and hospice provider number to program beneficiaries. Annual cost reports required under the Medicare and Medicaid programs are subject to routine audits, which may result in adjustments to the amounts ultimately determined to be due to HealthSouth under these reimbursement programs. These audits often require several years to reach the final determination of amounts earned under the programs. If actual results are not consistent with our assumptions and judgments, we may be exposed to gains or losses that could be material. CMS has been granted authority to suspend payments, in whole or in part, to Medicare providers if CMS possesses reliable information an overpayment, fraud, or willful misrepresentation exists. If CMS suspects payments are being made as the result of fraud or misrepresentation, CMS may suspend payment at any time without providing prior notice to us. The initial suspension period is limited to 180 days. However, the payment suspension period can be extended almost indefinitely if the matter is under investigation by the United States Department of Health and Human Services Office of Inspector General (the “HHS-OIG”) or the United States Department of Justice. Therefore, we are unable to predict if or when we may be subject to a suspension of payments by the Medicare and/or Medicaid programs, the possible length of the suspension period, or the potential cash flow impact of a payment suspension. Any such suspension would adversely impact our financial position, results of operations, and cash flows. Pursuant to legislative directives and authorizations from Congress, CMS has developed and instituted various Medicare audit programs under which CMS contracts with private companies to conduct claims and medical record audits. As a matter of course, we undertake significant efforts through training and education to ensure compliance with Medicare requirements. However, audits may lead to assertions we have been underpaid or overpaid by Medicare or submitted improper claims in some instances, require us to incur additional costs to respond to requests for records and defend the validity of payments and claims, and ultimately require us to refund any amounts determined to have been overpaid. We cannot predict when or how these audit programs will affect us. Inpatient Rehabilitation Revenues Our inpatient rehabilitation segment derived its Net operating revenues from the following payor sources: As of December 31, 2015 2014 2013 Medicare 73.2 % 73.9 % 74.2 % Managed care and other discount plans, including Medicare Advantage 19.0 % 18.8 % 18.7 % Medicaid 2.5 % 1.8 % 1.2 % Other third-party payors 2.0 % 1.8 % 1.8 % Workers’ compensation 1.1 % 1.2 % 1.3 % Patients 0.7 % 1.0 % 1.1 % Other income 1.5 % 1.5 % 1.7 % Total 100.0 % 100.0 % 100.0 % Revenues recognized by our inpatient rehabilitation segment are subject to a number of elements which impact both the overall amount of revenue realized as well as the timing of the collection of the related accounts receivable. Factors that are considered and could influence the level of our reserves include the patient’s total length of stay for in-house patients, each patient’s discharge destination, the proportion of patients with secondary insurance coverage and the level of reimbursement under that secondary coverage, and the amount of charges that will be disallowed by payors. Such additional factors are assumed to remain consistent with the experience for patients discharged in similar time periods for the same payor classes, and additional reserves are provided to account for these factors. In connection with CMS approved and announced Recovery Audit Contractors (“RACs”) audits related to inpatient rehabilitation facilities (“IRFs”), we received requests in 2014 and 2013 to review certain patient files for discharges occurring from 2010 to 2014. These post-payment RAC audits are focused on medical necessity requirements for admission to IRFs rather than targeting a specific diagnosis code as in previous pre-payment audits. Medical necessity is an assessment by an independent physician of a patient’s ability to tolerate and benefit from intensive multi-disciplinary therapy provided in an IRF setting. To date, the Medicare payments that are subject to these audit requests represent less than 1% of our Medicare patient discharges from 2010 to 2014, and not all of these patient file requests have resulted in payment denial determinations by the RACs. Because we have confidence in the medical judgment of both the referring and the admitting physicians who assess the treatment needs of their patients, we have appealed substantially all RAC denials arising from these audits using the same process we follow for appealing denials of certain diagnosis codes by Medicare Administrative Contractors (“MACs”) (see “Accounts Receivable and Allowance for Doubtful Accounts” below). Due to the delays announced by CMS in the related adjudication process, we believe the resolution of any claims that are subsequently denied as a result of these RAC audits could take in excess of three years. In addition, because we have limited experience with RACs in the context of post-payment reviews of this nature, we cannot provide assurance as to the future success of these disputes. As such, we make provisions for these claims based on our historical experience and success rates in the claims adjudication process, which is the same process we follow for appealing denials of certain diagnosis codes by MACs. As the ultimate results of these audits impact our estimates of amounts determined to be due to HealthSouth under these reimbursement programs, our provision for claims that are part of this post-payment review process are recorded to Net operating revenues . During 2015 and 2014, we adjusted our Net operating revenues by approximately ($0.6) million and $0.4 million , respectively, for post-payment claims that are part of this review process. Home Health and Hospice Revenues The results of operations for our home health and hospice segment in 2014 and 2013 included only the results of HealthSouth’s legacy hospital-based home health agencies. Our home health and hospice segment derived its Net operating revenues from the following payor sources: As of December 31, 2015 2014 2013 Medicare 83.7 % 96.9 % 95.8 % Managed care and other discount plans, including Medicare Advantage 10.7 % 1.8 % 2.5 % Medicaid 5.5 % — % — % Other third-party payors — % 1.0 % 1.4 % Workers’ compensation — % 0.3 % 0.3 % Patients 0.1 % — % — % Total 100.0 % 100.0 % 100.0 % Home health and hospice revenues are earned as services are performed either on an episode of care basis, on a per visit basis, or on a daily basis, depending upon the payment terms and conditions established with each payor for services provided. Home Health Under the Medicare home health prospective payment system, we are paid by Medicare based on episodes of care. An episode of care is defined as a length of stay up to 60 days, with multiple continuous episodes allowed. A base episode payment is established by the Medicare program through federal legislation. The base episode payment can be adjusted based on each patient’s health including clinical condition, functional abilities, and service needs, as well as for the applicable geographic wage index, low utilization, patient transfers, and other factors. The services covered by the episode payment include all disciplines of care in addition to medical supplies. A portion of reimbursement from each Medicare episode is billed near the start of each episode, and cash is typically received before all services are rendered. Revenue for the episode of care is recorded over an average length of treatment period using a calendar day prorating method. The amount of revenue recognized for episodes of care which are incomplete at period end is based on the pro rata number of days in the episode which have been completed as of the period end date. As of December 31, 2015 , the difference between the cash received from Medicare for a request for anticipated payment on episodes in progress and the associated estimated revenue was not material and was recorded in Other current liabilities in our condensed consolidated balance sheets. We are subject to certain Medicare regulations affecting outlier revenue if our patient’s care was unusually costly. Regulations require a cap on all outlier revenue at 10% of total Medicare revenue received by each provider during a cost reporting year. Management has reviewed the potential cap. Reserves recorded for the outlier cap were not material as of December 31, 2015 . For episodic-based rates that are paid by other insurance carriers, including Medicare Advantage, we recognize revenue in a similar manner as discussed above for Medicare revenues. However, these rates can vary based upon the negotiated terms. For non-episodic-based revenue, gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates. Contractual allowances are recorded for the differences between our standard rates and the applicable contracted rates. Hospice Medicare revenues for hospice are recorded on an accrual basis based on the number of days a patient has been on service at amounts equal to an estimated daily or hourly payment rate. The payment rate is dependent on whether a patient is receiving routine home care, general inpatient care, continuous home care or respite care. Adjustments to Medicare revenues are recorded based on an inability to obtain appropriate billing documentation or authorizations acceptable to the payor or other reasons unrelated to credit risk. Hospice companies are subject to two specific payment limit caps under the Medicare program. One limit relates to inpatient care days that exceed 20% of the total days of hospice care provided for the year. The second limit relates to an aggregate Medicare reimbursement cap calculated by the Medicare fiscal intermediary. Currently, we do not believe we are at risk for exceeding these caps and have not recorded a reserve for these caps as of December 31, 2015 . For non-Medicare hospice revenues, we record gross revenue on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per day rates, as applicable. Contractual adjustments are recorded for the difference between our established rates and the amounts estimated to be realizable from patients and third parties for services provided and are deducted from gross revenue to determine our net service revenue. We are subject to changes in government legislation that could impact Medicare payment levels and changes in payor patterns that may impact the level and timing of payments for services rendered. Cash and Cash Equivalents— Cash and cash equivalents include highly liquid investments with maturities of three months or less when purchased. Carrying values of Cash and cash equivalents approximate fair value due to the short-term nature of these instruments. We maintain amounts on deposit with various financial institutions, which may, at times, exceed federally insured limits. However, management periodically evaluates the credit-worthiness of those institutions, and we have not experienced any losses on such deposits. Marketable Securities— We record all equity securities with readily determinable fair values and for which we do not exercise significant influence as available-for-sale securities. We carry the available-for-sale securities at fair value and report unrealized holding gains or losses, net of income taxes, in Accumulated other comprehensive loss , which is a separate component of shareholders’ equity. We recognize realized gains and losses in our consolidated statements of operations using the specific identification method. Unrealized losses are charged against earnings when a decline in fair value is determined to be other than temporary. Management reviews several factors to determine whether a loss is other than temporary, such as the length of time a security is in an unrealized loss position, the extent to which fair value is less than cost, the financial condition and near term prospects of the issuer, industry, or geographic area and our ability and intent to hold the security for a period of time sufficient to allow for any anticipated recovery in fair value. Accounts Receivable and Allowance for Doubtful Accounts— We report accounts receivable at estimated net realizable amounts from services rendered from federal and state agencies (under the Medicare and Medicaid programs), managed care health plans, commercial insurance companies, workers’ compensation programs, employers, and patients. Our accounts receivable are geographically dispersed, but a significant portion of our revenues are concentrated by type of payors. The concentration of net patient service accounts receivable by payor class, as a percentage of total net patient service accounts receivable, is as follows: As of December 31, 2015 2014 Medicare 70.5 % 72.2 % Managed care and other discount plans, including Medicare Advantage 19.7 % 18.5 % Medicaid 2.9 % 1.8 % Other third-party payors 4.1 % 3.8 % Workers' compensation 1.9 % 1.9 % Patients 0.9 % 1.8 % Total 100.0 % 100.0 % While revenues and accounts receivable from the Medicare program are significant to our operations, we do not believe there are significant credit risks associated with this government agency. We do not believe there are any other significant concentrations of revenues from any particular payor that would subject us to any significant credit risks in the collection of our accounts receivable. We provide for accounts receivable that could become uncollectible by establishing an allowance to reduce the carrying value of such receivables to their estimated net realizable value. Additions to the allowance for doubtful accounts are made by means of the Provision for doubtful accounts . We write off uncollectible accounts (after exhausting collection efforts) against the allowance for doubtful accounts. Subsequent recoveries are recorded via the Provision for doubtful accounts . We estimate our allowance for doubtful accounts based on the aging of our accounts receivable, our historical collection experience for each type of payor, and other relevant factors so that the remaining receivables, net of allowances, are reflected at their estimated net realizable values. Accounts requiring collection efforts are reviewed via system-generated work queues that automatically stage (based on age and size of outstanding balance) accounts requiring collection efforts for patient account representatives. Collection efforts include contacting the applicable party (both in writing and by telephone), providing information (both financial and clinical) to allow for payment or to overturn payor decisions to deny payment, and arranging payment plans with self-pay patients, among other techniques. When we determine all in-house efforts have been exhausted or it is a more prudent use of resources, accounts may be turned over to a collection agency. Accounts are written off after all collection efforts (internal and external) have been exhausted. The collection of outstanding receivables from Medicare, managed care payors, other third-party payors, and patients is our primary source of cash and is critical to our operating performance. While it is our policy to verify insurance prior to a patient being admitted, there are various exceptions that can occur. Such exceptions include instances where we are (1) unable to obtain verification because the patient’s insurance company was unable to be reached or contacted, (2) a determination is made that a patient may be eligible for benefits under various government programs, such as Medicaid, and it takes several days, weeks, or months before qualification for such benefits is confirmed or denied, and (3) the patient is transferred to our hospital from an acute care hospital without having access to a credit card, cash, or check to pay the applicable patient responsibility amounts (i.e., deductibles and co-payments). Our primary collection risks relate to patient responsibility amounts and pre-payment claim reviews conducted by MACs. Patient responsibility amounts include accounts for which the patient was the primary payor or the primary insurance carrier has paid the amounts covered by the applicable agreement, but patient co-payment amounts remain outstanding. Changes in the economy, such as increased unemployment rates or periods of recession, can further exacerbate our ability to collect patient responsibility amounts. For several years, under programs designated as “widespread probes,” certain of our MACs have conducted pre-payment claim reviews of our billings and denied payment for certain diagnosis codes. We dispute, or “appeal,” most of these denials, and we have historically collected approximately 71% o f all amounts denied. For claims we choose to take to administrative law judge hearings, we have historically experienced an approxim ate 70% success rate. The resolution of these disputes can take in excess of three years, and we cannot provide assurance as to our ongoing and future success of these disputes. As such, we make provisions against these receivables in accordance with our accounting policy that necessarily considers historical collection trends of the receivables in this review process as part of our Provision for doubtful accounts . Because we do not write-off receivables until all collection efforts have been exhausted, we do not write off receivables related to denied claims while they are in this review process. When the amount collected related to denied claims differs from the net amount previously recorded, these collection differences are recorded in the Provision for doubtful accounts . As a result, the timing of these denials by MACs and their subsequent collection can create volatility in our Provision for doubtful accounts . If actual results are not consistent with our assumptions and judgments, we may be exposed to gains or losses that could be material. Changes in general economic conditions, business office operations, payor mix, or trends in federal or state governmental and private employer healthcare coverage could affect our collection of accounts receivable, financial position, results of operations, and cash flows. Property and Equipment— We report land, buildings, improvements, vehicles, and equipment at cost, net of accumulated depreciation and amortization and any asset impairments. We report assets under capital lease obligations at the lower of fair value or the present value of the aggregate future minimum lease payments at the beginning of the lease term. We depreciate our assets using the straight-line method over the shorter of the estimated useful life of the assets or life of the lease term, excluding any lease renewals, unless the lease renewals are reasonably assured. Useful lives are generally as follows: Years Buildings 10 to 30 Leasehold improvements 2 to 15 Vehicles 5 Furniture, fixtures, and equipment 3 to 10 Assets under capital lease obligations: Real estate 15 to 20 Vehicles 3 to 4 Equipment 3 to 5 Maintenance and repairs of property and equipment are expensed as incurred. We capitalize replacements and betterments that increase the estimated useful life of an asset. We capitalize pre-acquisition costs when they are directly identifiable with a specific property, the costs would be capitalizable if the property were already acquired, and acquisition of the property is probable. We capitalize interest expense on major construction and development projects while in progress. We retain fully depreciated assets in property and accumulated depreciation accounts until we remove them from service. In the case of sale, retirement, or disposal, the asset cost and related accumulated depreciation balances are removed from the respective accounts, and the resulting net amount, less any proceeds, is included as a component of income from continuing operations in the consolidated statements of operations. However, if the sale, retirement, or disposal involves a discontinued operation, the resulting net amount, less any proceeds, is included in the results of discontinued operations. We account for operating leases by recognizing rents, including any rent holidays, on a straight-line basis over the term of the lease. Goodwill and Other Intangible Assets— We are required to test our goodwill and indefini

Accounts Receivable

Accounts Receivable	12 Months Ended
	Dec. 31, 2015
Receivables [Abstract]
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]	Accounts Receivable : Accounts receivable consists of the following (in millions): As of December 31, 2015 2014 Current: Patient accounts receivable, net of allowance for doubtful accounts of $39.3 million in 2015; $22.2 million in 2014 $ 403.3 $ 309.3 Other accounts receivable 7.2 13.9 410.5 323.2 Noncurrent patient accounts receivable, net of allowance for doubtful accounts of $32.3 million in 2015; $20.8 million in 2014 96.6 51.4 Accounts receivable, net $ 507.1 $ 374.6 Because the resolution of claims that are part of Medicare audit programs can take in excess of three years, we review the patient receivables that are part of this adjudication process to determine their appropriate classification as either current or noncurrent. Amounts considered noncurrent are included in Other long-term assets in our consolidated balance sheet. At December 31, 2015 and 2014 , our allowance for doubtful accounts represented approximately 12.5% and 10.7% , respectively, of the total patient due accounts receivable balance. The following is the activity related to our allowance for doubtful accounts (in millions): For the Year Ended December 31, Balance at Beginning of Period Additions and Charges to Expense Deductions and Accounts Written Off Balance at End of Period 2015 $ 43.0 $ 47.2 $ (18.6 ) $ 71.6 2014 $ 33.1 $ 31.6 $ (21.7 ) $ 43.0 2013 $ 28.7 $ 26.0 $ (21.6 ) $ 33.1

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment : Property and equipment consists of the following (in millions): As of December 31, 2015 2014 Land $ 113.3 $ 108.1 Buildings 1,521.1 1,214.4 Leasehold improvements 96.2 79.1 Vehicles 10.0 9.3 Furniture, fixtures, and equipment 392.7 364.2 2,133.3 1,775.1 Less: Accumulated depreciation and amortization (874.3 ) (784.0 ) 1,259.0 991.1 Construction in progress 51.1 28.6 Property and equipment, net $ 1,310.1 $ 1,019.7 As of December 31, 2015 , approximately 75% of our consolidated Property and equipment, net held by HealthSouth Corporation and its guarantor subsidiaries was pledged to the lenders under our credit agreement. See Note 8, Long-term Debt , and Note 20, Condensed Consolidating Financial Information . Information related to fully depreciated assets and assets under capital lease obligations is as follows (in millions): As of December 31, 2015 2014 Fully depreciated assets $ 252.4 $ 240.9 Assets under capital lease obligations: Buildings $ 333.9 $ 124.4 Vehicles 6.5 5.2 Equipment 0.3 0.2 340.7 129.8 Less: Accumulated amortization (66.6 ) (55.2 ) Assets under capital lease obligations, net $ 274.1 $ 74.6 See also Note 2, Business Combinations. The amount of depreciation expense, amortization expense relating to assets under capital lease obligations, interest capitalized, and rent expense under operating leases is as follows (in millions): For the Year Ended December 31, 2015 2014 2013 Depreciation expense $ 91.0 $ 79.9 $ 67.9 Amortization expense $ 12.7 $ 7.5 $ 9.5 Interest capitalized $ 1.3 $ 1.5 $ 1.9 Rent expense: Minimum rent payments $ 48.8 $ 37.3 $ 40.3 Contingent and other rents 21.6 18.2 20.3 Other 3.8 3.9 4.2 Total rent expense $ 74.2 $ 59.4 $ 64.8 Leases— We lease certain land, buildings, and equipment under noncancelable operating leases generally expiring at various dates through 2028 . We also lease certain buildings and equipment under capital leases generally expiring at various dates through 2037 . Operating leases generally have 3 - to 15 -year terms, with one or more renewal options, with terms to be negotiated at the time of renewal. Various facility leases include provisions for rent escalation to recognize increased operating costs or require us to pay certain maintenance and utility costs. Contingent rents are included in rent expense in the year incurred. Some facilities are subleased to other parties. Rental income from subleases approximated $5.0 million , $5.1 million , and $4.9 million for the years ended December 31, 2015 , 2014 , and 2013 , respectively. Total expected future minimum rentals under these noncancelable subleases approximated $13.5 million as of December 31, 2015 . Certain leases contain annual escalation clauses based on changes in the Consumer Price Index while others have fixed escalation terms. The excess of cumulative rent expense (recognized on a straight-line basis) over cumulative rent payments made on leases with fixed escalation terms is recognized as straight-line rental accrual and is included in Other long-term liabilities in the accompanying consolidated balance sheets, as follows (in millions): As of December 31, 2015 2014 Straight-line rental accrual $ 11.8 $ 14.6 In March 2008, we sold our corporate campus to Daniel Corporation (“Daniel”), a Birmingham, Alabama-based real estate company. The sale included a deferred purchase price component related to an incomplete 13-story building located on the property, often referred to as the Digital Hospital. Under the agreement, Daniel was obligated upon sale of its interest in the building to pay to us 40% of the net profit realized from the sale. In June 2013, Daniel sold the building to Trinity Medical Center. In the third quarter of 2013, we received $10.8 million in cash from Daniel in connection with the sale of the building. The gain associated with this transaction is being deferred and amortized over five years, which is the remaining life of our lease agreement with Daniel for the portion of the property we continue to occupy with our corporate office, as a component of General and administrative expenses . Future minimum lease payments at December 31, 2015 , for those leases having an initial or remaining noncancelable lease term in excess of one year, are as follows (in millions): Year Ending December 31, Operating Leases Capital Lease Obligations Total 2016 $ 59.2 $ 32.8 $ 92.0 2017 52.1 34.1 86.2 2018 46.0 33.4 79.4 2019 41.2 30.3 71.5 2020 32.9 27.8 60.7 2021 and thereafter 156.2 384.7 540.9 $ 387.6 543.1 $ 930.7 Less: Interest portion (254.9 ) Obligations under capital leases $ 288.2 In addition to the above, and as discussed in Note 8, Long-term Debt , “Other Notes Payable,” we have two sale/leaseback transactions involving real estate accounted for as financings. Future minimum payments, which are accounted for as interest, under these obligations are $2.7 million in each of the next five years and $8.3 million thereafter.

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	12 Months Ended
	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets	Goodwill and Other Intangible Assets : The following table shows changes in the carrying amount of Goodwill for the years ended December 31, 2015 , 2014 , and 2013 (in millions): Amount Goodwill as of December 31, 2012 $ 437.3 Acquisition 13.7 Conversion of 100% owned hospital into a joint venture 6.2 Divestiture of skilled nursing facility beds (0.3 ) Goodwill as of December 31, 2013 456.9 Acquisitions 593.1 Consolidation of joint venture formerly accounted for under the equity method of accounting 34.0 Goodwill as of December 31, 2014 1,084.0 Acquisitions 806.1 Goodwill as of December 31, 2015 $ 1,890.1 Goodwill increased in 2013 as a result of our acquisition of Walton Rehabilitation Hospital and conversion of our 100% owned hospital in Jonesboro, Arkansas into a joint venture with St. Bernards Healthcare offset by the divestiture of 41 skilled nursing facility beds. Goodwill increased in 2014 as a result of our consolidation of Fairlawn and the remeasurement of our previously held equity interest at fair value and our acquisitions of Encompass and Quillen. Goodwill increased in 2015 as a result of our acquisitions of Reliant, CareSouth, and other inpatient and home health and hospice operations. See Note 2, Business Combinations and Note 11, Redeemable Noncontrolling Interests . We performed impairment reviews as of October 1, 2015 , 2014 , and 2013 and concluded no Goodwill impairment existed. As of December 31, 2015 , we had no accumulated impairment losses related to Goodwill . The following table provides information regarding our other intangible assets (in millions): Gross Carrying Amount Accumulated Amortization Net Certificates of need: 2015 $ 93.9 $ (6.9 ) $ 87.0 2014 27.9 (4.0 ) 23.9 Licenses: 2015 $ 138.9 $ (53.7 ) $ 85.2 2014 110.8 (46.3 ) 64.5 Noncompete agreements: 2015 $ 58.0 $ (37.0 ) $ 21.0 2014 46.2 (29.4 ) 16.8 Trade name - Encompass: 2015 $ 135.2 $ — $ 135.2 2014 135.2 — 135.2 Trade names - all other: 2015 $ 32.9 $ (11.5 ) $ 21.4 2014 19.9 (10.1 ) 9.8 Internal-use software: 2015 $ 155.7 $ (90.5 ) $ 65.2 2014 125.3 (74.5 ) 50.8 Market access assets: 2015 $ 13.2 $ (8.8 ) $ 4.4 2014 13.2 (8.1 ) 5.1 Total intangible assets: 2015 $ 627.8 $ (208.4 ) $ 419.4 2014 478.5 (172.4 ) 306.1 Amortization expense for other intangible assets is as follows (in millions): For the Year Ended December 31, 2015 2014 2013 Amortization expense $ 36.0 $ 20.3 $ 17.3 Total estimated amortization expense for our other intangible assets for the next five years is as follows (in millions): Year Ending December 31, Estimated Amortization Expense 2016 $ 45.4 2017 38.7 2018 30.3 2019 26.8 2020 23.3

Investments in and Advances to

Investments in and Advances to Nonconsolidated Affiliates	12 Months Ended
	Dec. 31, 2015
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures [Abstract]
Investments in and Advances to Nonconsolidated Affiliates	Investments in and Advances to Nonconsolidated Affiliates : Investments in and advances to nonconsolidated affiliates as of December 31, 2015 represents our investment in seven partially owned subsidiaries, of which six are general or limited partnerships, limited liability companies, or joint ventures in which HealthSouth or one of its subsidiaries is a general or limited partner, managing member, member, or venturer, as applicable. We do not control these affiliates but have the ability to exercise significant influence over the operating and financial policies of certain of these affiliates. Our ownership percentages in these affiliates range from approximately 1% to 60% . We account for these investments using the cost and equity methods of accounting. Our investments, which are included in Other long-term assets in our consolidated balance sheets, consist of the following (in millions): As of December 31, 2015 2014 Equity method investments: Capital contributions $ 0.9 $ 0.8 Cumulative share of income 88.0 77.3 Cumulative share of distributions (77.5 ) (69.9 ) 11.4 8.2 Cost method investments: Capital contributions, net of distributions and impairments 0.3 1.2 Total investments in and advances to nonconsolidated affiliates $ 11.7 $ 9.4 The following summarizes the combined assets, liabilities, and equity and the combined results of operations of our equity method affiliates (on a 100% basis, in millions): As of December 31, 2015 2014 Assets— Current $ 7.8 $ 9.6 Noncurrent 20.5 13.1 Total assets $ 28.3 $ 22.7 Liabilities and equity— Current liabilities $ 1.4 $ 0.7 Noncurrent liabilities 0.1 0.1 Partners’ capital and shareholders’ equity— HealthSouth 11.4 8.2 Outside partners 15.4 13.7 Total liabilities and equity $ 28.3 $ 22.7 Condensed statements of operations (in millions): For the Year Ended December 31, 2015 2014 2013 Net operating revenues $ 36.5 $ 50.2 $ 74.3 Operating expenses (15.0 ) (25.9 ) (43.6 ) Income from continuing operations, net of tax 18.9 30.9 24.6 Net income 18.9 30.9 24.6 See Note 2, Business Combinations .

Long-term Debt

Long-term Debt	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Long-term Debt	Long-term Debt : Our long-term debt outstanding consists of the following (in millions): As of December 31, 2015 2014 Credit Agreement— Advances under revolving credit facility $ 130.0 $ 325.0 Term loan facilities 443.3 447.5 Bonds payable— 8.125% Senior Notes due 2020 — 282.7 7.75% Senior Notes due 2022 174.3 223.7 5.125% Senior Notes due 2023 294.6 — 5.75% Senior Notes due 2024 1,192.6 447.4 5.75% Senior Notes due 2025 343.4 — 2.00% Convertible Senior Subordinated Notes due 2043 265.9 256.7 Other notes payable 39.2 41.5 Capital lease obligations 288.2 86.7 3,171.5 2,111.2 Less: Current portion (36.8 ) (20.8 ) Long-term debt, net of current portion $ 3,134.7 $ 2,090.4 On December 31, 2015, we adopted ASU 2015-03 and ASU No. 2015-15, which require debt issuance costs related to a recognized debt liability be presented on the consolidated balance sheet as a direct deduction from the debt liability, As of December 31, 2014, $20.4 million of debt issuance costs previously included in Other long-term assets have been reclassified to Long-term debt, net of current portion on our consolidated balance sheet. See Note 1, Summary of Significant Accounting Policies , “Recent Accounting Pronouncements.” The following chart shows scheduled principal payments due on long-term debt for the next five years and thereafter (in millions): Year Ending December 31, Face Amount Net Amount 2016 $ 37.0 $ 37.0 2017 36.1 36.1 2018 36.3 36.3 2019 39.5 39.4 2020 814.2 758.4 Thereafter 2,285.4 2,264.3 Total $ 3,248.5 $ 3,171.5 During 2015, we: • issued, in January 2015, an additional $400 million of our 5.75% Senior Notes due 2024 (the “2024 Notes”) at a price of 102% of the principal amount and used $250 million of the net proceeds to repay borrowings under our term loan facilities, with the remaining net proceeds used to repay borrowings under our revolving credit facility. As a result of the repayment of borrowings under our term loan facility, we recorded a $1.2 million Loss on early extinguishment of debt in the first quarter of 2015; • issued, in March 2015, $300 million of 5.125% Senior Notes due 2023 (the “2023 Notes”) at a price of 100.0% of the principal amount, which resulted in approximately $295 million in net proceeds used for the redemption of our 8.125% Senior Notes due 2020 (the “2020 Notes”) as discussed below; • redeemed, in April 2015, all of our 2020 Notes using the net proceeds from the 2023 Notes offering along with cash on hand. Pursuant to the terms of these notes, this redemption was made at a price of 104.063% , which resulted in a total cash outlay of approximately $302 million to retire the $290 million in principal. As a result of this redemption, we recorded an $18.8 million Loss on early extinguishment of debt in the second quarter of 2015; • amended, in June and July 2015, our existing credit agreement to, among other things, add $500 million of new term loan facilities, increase the amount of specifically permitted capital lease obligations from $200 million to $350 million , change the maximum leverage ratio in the financial covenants applicable for the period July 2015 through June 2017 from 4.25x to 4.5x and to 4.25x from then until maturity, and extend the maturity date for all borrowings to July 2020. Based on our issuance of additional senior notes in August 2015 and September 2015, as discussed below, our availability under the new term loan facilities was reduced to $250 million . In September, we borrowed $125 million of the new term loan facilities, the proceeds of which were used to fund a portion of the Reliant acquisition. In October, we utilized the remaining $125 million of term loan facility capacity to finance a portion of the CareSouth acquisition. See Note 2, Business Combinations ; • issued, in August 2015, an additional $350 million of our 2024 Notes at a price of 100.5% of the principal amount, which resulted in approximately $351 million in net proceeds from the private offering. We used the net proceeds to reduce borrowings under our revolving credit facility and fund a portion of the Reliant acquisition, as discussed in Note 2, Business Combinations ; • issued, in September 2015, $350 million of 5.75% Senior Notes due 2025 (the “2025 Notes”) at a price of 100.0% of the principal amount, which resulted in approximately $344 million in net proceeds from the private offering. We used the net proceeds to fund a portion of the Reliant acquisition, as discussed in Note 2, Business Combinations ; and • redeemed, in November 2015, $50 million of the outstanding principal amount of our existing 7.75% Senior Notes due 2022 (the “2022 Notes”) using borrowings under our senior secured credit facility. Pursuant to the terms of the 2022 Notes, this optional redemption was made at a price of 103.875% , which resulted in a total cash outlay of approximately $52 million . As a result of this redemption, we recorded a $2.4 million Loss on early extinguishment of debt in the fourth quarter of 2015. On February 23, 2016, we gave notice of, and made an irrevocable commitment for, the redemption of $50 million of the outstanding principal amount of the 2022 Notes. Pursuant to the terms of the 2022 Notes, this optional redemption will be at a price of 103.875% , which will result in a total cash outlay of approximately $52 million when the transaction closes, which is expected to be on March 24, 2016. We plan to use cash on hand and capacity under our revolving credit facility to fund the redemption. As a result of this redemption, we expect to record an approximate $2 million loss on early extinguishment of debt in the first quarter of 2016. During 2014, we: • issued, in September 2014, an additional $175 million of our 2024 Notes at a price of 103.625% of the principal amount, which resulted in approximately $182 million in net proceeds from the public offering. We used the net proceeds to redeem our 7.25% Senior Notes due 2018 (the “2018 Notes”) as discussed below; • amended, in September and December 2014, our existing credit agreement to, among other things, add $450 million of term loan facility capacity, permit unlimited restricted payments (as defined in the credit agreement) so long as the senior secured leverage ratio remains less than or equal to 1.75x, and extend the revolver maturity from June 2018 to September 2019; • redeemed, in October 2014, the outstanding principal amount of our 2018 Notes using the net proceeds from the September offering of our 2024 Notes, a $75 million draw under our term loan facilities, and cash on hand. Pursuant to the terms of the 2018 Notes, this redemption was made at a price of 103.625% , which resulted in a total cash outlay of approximately $281 million to retire the approximate $271 million in principal; and • redeemed, in December 2014, approximately $25 million of the outstanding principal amount of our existing 2022 Notes. Pursuant to the terms of the 2022 Notes, this optional redemption represented 10% of the outstanding principal amount of the notes at a price of 103% , which resulted in a total cash outlay of approximately $26 million . We used cash on hand for this redemption. As a result of the above 2014 redemptions, we recorded a $13.2 million Loss on early extinguishment of debt in 2014. Additionally, in December 2014, we drew $375 million under our term loan facilities and $325 million under our revolving credit facility to fund the acquisition of Encompass. See Note 2, Business Combinations . In November 2013, we redeemed approximately $30 million and approximately $28 million of the outstanding principal amount of our existing 2018 Notes and our existing 2022 Notes, respectively. Pursuant to the terms of these senior notes, this optional redemption represented 10% of the outstanding principal amount of the notes at a price of 103% , which resulted in a total cash outlay of approximately $60 million to retire the approximate $58 million in principal. We used a combination of cash on hand and availability under our revolving credit facility for these redemptions. As a result of these redemptions, we recorded a $2.4 million Loss on early extinguishment of debt in 2013. Additionally, in November 2013, we exchanged $320 million in aggregate principal amount of newly issued 2.00% Convertible Senior Subordinated Notes due 2043 for 257,110 shares of our outstanding 6.50% Series A Convertible Perpetual Preferred Stock. See Note 10, Convertible Perpetual Preferred Stock . Senior Secured Credit Agreement— 2015 Credit Agreement In June and July 2015, we amended our existing credit agreement, previously amended on December 23, 2014 (the “Credit Agreement”). The Credit Agreement provides for a $600 million revolving credit facility, with a $260 million letter of credit subfacility and a swingline loan subfacility, all of which mature in July 2020. Outstanding term loan borrowings are payable in equal consecutive quarterly installments, commencing on March 31, 2016, of 1.25% of the aggregate principal amount of the term loans outstanding as of December 31, 2015, with the remainder due at maturity. We have the right at any time to prepay, in whole or in part, any borrowing under the term loan facilities. Amounts drawn on the term loan facilities and the revolving credit facility bear interest at a rate per annum of, at our option, (1) LIBOR or (2) the higher of (a) Barclays’ Bank PLC’s (“Barclays”) prime rate and (b) the federal funds rate plus 0.5% , in each case, plus, in each case, an applicable margin that varies depending upon our leverage ratio. We are also subject to a commitment fee of 0.375% per annum on the daily amount of the unutilized commitments under the term loan facilities and revolving credit facility. The current interest rate on borrowings under the Credit Agreement is LIBOR plus 2.00% . The Credit Agreement contains affirmative and negative covenants and default and acceleration provisions, including a minimum interest coverage ratio and a maximum leverage ratio that change over time. Under one such negative covenant, we are restricted from paying common stock dividends, prepaying certain senior notes, and repurchasing preferred and common equity unless (1) we are not in default under the terms of the Credit Agreement and (2) our senior secured leverage ratio, as defined in the Credit Agreement, does not exceed 1.75x. In the event the senior secured leverage ratio exceeds 1.75x, these payments are subject to a limit of $200 million plus an amount equal to a portion of available excess cash flows each fiscal year. Our obligations under the Credit Agreement are secured by the current and future personal property of the Company and its subsidiary guarantors. The current maximum leverage ratio in the financial covenants is 4.50x. As of Decem ber 31, 2015, $130 million were drawn under the revolving credit facility with an interest rate of 2.3% . Amounts drawn as of December 31 , 2015 exclude $34.2 million utilized under the letter of credit subfacility, which were being used in the ordinary course of business to secure workers’ compensation and other insurance coverages and for general corporate purposes. 2014 Credit Agreement In September and December 2014, we amended our existing credit agreement, previously amended on June 11, 2013 (the “2014 Credit Agreement”). The 2014 Credit Agreement provided for $450 million of term loan capacity and a $600 million revolving credit facility, with a $260 million letter of credit subfacility and a swingline loan subfacility, all of which would have matured in September 2019. Outstanding term loan borrowings were payable in equal consecutive quarterly installments, commencing on March 31, 2015, of 1.25% of the aggregate principal amount of the term loans outstanding as of March 31, 2015 with the remainder due at maturity. The 2014 Credit Agreement contained the same affirmative and negative covenants and default and acceleration provisions as the Credit Agreement, except for the maximum leverage ratio was 4.25x. As of Dec ember 31, 2014, $325 million were drawn under the revolving credit facility with an interest rate of 2.0% . Amounts drawn as of December 31, 2014 excluded $31.8 million utilized under the letter of credit subfacility, which were being used in the ordinary course of business to secure workers’ compensation and other insurance coverages and for general corporate purposes. 2013 Credit Agreement On June 11, 2013, we amended our existing credit agreement, dated August 10, 2012 (the “ 2013 Credit Agreement”). The 2013 Credit Agreement provided for a $600 million revolving credit facility with a $260 million letter of credit subfacility and a swingline loan subfacility, all of which would have matured in June 2018. The 2013 Credit Agreement contained comparable affirmative and negative covenants and default and acceleration provisions as the 2014 Credit Agreement. Our obligations under the 2013 Credit Agreement were secured by substantially all of the real and personal property of us and our subsidiary guarantors, including mortgages with respect to certain of our material real property that we owned as of the date of the 2013 Credit Agreement. Bonds Payable— Nonconvertible Notes The Company’s 2020 Notes, 2022 Notes, 2023 Notes, 2024 Notes, and 2025 Notes (collectively, the “Senior Notes”) were issued pursuant to an indenture (the “Base Indenture”) dated as of December 1, 2009 between us and The Bank of Nova Scotia Trust Company of New York, as trustee (the “Original Trustee”), as supplemented by each Senior Notes respective supplemental indenture (together with the Base Indenture, the “Indenture”), among us, the Subsidiary Guarantors (as defined in the Indenture), and the Original Trustee. The Original Trustee notified us of its intention to discontinue its corporate trust operations and, accordingly, to resign upon the appointment of a successor trustee. Effective July 29, 2013, Wells Fargo Bank, National Association, was appointed as successor trustee under the Indenture. Pursuant to the terms of the Indenture, the Senior Notes are jointly and severally guaranteed on a senior, unsecured basis by all of our existing and future subsidiaries that guarantee borrowings under our Credit Agreement and other capital markets debt (see Note 20, Condensed Consolidating Financial Information ). The Senior Notes are senior, unsecured obligations of HealthSouth and rank equally with our other senior indebtedness, senior to any of our subordinated indebtedness, and effectively junior to our secured indebtedness to the extent of the value of the collateral securing such indebtedness. Upon the occurrence of a change in control (as defined in the Indenture), each holder of the Senior Notes may require us to repurchase all or a portion of the notes in cash at a price equal to 101% of the principal amount of the Senior Notes to be repurchased, plus accrued and unpaid interest. The Senior Notes contain covenants and default and acceleration provisions, that, among other things, limit our and certain of our subsidiaries’ ability to (1) incur additional debt, (2) make certain restricted payments, (3) consummate specified asset sales, (4) incur liens, and (5) merge or consolidate with another person. 2018 and 2022 Notes On October 7, 2010, we completed a public offering of $525.0 million aggregate principal amount of senior notes, which included $275.0 million of 2018 Notes at par and $250.0 million of 2022 Notes at par (collectively, the “2018 and 2022 Senior Notes”). We used the net proceeds from the initial offering of the 2018 and 2022 Senior Notes to repay amounts outstanding under the term loan facility of our former credit agreement dated March 2006. On March 7, 2011, we completed a public offering of $120 million aggregate principal amount of senior notes, which included an additional $60 million of the 2018 Notes at 103.25% of the principal amount and an additional $60 million of the 2022 Notes at 103.50% of the principal amount. Net proceeds from this offering were approximately $122 million . We used approximately $45 million of the net proceeds to repay a portion of the amounts outstanding under our revolving credit facility. In June 2011, the remainder of the net proceeds were used to redeem a portion of our former senior notes due 2016 outstanding at that time. On October 9, 2012, $64.5 million of the net proceeds from our public offering of the 2024 Notes were used to redeem $33.5 million of the outstanding principal amount of our existing 2018 Notes and $31.0 million of the outstanding principal amount of our existing 2022 Notes. The notes were redeemed at a price of 103% , which resulted in an additional cash outlay of $1.9 million from the net proceeds. On November 29, 2013, we redeemed $30.2 million and $27.9 million of the outstanding principal amount of our existing 2018 Notes and our existing 2022 Notes, respectively. Pursuant to the terms of these senior notes, this optional redemption represented 10% of the outstanding principal amount of the notes at a price of 103% , which resulted in a total cash outlay of approximately $60 million to retire the $58.1 million in principal. We used a combination of cash on hand and availability under our revolving credit facility for this redemption. On October 1, 2014, we redeemed the remaining $271.4 million outstanding principal amount of our 2018 Notes. Pursuant to the terms of the 2018 Notes, this redemption was made at a price of 103.625% , which resulted in a total cash outlay of approximately $281 million to retire the $271.4 million in principal. We used the net proceeds from the $175 million September offering of our existing 2024 Notes discussed below, a $75 million draw under our term loan facilities, and cash on hand for this redemption. The 2018 Notes would have matured on October 1, 2018 . Inclusive of financing costs, the effective interest rate on the 2018 Notes was 7.5% . Interest was payable semiannually in arrears on April 1 and October 1 of each year. On December 1, 2014, we redeemed $25.1 million of the outstanding principal amount of our existing 2022 Notes. Pursuant to the terms of the 2022 Notes, this optional redemption represented 10% of the outstanding principal amount of the notes at a price of 103% , which resulted in a total cash outlay of approximately $26 million to retire the $25.1 million in principal. We used cash on hand for this redemption. On November 30, 2015, we redeemed $50.0 million of the outstanding principal amount of our existing 2022 Notes. Pursuant to the terms of the 2022 Notes, this optional redemption was made at a price of 103.875% , which resulted in a total cash outlay of approximately $52 million . We used cash borrowings under our senior secured credit facility to fund the redemption. 2022 Notes The 2022 Notes mature on September 15, 2022 and bear interest at a per annum rate of 7.75% . Inclusive of financing costs, the effective interest rate on the 2022 Notes is 7.9% . Interest is payable semiannually in arrears on March 15 and September 15 of each year. We may redeem the 2022 Notes, in whole or in part, at any time on or after September 15, 2015, at the redemption prices set forth below: Period Redemption Price* 2015 103.875 % 2016 102.583 % 2017 101.292 % 2018 and thereafter 100.000 % * Expressed in percentage of principal amount 2020 Notes In December 2009, we issued $290.0 million of the 2020 Notes at 98.327% of par. We used the net proceeds from this transaction along with cash on hand to tender for and redeem all of our former floating rate senior notes due 2014 outstanding at that time. If not for the April 2015 redemption as discussed above, the 2020 Notes would have matured on February 15, 2020. Inclusive of discounts and financing costs, the effective interest rate on the 2020 Notes was 8.7% . Interest was payable semiannually in arrears on February 15 and August 15 of each year. 2023 Notes On March 12, 2015, we issued $300 million of the 2023 Notes at a price of 100.0% of the principal amount, which resulted in approximately $295 million in net proceeds from the public offering. The 2023 Notes mature on March 15, 2023 and bear interest at a per annum rate of 5.125% . Interest on the 2023 Notes is payable semiannually in arrears on March 15 and September 15, beginning on September 15, 2015. We may redeem the 2023 Notes, in whole or in part, at any time on or after March 15, 2018 at the redemption prices set forth below: Period Redemption Price* 2018 103.844 % 2019 102.563 % 2020 101.281 % 2021 and thereafter 100.000 % * Expressed in percentage of principal amount 2024 Notes On September 11, 2012, we completed a public offering of $275 million aggregate principal amount of the 2024 Notes at a public offering price of 100% of the principal amount. Net proceeds from this offering were approximately $270 million . We used $195 million of the net proceeds to repay the amounts outstanding under our revolving credit facility. Additionally, in October 2012, $64.5 million of the net proceeds were used to redeem a portion of our 2018 and 2022 Senior Notes. On September 18, 2014, we issued an additional $175 million of the 2024 Notes at a price of 103.625% of the principal amount, which resulted in approximately $182 million in net proceeds from the public offering. We used the net proceeds to redeem the 2018 Notes, as discussed above. On January 29, 2015, we issued an additional $400 million of the 2024 Notes at a price of 102% of the principal amount, which resulted in approximately $406 million in net proceeds from the public offering. We used $250 million of the net proceeds to repay borrowings under our term loan facilities, with the remaining net proceeds used to repay borrowings under our revolving credit facility. On August 7, 2015, we issued an additional $350 million of our 2024 Notes at a price of 100.5% of the principal amount, which resulted in approximately $351 million in net proceeds from the private offering. We used the net proceeds to reduce borrowings under our revolving credit facility and fund a portion of the Reliant acquisition, as discussed in Note 2, Business Combinations. The 2024 Notes mature on November 1, 2024 and bear interest at a per annum rate of 5.75% . Inclusive of financing costs, the effective interest rate on the 2024 Notes is 5.8% . Interest is payable semiannually in arrears on May 1 and November 1 of each year. We may redeem the 2024 Notes, in whole or in part, at any time on or after November 1, 2017, at the redemption prices set forth below: Period Redemption Price* 2017 102.875 % 2018 101.917 % 2019 100.958 % 2020 and thereafter 100.000 % * Expressed in percentage of principal amount 2025 Notes On September 16, 2015, we issued $350 million of the 2025 Notes at a price of 100.0% of the principal amount, which resulted in approximately $344 million in net proceeds from the private offering. We used the net proceeds from this borrowing to fund a portion of the Reliant acquisition. The 2025 Notes mature on September 15, 2025 and bear interest at a per annum rate of 5.75% . Interest on the 2025 Notes is payable semiannually in arrears on March 15 and September 15, beginning on March 15, 2016. We may redeem the 2025 Notes, in whole or in part, at any time on or after September 15, 2020, at the redemption prices set forth below: Period Redemption Price* 2020 102.875 % 2021 101.917 % 2022 100.958 % 2023 and thereafter 100.000 % * Expressed in percentage of principal amount Convertible Notes Convertible Senior Subordinated Notes Due 2043 On November 18, 2013, we exchanged $320 million in aggregate principal amount of newly issued 2.00% Convertible Senior Subordinated Notes due 2043 (the “Convertible Notes”) for 257,110 shares of our outstanding 6.50% Series A Convertible Perpetual Preferred Stock. The Company’s Convertible Notes were issued pursuant to an indenture dated November 18, 2013 (the “Convertible Notes Indenture”) between us and Wells Fargo Bank, National Association, as trustee and conversion agent. The Convertible Notes are senior subordinated unsecured obligations of the Company. As such, the Convertible Notes are subordinated to all our existing and future senior unsecured debt and are effectively subordinated to our existing and future secured debt to the extent of the value of the collateral securing such debt. Additionally, the Convertible Notes are structurally subordinated to all existing and future debt and other obligations of our subsidiaries. The Convertible Notes bear regular interest at a rate of 2.0% per year payable semiannually in arrears in cash on June 1 and December 1 of each year . Beginning with the six-month period starting December 1, 2018, contingent interest is payable, in addition to regular interest, if the trading price of the Convertible Notes for each of the five trading days ending two trading days prior to any six-month contingent interest period is equal to or greater than $1,200. The amount of contingent interest payable per $1,000 principal amount of the Convertible Notes in respect of any contingent interest period is equal to 0.25% of the average trading price of the Convertible Notes during the specified measurement period. Due to discounts and financing costs, the effective interest rate on the Convertible Notes is 6.0% . The Convertible Notes mature on December 1, 2043 , unless earlier redeemed, repurchased, or converted. The Convertible Notes are convertible, at the option of the holder, at any time on or prior to the close of business on the business day immediately preceding December 1, 2043 into shares of our common stock at an initial conversion rate of 25.2194 shares per $1,000 principal amount of the Convertible Notes, subject to customary antidilution adjustments. This conversion rate equates to an initial conversion price of $39.652 per share. We may elect to settle any conversion, in whole or in part, by delivering cash in lieu of shares. Upon the occurrence of certain change of control events and a redemption prior to December 2018, in either case, in connection with elections by holders to convert their Convertible Notes, we will pay a make-whole premium on any Convertible Notes converted by increasing the conversion rate on such Convertible Notes. The payment of dividends on our common stock has triggered and will continue to trigger, from time to time, the antidilutive adjustment provisions of the Convertible Notes, except in instances when such adjustments are deemed de minimis . The current conversion price of the Convertible Notes is $38.08 , and the current conversion rate i s 26.2583 for each $1,000 principal amount of the Convertible Notes. Prior to December 1, 2018, we may redeem all or any part of the Convertible Notes if the volume weighted-average price per share of our common stock is at least 120% of the conversion price of the Convertible Notes for at least 20 trading days during any 30 consecutive trading day period, at a redemption price equal to 100% of the principal amount of Convertible Notes to be redeemed, plus accrued and unpaid interest, provided that, as described above, the holders may elect to convert their Convertible Notes in lieu of the redemption and receive any make-whole premium due. On or after December 1, 2018, we may, at our option, redeem all or any part of the Convertible Notes at a redemption price equal to 100% of the principal amount of the Convertible Notes to be redeemed, plus accrued and unpaid interest. Upon the occurrence of a fundamental change (as defined in the Convertible Notes Indenture), each holder of the Convertible Notes may require us to repurchase for cash all or any portion of such holders’ Convertible Notes at a price equal to 100% of the principal amount of the repurchased Convertible Notes, plus accrued and unpaid interest thereon to, but excluding, the repurchase date and, if the fundamental change also constitutes a nonstock change of control (as defined in the Convertible Notes Indenture), the amount of any make-whole premium due. Holders may, at their option, also require us to repurchase all or any portion of such holders’ Convertible Notes on December 1 of 2020, 2027, 2034, and 2041 at a price equal to 100% of the principal amount of the repurchased Convertible Notes, plus accrued and unpaid interest thereon to, but excluding, the repurchase date. The Convertible Notes Indenture contains customary events of default, which includes, among other things, a default in the obligation of the Company to convert the Convertible Notes that continues for five business days. See also Note 10, Convertible Perpetual Preferred Stock . Other Notes Payable— Our notes payable consist of the following (in millions): As of December 31, 2015 2014 Interest Rates Sale/leaseback transactions involving real estate accounted for as financings $ 28.0 $ 28.0 8.1% to 11.2% Acquisition of an inpatient rehabilitation unit 1.3 2.9 7.8% Construction of a new hospital 9.6 10.3 LIBOR + 2.5%; Other 0.3 0.3 6.8% Other notes payable $ 39.2 $ 41.5 Capital Lease Obligations— We engage in a significant number of leasing transactions including real estate and other equipment utilized in operations. Leases meeting certain accounting criteria have been recorded as an asset and liability at the lower of fair value or the net present value of the aggregate future minimum lease payments at the inception of the lease. Interest rates used in computing the net present value of the lease payments generally ranged from 2% to 11% based on our incremental borrowing rate at the inception of the lease. Our leasing transactions include arrangements for vehicles with major finance companies and manufacturers who retain ownership in the equipment during the term of the lease and with a variety of both small and large real estate owners.

Self-Insured Risks

Self-Insured Risks	12 Months Ended
	Dec. 31, 2015
Self-Insured Risks [Abstract]
Self-Insured Risks	Self-Insured Risks : We insure a substantial portion of our professional liability, general liability, and workers’ compensation risks through a self-insured retention program (“SIR”) underwritten by our consolidated wholly owned offshore captive insurance subsidiary, HCS, Ltd., which we fund via regularly scheduled premium payments. HCS is an insurance company licensed by the Cayman Island Monetary Authority. We use HCS to fund our first layer of insurance coverage up to approximately $25 million for annual aggregate losses associated with general and professional liability risks. Workers’ compensation exposures are capped on a per claim basis. Risks in excess of specified limits per claim and in excess of our aggregate SIR amount are covered by unrelated commercial carriers. The following table presents the changes in our self-insurance reserves for the years ended December 31, 2015 , 2014 , and 2013 (in millions): 2015 2014 2013 Balance at beginning of period, gross $ 134.3 $ 140.3 $ 148.3 Less: Reinsurance receivables (26.0 ) (32.6 ) (29.4 ) Balance at beginning of period, net 108.3 107.7 118.9 Increase for the provision of current year claims 37.1 34.7 34.4 Decrease for the provision of prior year claims (4.6 ) (3.5 ) (5.9 ) Decrease related to change in statistical confidence level — — (6.7 ) Expenses related to discontinued operations (0.5 ) (0.3 ) (1.8 ) Payments related to current year claims (4.7 ) (4.4 ) (3.9 ) Payments related to prior year claims (22.5 ) (25.9 ) (27.3 ) Acquisitions 2.4 — — Balance at end of period, net 115.5 108.3 107.7 Add: Reinsurance receivables 26.6 26.0 32.6 Balance at end of period, gross $ 142.1 $ 134.3 $ 140.3 As of December 31, 2015 and 2014 , $40.5 million and $35.6 million , respectively, of these reserves are included in Other current liabilities in our consolidated balance sheets. Provisions for these risks are based primarily upon actuarially determined estimates. These reserves represent the unpaid portion of the estimated ultimate cost of all reported and unreported losses incurred through the respective consolidated balance sheet dates. The reserves are estimated using individual case-basis valuations and actuarial analyses. Those estimates are subject to the effects of trends in loss severity and frequency. The estimates are continually reviewed and adjustments are recorded as experience develops or new information becomes known. The changes to the estimated ultimate loss amounts are included in current operating results. In the years leading up to 2013, we experienced volatility in our estimates of prior year claim reserves due primarily to favorable trends in claims and industry-wide loss development trends. Our efforts to improve patient safety and overall quality of care, as well as our efforts to reduce workplace injuries, helped contain our ultimate claim costs. With the accumulation of this additional historical data and favorable trends, when we analyzed our assumptions during our semi-annual review of our self-insurance reserves in the fourth quarter of 2013, we lowered the statistical confidence level used to determine our self-insurance reserves from 70% to 50% . This change reduced our reserves included in continuing operations by $6.7 million in the fourth quarter of 2013. The reserves for these self-insured risks cover approximately 1,100 individual claims at December 31, 2015 and 2014 , and estimates for potential unreported claims. The time period required to resolve these claims can vary depending upon the jurisdiction, the nature, and the form of resolution of the claims. The estimation of the timing of payments beyond a year can vary significantly. Although considerable variability is inherent in reserve estimates, management believes the reserves for losses and loss expenses are adequate; however, there can be no assurance the ultimate liability will not exceed management’s estimates.

Convertible Perpetual Preferred

Convertible Perpetual Preferred Stock	12 Months Ended
	Dec. 31, 2015
Convertible Perpetual Preferred Stock [Abstract]
Convertible Perpetual Preferred Stock	Convertible Perpetual Preferred Stock : On March 7, 2006 , we completed the sale of 400,000 shares of our 6.50% Series A Convertible Perpetual Preferred Stock. The preferred stock has a liquidation preference of $1,000 per share of preferred stock, which is contingently subject to accretion. Holders of the preferred stock are entitled to receive, when and if declared by our board of directors, cash dividends at the rate of 6.50% per annum on the accreted liquidation preference per share, payable quarterly in arrears. Dividends on the preferred stock are cumulative. Each holder of preferred stock has one vote for each share held by the holder on all matters voted upon by the holders of our common stock. The preferred stock is convertible, at the option of the holder, at any time into shares of our common stock. We may at any time cause the shares of preferred stock to be automatically converted into shares of our common stock at the conversion rate then in effect if the closing sale price of our common stock for 20 trading days within a period of 30 consecutive trading days ending on the trading day before the date we give the notice of forced conversion exceeds 150% of the conversion price of the preferred stock. If we are subject to a fundamental change, as defined in the certificate of designation of the preferred stock, each holder of shares of preferred stock has the right, subject to certain limitations, to require us to purchase with cash any or all of its shares of preferred stock at a purchase price equal to 100% of the accreted liquidation preference, plus any accrued and unpaid dividends to the date of purchase. In addition, if holders of the preferred stock elect to convert shares of preferred stock in connection with certain fundamental changes, we will in certain circumstances increase the conversion rate for such shares of preferred stock. As redemption of the preferred stock is contingent upon the occurrence of a fundamental change, and since we do not deem a fundamental change probable of occurring, accretion of our Convertible perpetual preferred stock is not necessary. The agreement underlying the preferred stock includes antidilutive protection that requires adjustments to the number of shares of common stock issuable upon conversion and the exercise price for common stock upon the occurrence of certain events, including payment of cash dividends on our common stock after a de minimis threshold. At issuance, the preferred stock had a conversion price of $30.50 per share, which was equal to an initial conversion rate of 32.7869 shares of common stock per share of preferred stock. In the fourth quarter of 2013, we exchanged $320.0 million in aggregate principal amount of newly issued 2.00% Convertible Senior Subordinated Notes due 2043 for 257,110 shares of our outstanding preferred stock. No common stock was issued as part of these exchange transactions. See Note 8, Long-term Debt . On April 22, 2015, we delivered notice of the exercise of our rights to force conversion of all outstanding shares of our Convertible perpetual preferred stock (par value of $0.10 per share and liquidation preference of $1,000 per share) pursuant to the underlying certificate of designations. The effective date of the conversion was April 23, 2015. On that date, each share of preferred stock automatically converted into 33.9905 shares of our common stock (par value of $0.01 per share). We completed the forced conversion by issuing and delivering in the aggregate 3,271,415 shares of our common stock to the registered holders of the 96,245 shares of the preferred stock outstanding and paying cash in lieu of fractional shares due to those holders. The following is a summary of the activity related to our Convertible perpetual preferred stock from December 31, 2012 to December 31, 2015 (in millions, except share data): Number of Shares Outstanding Amount Balance as of December 31, 2012 353,355 $ 342.2 Repurchase of preferred stock (257,110 ) (249.0 ) Balance as of December 31, 2013 and 2014 96,245 93.2 Conversion of preferred stock (96,245 ) (93.2 ) Balance as of December 31, 2015 — $ — The allocation of the consideration exchanged for repurchases of preferred stock is as follows (in millions): For the Year Ended December 31, 2013 Carrying value of shares repurchased $ 249.0 Cumulative dividends included as part of repurchase price 2.2 Excess exchanged in transaction 71.6 $ 322.8 For 2013, the difference between the fair value of the consideration paid to the holders of the preferred stock, or $322.8 million (including fees), and the carrying value of the preferred stock in our balance sheet, or $249.0 million , resulted in a charge of $73.8 million to Capital in excess of par value that was treated like a dividend and subtracted from Net income to arrive at Net income attributable to HealthSouth common shareholders in our consolidated statement of operations. Of this amount, $2.2 million represents cumulative dividends through the date of the repurchase transactions. We declared $1.6 million , $6.3 million , and $21.0 million in dividends on our preferred stock in the years ended December 31, 2015, 2014, and 2013, respectively. As of December 31, 2014, accrued dividends of $1.6 million were included in Other current liabilities on our consolidated balance sheet and was paid in January 2015 .

Redeemable Noncontrolling Inter

Redeemable Noncontrolling Interests	12 Months Ended
	Dec. 31, 2015
Redeemable Noncontrolling Interests [Abstract]
Redeemable Noncontolling Interests	Redeemable Noncontrolling Interests The following is a summary of the activity related to our Redeemable noncontrolling interests (in millions): For the Year Ended December 31, 2015 2014 2013 Balance at beginning of period $ 84.7 $ 13.5 $ 7.2 Acquisition of Encompass — 64.5 — Net income attributable to noncontrolling interests 13.8 6.6 5.8 Distributions (7.3 ) (8.5 ) (4.9 ) Contribution to joint venture — 4.3 7.1 Change in fair value 29.9 4.3 (1.7 ) Balance at end of period $ 121.1 $ 84.7 $ 13.5 The following table reconciles the net income attributable to nonredeemable Noncontrolling interests , as recorded in the shareholders’ equity section of the consolidated balance sheets, and the net income attributable to Redeemable noncontrolling interests , as recorded in the mezzanine section of the consolidated balance sheets, to the Net income attributable to noncontrolling interests presented on the consolidated statements of operations (in millions): For the Year Ended December 31, 2015 2014 2013 Net income attributable to nonredeemable noncontrolling interests $ 55.9 $ 53.1 $ 52.0 Net income attributable to redeemable noncontrolling interests 13.8 6.6 5.8 Net income attributable to noncontrolling interests $ 69.7 $ 59.7 $ 57.8 See also Note 2, Business Combinations .

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements : Our financial assets and liabilities that are measured at fair value on a recurring basis are as follows (in millions): Fair Value Measurements at Reporting Date Using As of December 31, 2015 Fair Value Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Valuation Technique (1) Prepaid expenses and other current assets: Current portion of restricted marketable securities $ 16.1 $ — $ 16.1 $ — M Other long-term assets: Restricted marketable securities 40.1 — 40.1 — M Redeemable noncontrolling interests 121.1 — — 121.1 I As of December 31, 2014 Prepaid expenses and other current assets: Current portion of restricted marketable securities $ 4.6 $ — $ 4.6 $ — M Other long-term assets: Option to purchase SCA stock 9.9 — — 9.9 M Restricted marketable securities 45.9 — 45.9 — M Redeemable noncontrolling interests 84.7 — — 84.7 I (1) The three valuation techniques are: market approach (M), cost approach (C), and income approach (I). In connection with the 2007 sale of our surgery centers division, now known as Surgical Care Affiliates (“SCA”), to ASC Acquisition LLC, an affiliate of TPG Partners V, L.P. (“TPG”), a private investment partnership, we received an option, subject to terms and conditions set forth below, to purchase up to a 5% equity interest in SCA. The price of the option was equal to the original issuance price of the units subscribed for by TPG and certain other co-investors in connection with the acquisition plus a 15% premium, compounded annually. The option had a term of ten years and was exercisable upon certain liquidity events, including a public offering of SCA’s shares of common stock that resulted in 30% or more of SCA’s common stock being listed or traded on a national securities exchange. On November 4, 2013, SCA announced the closing of its initial public offering, which did not reach the 30% threshold to trigger a qualifying liquidity event. During the second quarter of 2014, we entered into an amendment to the option agreement that required us to settle the option net of our exercise price. The addition of this new feature resulted in the option becoming a derivative that must be recorded as an asset or liability on our consolidated balance sheet and marked to market each period. As of December 31, 2014, the fair value of this option was $9.9 million and is included in Other long-term assets in our consolidated balance sheet. Income from discontinued operations, net of tax for the year ended December 31, 2014 included a $9.9 million gain resulting from the initial recording of this option as a derivative and its fair value adjustments during 2014. Income from discontinued operations, net of tax for the year ended December 31, 2015 included a $0.4 million net loss resulting from the change in fair value of this option from December 31, 2014 to March 31, 2015. On April 1, 2015, TPG closed a secondary offering of SCA common stock, which resulted in greater than 30% of SCA’s common stock being listed or traded on a national securities exchange, and our option became exercisable. On April 9, 2015, we delivered notice of exercise of the option to SCA. On April 13, 2015, SCA settled the net exercise of the option by delivering to us 326,242 shares of SCA common stock. The closing price of the stock on that date was $35.43 per share. Other income for the year ended December 31, 2015 included a $2.0 million gain resulting from the change in fair value of this option from April 1, 2015, the date the option became exercisable, to April 13, 2015, the date we settled the net exercise of the option and received shares of SCA common stock. During the second and third quarter of 2015, we sold all of our shares of SCA common stock resulting in a realized gain of $1.2 million that is included in Other income in our consolidated statements of operations for the year ended December 31, 2015 . The fair value of the option and related adjustments were determined using a lattice model. Inputs into the model included the historical price volatility of SCA’s common stock, the risk free interest rate, and probability factors for the timing of when the option will be exercisable. In addition to assets and liabilities recorded at fair value on a recurring basis, we are also required to record assets and liabilities at fair value on a nonrecurring basis. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges or similar adjustments made to the carrying value of the applicable assets. During the year ended December 31, 2015 , we did not record any gains or losses related to our nonfinancial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a nonrecurring basis as part of our continuing operations. As a result of our consolidation of Fairlawn in 2014 and the remeasurement of our previously held equity interest at fair value, we recorded a $27.2 million gain as part of Other income during the year ended December 31, 2014. We determined the fair value of our previously held equity interest using the income approach. The income approach included the use of Fairlawn’s projected operating results and cash flows discounted using a rate that reflects market participant assumptions. The projected operating results used management’s best estimates of economic and market conditions over the forecasted period including assumptions for pricing and volume, operating expenses, and capital expenditures. See Note 2, Business Combinations . As discussed in Note 1, Summary of Significant Accounting Policies , “Fair Value Measurements,” the carrying value equals fair value for our financial instruments that are not included in the table below and are classified as current in our consolidated balance sheets. The carrying amounts and estimated fair values for our other financial instruments are presented in the following table (in millions): As of December 31, 2015 As of December 31, 2014 Carrying Amount Estimated Fair Value Carrying Amount Estimated Fair Value Long-term debt: Advances under revolving credit facility $ 130.0 $ 130.0 $ 325.0 $ 325.0 Term loan facilities 443.3 445.0 447.5 450.0 8.125% Senior Notes due 2020 — — 282.7 302.5 7.75% Senior Notes due 2022 174.3 183.7 223.7 240.7 5.125% Senior Notes due 2023 294.6 288.0 — — 5.75% Senior Notes due 2024 1,192.6 1,146.0 447.4 471.4 5.75% Senior Notes due 2025 343.4 332.5 — — 2.00% Convertible Senior Subordinated Notes due 2043 265.9 345.0 256.7 358.4 Other notes payable 39.2 39.2 41.5 41.5 Financial commitments: Letters of credit — 34.2 — 31.8 Fair values for our long-term debt and financial commitments are determined using inputs, including quoted prices in nonactive markets, that are observable either directly or indirectly, or Level 2 inputs within the fair value hierarchy. See Note 1, Summary of Significant Accounting Policies , “Fair Value Measurements.” See also Note 11, Redeemable Noncontrolling Interests .

Share-Based Payments

Share-Based Payments	12 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	Share-Based Payments : The Company has awarded employee stock-based compensation in the form of stock options, SARs, and restricted stock awards under the terms of share-based incentive plans designed to align employee and executive interests to those of its stockholders. Excluding SARs issued in 2014, all employee stock-based compensation awarded in 2015, 2014, and 2013 was issued under the Amended and Restated 2008 Equity Incentive Plan, a stockholder-approved plan that reserves and provides for the grant of up to nine million shares of common stock. This plan allows the grants of nonqualified stock options, incentive stock options, restricted stock, stock appreciation rights, performance shares, performance share units, dividend equivalents, restricted stock units (“RSUs”), and/or other stock-based awards. Stock Options— Under our share-based incentive plans, officers and employees are given the right to purchase shares of HealthSouth common stock at a fixed grant price determined on the day the options are granted. The terms and conditions of the options, including exercise prices and the periods in which options are exercisable, are generally at the discretion of the compensation committee of our board of directors. However, no options are exercisable beyond ten years from the date of grant. Granted options vest over the awards’ requisite service periods, which are generally three years. The fair values of the options granted during the years ended December 31, 2015 , 2014 , and 2013 have been estimated at the grant date using the Black-Scholes option-pricing model with the following weighted-average assumptions: For the Year Ended December 31, 2015 2014 2013 Expected volatility 39.5 % 40.3 % 41.8 % Risk-free interest rate 1.9 % 2.2 % 1.4 % Expected life (years) 7.7 7.2 7.2 Dividend yield 2.1 % 2.1 % 0.0 % The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options which have no vesting restrictions and are fully transferable. In addition, option-pricing models require the input of highly subjective assumptions, including the expected stock price volatility. We estimate our expected term through an analysis of actual, historical post-vesting exercise, cancellation, and expiration behavior by our employees and projected post-vesting activity of outstanding options. We calculate volatility based on the historical volatility of our common stock over the period commensurate with the expected life of the options. The risk-free interest rate is the implied daily yield currently available on U.S. Treasury issues with a remaining term closely approximating the expected term used as the input to the Black-Scholes option-pricing model. While our board of directors initiated quarterly cash dividends on our common stock in 2013 (see Note 16, Earnings per Common Share ), we did not include a dividend payment as part of our pricing model in 2013 because we had not historically paid dividends at the time of our option grants. In 2015 and 2014, we estimated our dividend yield based on our annual dividend rate and our stock price on the dividend payment dates. We estimate forfeitures through an analysis of actual, historical pre-vesting option forfeiture activity. Under the Black-Scholes option-pricing model, the weighted-average fair value per share of employee stock options granted during the years ended December 31, 2015 , 2014 , and 2013 was $15.11 , $11.41 , and $10.96 , respectively. A summary of our stock option activity and related information is as follows: Shares (In Thousands) Weighted- Average Exercise Price per Share Weighted- Average Remaining Life (Years) Aggregate Intrinsic Value (In Millions) Outstanding, December 31, 2014 2,207 $ 20.85 Granted 108 43.14 Exercised (257 ) 26.06 Forfeitures (2 ) 24.85 Expirations — — Outstanding, December 31, 2015 2,056 21.37 4.1 $ 28.5 Exercisable, December 31, 2015 1,811 19.47 3.5 27.8 We recognized approximatel y $1.6 million , $1.9 million , and $2.1 million of compensation expense related to our stock options for the years ended December 31, 2015 , 2014 , and 2013 , respectively. As of December 31, 2015 , there was $1.8 million o f unrecognized compensation cost related to unvested stock options. This cost is expected to be recognized over a weighted-average period of 21 months. The total intrinsic value of options exercised during the years ended December 31, 2015 , 2014 , and 2013 was $4.2 million , $2.4 million , and $1.9 million , respectively. Stock Appreciation Rights— In conjunction with the Encompass acquisition, we granted SARs based on Holdings’ common stock to certain members of Encompass management at closing on December 31, 2014. Under a separate plan, we granted 122,976 SARs that vest based on continued employment and an additional 129,124 SARs that vest based on continued employment and the extent of Encompass’ attainment of a target 2017 specified performance measure. In general terms, half of the SARs of each type will vest on December 31, 2018 with the remainder vesting on December 31, 2019. The SARs that ultimately vest will expire on the tenth anniversary of the grant date or within a specified period following any earlier termination of employment. Upon exercise, each SAR must be settled for cash in the amount by which the per share fair value of Holdings’ common stock on the exercise date exceeds the agreed upon per share fair value on the acquisition date. The fair value of Holdings’ common stock is determined using the product of the trailing 12-month specified performance measure for Holdings and a specified median market price multiple based on a basket of public home health companies. The fair values of the SARs granted in conjunction with the Encompass acquisition have been estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions: an expected volatility of 30.7% , risk-free interest rate of 2.1% , and an expected life of 6.3 years. We did not include a dividend payment as part of our pricing model because Holdings currently does not pay dividends on their common stock. Under the Black-Scholes option-pricing model, the weighted-average fair value per share of SARs granted in conjunction with the Encompass acquisition was $64.09 . We recognized approximately $3.5 million of compensation expense related to our SARs for the year ended December 31, 2015 . As of December 31, 2015 , there was $12.2 million of unrecognized compensation cost related to unvested SARs. This cost is expected to be recognized over a weighted-average period of 6.25 years. As of December 31, 2015 , 252,100 SARs were outstanding. Restricted Stock— The restricted stock awards granted in 2015 , 2014 , and 2013 included service-based awards, performance-based awards (that also included a service requirement), and market condition awards (that also included a service requirement). These awards generally vest over a three-year requisite service period. For awards with a service and/or performance requirement, the fair value of the award is determined by the closing price of our common stock on the grant date. For awards with a market condition, the fair value of the awards is determined using a lattice model. Inputs into the model include the historical price volatility of our common stock, the historical volatility of the common stock of the companies in the defined peer group, and the risk-free interest rate. Utilizing these inputs and potential future changes in stock prices, multiple trials are run to determine the fair value. A summary of our issued restricted stock awards is as follows (share information in thousands): Shares Weighted-Average Grant Date Fair Value Nonvested shares at December 31, 2014 1,197 $ 23.31 Granted 689 27.86 Vested (1,005 ) 22.18 Forfeited (39 ) 30.03 Nonvested shares at December 31, 2015 842 28.05 The weighted-average grant date fair value of restricted stock granted during the years ended December 31, 2014 and 2013 was $23.94 and $23.55 per share, respectively. We recognized approximate ly $19.5 million , $20.8 million , and $21.6 million of compensation expense related to our restricted stock awards for the years ended December 31, 2015 , 2014 , and 2013 , respectively. As of December 31, 2015 , there was $16.2 million of unrecognized compensation expense related to unvested restricted stock. This cost is expected to be recognized over a weighted-average period of 21 months. T he remaining unrecognized compensation expense for the performance-based awards may vary each reporting period based on changes in the expected achievement of performance measures. The total fair value of shares vested during the years ended December 31, 2015 , 2014 , and 2013 wa s $41.0 million , $25.9 million , and $15.7 million , respectively. Nonemployee Stock-Based Compensation Plans— During the years ended December 31, 2015 , 2014 , and 2013 , we provided incentives to our nonemployee members of our board of directors through the issuance of RSUs out of our share-based incentive plans. RSUs are fully vested when awarded and receive dividend equivalents in the form of additional RSUs upon the payment of a cash dividend on our common stock. During the years ended December 31, 2015 , 2014 , and 2013 , we issued 30,744 , 36,350 , and 51,180 RSUs, respectively, with a fair value of $42.46 , $33.02 , and $22.47 , respectively, per unit. We recognized approximately $1.3 million , $1.2 million , and $1.2 million , respectively, of compensation expense upon their issuance in 2015 , 2014 , and 2013 . There was no unrecognized compensation related to unvested shares as of December 31, 2015 . During the years ended Decemb er 31, 2015, 2014, and 2013, we issued an a dditional 7,645 , 8,149 , and 1,831 , respectively, of RSUs as dividend equivalents. As of December 31, 2015 , 391,855 RSUs were ou tstanding.

Employee Benefit Plans

Employee Benefit Plans	12 Months Ended
	Dec. 31, 2015
Employee Benefit Plans [Abstract]
Employee Benefit Plans	Employee Benefit Plans : Substantially all HealthSouth hospital employees are eligible to enroll in HealthSouth-sponsored healthcare plans, including coverage for medical and dental benefits. Our primary healthcare plans are national plans administered by third-party administrators. We are self-insured for these plans. During 2015 , 2014 , and 2013 , costs associated with these plans, net of amounts paid by employees, approximated $109.3 million , $85.2 million , and $73.4 million , respectively. The HealthSouth Retirement Investment Plan is a qualified 401(k) savings plan. The plan allows eligible employees to contribute up to 100% of their pay on a pre-tax basis into their individual retirement account in the plan subject to the normal maximum limits set annually by the Internal Revenue Service. HealthSouth’s employer matching contribution is 50% of the first 6% of each participant’s elective deferrals . All contributions to the plan are in the form of cash. Employees who are at least 21 years of age are eligible to participate in the plan. Employer contributions vest 100% after three years of service. Participants are always fully vested in their own contributions. Employer contributions to the HealthSouth Retirement Investment Plan approximated $15.0 million , $13.9 million , and $13.2 million in 2015 , 2014 , and 2013 , respectively. In 2015 , 2014 , and 2013 , approximately $0.9 million , $0.5 million , and $0.5 million , respectively, from the plan’s forfeiture account were used to fund the matching contributions in accordance with the terms of the plan. Senior Management Bonus Program— We maintain a Senior Management Bonus Program to reward senior management for performance based on a combination of corporate or regional goals and individual goals. The corporate and regional goals are approved on an annual basis by our board of directors as part of our routine budgeting and financial planning process. The individual goals, which are weighted according to importance, are determined between each participant and his or her immediate supervisor. The program applies to persons who join the Company in, or are promoted to, senior management positions. In 2016 , we expect to pay approximately $9.1 million under the program for the year ended December 31, 2015 . In February 2015 and 2014 , we paid $9.0 million and $11.5 million , respectively, under the program for the years ended December 31, 2014 and 2013 .

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes : The significant components of the Provision for income tax expense related to continuing operations are as follows (in millions): For the Year Ended December 31, 2015 2014 2013 Current: Federal $ 2.6 $ 2.5 $ 0.9 State and other 12.2 10.8 5.4 Total current expense 14.8 13.3 6.3 Deferred: Federal 113.9 95.3 11.3 State and other 13.2 2.1 (4.9 ) Total deferred expense 127.1 97.4 6.4 Total income tax expense related to continuing operations $ 141.9 $ 110.7 $ 12.7 A reconciliation of differences between the federal income tax at statutory rates and our actual income tax expense on our income from continuing operations, which include federal, state, and other income taxes, is presented below: For the Year Ended December 31, 2015 2014 2013 Tax expense at statutory rate 35.0 % 35.0 % 35.0 % Increase (decrease) in tax rate resulting from: State and other income taxes, net of federal tax benefit 3.6 % 4.3 % 4.0 % Increase (decrease) in valuation allowance 1.2 % (1.9 )% (2.3 )% Settlement of tax claims 0.1 % — % (28.7 )% Noncontrolling interests (5.3 )% (5.1 )% (5.1 )% Acquisition of additional equity interest in Fairlawn — % (3.6 )% — % Other, net 1.3 % (0.1 )% 0.3 % Income tax expense 35.9 % 28.6 % 3.2 % The Provision for income tax expense in 2015 was greater than the federal statutory rate primarily due to: 1) state and other income tax expense and (2) an increase in our valuation allowance offset by (3) the impact of noncontrolling interests. See Note 1, Summary of Significant Accounting Policies , “Income Taxes,” for a discussion of the allocation of income or loss related to pass-through entities, which is referred to as the impact of noncontrolling interests in this discussion. The increase in our valuation allowance in 2015 related primarily to changes to our state apportionment percentages resulting from the acquisitions of Encompass, Reliant, and CareSouth and changes to our current forecast of earnings in each jurisdiction. The Provision for income tax expense in 2014 was less than the federal statutory rate primarily due to: (1) the impact of noncontrolling interests, (2) the nontaxable gain discussed in Note 2, Business Combinations , related to our acquisition of an additional 30% equity interest in Fairlawn, and (3) a decrease in our valuation allowance offset by (4) state and other income tax expense. As a result of the Fairlawn transaction, we released the deferred tax liability associated with the outside tax basis of our investment in Fairlawn because we now possess sufficient ownership to allow for the historical outside tax basis difference to be resolved through a tax-free transaction in the future. The Provision for income tax expense in 2013 was less than the federal statutory rate primarily due to: (1) the IRS settlement discussed below, (2) the impact of noncontrolling interests, and (3) a decrease in our valuation allowance, as discussed below, offset by (4) state and other income tax expense. In April 2013, we entered into closing agreements with the IRS that settled federal income tax matters related to the previous restatement of our 2000 and 2001 financial statements, as well as certain other tax matters, through December 31, 2008. As a result of these closing agreements, we increased our deferred tax assets, primarily our federal net operating loss carryforward (“NOL”), and recorded a net federal income tax benefit of approximately $115 million in the second quarter of 2013. This federal income tax benefit primarily resulted from an approximate $283 million increase to our federal NOL on a gross basis. Deferred income taxes recognize the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and amounts used for income tax purposes and the impact of available NOLs. The significant components of HealthSouth’s deferred tax assets and liabilities are presented in the following table (in millions): As of December 31, 2015 2014 Deferred income tax assets: Net operating loss $ 161.1 $ 301.3 Property, net 48.2 40.7 Insurance reserve 26.0 25.6 Stock-based compensation 23.4 23.7 Allowance for doubtful accounts 24.5 18.0 Alternative minimum tax 10.6 10.5 Carrying value of partnerships 22.1 23.8 Other accruals 25.7 20.6 Tax credits 14.0 9.9 Noncontrolling interest 10.6 — Other 0.8 1.6 Total deferred income tax assets 367.0 475.7 Less: Valuation allowance (27.6 ) (23.0 ) Net deferred income tax assets 339.4 452.7 Deferred income tax liabilities: Intangibles (112.8 ) (97.5 ) Convertible debt interest (35.3 ) (31.7 ) Other (0.5 ) (5.7 ) Total deferred income tax liabilities (148.6 ) (134.9 ) Net deferred income tax assets 190.8 317.8 Less: Current deferred tax assets — 188.4 Noncurrent deferred tax assets $ 190.8 $ 129.4 In the consolidated statements of shareholders’ equity, the fair value adjustments to redeemable noncontrolling interests have been reported net of tax for each period presented. The amount of tax (benefit) expense allocated to Capital in excess of par value was ($11.7) million , ($1.8) million , and $2.9 million for the years ended December 31, 2015, 2014, and 2013, respectively. At December 31, 2015 , we had an unused federal NOL of $91.6 million (approximately $261.6 million on a gross basis) and state NOLs of $69.5 million . Such losses expire in various amounts at varying times through 2031 . Our reported federal NOL as of December 31, 2015 excludes $14.6 million related to operating loss carryforwards resulting from excess tax benefits related to share-based awards, the tax benefits of which, when recognized, will be accounted for as a credit to additional paid-in-capital when they reduce taxes payable. At December 31, 2015, we had unused federal tax credit carryforwards of $14.0 million . These credit carryforwards expire in various amounts at various times through 2035. For the years ended December 31, 2015 , 2014 , and 2013 , the net changes in our valuation allowance were $4.6 million , ($7.7) million , and ($9.1) million , respectively. The increase in our valuation allowance in 2015 related primarily to changes to our state apportionment percentages resulting from the acquisitions of Encompass, Reliant, and CareSouth and changes to our current forecast of earnings in each jurisdiction. The decrease in our valuation allowance in 2014 related primarily to the expiration of state NOLs in certain jurisdictions, our current forecast of future earnings in each jurisdiction, and changes in certain state tax laws. The decrease in our valuation allowance in 2013 related primarily to our capital loss carryforwards, our then current forecast of future earnings in each jurisdiction, and changes in certain state tax laws. During the second quarter of 2013, we determined a valuation allowance related to our capital loss carryforwards was no longer required as sufficient positive evidence existed to substantiate their utilization. This evidence included our partial utilization of these assets as a result of realizing capital gains in 2013 and the identification of sufficient taxable capital gain income within the available capital loss carryforward period. As of December 31, 2015 , we have a remaining valuation allowance of $27.6 million . This valuation allowance remains recorded due to uncertainties regarding our ability to utilize a portion of our state NOLs and other credits before they expire. The amount of the valuation allowance has been determined for each tax jurisdiction based on the weight of all available evidence including management’s estimates of taxable income for each jurisdiction in which we operate over the periods in which the related deferred tax assets will be recoverable. It is possible we may be required to increase or decrease our valuation allowance at some future time if our forecast of future earnings varies from actual results on a consolidated basis or in the applicable state tax jurisdictions, or if the timing of future tax deductions our credit utilizations differs from our expectations. As of January 1, 2013 , total remaining gross unrecognized tax benefits were $78.0 million , $76.0 million of which would have affected our effective tax rate if recognized. The amount of unrecognized tax benefits changed during 2013 primarily due to the April 2013 IRS settlement discussed above. Total remaining gross unrecognized tax benefits were $1.1 million as of December 31, 2013, $0.4 million of which would have affected our effective tax rate if recognized. The amount of unrecognized tax benefits did not change significantly during 2014. Total remaining gross unrecognized tax benefits were $0.9 million as of December 31, 2014, all of which would have affected our effective tax rate if recognized. The amount of unrecognized tax benefits did not change significantly during 2015. Total remaining gross unrecognized tax benefits were $2.9 million as of December 31, 2015, all of which would affect our effective tax rate if recognized. A reconciliation of the beginning and ending liability for unrecognized tax benefits is as follows (in millions): Gross Unrecognized Income Tax Benefits Accrued Interest and Penalties January 1, 2013 $ 78.0 $ — Gross amount of increases in unrecognized tax benefits related to prior periods 46.7 0.3 Gross amount of decreases in unrecognized tax benefits related to prior periods (1.9 ) — Decreases in unrecognized tax benefits relating to settlements with taxing authorities (121.7 ) — December 31, 2013 1.1 0.3 Gross amount of increases in unrecognized tax benefits related to prior periods 0.7 0.1 Gross amount of decreases in unrecognized tax benefits related to prior periods (0.9 ) (0.4 ) December 31, 2014 0.9 — Gross amount of increases in unrecognized tax benefits related to prior periods 1.7 — Gross amount of increases in unrecognized tax benefits related to current period 0.3 — December 31, 2015 $ 2.9 $ — Our continuing practice is to recognize interest and penalties related to income tax matters in income tax expense. Interest recorded as part of our income tax provision during 2015, 2014, and 2013 was not material. Accrued interest income related to income taxes as of December 31, 2015 and 2014 was not material. In December 2014, we signed an agreement with the IRS to begin participating in their Compliance Assurance Process, a program in which we and the IRS endeavor to agree on the treatment of significant tax positions prior to the filing of our federal income tax return. We renewed this agreement in December 2015 for the 2016 tax year. As a result of this agreement, the IRS surveyed our 2013, 2012, and 2011 federal income tax returns and will examine our 2015 and 2016 returns when filed. Our 2014 federal income tax return has been filed, and the IRS has not indicated its intent to examine or survey this return. The IRS is also separately examining the 2013 return of one of our partnership affiliates acquired in the CareSouth transaction. We have settled federal income tax examinations with the IRS for all tax years through 2010. Our state income tax returns are also periodically examined by various regulatory taxing authorities. We are currently under audit by seven states for tax years ranging from 2007 through 2014. For the tax years that remain open under the applicable statutes of limitations, amounts related to these unrecognized tax benefits have been considered by management in its estimate of our potential net recovery of prior years’ income taxes. Based on discussions with taxing authorities, we anticipate $0.5 million to $2.9 million of our unrecognized tax benefits may be released within the next 12 months. See also Note 1, Summary of Significant Accounting Policies , “Recent Accounting Pronouncements.”

Earnings per Common Share

Earnings per Common Share	12 Months Ended
	Dec. 31, 2015
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	Earnings per Common Share : The following table sets forth the computation of basic and diluted earnings per common share (in millions, except per share amounts): For the Year Ended December 31, 2015 2014 2013 Basic: Numerator: Income from continuing operations $ 253.7 $ 276.2 $ 382.5 Less: Net income attributable to noncontrolling interests included in continuing operations (69.7 ) (59.7 ) (57.8 ) Less: Income allocated to participating securities (1.0 ) (2.3 ) (3.4 ) Less: Convertible perpetual preferred stock dividends (1.6 ) (6.3 ) (21.0 ) Less: Repurchase of convertible perpetual preferred stock — — (71.6 ) Income from continuing operations attributable to HealthSouth common shareholders 181.4 207.9 228.7 (Loss) income from discontinued operations, net of tax, attributable to HealthSouth common shareholders (0.9 ) 5.5 (1.1 ) Less: Income from discontinued operations allocated to participating securities — (0.1 ) — Net income attributable to HealthSouth common shareholders $ 180.5 $ 213.3 $ 227.6 Denominator: Basic weighted average common shares outstanding 89.4 86.8 88.1 Basic earnings per share attributable to HealthSouth common shareholders: Continuing operations $ 2.03 $ 2.40 $ 2.59 Discontinued operations (0.01 ) 0.06 (0.01 ) Net income $ 2.02 $ 2.46 $ 2.58 Diluted: Numerator: Income from continuing operations $ 253.7 $ 276.2 $ 382.5 Less: Net income attributable to noncontrolling interests included in continuing operations (69.7 ) (59.7 ) (57.8 ) Add: Interest on convertible debt, net of tax 9.4 9.0 1.0 Income from continuing operations attributable to HealthSouth common shareholders 193.4 225.5 325.7 (Loss) income from discontinued operations, net of tax, attributable to HealthSouth common shareholders (0.9 ) 5.5 (1.1 ) Net income attributable to HealthSouth common shareholders $ 192.5 $ 231.0 $ 324.6 Denominator: Diluted weighted average common shares outstanding 101.0 100.7 102.1 Diluted earnings per share attributable to HealthSouth common shareholders: Continuing operations $ 1.92 $ 2.24 $ 2.59 Discontinued operations (0.01 ) 0.05 (0.01 ) Net income $ 1.91 $ 2.29 $ 2.58 The following table sets forth the reconciliation between basic weighted average common shares outstanding and diluted weighted average common shares outstanding (in millions): For the Year Ended December 31, 2015 2014 2013 Basic weighted average common shares outstanding 89.4 86.8 88.1 Convertible perpetual preferred stock 1.0 3.2 10.5 Convertible senior subordinated notes 8.3 8.2 1.0 Restricted stock awards, dilutive stock options, and restricted stock units 2.3 2.5 2.5 Diluted weighted average common shares outstanding 101.0 100.7 102.1 For the year ended December 31, 2013, adding back amounts related to the repurchase of our preferred stock to our Income from continuing operations attributable to HealthSouth common shareholders causes a per share increase when calculating diluted earnings per common share resulting in an antidilutive per share amount. See Note 10, Convertible Perpetual Preferred Stock . Therefore, basic and diluted earnings per common share is the same for the year ended December 31, 2013. Options to purchase approximately 0.1 million shares of common stock were outstanding as of December 31, 2015 and 2014 but were not included in the computation of diluted weighted-average shares because to do so would have been antidilutive. In February 2013, our board of directors approved an increase in our existing common stock repurchase authorization from $125 million (authorized in October 2011) to $350 million . During the first quarter of 2013, we completed a tender offer for our common stock. As a result of the tender offer, we purchased 9.1 million shares at a price of $25.50 per share for a total cost of $234.1 million , including fees and expenses relating to the tender offer. The remaining repurchase authorization expired at the end of the tender offer. In October 2013, our board of directors authorized the repurchase of up to $200 million of our common stock. In February 2014, our board of directors approved an increase in this common stock repurchase authorization from $200 million to $250 million . The repurchase authorization does not require the repurchase of a specific number of shares, has an indefinite term, and is subject to termination at any time by our board of directors. During 2015 and 2014, we repurchased 1.3 million and 1.3 million shares of our common stock in the open market for $45.3 million and $43.1 million , respectively. In July 2013, our board of directors approved the initiation of a quarterly cash dividend of $0.18 per share on our common stock. The first quarterly dividend was declared in July 2013 and paid in October 2013. This $0.18 per share cash dividend on our common stock was declared and paid each quarter through July 2014. In July 2014, our board of directors approved an increase in the quarterly cash dividend on our common stock and declared a dividend of $0.21 per share. The cash dividend of $0.21 per common share was declared and paid each quarter through July 2015. In July 2015, our board of directors approved an increase in the quarterly cash dividend and declared a dividend of $0.23 per share. The cash dividend of $0.23 per common share was declared in July 2015 and October 2015 and paid in October 2015 and January 2016. As of December 31, 2015 and 2014, accrued common stock dividends of $21.3 million and $18.6 million were included in Other current liabilities in our consolidated balance sheet. Future dividend payments are subject to declaration by our board of directors. In January 2004, we repaid our then-outstanding 3.25% Convertible Debentures using the net proceeds of a loan arranged by Credit Suisse First Boston. In connection with this transaction, we issued ten million warrants with an expiration date of January 16, 2014 to the lender to purchase shares of our common stock. The agreement underlying these warrants included antidilutive protection that required adjustments to the number of shares of common stock purchasable upon exercise and the exercise price for common stock upon the occurrence of certain events. Following our one-for-five reverse stock split in October 2006, the warrants were exercisable for two million shares of our common stock at an exercise price of $32.50 . This antidilution protection also provided for adjustment upon payment of cash dividends on our common stock after a de minimis threshold. The payment in January 2014 of an $0.18 per share dividend on our common stock triggered the antidilutive adjustment for these warrants. When these warrants expired in January 2014, the resulting exercise price of each warrant was $32.16 , and the resulting exercise rate was 0.2021 for each warrant. The warrants were not assumed exercised for dilutive shares outstanding for the year ended December 31, 2012 because they were antidilutive in that period. The following table summarizes information relating to these warrants and their activity during 2013 and through their expiration date (number of warrants in millions): Number of Warrants Weighted Average Exercise Price Common stock warrants outstanding as of December 31, 2012 10.0 $ 32.50 Cashless exercise (4.8 ) 32.50 Cash exercise (2.3 ) 32.50 Common stock warrants outstanding as of December 31, 2013 2.9 32.50 Cashless exercise (1.8 ) 32.16 Cash exercise (1.0 ) 32.16 Expired (0.1 ) 32.16 Common stock warrants outstanding as of January 16, 2014 — The above exercises resulted in the issuance of 0.5 million and 0.2 million shares of common stock in 2013 and 2014, respectively. Cash exercises resulted in gross proceeds of $15.3 million and $6.3 million during 2013 and 2014, respectively. On September 30, 2009, we issued 5.0 million shares of common stock and 8.2 million common stock warrants in full satisfaction of our obligation to do so under the January 2007 comprehensive settlement of the consolidated securities action brought against us by our stockholders and bondholders. Each warrant has a term of approximately seven years from the date of issuance and an exercise price of $41.40 per share. The warrants were not assumed exercised for dilutive shares outstanding because they were antidilutive in the periods presented. See also Note 8, Long-term Debt , and Note 10, Convertible Perpetual Preferred Stock .

Contingencies and Other Commitm

Contingencies and Other Commitments	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Contingencies and Other Commitments	Contingencies and Other Commitments : We operate in a highly regulated and litigious industry. As a result, various lawsuits, claims, and legal and regulatory proceedings have been and can be expected to be instituted or asserted against us. The resolution of any such lawsuits, claims, or legal and regulatory proceedings could materially and adversely affect our financial position, results of operations, and cash flows in a given period. General Medicine Action— On August 16, 2004, General Medicine, P.C. filed a lawsuit in the Circuit Court of Jefferson County, Alabama (the “Alabama Action”) against us captioned General Medicine, P.C. v. HealthSouth Corp. seeking the recovery of allegedly fraudulent transfers involving assets of Horizon/CMS Healthcare Corporation, a former subsidiary of HealthSouth. General Medicine’s underlying claim against Horizon/CMS originates from a services contract entered into in 1995 between General Medicine and Horizon/CMS whereby General Medicine agreed to provide medical director services to skilled nursing facilities owned by Horizon/CMS for a term of three years . Horizon/CMS terminated the agreement for cause six months after it was executed, and General Medicine then initiated a lawsuit against Horizon/CMS in the United States District Court for the Eastern District of Michigan in 1996 (the “Michigan Action”). General Medicine’s complaint in the Michigan Action alleged that Horizon/CMS breached the services contract by wrongfully terminating General Medicine. We acquired Horizon/CMS in 1997 and sold it to Meadowbrook Healthcare, Inc. in 2001 pursuant to a stock purchase agreement. In 2004, Meadowbrook, without the knowledge of HealthSouth, consented to the entry of a final judgment in the Michigan Action in favor of General Medicine against Horizon/CMS for the alleged wrongful termination of the contract with General Medicine in the amount of $376 million (the “Consent Judgment”). The $376 million damages figure was unilaterally selected by General Medicine and was not tested or opposed by Meadowbrook. Additionally, the settlement agreement (the “Settlement”) used as the basis for the Consent Judgment provided that Meadowbrook would pay only $300,000 to General Medicine to settle the Michigan Action and that General Medicine would seek to recover the remaining balance of the Consent Judgment solely from us. We were not a party to the Michigan Action, the Settlement negotiated by Meadowbrook, or the Consent Judgment. The complaint filed by General Medicine against us in the Alabama Action alleged that while Horizon/CMS was our wholly owned subsidiary, General Medicine was an existing creditor of Horizon/CMS by virtue of the breach of contract claim underlying the Settlement. The complaint also alleged we caused Horizon/CMS to transfer its assets to us for less than a reasonably equivalent value or, in the alternative, with the actual intent to defraud creditors of Horizon/CMS, including General Medicine, in violation of the Alabama Uniform Fraudulent Transfer Act. General Medicine further alleged in its amended complaint that we were liable for the Consent Judgment despite not being a party to it because as Horizon/CMS’s parent we failed to observe corporate formalities in our operation and ownership of Horizon/CMS, misused our control of Horizon/CMS, stripped assets from Horizon/CMS, and engaged in other conduct which amounted to a fraud on Horizon/CMS’s creditors. General Medicine requested relief including recovery of the unpaid amount of the Consent Judgment, the avoidance of the subject transfers of assets, attachment of the assets transferred to us, appointment of a receiver over the transferred properties, and a monetary judgment for the value of properties transferred. We denied liability to General Medicine and asserted defenses and a counterclaim against General Medicine that the Consent Judgment was the product of collusion by General Medicine and Meadowbrook. Consequently, we asserted that the Consent Judgment was not evidence of a legitimate debt owed by Horizon/CMS to General Medicine that was collectible from HealthSouth under any theory of liability. The trial in the Alabama Action began on March 9, 2015. On March 22, 2015, we entered into an agreement with General Medicine to settle the Alabama Action . Although the specific terms of this settlement agreement are confidential, both parties agreed to dismiss with prejudice the lawsuit pending in the Circuit Court of Jefferson County, Alabama and to release all claims between the parties. In exchange for General Medicine’s release, we agreed to pay an amount of cash that is not material. Other Litigation— We have been named as a defendant in a lawsuit filed March 28, 2003 by several individual stockholders in the Circuit Court of Jefferson County, Alabama, captioned Nichols v. HealthSouth Corp . The plaintiffs allege that we, some of our former officers, and our former investment bank engaged in a scheme to overstate and misrepresent our earnings and financial position. The plaintiffs are seeking compensatory and punitive damages. This case was consolidated with a now resolved case for discovery and other pretrial purposes and was stayed in the Circuit Court on August 8, 2005. The plaintiffs filed an amended complaint on November 9, 2010 to which we responded with a motion to dismiss filed on December 22, 2010. During a hearing on February 24, 2012, plaintiffs’ counsel indicated his intent to dismiss certain claims against us. Instead, on March 9, 2012, the plaintiffs amended their complaint to include additional securities fraud claims against HealthSouth and add several former officers to the lawsuit. On September 12, 2012, the plaintiffs further amended their complaint to request certification as a class action. One of those named officers has repeatedly attempted to remove the case to federal district court, most recently on December 11, 2012. We filed our latest motion to remand the case back to state court on January 10, 2013. On September 27, 2013, the federal court remanded the case back to state court. On November 25, 2014, the plaintiffs filed another amended complaint to assert new allegations relating to the time period of 1997 to 2002. On December 10, 2014, we filed a motion to dismiss on the grounds the plaintiffs lack standing because their claims are derivative in nature, and the claims are time-barred by the statute of limitations. A hearing on our motion has not yet been set. We intend to vigorously defend ourselves in this case. Based on the stage of litigation, review of the current facts and circumstances as we understand them, the nature of the underlying claim, the results of the proceedings to date, and the nature and scope of the defense we continue to mount, we do not believe an adverse judgment or settlement is probable in this matter, and it is also not possible to estimate the amount of loss, if any, or range of possible loss that might result from an adverse judgment or settlement of this case. Governmental Inquiries and Investigations— On June 24, 2011, we received a document subpoena addressed to HealthSouth Hospital of Houston, a long-term acute care hospital (“LTCH”) we closed in August 2011, and issued from the Dallas, Texas office of the HHS-OIG. The subpoena stated it was in connection with an investigation of possible false or otherwise improper claims submitted to Medicare and Medicaid and requested documents and materials relating to patient admissions, length of stay, and discharge matters at this closed LTCH. We furnished the documents requested and have heard nothing from the HHS-OIG since December 2012. On March 4, 2013, we received document subpoenas from an office of the HHS-OIG addressed to four of our hospitals. Those subpoenas also requested complete copies of medical records for 100 patients treated at each of those hospitals between September 2008 and June 2012. The investigation is being conducted by the United States Department of Justice (the “DOJ”). On April 24, 2014, we received document subpoenas relating to an additional seven of our hospitals. The new subpoenas reference substantially similar investigation subject matter as the original subpoenas and request materials from the period January 2008 through December 2013. Two of the four hospitals addressed in the original set of subpoenas have received supplemental subpoenas to cover this new time period. The most recent subpoenas do not include requests for specific patient files. However, in February 2015, the DOJ requested the voluntary production of the medical records of an additional 70 patients, some of whom were treated in hospitals not subject to the subpoenas, and we provided these records. All of the subpoenas are in connection with an investigation of alleged improper or fraudulent claims submitted to Medicare and Medicaid and request documents and materials relating to practices, procedures, protocols and policies, of certain pre- and post-admissions activities at these hospitals including, among other things, marketing functions, pre-admission screening, post-admission physician evaluations, patient assessment instruments, individualized patient plans of care, and compliance with the Medicare 60% rule. Under the Medicare rule commonly referred to as the “ 60% rule,” an inpatient rehabilitation hospital must treat 60% or more of its patients from at least one of a specified list of medical conditions in order to be reimbursed at the inpatient rehabilitation hospital payment rates, rather than at the lower acute care hospital payment rates. We are cooperating fully with the DOJ in connection with these subpoenas and are currently unable to predict the timing or outcome of the related investigations. Other Matters— The False Claims Act, 18 U.S.C. § 287, allows private citizens, called “relators,” to institute civil proceedings alleging violations of the False Claims Act. These qui tam cases are sealed by the court at the time of filing. Prior to the release of the seal by the presiding court, the only parties typically privy to the information contained in the complaint are the relator, the federal government, and the court. It is possible that qui tam lawsuits have been filed against us and that those suits remain under seal or that we are unaware of such filings or prevented by existing law or court order from discussing or disclosing the filing of such suits. We may be subject to liability under one or more undisclosed qui tam cases brought pursuant to the False Claims Act. It is our obligation as a participant in Medicare and other federal healthcare programs to routinely conduct audits and reviews of the accuracy of our billing systems and other regulatory compliance matters. As a result of these reviews, we have made, and will continue to make, disclosures to the HHS-OIG and CMS relating to amounts we suspect represent over-payments from these programs, whether due to inaccurate billing or otherwise. Some of these disclosures have resulted in, or may result in, HealthSouth refunding amounts to Medicare or other federal healthcare programs. Other Commitments— We are a party to service and other contracts in connection with conducting our business. Minimum amounts due under these agreements are $33.3 million in 2016 , $28.2 million in 2017 , $21.1 million in 2018 , $12.6 million in 2019 , $11.9 million in 2020 , and $7.2 million thereafter. These contracts primarily relate to software licensing and support.

Segment Reporting Segment Repor

Segment Reporting Segment Reporting	12 Months Ended
	Dec. 31, 2015
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	18. Segment Reporting : As described in Note 2, Business Combinations , we completed the acquisition of Encompass on December 31, 2014. As a result of this transaction, in the first quarter of 2015, management changed the way it manages and operates the consolidated reporting entity and modified the reports used by our chief operating decision maker to assess performance and allocate resources. These changes required us to revise our segment reporting from our historic presentation of only one reportable segment. Our internal financial reporting and management structure is focused on the major types of services provided by HealthSouth. Beginning in the first quarter of 2015, we manage our operations using two operating segments which are also our reportable segments: (1) inpatient rehabilitation and (2) home health and hospice. Prior period information has been adjusted to conform to the current period presentation. Specifically, HealthSouth’s legacy 25 hospital-based home health agencies have been reclassified from our inpatient rehabilitation segment to our home health and hospice segment for all periods presented. These reportable operating segments are consistent with information used by our chief executive officer, who is our chief operating decision maker, to assess performance and allocate resources. The following is a brief description of our reportable segments: • Inpatient Rehabilitation - Our national network of inpatient rehabilitation hospitals stretches across 29 states and Puerto Rico, with a concentration of hospitals in the eastern half of the United States and Texas. As of December 31, 2015 , we operate 121 inpatient rehabilitation hospitals, including one hospital that operates as a joint venture which we account for using the equity method of accounting. In addition, we manage three inpatient rehabilitation units through management contracts. We provide specialized rehabilitative treatment on both an inpatient and outpatient basis. Our inpatient rehabilitation hospitals provide a higher level of rehabilitative care to patients who are recovering from conditions such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations. • Home Health and Hospice - As of December 31, 2015 , we provide home health and hospice services in 213 locations across 23 states. In addition, two of these agencies operate as joint ventures which we account for using the equity method of accounting. Our home health services include a comprehensive range of Medicare-certified home nursing services to adult patients in need of care. These services include, among others, skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. We also provide specialized home care services in Texas and Kansas for pediatric patients with severe medical conditions. Our hospice services primarily include in-home services to terminally ill patients and their families to address patients’ physical needs, including pain control and symptom management, and to provide emotional and spiritual support. The accounting policies of our reportable segments are the same as those described in Note 1, Summary of Significant Accounting Policies , “Net Operating Revenues” and “Accounts Receivable and Allowance for Doubtful Accounts.” All revenues for our services are generated through external customers. See Note 1, Summary of Significant Accounting Policies , “Net Operating Revenues,” for the payor composition of our revenues. No corporate overhead is allocated to either of our reportable segments. Our chief operating decision maker evaluates the performance of our segments and allocates resources to them based on adjusted earnings before interest, taxes, depreciation, and amortization (“Segment Adjusted EBITDA”). Selected financial information for our reportable segments is as follows (in millions): Inpatient Rehabilitation Home Health and Hospice For the Year Ended December 31, For the Year Ended December 31, 2015 2014 2013 2015 2014 2013 Net operating revenues $ 2,653.1 $ 2,377.3 $ 2,244.4 $ 509.8 $ 28.6 $ 28.8 Less: Provision for doubtful accounts (44.7 ) (31.2 ) (25.6 ) (2.5 ) (0.4 ) (0.4 ) Net operating revenues less provision for doubtful accounts 2,608.4 2,346.1 2,218.8 507.3 28.2 28.4 Operating expenses: Inpatient rehabilitation: Salaries and benefits 1,310.6 1,141.0 1,069.7 — — — Other operating expenses 387.7 342.5 314.7 — — — Supplies 120.9 111.5 105.2 — — — Occupancy costs 46.2 41.2 46.5 — — — Home health and hospice: Cost of services sold (excluding depreciation and amortization) — — — 244.8 17.0 16.7 Support and overhead costs — — — 172.7 6.9 6.6 1,865.4 1,636.2 1,536.1 417.5 23.9 23.3 Other income (2.3 ) (4.0 ) (4.5 ) — — — Equity in net income of nonconsolidated affiliates (8.6 ) (10.7 ) (11.2 ) (0.1 ) — — Noncontrolling interests 62.9 59.3 57.2 6.8 0.4 0.6 Segment Adjusted EBITDA $ 691.0 $ 665.3 $ 641.2 $ 83.1 $ 3.9 $ 4.5 Capital expenditures $ 151.7 $ 187.9 $ 216.5 $ 5.8 $ — $ — Inpatient Rehabilitation Home Health and Hospice HealthSouth Consolidated As of December 31, 2015 Total assets $ 3,589.0 $ 1,088.4 $ 4,606.1 Investments in and advances to nonconsolidated affiliates 9.3 2.4 11.7 As of December 31, 2014 Total assets $ 2,576.3 $ 876.3 $ 3,388.3 Investments in and advances to nonconsolidated affiliates 9.4 — 9.4 Segment reconciliations (in millions): For the Year Ended December 31, 2015 2014 2013 Total segment Adjusted EBITDA $ 774.1 $ 669.2 $ 645.7 General and administrative expenses (133.3 ) (124.8 ) (119.1 ) Depreciation and amortization (139.7 ) (107.7 ) (94.7 ) Loss on disposal or impairment of assets (2.6 ) (6.7 ) (5.9 ) Government, class action, and related settlements (7.5 ) 1.7 23.5 Professional fees - accounting, tax, and legal (3.0 ) (9.3 ) (9.5 ) Loss on early extinguishment of debt (22.4 ) (13.2 ) (2.4 ) Interest expense and amortization of debt discounts and fees (142.9 ) (109.2 ) (100.4 ) Gain on consolidation of former equity method hospital — 27.2 — Net income attributable to noncontrolling interests 69.7 59.7 57.8 Gain related to SCA equity interest 3.2 — — Other — — 0.2 Income from continuing operations before income tax expense $ 395.6 $ 386.9 $ 395.2 As of December 31, 2015 As of December 31, 2014 Total assets for reportable segments $ 4,677.4 $ 3,452.6 Reclassification of noncurrent deferred income tax liabilities to net noncurrent deferred income tax assets (71.3 ) (64.3 ) Total consolidated assets $ 4,606.1 $ 3,388.3 Additional detail regarding the revenues of our operating segments by service line follows (in millions): For the Year Ended December 31, 2015 2014 2013 Inpatient rehabilitation: Inpatient $ 2,547.2 $ 2,272.5 $ 2,130.8 Outpatient and other 105.9 104.8 113.6 Total inpatient rehabilitation 2,653.1 2,377.3 2,244.4 Home health and hospice: Home health 478.1 28.6 28.8 Hospice 31.7 — — Total home health and hospice 509.8 28.6 28.8 Total net operating revenues $ 3,162.9 $ 2,405.9 $ 2,273.2

Quarterly Data (Unaudited)

Quarterly Data (Unaudited)	12 Months Ended
	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Quarterly Data (Unaudited)	Quarterly Data (Unaudited) : 2015 First Second Third Fourth Total (In Millions, Except Per Share Data) Net operating revenues $ 740.6 $ 764.4 $ 778.6 $ 879.3 $ 3,162.9 Operating earnings (a) 105.6 123.4 121.2 135.5 485.7 Provision for income tax expense 30.3 32.2 35.9 43.5 141.9 Income from continuing operations 59.3 61.8 67.5 65.1 253.7 (Loss) income from discontinued operations, net of tax (0.3 ) (1.6 ) 0.3 0.7 (0.9 ) Net income 59.0 60.2 67.8 65.8 252.8 Less: Net income attributable to noncontrolling interests (16.5 ) (17.3 ) (17.1 ) (18.8 ) (69.7 ) Net income attributable to HealthSouth $ 42.5 $ 42.9 $ 50.7 $ 47.0 $ 183.1 Earnings per common share: Basic earnings per share attributable to HealthSouth common shareholders: (b) Continuing operations $ 0.47 $ 0.49 $ 0.56 $ 0.51 $ 2.03 Discontinued operations — (0.02 ) — 0.01 (0.01 ) Net income $ 0.47 $ 0.47 $ 0.56 $ 0.52 $ 2.02 Diluted earnings per share attributable to HealthSouth common shareholders: (b) Continuing operations $ 0.44 $ 0.47 $ 0.52 $ 0.48 $ 1.92 Discontinued operations — (0.02 ) — 0.01 (0.01 ) Net income $ 0.44 $ 0.45 $ 0.52 $ 0.49 $ 1.91 (a) We define operating earnings as income from continuing operations attributable to HealthSouth before (1) loss on early extinguishment of debt; (2) interest expense and amortization of debt discounts and fees; (3) other income; and (4) income tax expense. (b) Per share amounts may not sum due to the weighted average common shares outstanding during each quarter compared to the weighted average common shares outstanding during the entire year. 2014 First Second Third Fourth Total (In Millions, Except Per Share Data) Net operating revenues $ 591.2 $ 604.4 $ 596.9 $ 613.4 $ 2,405.9 Operating earnings (a) 105.8 115.4 100.7 96.5 418.4 Provision for income tax expense 32.8 36.5 22.1 19.3 110.7 Income from continuing operations 61.6 94.1 65.7 54.8 276.2 (Loss) income from discontinued operations, net of tax (0.1 ) 3.8 (0.9 ) 2.7 5.5 Net income 61.5 97.9 64.8 57.5 281.7 Less: Net income attributable to noncontrolling interests (14.8 ) (14.8 ) (14.7 ) (15.4 ) (59.7 ) Net income attributable to HealthSouth $ 46.7 $ 83.1 $ 50.1 $ 42.1 $ 222.0 Earnings per common share: Basic earnings per share attributable to HealthSouth common shareholders: (b) Continuing operations $ 0.51 $ 0.89 $ 0.56 $ 0.43 $ 2.40 Discontinued operations — 0.04 (0.01 ) 0.03 0.06 Net income $ 0.51 $ 0.93 $ 0.55 $ 0.46 $ 2.46 Diluted earnings per share attributable to HealthSouth common shareholders: Continuing operations $ 0.48 $ 0.81 $ 0.53 $ 0.41 $ 2.24 Discontinued operations — 0.04 (0.01 ) 0.03 0.05 Net income $ 0.48 $ 0.85 $ 0.52 $ 0.44 $ 2.29 (a) We define operating earnings as income from continuing operations attributable to HealthSouth before (1) loss on early extinguishment of debt; (2) interest expense and amortization of debt discounts and fees; (3) other income; and (4) income tax expense or benefit. (b) Per share amounts may not sum due to the weighted average common shares outstanding during each quarter compared to the weighted average common shares outstanding during the entire year.

Condensed Consolidating Financi

Condensed Consolidating Financial Information	12 Months Ended
	Dec. 31, 2015
Condensed Consolidating Financial Information [Abstract]
Condensed Consolidating Financial Information [Text Block]	Condensed Consolidating Financial Information : The accompanying condensed consolidating financial information has been prepared and presented pursuant to SEC Regulation S-X, Rule 3-10, “Financial Statements of Guarantors and Issuers of Guaranteed Securities Registered or Being Registered.” Each of the subsidiary guarantors is 100% owned by HealthSouth, and all guarantees are full and unconditional and joint and several, subject to certain customary conditions for release. HealthSouth’s investments in its consolidated subsidiaries, as well as guarantor subsidiaries’ investments in nonguarantor subsidiaries and nonguarantor subsidiaries’ investments in guarantor subsidiaries, are presented under the equity method of accounting with the related investment presented within the line items Intercompany receivable and Intercompany payable in the accompanying condensed consolidating balance sheets. The terms of our credit agreement allow us to declare and pay cash dividends on our common stock so long as: (1) we are not in default under our credit agreement and (2) our senior secured leverage ratio (as defined in our credit agreement) remains less than or equal to 1.75 x. The terms of our senior note indenture allow us to declare and pay cash dividends on our common stock so long as (1) we are not in default, (2) the consolidated coverage ratio (as defined in the indenture) exceeds 2 x or we are otherwise allowed under the indenture to incur debt, and (3) we have capacity under the indenture’s restricted payments covenant to declare and pay dividends. See Note 8, Long-term Debt . In the first quarter of 2015, we revised our condensed consolidating balance sheet as of December 31, 2014 to correct the classification of $51.4 million of net noncurrent deferred tax liabilities of our Nonguarantor Subsidiaries from noncurrent Deferred income tax assets to Other long-term liabilities . The impact of this revision was to increase total assets and increase liabilities for Nonguarantor Subsidiaries, with an offset to Eliminating Entries. This revision was not material to the related financial statements as of and for the year ended December 31, 2014 and had no impact on our condensed consolidated balance sheet as of December 31, 2014. Periodically, certain wholly owned subsidiaries of HealthSouth make dividends or distributions of available cash and/or intercompany receivable balances to their parents. In addition, HealthSouth makes contributions to certain wholly owned subsidiaries. When made, these dividends, distributions, and contributions impact the Intercompany receivable , Intercompany payable , and HealthSouth shareholders’ equity line items in the accompanying condensed consolidating balance sheet but have no impact on the consolidated financial statements of HealthSouth Corporation. For the Year Ended December 31, 2015 HealthSouth Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries HealthSouth Consolidated (In Millions) Net operating revenues $ 19.4 $ 1,927.0 $ 1,320.0 $ (103.5 ) $ 3,162.9 Less: Provision for doubtful accounts — (34.6 ) (12.6 ) — (47.2 ) Net operating revenues less provision for doubtful accounts 19.4 1,892.4 1,307.4 (103.5 ) 3,115.7 Operating expenses: Salaries and benefits 49.4 893.2 745.3 (17.1 ) 1,670.8 Other operating expenses 31.3 274.7 167.4 (41.3 ) 432.1 Occupancy costs 4.0 69.4 25.6 (45.1 ) 53.9 Supplies — 85.2 43.5 — 128.7 General and administrative expenses 128.3 — 5.0 — 133.3 Depreciation and amortization 9.9 84.3 45.5 — 139.7 Government, class action, and related settlements 7.5 — — — 7.5 Professional fees—accounting, tax, and legal 3.0 — — — 3.0 Total operating expenses 233.4 1,406.8 1,032.3 (103.5 ) 2,569.0 Loss on early extinguishment of debt 22.4 — — — 22.4 Interest expense and amortization of debt discounts and fees 130.0 11.9 12.4 (11.4 ) 142.9 Other income (13.6 ) (0.2 ) (3.1 ) 11.4 (5.5 ) Equity in net income of nonconsolidated affiliates — (8.5 ) (0.2 ) — (8.7 ) Equity in net income of consolidated affiliates (322.7 ) (34.5 ) — 357.2 — Management fees (119.7 ) 91.6 28.1 — — Income from continuing operations before income tax (benefit) expense 89.6 425.3 237.9 (357.2 ) 395.6 Provision for income tax (benefit) expense (94.6 ) 169.7 66.8 — 141.9 Income from continuing operations 184.2 255.6 171.1 (357.2 ) 253.7 (Loss) income from discontinued operations, net of tax (1.1 ) — 0.2 — (0.9 ) Net income 183.1 255.6 171.3 (357.2 ) 252.8 Less: Net income attributable to noncontrolling interests — — (69.7 ) — (69.7 ) Net income attributable to HealthSouth $ 183.1 $ 255.6 $ 101.6 $ (357.2 ) $ 183.1 Comprehensive income $ 182.4 $ 255.6 $ 171.3 $ (357.2 ) $ 252.1 Comprehensive income attributable to HealthSouth $ 182.4 $ 255.6 $ 101.6 $ (357.2 ) $ 182.4 For the Year Ended December 31, 2014 HealthSouth Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries HealthSouth Consolidated (In Millions) Net operating revenues $ 16.1 $ 1,719.1 $ 761.1 $ (90.4 ) $ 2,405.9 Less: Provision for doubtful accounts — (22.3 ) (9.3 ) — (31.6 ) Net operating revenues less provision for doubtful accounts 16.1 1,696.8 751.8 (90.4 ) 2,374.3 Operating expenses: Salaries and benefits 22.3 795.7 358.8 (15.1 ) 1,161.7 Other operating expenses 21.6 246.7 120.1 (36.8 ) 351.6 Occupancy costs 4.2 58.2 17.7 (38.5 ) 41.6 Supplies — 78.6 33.3 — 111.9 General and administrative expenses 124.8 — — — 124.8 Depreciation and amortization 9.7 71.9 26.1 — 107.7 Government, class action, and related settlements (1.7 ) — — — (1.7 ) Professional fees—accounting, tax, and legal 9.3 — — — 9.3 Total operating expenses 190.2 1,251.1 556.0 (90.4 ) 1,906.9 Loss on early extinguishment of debt 13.2 — — — 13.2 Interest expense and amortization of debt discounts and fees 99.8 7.8 2.8 (1.2 ) 109.2 Other income (0.7 ) (28.5 ) (3.2 ) 1.2 (31.2 ) Equity in net income of nonconsolidated affiliates — (10.7 ) — — (10.7 ) Equity in net income of consolidated affiliates (314.0 ) (30.6 ) — 344.6 — Management fees (107.9 ) 82.2 25.7 — — Income from continuing operations before income tax (benefit) expense 135.5 425.5 170.5 (344.6 ) 386.9 Provision for income tax (benefit) expense (80.8 ) 148.0 43.5 — 110.7 Income from continuing operations 216.3 277.5 127.0 (344.6 ) 276.2 Income (loss) from discontinued operations, net of tax 5.7 — (0.2 ) — 5.5 Net income 222.0 277.5 126.8 (344.6 ) 281.7 Less: Net income attributable to noncontrolling interests — — (59.7 ) — (59.7 ) Net income attributable to HealthSouth $ 222.0 $ 277.5 $ 67.1 $ (344.6 ) $ 222.0 Comprehensive income $ 221.6 $ 277.5 $ 126.8 $ (344.6 ) $ 281.3 Comprehensive income attributable to HealthSouth $ 221.6 $ 277.5 $ 67.1 $ (344.6 ) $ 221.6 For the Year Ended December 31, 2013 HealthSouth Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries HealthSouth Consolidated (In Millions) Net operating revenues $ 12.2 $ 1,622.4 $ 709.8 $ (71.2 ) $ 2,273.2 Less: Provision for doubtful accounts — (18.3 ) (7.7 ) — (26.0 ) Net operating revenues less provision for doubtful accounts 12.2 1,604.1 702.1 (71.2 ) 2,247.2 Operating expenses: Salaries and benefits 12.1 757.7 334.4 (14.5 ) 1,089.7 Other operating expenses 10.8 238.5 107.5 (33.8 ) 323.0 Occupancy costs 4.1 48.3 17.5 (22.9 ) 47.0 Supplies — 73.8 31.6 — 105.4 General and administrative expenses 119.1 — — — 119.1 Depreciation and amortization 8.8 65.1 20.8 — 94.7 Government, class action, and related settlements (23.5 ) — — — (23.5 ) Professional fees—accounting, tax, and legal 9.5 — — — 9.5 Total operating expenses 140.9 1,183.4 511.8 (71.2 ) 1,764.9 Loss on early extinguishment of debt 2.4 — — — 2.4 Interest expense and amortization of debt discounts and fees 90.4 8.1 3.1 (1.2 ) 100.4 Other income (1.0 ) (1.2 ) (3.5 ) 1.2 (4.5 ) Equity in net income of nonconsolidated affiliates (3.6 ) (7.5 ) (0.1 ) — (11.2 ) Equity in net income of consolidated affiliates (268.0 ) (20.6 ) — 288.6 — Management fees (102.3 ) 78.6 23.7 — — Income from continuing operations before income tax (benefit) expense 153.4 363.3 167.1 (288.6 ) 395.2 Provision for income tax (benefit) expense (169.0 ) 134.4 47.3 — 12.7 Income from continuing operations 322.4 228.9 119.8 (288.6 ) 382.5 Income (loss) from discontinued operations, net of tax 1.2 (0.8 ) (1.5 ) — (1.1 ) Net income 323.6 228.1 118.3 (288.6 ) 381.4 Less: Net income attributable to noncontrolling interests — — (57.8 ) — (57.8 ) Net income attributable to HealthSouth $ 323.6 $ 228.1 $ 60.5 $ (288.6 ) $ 323.6 Comprehensive income $ 322.1 $ 228.1 $ 118.3 $ (288.6 ) $ 379.9 Comprehensive income attributable to HealthSouth $ 322.1 $ 228.1 $ 60.5 $ (288.6 ) $ 322.1 As of December 31, 2015 HealthSouth Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries HealthSouth Consolidated (In Millions) Assets Current assets: Cash and cash equivalents $ 41.2 $ 1.3 $ 19.1 $ — $ 61.6 Restricted cash — — 45.9 — 45.9 Accounts receivable, net — 267.2 143.3 — 410.5 Prepaid expenses and other current assets 29.3 22.7 47.5 (18.8 ) 80.7 Total current assets 70.5 291.2 255.8 (18.8 ) 598.7 Property and equipment, net 14.5 965.7 329.9 — 1,310.1 Goodwill — 863.2 1,026.9 — 1,890.1 Intangible assets, net 8.8 123.2 287.4 — 419.4 Deferred income tax assets 176.2 64.1 — (49.5 ) 190.8 Other long-term assets 48.6 75.3 73.1 — 197.0 Intercompany notes receivable 546.6 — — (546.6 ) — Intercompany receivable and investments in consolidated affiliates 2,779.7 — — (2,779.7 ) — Total assets $ 3,644.9 $ 2,382.7 $ 1,973.1 $ (3,394.6 ) $ 4,606.1 Liabilities and Shareholders’ Equity Current liabilities: Current portion of long-term debt $ 40.0 $ 6.8 $ 7.5 $ (17.5 ) $ 36.8 Accounts payable 5.8 35.2 20.6 — 61.6 Accrued payroll 27.7 50.7 47.8 — 126.2 Accrued interest payable 26.5 2.9 0.3 — 29.7 Other current liabilities 68.0 19.0 86.4 (1.3 ) 172.1 Total current liabilities 168.0 114.6 162.6 (18.8 ) 426.4 Long-term debt, net of current portion 2,821.9 255.6 57.2 — 3,134.7 Intercompany notes payable — — 546.6 (546.6 ) — Self-insured risks 19.8 — 81.8 — 101.6 Other long-term liabilities 23.8 12.4 55.9 (49.1 ) 43.0 Intercompany payable — 141.7 179.1 (320.8 ) — 3,033.5 524.3 1,083.2 (935.3 ) 3,705.7 Commitments and contingencies Redeemable noncontrolling interests — — 121.1 — 121.1 Shareholders’ equity: HealthSouth shareholders’ equity 611.4 1,858.4 600.9 (2,459.3 ) 611.4 Noncontrolling interests — — 167.9 — 167.9 Total shareholders’ equity 611.4 1,858.4 768.8 (2,459.3 ) 779.3 Total liabilities and shareholders’ equity $ 3,644.9 $ 2,382.7 $ 1,973.1 $ (3,394.6 ) $ 4,606.1 As of December 31, 2014 HealthSouth Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries HealthSouth Consolidated (In Millions) Assets Current assets: Cash and cash equivalents $ 41.9 $ 1.5 $ 23.3 $ — $ 66.7 Restricted cash — — 45.6 — 45.6 Accounts receivable, net — 202.6 120.6 — 323.2 Deferred income tax assets 125.0 39.8 23.6 — 188.4 Prepaid expenses and other current assets 30.9 15.4 35.2 (18.8 ) 62.7 Total current assets 197.8 259.3 248.3 (18.8 ) 686.6 Property and equipment, net 16.1 752.0 251.6 — 1,019.7 Goodwill — 279.6 804.4 — 1,084.0 Intangible assets, net 11.3 50.6 244.2 — 306.1 Deferred income tax assets 163.3 17.5 — (51.4 ) 129.4 Other long-term assets 55.8 42.5 64.2 — 162.5 Intercompany notes receivable 385.2 — — (385.2 ) — Intercompany receivable and investments in consolidated affiliates 1,898.7 — — (1,898.7 ) — Total assets $ 2,728.2 $ 1,401.5 $ 1,612.7 $ (2,354.1 ) $ 3,388.3 Liabilities and Shareholders’ Equity Current liabilities: Current portion of long-term debt $ 27.9 $ 4.2 $ 6.2 $ (17.5 ) $ 20.8 Accounts payable 9.3 29.5 14.6 — 53.4 Accrued payroll 17.5 55.6 50.2 — 123.3 Accrued interest payable 19.2 1.8 0.2 — 21.2 Other current liabilities 70.4 15.2 61.3 (1.3 ) 145.6 Total current liabilities 144.3 106.3 132.5 (18.8 ) 364.3 Long-term debt, net of current portion 1,973.4 83.9 33.1 — 2,090.4 Intercompany notes payable — — 385.2 (385.2 ) — Self-insured risks 22.9 — 75.8 — 98.7 Other long-term liabilities 21.2 12.7 55.0 (51.4 ) 37.5 Intercompany payable — 381.0 173.2 (554.2 ) — 2,161.8 583.9 854.8 (1,009.6 ) 2,590.9 Commitments and contingencies Convertible perpetual preferred stock 93.2 — — — 93.2 Redeemable noncontrolling interests — — 84.7 — 84.7 Shareholders’ equity: HealthSouth shareholders’ equity 473.2 817.6 526.9 (1,344.5 ) 473.2 Noncontrolling interests — — 146.3 — 146.3 Total shareholders’ equity 473.2 817.6 673.2 (1,344.5 ) 619.5 Total liabilities and shareholders’ equity $ 2,728.2 $ 1,401.5 $ 1,612.7 $ (2,354.1 ) $ 3,388.3 For the Year Ended December 31, 2015 HealthSouth Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries HealthSouth Consolidated (In Millions) Net cash provided by operating activities $ 29.6 $ 222.6 $ 232.2 $ 0.4 $ 484.8 Cash flows from investing activities: Acquisition of businesses, net of cash acquired (954.6 ) — (30.5 ) — (985.1 ) Purchases of property and equipment (15.9 ) (46.1 ) (66.4 ) — (128.4 ) Capitalized software costs (24.5 ) (0.4 ) (3.2 ) — (28.1 ) Proceeds from sale of restricted investments — — 0.2 — 0.2 Proceeds from sale of marketable securities 12.8 — — — 12.8 Purchases of restricted investments — — (7.1 ) — (7.1 ) Net change in restricted cash — — 2.7 — 2.7 Funding of intercompany note receivable (2.0 ) — — 2.0 — Proceeds from repayment of intercompany note receivable 24.0 — — (24.0 ) — Other (0.5 ) 2.3 0.9 — 2.7 Net cash provided by investing activities of discontinued operations 0.5 — — — 0.5 Net cash used in investing activities (960.2 ) (44.2 ) (103.4 ) (22.0 ) (1,129.8 ) Cash flows from financing activities: Principal borrowings on term loan facilities 250.0 — 2.0 (2.0 ) 250.0 Proceeds from bond issuance 1,400.0 — — — 1,400.0 Principal payments on debt, including pre-payments (595.0 ) (1.6 ) (0.8 ) — (597.4 ) Principal payments on intercompany note payable — — (24.0 ) 24.0 — Borrowings on revolving credit facility 540.0 — — — 540.0 Payments on revolving credit facility (735.0 ) — — — (735.0 ) Debt amendment and issuance costs (31.9 ) — — — (31.9 ) Principal payments under capital lease obligations (0.3 ) (4.5 ) (6.2 ) — (11.0 ) Repurchases of common stock, including fees and expenses (45.3 ) — — — (45.3 ) Dividends paid on common stock (77.2 ) — — — (77.2 ) Dividends paid on convertible perpetual preferred stock (3.1 ) — — — (3.1 ) Distributions paid to noncontrolling interests of consolidated affiliates — — (54.4 ) — (54.4 ) Other 2.2 1.5 1.5 — 5.2 Change in intercompany advances 225.5 (174.0 ) (51.1 ) (0.4 ) — Net cash provided by (used in) financing activities 929.9 (178.6 ) (133.0 ) 21.6 639.9 Decrease in cash and cash equivalents (0.7 ) (0.2 ) (4.2 ) — (5.1 ) Cash and cash equivalents at beginning of year 41.9 1.5 23.3 — 66.7 Cash and cash equivalents at end of year $ 41.2 $ 1.3 $ 19.1 $ — $ 61.6 Supplemental schedule of noncash investing activity: Conversion of preferred stock to common stock $ 93.2 $ — $ — $ — $ 93.2 Intercompany note activity (183.5 ) — 183.5 — — For the Year Ended December 31, 2014 HealthSouth Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries HealthSouth Consolidated (In Millions) Net cash provided by operating activities $ 21.9 $ 260.1 $ 162.9 $ — $ 444.9 Cash flows from investing activities: Acquisition of businesses, net of cash acquired (674.6 ) — (20.2 ) — (694.8 ) Purchases of property and equipment (15.6 ) (124.0 ) (31.3 ) — (170.9 ) Capitalized software costs (8.6 ) (1.4 ) (7.0 ) — (17.0 ) Proceeds from sale of restricted investments — — 0.3 — 0.3 Purchases of restricted investments — — (3.5 ) — (3.5 ) Net change in restricted cash 1.0 — 5.8 — 6.8 Other — (0.7 ) 2.9 — 2.2 Net cash used in investing activities (697.8 ) (126.1 ) (53.0 ) — (876.9 ) Cash flows from financing activities: Principal borrowings on term loan facilities 450.0 — — — 450.0 Proceeds from bond issuance 175.0 — — — 175.0 Principal payments on debt, including pre-payments (298.0 ) (1.5 ) (3.1 ) — (302.6 ) Borrowings on revolving credit facility 440.0 — — — 440.0 Payments on revolving credit facility (160.0 ) — — — (160.0 ) Principal payments under capital lease obligations (0.3 ) (2.5 ) (3.3 ) — (6.1 ) Debt amendment and issuance costs (6.5 ) — — — (6.5 ) Repurchases of common stock, including fees and expenses (43.1 ) — — — (43.1 ) Dividends paid on common stock (65.8 ) — — — (65.8 ) Dividends paid on convertible perpetual preferred stock (6.3 ) — — — (6.3 ) Distributions paid to noncontrolling interests of consolidated affiliates — — (54.1 ) — (54.1 ) Proceeds from exercising stock warrants 6.3 — — — 6.3 Other 7.4 — — — 7.4 Change in intercompany advances 158.6 (130.8 ) (27.8 ) — — Net cash provided by (used in) financing activities 657.3 (134.8 ) (88.3 ) — 434.2 (Decrease) increase in cash and cash equivalents (18.6 ) (0.8 ) 21.6 — 2.2 Cash and cash equivalents at beginning of year 60.5 2.3 1.7 — 64.5 Cash and cash equivalents at end of year $ 41.9 $ 1.5 $ 23.3 $ — $ 66.7 Supplemental schedule of noncash financing activities: Equity rollover from Encompass management $ — $ — $ 64.5 $ — $ 64.5 For the Year Ended December 31, 2013 HealthSouth Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries HealthSouth Consolidated (In Millions) Net cash provided by operating activities $ 113.2 $ 235.7 $ 121.4 $ — $ 470.3 Cash flows from investing activities: Acquisition of businesses, net of cash acquired — (28.9 ) — — (28.9 ) Purchases of property and equipment (2.8 ) (167.9 ) (24.5 ) — (195.2 ) Capitalized software costs (6.0 ) (11.1 ) (4.2 ) — (21.3 ) Proceeds from sale of restricted investments — — 16.9 — 16.9 Proceeds from sale of Digital Hospital 10.8 — — — 10.8 Purchases of restricted investments — — (9.2 ) — (9.2 ) Net change in restricted cash (0.2 ) — (2.9 ) — (3.1 ) Other — 0.9 (0.4 ) — 0.5 Net cash provided by investing activities of discontinued operations — 3.1 0.2 — 3.3 Net cash provided by (used in) investing activities 1.8 (203.9 ) (24.1 ) — (226.2 ) Cash flows from financing activities: Principal payments on debt, including pre-payments (59.5 ) (1.3 ) (1.7 ) — (62.5 ) Principal borrowings on notes — — 15.2 — 15.2 Borrowings on revolving credit facility 197.0 — — — 197.0 Payments on revolving credit facility (152.0 ) — — — (152.0 ) Principal payments under capital lease obligations (0.3 ) (6.3 ) (3.5 ) — (10.1 ) Debt amendment and issuance costs (2.6 ) — — — (2.6 ) Repurchases of common stock, including fees and expenses (234.1 ) — — — (234.1 ) Dividends paid on common stock (15.7 ) — — — (15.7 ) Dividends paid on convertible perpetual preferred stock (23.0 ) — — — (23.0 ) Distributions paid to noncontrolling interests of consolidated affiliates — — (46.3 ) — (46.3 ) Proceeds from exercising stock warrants 15.3 — — — 15.3 Other 4.8 — 1.6 — 6.4 Change in intercompany advances 84.3 (22.2 ) (62.1 ) — — Net cash used in financing activities (185.8 ) (29.8 ) (96.8 ) — (312.4 ) (Decrease) increase in cash and cash equivalents (70.8 ) 2.0 0.5 — (68.3 ) Cash and cash equivalents at beginning of year 131.3 0.3 1.2 — 132.8 Cash and cash equivalents at end of year $ 60.5 $ 2.3 $ 1.7 $ — $ 64.5 Supplemental schedule of noncash financing activities: Convertible debt issued $ 320.0 $ — $ — $ — $ 320.0 Repurchase of preferred stock (320.0 ) — — — (320.0 )

Business Combinations

Business Combinations	12 Months Ended
	Dec. 31, 2015
Business Combinations [Abstract]
Business Combinations	Business Combinations : 2015 Acquisitions Inpatient Rehabilitation Reliant Acquisition In October 2015, we completed the previously announced acquisition of the operations of Reliant Hospital Partners, LLC and affiliated entities (“Reliant”). Reliant operates a portfolio of 11 inpatient rehabilitation hospitals in Texas, Massachusetts, and Ohio with a total of 902 beds. All of the Reliant hospitals are leased, and seven of the leases are treated as capital leases for accounting purposes. We assumed all of these lease obligations. The amount of the capital lease obligation initially recognized on our balance sheet was approximately $210 million . At closing, one Reliant hospital entity had a remaining minority limited partner interest of 0.5%. The cash purchase price was reduced by the estimated fair value of this interest. We funded the cash purchase price in the acquisition with proceeds from our August and September 2015 senior notes issuances and borrowings under our senior secured credit facility. See Note 8, Long-term Debt . With this acquisition, we are able to offer comprehensive, high-quality and cost-effective facility-based care across new and existing service areas. We expect approximately 86% of the goodwill resulting from this transaction to be deductible for federal income tax purposes. The goodwill reflects our expectations of our ability to gain access to and penetrate each acquired hospital’s historical patient base and the benefits of being able to leverage operational efficiencies with favorable growth opportunities based on positive demographic trends in these markets. We accounted for this transaction under the acquisition method of accounting and reported the results of operations of Reliant from its date of acquisition. Assets acquired, liabilities assumed, and noncontrolling interests were recorded at their estimated fair values as of the acquisition date. Estimated fair values were based on various valuation methodologies including: replacement cost and continued use methods for property and equipment; an income approach using primarily discounted cash flow techniques for the noncompete and license intangible assets and capital lease liabilities; an income approach utilizing the relief-from-royalty method for the trade name intangible assets; an income approach utilizing the excess earnings method for the certificate of need intangible assets; and an estimated realizable value approach using historical trends and other relevant information for accounts receivable and certain accrued liabilities. The aforementioned income methods utilize management’s estimates of future operating results and cash flows discounted using a weighted average cost of capital that reflects market participant assumptions. For all other assets and liabilities, the fair value was assumed to represent carrying value due to their short maturities. The excess of the fair value of the consideration conveyed over the fair value of the net assets acquired was recorded as goodwill. The fair values recorded were based upon a preliminary valuation. Estimates and assumptions used in such valuation are subject to change, which could be significant, within the measurement period (up to one year from the acquisition date). The primary areas of the preliminary valuation that are not yet finalized relate to the fair values of amounts for income taxes, adjustments to working capital, and the final amount of residual goodwill. We expect to continue to obtain information to assist us in determining the fair values of the net assets acquired at the acquisition date during the measurement period. The preliminary fair value of the assets acquired and liabilities assumed at the acquisition date were as follows (in millions): Cash and cash equivalents $ 42.6 Accounts receivable 25.7 Prepaid expenses and other current assets 2.8 Property and equipment 220.6 Identifiable intangible assets: Noncompete agreements (useful lives of 1 to 2 years) 9.7 Trade names (useful lives of 20 years) 8.9 Certificates of need (useful lives of 20 years) 36.6 Licenses (useful lives of 20 years) 11.4 Goodwill 642.6 Other long-term assets 0.9 Total assets acquired 1,001.8 Liabilities assumed: Current portion of long-term debt 4.1 Accounts payable 1.7 Accrued payroll 3.7 Other current liabilities 10.8 Long-term debt, net of current portion 205.8 Deferred tax liabilities 3.9 Total liabilities assumed 230.0 Noncontrolling interests 0.4 Net assets acquired $ 771.4 Information regarding the net cash paid for the acquisition of Reliant is as follows (in millions): Fair value of assets acquired, net of $42.6 million of cash acquired $ 316.6 Goodwill 642.6 Fair value of liabilities assumed (230.0 ) Noncontrolling interests (0.4 ) Net cash paid for acquisition $ 728.8 Other Inpatient Rehabilitation Acquisitions In April 2015, we acquired 83% of the inpatient rehabilitation hospital at Memorial University Medical Center (“Memorial”), a 50 -bed inpatient rehabilitation hospital in Savannah, Georgia, through a joint venture with Memorial Health. The joint venture, which was funded using cash on hand, was not material to our financial position, results of operations, or cash flows. The Memorial transaction was made to enhance our position and ability to provide inpatient rehabilitative services to patients in Savannah and its surrounding areas. As a result of this transaction, Goodwill increased by $0.7 million , none of which is deductible for federal income tax purposes. In May 2015, we acquired Cardinal Hill Rehabilitation Hospital (“Cardinal Hill”), comprised of 158 licensed inpatient rehabilitation beds, 74 licensed skilled nursing beds, and one home health location, in Lexington, Kentucky. This acquisition was made to enhance our position and ability to provide inpatient rehabilitative and home health services to patients in Lexington, Kentucky and its surrounding areas. The acquisition, which was funded using availability under our revolving credit facility, was not material to our financial position, results of operations, or cash flows. Goodwill did not increase as a result of this transaction. We accounted for these transactions under the acquisition method of accounting and reported the results of operations of the acquired hospitals from their respective dates of acquisition. Assets acquired, liabilities assumed, and noncontrolling interests, if any, were recorded at their estimated fair values as of the respective acquisition dates. The fair values of identifiable intangible assets were based on valuations using the cost and income approaches. The cost approach is based on amounts that would be required to replace the asset (i.e., replacement cost). The income approach, which was also used to estimate the fair value of any noncontrolling interest, is based on management’s estimates of future operating results and cash flows discounted using a weighted-average cost of capital that reflects market participant assumptions. The excess of the fair value of the consideration conveyed over the fair value of the net assets acquired, if any, was recorded as goodwill. The goodwill reflects our expectations of our ability to gain access to and penetrate the acquired or consolidated hospitals’ historical patient base and the benefits of being able to leverage operational efficiencies with favorable growth opportunities based on positive demographic trends in these markets. The fair value of the assets acquired and liabilities assumed at the acquisition dates for the other inpatient rehabilitation transactions completed in 2015 were as follows (in millions): Total current assets $ 10.1 Property and equipment 42.7 Identifiable intangible assets: Noncompete agreements (useful lives of 2 to 3 years) 0.1 Trade names (useful lives of 20 years) 0.8 Certificates of need (useful lives of 20 years) 8.8 Licenses (useful lives of 20 years) 0.2 Goodwill 0.7 Total assets acquired 63.4 Total liabilities assumed (2.7 ) Net assets acquired $ 60.7 Information regarding the net cash paid for other inpatient rehabilitation acquisitions during each period presented is as follows (in millions): For the Year Ended December 31, 2015 2014 2013 Fair value of assets acquired $ 62.8 $ 60.1 $ 15.6 Goodwill 0.7 34.6 13.7 Fair value of liabilities assumed (2.7 ) (21.2 ) (0.4 ) Fair value of noncontrolling interest owned by joint venture partner (4.2 ) (18.3 ) — Fair value of equity interest prior to acquisition — (35.0 ) — Net cash paid for acquisitions $ 56.6 $ 20.2 $ 28.9 See also Note 7, Investments in and Advances to Nonconsolidated Affiliates . Home Health and Hospice CareSouth Acquisition In November 2015, Encompass, a subsidiary of HealthSouth, completed its previously announced acquisition of the home health agency operations of CareSouth Health System, Inc. (“CareSouth”). CareSouth operates a portfolio of 44 home health agencies and 3 hospice agencies in Alabama, Florida, Georgia, North Carolina, South Carolina, Tennessee, and Virginia. In addition, two of these home health agencies operate as joint ventures which we account for using the equity method of accounting. We funded the cash purchase price in the acquisition with our term loan facility capacity and cash on hand. See Note 8, Long-term Debt . With this acquisition, we are able to offer comprehensive, high-quality and cost-effective home-based care across new and existing service areas. We expect approximately 6.5% of the goodwill resulting from this transaction to be deductible for federal income tax purposes. The goodwill reflects our expectations of favorable growth opportunities in the home health and hospice markets based on positive demographic trends. We accounted for this transaction under the acquisition method of accounting and reported the results of operations of CareSouth from its date of acquisition. Assets acquired, liabilities assumed, and noncontrolling interests were recorded at their estimated fair values as of the acquisition date. Estimated fair values were based on various valuation methodologies including: replacement cost and continued use methods for property and equipment; an income approach using primarily discounted cash flow techniques for the noncompete and license intangible assets and capital lease liabilities; an income approach utilizing the relief-from-royalty method for the trade name intangible asset; an income approach utilizing the excess earnings method for the certificate of need intangible assets; and an estimated realizable value approach using historical trends and other relevant information for accounts receivable and certain accrued liabilities. The aforementioned income methods utilize management’s estimates of future operating results and cash flows discounted using a weighted average cost of capital that reflects market participant assumptions. For all other assets and liabilities, the fair value was assumed to represent carrying value due to their short maturities. The excess of the fair value of the consideration conveyed over the fair value of the net assets acquired was recorded as goodwill. The fair values recorded were based upon a preliminary valuation. Estimates and assumptions used in such valuation are subject to change, which could be significant, within the measurement period (up to one year from the acquisition date). The primary areas of the preliminary valuation that are not yet finalized relate to the fair values of amounts for income taxes, adjustments to working capital, and the final amount of residual goodwill. We expect to continue to obtain information to assist us in determining the fair values of the net assets acquired at the acquisition date during the measurement period. The preliminary fair value of the assets acquired and liabilities assumed at the acquisition date were as follows (in millions): Cash and cash equivalents $ 0.4 Accounts receivable 10.5 Prepaid expenses and other current assets 2.4 Property and equipment 0.7 Identifiable intangible assets: Noncompete agreements (useful lives of 3 years) 0.8 Trade name (useful life of 5 years) 2.8 Certificates of need (useful lives of 10 years) 15.6 Licenses (useful lives of 10 years) 13.0 Internal use software 0.4 Goodwill 142.5 Investment in nonconsolidated subsidiaries 2.2 Total assets acquired 191.3 Liabilities assumed: Current portion of long-term debt 0.1 Accounts payable 2.4 Accrued payroll 2.4 Other current liabilities 2.8 Long-term debt, net of current portion 0.2 Deferred tax liabilties 9.4 Total liabilities assumed 17.3 Noncontrolling interests 4.3 Net assets acquired $ 169.7 Information regarding the net cash paid for the acquisition of CareSouth is as follows (in millions): Fair value of assets acquired, net of $0.4 million of cash acquired $ 48.4 Goodwill 142.5 Fair value of liabilities assumed (17.3 ) Fair value of noncontrolling interest owned by joint venture partner (4.3 ) Net cash paid for acquisitions $ 169.3 Other Home Health and Hospice Acquisitions Other than the CareSouth acquisition discussed above, we completed the following home health and hospice acquisitions, none of which were individually material to our financial position, results of operations, or cash flows. Each acquisition was made to enhance our position and ability to provide post-acute healthcare services to patients in the applicable geographic areas. Each acquisition was funded with cash on hand. • In March 2015, we acquired Integrity Home Health Care, Inc. (“Integrity”), a home health company with two locations in the Las Vegas, Nevada area. • In April 2015, we acquired Harvey Home Health Services, Inc. (“Harvey”), a home health company in Houston, Texas. • In May 2015, we acquired Heritage Home Health Care, LLC (“Heritage”), a home health company in Texarkana, Arkansas. • In June 2015, we acquired Washington County Home Health Care, Inc. and Benton County Home Health, Inc., doing business as Alliance Home Health (“Alliance”), a home health company with two locations in the Fayetteville, Arkansas area. • In July 2015, we acquired Southern Utah Home Health, Inc. (“Southern Utah”), a home health and hospice company with two home health locations and two hospice locations in southern Utah. • In July 2015, we acquired Orthopedic Rehab Specialist, LLC (“ORS”), a home health company in Ocala, Florida. We accounted for all of these transactions under the acquisition method of accounting and reported the results of operations of the acquired locations from their respective dates of acquisition. Assets acquired and liabilities assumed were recorded at their estimated fair values as of the respective acquisition dates. The fair values of identifiable intangible assets were based on valuations using the cost and income approaches. The cost approach is based on amounts that would be required to replace the asset (i.e., replacement cost). The income approach is based on management’s estimates of future operating results and cash flows discounted using a weighted-average cost of capital that reflects market participant assumptions. The excess of the fair value of the consideration conveyed over the fair value of the net assets acquired was recorded as goodwill. The goodwill reflects our expectations of our ability to utilize the acquired locations’ mobile workforce and established relationships within each community and the benefits of being able to leverage operational efficiencies with favorable growth opportunities based on positive demographic trends in these markets. All goodwill recorded as a result of these transactions is deductible for federal income tax purposes. The fair value of the assets acquired and liabilities assumed at the acquisition dates for the other home health and hospice transactions completed in 2015 were as follows (in millions): Property and equipment $ 0.1 Identifiable intangible assets: Noncompete agreements (useful lives of 2 to 5 years) 1.3 Trade names (useful lives of 1 year) 0.5 Certificates of need (useful lives of 10 years) 4.9 Licenses (useful lives of 10 years) 3.6 Goodwill 20.3 Total assets acquired 30.7 Total liabilities assumed (0.2 ) Net assets acquired $ 30.5 Information regarding the net cash paid for the other home health and hospice acquisitions during each period presented is as follows (in millions): For the Year Ended December 31, 2015 2014 2013 Fair value of assets acquired $ 10.4 $ — $ — Goodwill 20.3 — — Fair value of liabilities assumed (0.2 ) — — Net cash paid for acquisitions $ 30.5 $ — $ — 2015 Pro Forma Results of Operations The following table summarizes the results of operations of the above mentioned transactions from their respective dates of acquisition included in our consolidated results of operations and the unaudited pro forma results of operations of the combined entity had the date of the acquisitions been January 1, 2014 (in millions): Net Operating Revenues Net Income Attributable to HealthSouth Acquired entities only: Actual from acquisition date to December 31, 2015:* Reliant $ 63.7 $ 11.2 All Other Inpatient 54.7 1.7 CareSouth 19.2 2.5 All Other Home Health and Hospice 17.8 1.2 Combined entity: Supplemental pro forma from 1/01/2015-12/31/2015 (unaudited) 3,479.9 234.0 Combined entity: Supplemental pro forma from 1/01/2014-12/31/2014 (unaudited) 2,851.0 276.9 * Savannah - includes operating results from April 1, 2015 through December 31, 2015 Cardinal Hill - includes operating results from May 1, 2015 through December 31, 2015 Integrity - includes operating results from March 3, 2015 through December 31, 2015 Harvey - includes operating results from April 15, 2015 through December 31, 2015 Heritage - includes operating results from May 1, 2015 through December 31, 2015 Alliance - includes operating results from June 4, 2015 through December 31, 2015 Southern Utah - includes operating results from July 1, 2015 through December 31, 2015 ORS - includes operating results from July 13, 2015 through December 31, 2015 Reliant - includes operating results from October 1, 2015 through December 31, 2015 CareSouth - includes operating results from November 2, 2015 through December 31, 2015 The information presented above is for illustrative purposes only and is not necessarily indicative of results that would have been achieved if the acquisitions had occurred as of the beginning of our 2014 reporting period. For the Reliant and CareSouth acquisitions, the unaudited pro forma information above includes adjustments for: (1) acquisition costs; (2) amortization of incremental identifiable intangible assets; (3) management fees paid to their former equity holders; (4) interest on debt incurred to fund the acquisitions (see Note 8 , Long-term Debt ); (5) income taxes using a rate of 40%; and (6) noncontrolling interests. 2014 and 2013 Acquisitions Encompass Acquisition On December 31, 2014, we completed the acquisition of EHHI and its Encompass Home Health and Hospice business. On the acquisition date, Encompass provided home health and hospice services out of 135 locations across 12 states. In the acquisition, we acquired all of the issued and outstanding equity interests of EHHI, other than equity interests contributed to HealthSouth Home Health Holdings, Inc. (“Holdings”), a subsidiary of HealthSouth and now indirect parent of EHHI, by certain sellers in exchange for shares of common stock of Holdings. These certain sellers, who are members of Encompass management, including April Anthony, the Chief Executive Officer of Encompass, contributed a portion of their shares of common stock of EHHI, valued at approximately $64.5 million , in exchange for shares of common stock of Holdings. As a result of that contribution, they hold approximately 16.7% of the outstanding common stock of Holdings, while HealthSouth owns the remainder. In addition, Ms. Anthony and certain other employees of Encompass entered into amended and restated employment agreements, each agreement having an initial term of three years. We funded the cash purchase price in the acquisition entirely with draws under the revolving and expanded term loan facilities of our credit agreement. See Note 8, Long-term Debt . This acquisition was made to enhance our position and expand our ability to provide post-acute healthcare services to patients. Approximately 23% of the goodwill resulting from this transaction is deductible for federal income tax purposes. The goodwill reflects our expectations of favorable growth opportunities in the home health and hospice markets based on positive demographic trends. We accounted for this transaction under the acquisition method of accounting. Because the acquisition took place on December 31, 2014, our consolidated results of operations for the year ended December 31, 2014 do not include any results of operations from Encompass. Assets acquired, liabilities assumed, and redeemable noncontrolling interests were recorded at their estimated fair values as of the acquisition date. Fair values were based on various valuation methodologies including: replacement cost and continued use methods for property and equipment; an income approach using primarily discounted cash flow techniques for amortizable intangible assets; an income approach utilizing the relief-from-royalty method for the indefinite-lived intangible asset; and an estimated realizable value approach using historical trends and other relevant information for accounts receivable and certain accrued liabilities. For all other assets and liabilities, the fair value was assumed to represent carrying value due to their short maturities. The excess of the fair value of the consideration conveyed over the fair value of the net assets acquired was recorded as goodwill. The fair value of the assets acquired and liabilities assumed at the acquisition date for Encompass were as follows (in millions): Cash and cash equivalents $ 20.9 Accounts receivable 37.6 Prepaid expenses and other current assets 8.6 Property and equipment 9.6 Identifiable intangible assets: Noncompete agreements (useful life of 2 to 5 years) 5.6 Trade name (indefinite life) 135.2 Licenses (useful life of 10 years) 58.2 Internal-use software (useful life of 3 years) 3.2 Goodwill 592.5 Other long-term assets 2.1 Total assets acquired 873.5 Current portion of long-term debt 2.0 Accounts payable 0.9 Accrued payroll 25.8 Other current liabilities 18.5 Long-term debt, net of current portion 2.0 Deferred tax liabilities 64.3 Total liabilities assumed 113.5 Redeemable noncontrolling interests 64.5 Net assets acquired $ 695.5 Information regarding the net cash paid for the acquisition of Encompass is as follows (in millions): Fair value of assets acquired, net of $20.9 million of cash acquired $ 260.1 Goodwill 592.5 Fair value of liabilities assumed (113.5 ) Redeemable noncontrolling interests (64.5 ) Net cash paid for acquisition $ 674.6 See also Note 11, Redeemable Noncontrolling Interests . Other Acquisitions In June 2014, using cash on hand, we acquired an additional 30% equity interest from UMass Memorial Health Care, our joint venture partner in Fairlawn Rehabilitation Hospital (“Fairlawn”) in Worcester, Massachusetts. This transaction increased our ownership interest from 50% to 80% and resulted in a change in accounting for this hospital from the equity method of accounting to a consolidated entity. As a result of our consolidation of this hospital and the remeasurement of our previously held equity interest at fair value, Goodwill increased by $34.0 million , and we recorded a $27.2 million gain as part of Other income during 2014. The Fairlawn transaction was made to increase our ownership in a profitable hospital and continue to grow our core business by consolidating its operations. None of the goodwill resulting from this transaction is deductible for federal income tax purposes. See also Note 15, Income Taxes . In November 2014, we acquired 50.1% of the James H. & Cecile C. Quillen Rehabilitation Hospital (“Quillen”), a 26 -bed inpatient rehabilitation hospital in Johnson City, Tennessee, through a joint venture with Mountain States Health Alliance. The joint venture, which was funded using cash on hand, was not material to our financial position, results of operations, or cash flows. The Quillen transaction was made to enhance our position and ability to provide inpatient rehabilitative services to patients in Johnson City and its surrounding areas. As a result of this transaction, Goodwill increased by $0.6 million , none of which is deductible for federal income tax purposes. The noncontrolling interest associated with this agreement includes redemption features that are not solely within our control and, therefore, is considered Redeemable noncontrolling interests. See Note 11, Redeemable Noncontrolling Interests . In April 2013, we closed the transaction to acquire Walton Rehabilitation Hospital, a 58 -bed inpatient rehabilitation hospital in Augusta, Georgia. This acquisition was made to enhance our position and ability to provide inpatient rehabilitative services to patients in Augusta, Georgia and its surrounding areas. The acquisition, which was funded using availability under our revolving credit facility, was not material to our financial position, results of operations, or cash flows. As a result of this transaction, Goodwill increased by $13.7 million , all of which is deductible for federal income tax purposes. We accounted for all of these transactions under the acquisition method of accounting and reported the results of operations of the acquired or newly consolidated hospitals from their respective dates of acquisition. Assets acquired and liabilities assumed were recorded at their estimated fair values as of the respective acquisition dates. The fair values of identifiable intangible assets were based on valuations using the cost and income approaches. The cost approach is based on amounts that would be required to replace the asset (i.e., replacement cost). The income approach is based on management’s estimates of future operating results and cash flows discounted using a weighted-average cost of capital that reflects market participant assumptions. The excess of the fair value of the consideration conveyed over the fair value of the net assets acquired was recorded as goodwill. The goodwill reflects our expectations of our ability to gain access to and penetrate the acquired or consolidated hospitals’ historical patient base and the benefits of being able to leverage operational efficiencies with favorable growth opportunities based on positive demographic trends in these markets. The fair value of the assets acquired and liabilities assumed at the acquisition dates for the other acquisitions completed in 2014 were as follows (in millions): Total current assets $ 12.1 Property and equipment, net 36.9 Identifiable intangible assets: Noncompete agreements (useful lives of 2 to 3 years) 0.4 Trade names (useful lives of 20 years) 2.9 Certificates of need (useful lives of 20 years) 10.8 Licenses (useful lives of 20 years) 2.1 Goodwill 34.6 Total assets acquired 99.8 Total current liabilities assumed (7.8 ) Total long-term liabilities assumed (13.4 ) Net assets acquired $ 78.6 Information regarding the net cash paid for all other acquisitions during each period presented is as follows (in millions): For the Year Ended December 31, 2014 2013 Fair value of assets acquired, net of $5.1 million of cash acquired in 2014 $ 60.1 $ 15.6 Goodwill 34.6 13.7 Fair value of liabilities assumed (21.2 ) (0.4 ) Fair value of noncontrolling interest owned by joint venture partner (18.3 ) — Fair value of equity interest prior to acquisition (35.0 ) — Net cash paid for acquisitions $ 20.2 $ 28.9 See also Note 7, Investments in and Advances to Nonconsolidated Affiliates . 2014 Pro Forma Results of Operations The following table summarizes the results of operations of the above 2014 transactions from their respective dates of acquisition included in our consolidated results of operations and the unaudited pro forma results of operations of the combined entity had the date of the acquisitions been January 1, 2013 (in millions): Net Operating Revenues Net Income Attributable to HealthSouth Acquired entities only: Actual from acquisition date to December 31, 2014* $ 27.2 $ 4.0 Combined entity: Supplemental pro forma from 1/01/2014-12/31/2014 (unaudited) 2,799.8 237.5 Combined entity: Supplemental pro forma from 1/01/2013-12/31/2013 (unaudited) 2,627.6 311.3 * Encompass - Actual amounts are zero due to the acquisition of Encompass on December 31, 2014. Fairlawn - includes operating results from June 1, 2014 through December 31, 2014 Quillen - includes operating results from November 1, 2014 through December 31, 2014 The information presented above is for illustrative purposes only and is not necessarily indicative of results that would have been achieved if the acquisitions had occurred as of the beginning of our 2013 reporting period. For the Encompass acquisition, the unaudited pro forma information above includes adjustments for: (1) acquisition costs; (2) amortization of incremental identifiable intangible assets; (3) management fees paid to Encompass’ former equity holders; (4) interest on debt incurred to fund the acquisition (see Note 8, Long-term Debt ); (5) income taxes using a rate of 40%; and (6) noncontrolling interests.

Summary of Significant Accoun28

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Organization and Description of Business— HealthSouth Corporation, incorporated in Delaware in 1984 , including its subsidiaries, is one of the nation’s largest providers of post-acute healthcare services, offering both facility-based and home-based post-acute services in 34 states and Puerto Rico through our network of inpatient rehabilitation hospitals, home health agencies, and hospice agencies. As a result of the December 31, 2014 acquisition of Encompass Home Health and Hospice (“Encompass”), management changed the way it manages and operates the consolidated reporting entity and modified the reports used by its chief operating decision maker to assess performance and allocate resources. These changes required us to revise our segment reporting from our historic presentation of only one reportable segment. We now manage our operations and disclose financial information using two reportable segments: (1) inpatient rehabilitation and (2) home health and hospice. See Note 18 , Segment Reporting .
Basis of Presentation and Consolidation	Basis of Presentation and Consolidation— The accompanying consolidated financial statements of HealthSouth and its subsidiaries were prepared in accordance with generally accepted accounting principles in the United States of America and include the assets, liabilities, revenues, and expenses of all wholly-owned subsidiaries, majority-owned subsidiaries over which we exercise control, and, when applicable, entities in which we have a controlling financial interest. We use the equity method to account for our investments in entities we do not control, but where we have the ability to exercise significant influence over operating and financial policies. Consolidated Net income attributable to HealthSouth includes our share of the net earnings of these entities. The difference between consolidation and the equity method impacts certain of our financial ratios because of the presentation of the detailed line items reported in the consolidated financial statements for consolidated entities compared to a one line presentation of equity method investments. We use the cost method to account for our investments in entities we do not control and for which we do not have the ability to exercise significant influence over operating and financial policies. In accordance with the cost method, these investments are recorded at the lower of cost or fair value, as appropriate. We also consider the guidance for consolidating variable interest entities. We eliminate all significant intercompany accounts and transactions from our financial results.
Use of Estimates and Assumptions	Use of Estimates and Assumptions— The preparation of our consolidated financial statements in conformity with GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions are used for, but not limited to: (1) allowance for contractual revenue adjustments; (2) allowance for doubtful accounts; (3) fair value of acquired assets and assumed liabilities in business combinations; (4) asset impairments, including goodwill; (5) depreciable lives of assets; (6) useful lives of intangible assets; (7) economic lives and fair value of leased assets; (8) income tax valuation allowances; (9) uncertain tax positions; (10) fair value of stock options and restricted stock containing a market condition; (11) fair value of redeemable noncontrolling interests; (12) reserves for self-insured healthcare plans; (13) reserves for professional, workers’ compensation, and comprehensive general insurance liability risks; and (14) contingency and litigation reserves. Future events and their effects cannot be predicted with certainty; accordingly, our accounting estimates require the exercise of judgment. The accounting estimates used in the preparation of our consolidated financial statements will change as new events occur, as more experience is acquired, as additional information is obtained, and as our operating environment changes. We evaluate and update our assumptions and estimates on an ongoing basis and may employ outside experts to assist in our evaluation, as considered necessary. Actual results could differ from those estimates.
Net Operating Revenues	Net Operating Revenues— We derived consolidated Net operating revenues from the following payor sources: For the Year Ended December 31, 2015 2014 2013 Medicare 74.9 % 74.1 % 74.5 % Managed care and other discount plans, including Medicare Advantage 17.7 % 18.6 % 18.5 % Medicaid 3.0 % 1.8 % 1.2 % Other third-party payors 1.7 % 1.8 % 1.8 % Workers' compensation 0.9 % 1.2 % 1.2 % Patients 0.6 % 1.0 % 1.1 % Other income 1.2 % 1.5 % 1.7 % Total 100.0 % 100.0 % 100.0 % We record gross service charges in our accounting records on an accrual basis using our established rates for the type of service provided to the patient. We recognize an estimated contractual allowance and an estimate of potential subsequent adjustments that may arise from post-payment and other reviews to reduce gross patient charges to the amount we estimate we will actually realize for the service rendered based upon previously agreed to rates with a payor. Our accounting systems calculate contractual allowances on a patient-by-patient basis based on the rates in effect for each primary third-party payor. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms that result from contract renegotiations and renewals. Due to complexities involved in determining amounts ultimately due under reimbursement arrangements with third-party payors, which are often subject to interpretation, we may receive reimbursement for healthcare services authorized and provided that is different from our estimates, and such differences could be material. In addition, laws and regulations governing the Medicare and Medicaid programs are complex, subject to interpretation, and are routinely modified for provider reimbursement. All healthcare providers participating in the Medicare and Medicaid programs are required to meet certain financial reporting requirements. Federal regulations require submission of annual cost reports covering medical costs and expenses associated with the services provided under each hospital, home health, and hospice provider number to program beneficiaries. Annual cost reports required under the Medicare and Medicaid programs are subject to routine audits, which may result in adjustments to the amounts ultimately determined to be due to HealthSouth under these reimbursement programs. These audits often require several years to reach the final determination of amounts earned under the programs. If actual results are not consistent with our assumptions and judgments, we may be exposed to gains or losses that could be material. CMS has been granted authority to suspend payments, in whole or in part, to Medicare providers if CMS possesses reliable information an overpayment, fraud, or willful misrepresentation exists. If CMS suspects payments are being made as the result of fraud or misrepresentation, CMS may suspend payment at any time without providing prior notice to us. The initial suspension period is limited to 180 days. However, the payment suspension period can be extended almost indefinitely if the matter is under investigation by the United States Department of Health and Human Services Office of Inspector General (the “HHS-OIG”) or the United States Department of Justice. Therefore, we are unable to predict if or when we may be subject to a suspension of payments by the Medicare and/or Medicaid programs, the possible length of the suspension period, or the potential cash flow impact of a payment suspension. Any such suspension would adversely impact our financial position, results of operations, and cash flows. Pursuant to legislative directives and authorizations from Congress, CMS has developed and instituted various Medicare audit programs under which CMS contracts with private companies to conduct claims and medical record audits. As a matter of course, we undertake significant efforts through training and education to ensure compliance with Medicare requirements. However, audits may lead to assertions we have been underpaid or overpaid by Medicare or submitted improper claims in some instances, require us to incur additional costs to respond to requests for records and defend the validity of payments and claims, and ultimately require us to refund any amounts determined to have been overpaid. We cannot predict when or how these audit programs will affect us. Inpatient Rehabilitation Revenues Our inpatient rehabilitation segment derived its Net operating revenues from the following payor sources: As of December 31, 2015 2014 2013 Medicare 73.2 % 73.9 % 74.2 % Managed care and other discount plans, including Medicare Advantage 19.0 % 18.8 % 18.7 % Medicaid 2.5 % 1.8 % 1.2 % Other third-party payors 2.0 % 1.8 % 1.8 % Workers’ compensation 1.1 % 1.2 % 1.3 % Patients 0.7 % 1.0 % 1.1 % Other income 1.5 % 1.5 % 1.7 % Total 100.0 % 100.0 % 100.0 % Revenues recognized by our inpatient rehabilitation segment are subject to a number of elements which impact both the overall amount of revenue realized as well as the timing of the collection of the related accounts receivable. Factors that are considered and could influence the level of our reserves include the patient’s total length of stay for in-house patients, each patient’s discharge destination, the proportion of patients with secondary insurance coverage and the level of reimbursement under that secondary coverage, and the amount of charges that will be disallowed by payors. Such additional factors are assumed to remain consistent with the experience for patients discharged in similar time periods for the same payor classes, and additional reserves are provided to account for these factors. In connection with CMS approved and announced Recovery Audit Contractors (“RACs”) audits related to inpatient rehabilitation facilities (“IRFs”), we received requests in 2014 and 2013 to review certain patient files for discharges occurring from 2010 to 2014. These post-payment RAC audits are focused on medical necessity requirements for admission to IRFs rather than targeting a specific diagnosis code as in previous pre-payment audits. Medical necessity is an assessment by an independent physician of a patient’s ability to tolerate and benefit from intensive multi-disciplinary therapy provided in an IRF setting. To date, the Medicare payments that are subject to these audit requests represent less than 1% of our Medicare patient discharges from 2010 to 2014, and not all of these patient file requests have resulted in payment denial determinations by the RACs. Because we have confidence in the medical judgment of both the referring and the admitting physicians who assess the treatment needs of their patients, we have appealed substantially all RAC denials arising from these audits using the same process we follow for appealing denials of certain diagnosis codes by Medicare Administrative Contractors (“MACs”) (see “Accounts Receivable and Allowance for Doubtful Accounts” below). Due to the delays announced by CMS in the related adjudication process, we believe the resolution of any claims that are subsequently denied as a result of these RAC audits could take in excess of three years. In addition, because we have limited experience with RACs in the context of post-payment reviews of this nature, we cannot provide assurance as to the future success of these disputes. As such, we make provisions for these claims based on our historical experience and success rates in the claims adjudication process, which is the same process we follow for appealing denials of certain diagnosis codes by MACs. As the ultimate results of these audits impact our estimates of amounts determined to be due to HealthSouth under these reimbursement programs, our provision for claims that are part of this post-payment review process are recorded to Net operating revenues . During 2015 and 2014, we adjusted our Net operating revenues by approximately ($0.6) million and $0.4 million , respectively, for post-payment claims that are part of this review process. Home Health and Hospice Revenues The results of operations for our home health and hospice segment in 2014 and 2013 included only the results of HealthSouth’s legacy hospital-based home health agencies. Our home health and hospice segment derived its Net operating revenues from the following payor sources: As of December 31, 2015 2014 2013 Medicare 83.7 % 96.9 % 95.8 % Managed care and other discount plans, including Medicare Advantage 10.7 % 1.8 % 2.5 % Medicaid 5.5 % — % — % Other third-party payors — % 1.0 % 1.4 % Workers’ compensation — % 0.3 % 0.3 % Patients 0.1 % — % — % Total 100.0 % 100.0 % 100.0 % Home health and hospice revenues are earned as services are performed either on an episode of care basis, on a per visit basis, or on a daily basis, depending upon the payment terms and conditions established with each payor for services provided. Home Health Under the Medicare home health prospective payment system, we are paid by Medicare based on episodes of care. An episode of care is defined as a length of stay up to 60 days, with multiple continuous episodes allowed. A base episode payment is established by the Medicare program through federal legislation. The base episode payment can be adjusted based on each patient’s health including clinical condition, functional abilities, and service needs, as well as for the applicable geographic wage index, low utilization, patient transfers, and other factors. The services covered by the episode payment include all disciplines of care in addition to medical supplies. A portion of reimbursement from each Medicare episode is billed near the start of each episode, and cash is typically received before all services are rendered. Revenue for the episode of care is recorded over an average length of treatment period using a calendar day prorating method. The amount of revenue recognized for episodes of care which are incomplete at period end is based on the pro rata number of days in the episode which have been completed as of the period end date. As of December 31, 2015 , the difference between the cash received from Medicare for a request for anticipated payment on episodes in progress and the associated estimated revenue was not material and was recorded in Other current liabilities in our condensed consolidated balance sheets. We are subject to certain Medicare regulations affecting outlier revenue if our patient’s care was unusually costly. Regulations require a cap on all outlier revenue at 10% of total Medicare revenue received by each provider during a cost reporting year. Management has reviewed the potential cap. Reserves recorded for the outlier cap were not material as of December 31, 2015 . For episodic-based rates that are paid by other insurance carriers, including Medicare Advantage, we recognize revenue in a similar manner as discussed above for Medicare revenues. However, these rates can vary based upon the negotiated terms. For non-episodic-based revenue, gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates. Contractual allowances are recorded for the differences between our standard rates and the applicable contracted rates. Hospice Medicare revenues for hospice are recorded on an accrual basis based on the number of days a patient has been on service at amounts equal to an estimated daily or hourly payment rate. The payment rate is dependent on whether a patient is receiving routine home care, general inpatient care, continuous home care or respite care. Adjustments to Medicare revenues are recorded based on an inability to obtain appropriate billing documentation or authorizations acceptable to the payor or other reasons unrelated to credit risk. Hospice companies are subject to two specific payment limit caps under the Medicare program. One limit relates to inpatient care days that exceed 20% of the total days of hospice care provided for the year. The second limit relates to an aggregate Medicare reimbursement cap calculated by the Medicare fiscal intermediary. Currently, we do not believe we are at risk for exceeding these caps and have not recorded a reserve for these caps as of December 31, 2015 . For non-Medicare hospice revenues, we record gross revenue on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per day rates, as applicable. Contractual adjustments are recorded for the difference between our established rates and the amounts estimated to be realizable from patients and third parties for services provided and are deducted from gross revenue to determine our net service revenue. We are subject to changes in government legislation that could impact Medicare payment levels and changes in payor patterns that may impact the level and timing of payments for services rendered.
Cash and Cash Equivalents	Cash and Cash Equivalents— Cash and cash equivalents include highly liquid investments with maturities of three months or less when purchased. Carrying values of Cash and cash equivalents approximate fair value due to the short-term nature of these instruments. We maintain amounts on deposit with various financial institutions, which may, at times, exceed federally insured limits. However, management periodically evaluates the credit-worthiness of those institutions, and we have not experienced any losses on such deposits.
Marketable Securities	Marketable Securities— We record all equity securities with readily determinable fair values and for which we do not exercise significant influence as available-for-sale securities. We carry the available-for-sale securities at fair value and report unrealized holding gains or losses, net of income taxes, in Accumulated other comprehensive loss , which is a separate component of shareholders’ equity. We recognize realized gains and losses in our consolidated statements of operations using the specific identification method. Unrealized losses are charged against earnings when a decline in fair value is determined to be other than temporary. Management reviews several factors to determine whether a loss is other than temporary, such as the length of time a security is in an unrealized loss position, the extent to which fair value is less than cost, the financial condition and near term prospects of the issuer, industry, or geographic area and our ability and intent to hold the security for a period of time sufficient to allow for any anticipated recovery in fair value.
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts— We report accounts receivable at estimated net realizable amounts from services rendered from federal and state agencies (under the Medicare and Medicaid programs), managed care health plans, commercial insurance companies, workers’ compensation programs, employers, and patients. Our accounts receivable are geographically dispersed, but a significant portion of our revenues are concentrated by type of payors. The concentration of net patient service accounts receivable by payor class, as a percentage of total net patient service accounts receivable, is as follows: As of December 31, 2015 2014 Medicare 70.5 % 72.2 % Managed care and other discount plans, including Medicare Advantage 19.7 % 18.5 % Medicaid 2.9 % 1.8 % Other third-party payors 4.1 % 3.8 % Workers' compensation 1.9 % 1.9 % Patients 0.9 % 1.8 % Total 100.0 % 100.0 % While revenues and accounts receivable from the Medicare program are significant to our operations, we do not believe there are significant credit risks associated with this government agency. We do not believe there are any other significant concentrations of revenues from any particular payor that would subject us to any significant credit risks in the collection of our accounts receivable. We provide for accounts receivable that could become uncollectible by establishing an allowance to reduce the carrying value of such receivables to their estimated net realizable value. Additions to the allowance for doubtful accounts are made by means of the Provision for doubtful accounts . We write off uncollectible accounts (after exhausting collection efforts) against the allowance for doubtful accounts. Subsequent recoveries are recorded via the Provision for doubtful accounts . We estimate our allowance for doubtful accounts based on the aging of our accounts receivable, our historical collection experience for each type of payor, and other relevant factors so that the remaining receivables, net of allowances, are reflected at their estimated net realizable values. Accounts requiring collection efforts are reviewed via system-generated work queues that automatically stage (based on age and size of outstanding balance) accounts requiring collection efforts for patient account representatives. Collection efforts include contacting the applicable party (both in writing and by telephone), providing information (both financial and clinical) to allow for payment or to overturn payor decisions to deny payment, and arranging payment plans with self-pay patients, among other techniques. When we determine all in-house efforts have been exhausted or it is a more prudent use of resources, accounts may be turned over to a collection agency. Accounts are written off after all collection efforts (internal and external) have been exhausted. The collection of outstanding receivables from Medicare, managed care payors, other third-party payors, and patients is our primary source of cash and is critical to our operating performance. While it is our policy to verify insurance prior to a patient being admitted, there are various exceptions that can occur. Such exceptions include instances where we are (1) unable to obtain verification because the patient’s insurance company was unable to be reached or contacted, (2) a determination is made that a patient may be eligible for benefits under various government programs, such as Medicaid, and it takes several days, weeks, or months before qualification for such benefits is confirmed or denied, and (3) the patient is transferred to our hospital from an acute care hospital without having access to a credit card, cash, or check to pay the applicable patient responsibility amounts (i.e., deductibles and co-payments). Our primary collection risks relate to patient responsibility amounts and pre-payment claim reviews conducted by MACs. Patient responsibility amounts include accounts for which the patient was the primary payor or the primary insurance carrier has paid the amounts covered by the applicable agreement, but patient co-payment amounts remain outstanding. Changes in the economy, such as increased unemployment rates or periods of recession, can further exacerbate our ability to collect patient responsibility amounts. For several years, under programs designated as “widespread probes,” certain of our MACs have conducted pre-payment claim reviews of our billings and denied payment for certain diagnosis codes. We dispute, or “appeal,” most of these denials, and we have historically collected approximately 71% o f all amounts denied. For claims we choose to take to administrative law judge hearings, we have historically experienced an approxim ate 70% success rate. The resolution of these disputes can take in excess of three years, and we cannot provide assurance as to our ongoing and future success of these disputes. As such, we make provisions against these receivables in accordance with our accounting policy that necessarily considers historical collection trends of the receivables in this review process as part of our Provision for doubtful accounts . Because we do not write-off receivables until all collection efforts have been exhausted, we do not write off receivables related to denied claims while they are in this review process. When the amount collected related to denied claims differs from the net amount previously recorded, these collection differences are recorded in the Provision for doubtful accounts . As a result, the timing of these denials by MACs and their subsequent collection can create volatility in our Provision for doubtful accounts . If actual results are not consistent with our assumptions and judgments, we may be exposed to gains or losses that could be material. Changes in general economic conditions, business office operations, payor mix, or trends in federal or state governmental and private employer healthcare coverage could affect our collection of accounts receivable, financial position, results of operations, and cash flows.
Property and Equipment	Property and Equipment— We report land, buildings, improvements, vehicles, and equipment at cost, net of accumulated depreciation and amortization and any asset impairments. We report assets under capital lease obligations at the lower of fair value or the present value of the aggregate future minimum lease payments at the beginning of the lease term. We depreciate our assets using the straight-line method over the shorter of the estimated useful life of the assets or life of the lease term, excluding any lease renewals, unless the lease renewals are reasonably assured. Useful lives are generally as follows: Years Buildings 10 to 30 Leasehold improvements 2 to 15 Vehicles 5 Furniture, fixtures, and equipment 3 to 10 Assets under capital lease obligations: Real estate 15 to 20 Vehicles 3 to 4 Equipment 3 to 5 Maintenance and repairs of property and equipment are expensed as incurred. We capitalize replacements and betterments that increase the estimated useful life of an asset. We capitalize pre-acquisition costs when they are directly identifiable with a specific property, the costs would be capitalizable if the property were already acquired, and acquisition of the property is probable. We capitalize interest expense on major construction and development projects while in progress. We retain fully depreciated assets in property and accumulated depreciation accounts until we remove them from service. In the case of sale, retirement, or disposal, the asset cost and related accumulated depreciation balances are removed from the respective accounts, and the resulting net amount, less any proceeds, is included as a component of income from continuing operations in the consolidated statements of operations. However, if the sale, retirement, or disposal involves a discontinued operation, the resulting net amount, less any proceeds, is included in the results of discontinued operations. We account for operating leases by recognizing rents, including any rent holidays, on a straight-line basis over the term of the lease.
Goodwill and Other Intangible Assets	Goodwill and Other Intangible Assets— We are required to test our goodwill and indefinite-lived intangible asset for impairment at least annually, absent some triggering event that would accelerate an impairment assessment. Absent any impairment indicators, we perform this impairment testing as of October 1st of each year. We recognize an impairment charge for any amount by which the carrying amount of the asset exceeds its implied fair value. We present an impairment charge as a separate line item within income from continuing operations in the consolidated statements of operations, unless the impairment is associated with a discontinued operation. In that case, we include the impairment charge, on a net-of-tax basis, within the results of discontinued operations. We assess qualitative factors in our inpatient rehabilitation and home health and hospice reporting units to determine whether it is necessary to perform the first step of the two-step quantitative impairment test. If, based on this qualitative assessment, we were to believe we must proceed to Step 1, we would determine the fair value of our reporting units using generally accepted valuation techniques including the income approach and the market approach. The income approach includes the use of each reporting unit’s discounted projected operating results and cash flows. This approach includes many assumptions related to pricing and volume, operating expenses, capital expenditures, discount factors, tax rates, etc. Changes in economic and operating conditions impacting these assumptions could result in goodwill impairment in future periods. We reconcile the estimated fair value of our reporting units to our market capitalization. When we dispose of a hospital or home health or hospice agency, goodwill is allocated to the gain or loss on disposition using the relative fair value methodology. We assess qualitative factors related to our indefinite-lived intangible asset to determine whether it is necessary to perform the first step of the two-step quantitative impairment test. If, based on this qualitative assessment, we were to believe we must proceed to Step 1, we would determine the fair value of our indefinite-lived intangible asset using generally accepted valuation techniques including the relief-from-royalty method. This method is a form of the income approach in which value is equated to a series of cash flows and discounted at a risk-adjusted rate. It is based on a hypothetical royalty, calculated as a percentage of forecasted revenue, that we would otherwise be willing to pay to use the asset, assuming it were not already owned. This approach includes assumptions related to pricing and volume, as well as a royalty rate a hypothetical third party would be willing to pay for use of the asset. When making our royalty rate assumption, we look to rates paid in arms-length licensing transactions for assets comparable to our asset. We amortize the cost of intangible assets with finite useful lives over their respective estimated useful lives to their estimated residual value. As of December 31, 2015 , none of our finite useful lived intangible assets has an estimated residual value. We also review these assets for impairment whenever events or changes in circumstances indicate we may not be able to recover the asset’s carrying amount. The range of estimated useful lives and the amortization basis for our intangible assets, excluding goodwill, are generally as follows: Estimated Useful Life and Amortization Basis Certificates of need 10 to 30 years using straight-line basis Licenses 10 to 20 years using straight-line basis Noncompete agreements 1 to 18 years using straight-line basis Trade names: Encompass indefinite-lived asset All other 1 to 20 years using straight-line basis Internal-use software 3 to 7 years using straight-line basis Market access assets 20 years using accelerated basis We capitalize the costs of obtaining or developing internal-use software, including external direct costs of material and services and directly related payroll costs. Amortization begins when the internal-use software is ready for its intended use. Costs incurred during the preliminary project and post-implementation stages, as well as maintenance and training costs, are expensed as incurred. Our market access assets are valued using discounted cash flows under the income approach. The value of the market access assets is attributable to our ability to gain access to and penetrate an acquired facility’s historical market patient base. To determine this value, we first develop a debt-free net cash flow forecast under various patient volume scenarios. The debt-free net cash flow is then discounted back to present value using a discount factor, which includes an adjustment for company-specific risk. As noted in the above table, we amortize these assets over 20 years using an accelerated basis that reflects the pattern in which we believe the economic benefits of the market access will be consumed.
Impairment of Long-Lived Assets and Other Intangible Assets	Impairment of Long-Lived Assets and Other Intangible Assets— We assess the recoverability of long-lived assets (excluding goodwill and our indefinite-lived asset) and identifiable acquired intangible assets with finite useful lives, whenever events or changes in circumstances indicate we may not be able to recover the asset’s carrying amount. We measure the recoverability of assets to be held and used by a comparison of the carrying amount of the asset to the expected net future cash flows to be generated by that asset, or, for identifiable intangibles with finite useful lives, by determining whether the amortization of the intangible asset balance over its remaining life can be recovered through undiscounted future cash flows. The amount of impairment of identifiable intangible assets with finite useful lives, if any, to be recognized is measured based on projected discounted future cash flows. We measure the amount of impairment of other long-lived assets (excluding goodwill) as the amount by which the carrying value of the asset exceeds the fair market value of the asset, which is generally determined based on projected discounted future cash flows or appraised values. We classify long-lived assets to be disposed of other than by sale as held and used until they are disposed. We report long-lived assets to be disposed of by sale as held for sale and recognize those assets in the balance sheet at the lower of carrying amount or fair value less cost to sell, and we cease depreciation.
Investments in and Advances to Nonconsolidated Affiliates	Investments in and Advances to Nonconsolidated Affiliates— Investments in entities we do not control but in which we have the ability to exercise significant influence over the operating and financial policies of the investee are accounted for under the equity method. Equity method investments are recorded at original cost and adjusted periodically to recognize our proportionate share of the investees’ net income or losses after the date of investment, additional contributions made, dividends or distributions received, and impairment losses resulting from adjustments to net realizable value. We record equity method losses in excess of the carrying amount of an investment when we guarantee obligations or we are otherwise committed to provide further financial support to the affiliate. We use the cost method to account for equity investments for which the equity securities do not have readily determinable fair values and for which we do not have the ability to exercise significant influence. Under the cost method of accounting, private equity investments are carried at cost and are adjusted only for other-than-temporary declines in fair value, additional investments, or distributions deemed to be a return of capital. Management periodically assesses the recoverability of our equity method and cost method investments and equity method goodwill for impairment. We consider all available information, including the recoverability of the investment, the earnings and near-term prospects of the affiliate, factors related to the industry, conditions of the affiliate, and our ability, if any, to influence the management of the affiliate. We assess fair value based on valuation methodologies, as appropriate, including discounted cash flows, estimates of sales proceeds, and external appraisals, as appropriate. If an investment or equity method goodwill is considered to be impaired and the decline in value is other than temporary, we record an appropriate write-down.
Financing Costs	Financing Costs— We amortize financing costs using the effective interest method over the expected life of the related debt. Excluding financing costs related to our revolving line of credit (which is included in Other long-term assets ), financing costs are presented as a direct deduction from the face amount of the financings. The related expense is included in Interest expense and amortization of debt discounts and fees in our consolidated statements of operations. See the Recent Accounting Pronouncements section of this note. We accrete discounts and amortize premiums using the effective interest method over the expected life of the related debt, and we report discounts or premiums as a direct deduction from, or addition to, the face amount of the financing. The related income or expense is included in Interest expense and amortization of debt discounts and fees in our consolidated statements of operations.
Fair Value Measurements	Fair Value Measurements— Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions market participants would use in pricing an asset or liability. The basis for these assumptions establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: • Level 1 – Observable inputs such as quoted prices in active markets; • Level 2 – Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and • Level 3 – Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. Assets and liabilities measured at fair value are based on one or more of three valuation techniques. The three valuation techniques are as follows: • Market approach – Prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities; • Cost approach – Amount that would be required to replace the service capacity of an asset (i.e., replacement cost); and • Income approach – Techniques to convert future cash flows to a single present amount based on market expectations (including present value techniques, option-pricing models, and lattice models). Our financial instruments consist mainly of cash and cash equivalents, restricted cash, restricted marketable securities, accounts receivable, accounts payable, letters of credit, and long-term debt. The carrying amounts of cash and cash equivalents, restricted cash, accounts receivable, and accounts payable approximate fair value because of the short-term maturity of these instruments. The fair value of our letters of credit is deemed to be the amount of payment guaranteed on our behalf by third-party financial institutions. We determine the fair value of our long-term debt using quoted market prices, when available, or discounted cash flows based on various factors, including maturity schedules, call features, and current market rates. On a recurring basis, we are required to measure our available-for-sale restricted marketable securities at fair value. The fair values of our available-for-sale restricted marketable securities are determined based on quoted market prices in active markets or quoted prices, dealer quotations, or alternative pricing sources supported by observable inputs in markets that are not considered to be active. On a nonrecurring basis, we are required to measure property and equipment, goodwill, other intangible assets, investments in nonconsolidated affiliates, and assets and liabilities of discontinued operations at fair value. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges or similar adjustments made to the carrying value of the applicable assets. The fair value of our property and equipment is determined using discounted cash flows and significant unobservable inputs, unless there is an offer to purchase such assets, which could be the basis for determining fair value. The fair value of our intangible assets, excluding goodwill, is determined using discounted cash flows and significant unobservable inputs. The fair value of our investments in nonconsolidated affiliates is determined using quoted prices in private markets, discounted cash flows or earnings, or market multiples derived from a set of comparables. The fair value of our assets and liabilities of discontinued operations is determined using discounted cash flows and significant unobservable inputs unless there is an offer to purchase such assets and liabilities, which would be the basis for determining fair value. The fair value of our goodwill is determined using discounted projected operating results and cash flows, which involve significant unobservable inputs. See also the “Redeemable Noncontrolling Interests” section of this note.
Noncontrolling Interests in Consolidated Affiliates	Noncontrolling Interests in Consolidated Affiliates— The consolidated financial statements include all assets, liabilities, revenues, and expenses of less-than-100%-owned affiliates we control. Accordingly, we have recorded noncontrolling interests in the earnings and equity of such entities. We record adjustments to noncontrolling interests for the allocable portion of income or loss to which the noncontrolling interests holders are entitled based upon their portion of the subsidiaries they own. Distributions to holders of noncontrolling interests are adjusted to the respective noncontrolling interests holders’ balance.
Convertible Perpetual Preferred Stock	Convertible Perpetual Preferred Stock— Our Convertible perpetual preferred stock contained fundamental change provisions that allowed the holder to require us to redeem the preferred stock for cash if certain events occurred. As redemption under these provisions was not solely within our control, we classified our Convertible perpetual preferred stock as temporary equity.
Redeemable Noncontrolling Interests	Redeemable Noncontrolling Interests— Certain of our joint venture agreements contain provisions that allow our partners to require us to purchase their interests in the joint venture at fair value at certain points in the future. Likewise, and as discussed in Note 2, Business Combinations , certain members of Encompass management hold similar put rights regarding their interests in our home health and hospice business. Because these noncontrolling interests provide for redemption features that are not solely within our control, we classify them as Redeemable noncontrolling interests outside of permanent equity in our consolidated balance sheets. At the end of each reporting period, we compare the carrying value of the Redeemable noncontrolling interests to their estimated redemption value. If the estimated redemption value is greater than the current carrying value, the carrying value is adjusted to the estimated redemption value, with the adjustments recorded through equity in the line item Capital in excess of par value . The fair value of the Redeemable noncontrolling interests related to our home health segment is determined using the product of a twelve-month specified performance measure and a specified median market price multiple based on a basket of public health companies. The fair value of our Redeemable noncontrolling interests in our joint venture hospitals is determined primarily using the income approach. The income approach includes the use of the hospital’s projected operating results and cash flows discounted using a rate that reflects market participant assumptions for the applicable hospitals, or Level 3 inputs. The projected operating results use management’s best estimates of economic and market conditions over the forecasted periods including assumptions for pricing and volume, operating expenses, and capital expenditures.
Share-Based Payments	Share-Based Payments— HealthSouth has shareholder-approved stock-based compensation plans that provide for the granting of stock-based compensation to certain employees and directors. All share-based payments to employees, excluding stock appreciation rights (“SARs”), are recognized in the financial statements based on their estimated grant-date fair value and amortized on a straight-line basis over the applicable requisite service period. Share-based payments to employees in the form of SARs are recognized in the financial statements based on their current fair value and expensed ratably over the applicable service period.
Litigation Reserves	Litigation Reserves— We accrue for loss contingencies associated with outstanding litigation for which management has determined it is probable a loss contingency exists and the amount of loss can be reasonably estimated. If the accrued amount associated with a loss contingency is greater than $5.0 million , we also accrue estimated future legal fees associated with the loss contingency. This requires management to estimate the amount of legal fees that will be incurred in the defense of the litigation. These estimates are based on our expectations of the scope, length to complete, and complexity of the claims. In the future, additional adjustments may be recorded as the scope, length, or complexity of outstanding litigation changes.
Advertising Costs	Advertising Costs— We expense costs of print, radio, television, and other advertisements as incurred. Advertising expenses, primarily included in Other operating expenses within the accompanying consolidated statements of operations, were $7.3 million , $5.3 million , and $5.2 million in each of the years ended December 31, 2015 , 2014 , and 2013 , respectively.
Professional Fees - Accounting, Tax, and Legal	Professional Fees—Accounting, Tax, and Legal— In 2015 , 2014 , and 2013 , Professional fees—accounting, tax, and legal related primarily to legal and consulting fees for continued litigation and support matters discussed in Note 17, Contingencies and Other Commitments .
Income Taxes	Income Taxes— We provide for income taxes using the asset and liability method . This approach recognizes the amount of income taxes payable or refundable for the current year, as well as deferred tax assets and liabilities for the future tax consequence of events recognized in the consolidated financial statements and income tax returns. Deferred income tax assets and liabilities are adjusted to recognize the effects of changes in tax laws or enacted tax rates. A valuation allowance is required when it is more likely than not some portion of the deferred tax assets will not be realized. Realization is dependent on generating sufficient future taxable income in the applicable tax jurisdiction. On a quarterly basis, we assess the likelihood of realization of our deferred tax assets considering all available evidence, both positive and negative. Our most recent operating performance, the scheduled reversal of temporary differences, our forecast of taxable income in future periods by jurisdiction, our ability to sustain a core level of earnings, and the availability of prudent tax planning strategies are important considerations in our assessment. We evaluate our tax positions and establish assets and liabilities in accordance with the applicable accounting guidance on uncertainty in income taxes. We review these tax uncertainties in light of changing facts and circumstances, such as the progress of tax audits, and adjust them accordingly. We use the with-and-without method to determine when we will recognize excess tax benefits from stock-based compensation. Under this method, we recognize these excess tax benefits only after we fully realize the tax benefits of net operating losses. HealthSouth and its corporate subsidiaries file a consolidated federal income tax return. Some subsidiaries consolidated for financial reporting purposes are not part of the consolidated group for federal income tax purposes and file separate federal income tax returns. State income tax returns are filed on a separate, combined, or consolidated basis in accordance with relevant state laws and regulations. Partnerships, limited liability companies, and other pass-through entities we consolidate or account for using the equity method of accounting file separate federal and state income tax returns. We include the allocable portion of each pass-through entity’s income or loss in our federal income tax return. We allocate the remaining income or loss of each pass-through entity to the other partners or members who are responsible for their portion of the taxes.
Assets and Liabilities in and Results of Discontinued Operations	Assets and Liabilities in and Results of Discontinued Operations— Effective January 1, 2015, in connection with a new standard issued by the FASB, we changed our criteria for determining which disposals are presented as discontinued operations. Historically, any component that had been disposed of or was classified as held for sale qualified for discontinued operations reporting unless there was significant continuing involvement with the disposed component or continuing cash flows. In contrast, we now report the disposal of the component, or group of components, as discontinued operations only when it represents a strategic shift that has, or will have, a major effect on our operations and financial results. As a result, the sale or disposal of a single HealthSouth facility no longer qualifies as a discontinued operation. This accounting change was made prospectively. No new components were recognized as discontinued operations during 2015. In the period a component of an entity has been disposed of or classified as held for sale, we reclassify the results of operations for current and prior periods into a single caption titled (Loss) income from discontinued operations, net of tax . In addition, we classify the assets and liabilities of those components as current and noncurrent assets and liabilities within Prepaid expenses and other current assets , Other long-term assets , Other current liabilities , and Other long-term liabilities in our consolidated balance sheets. We also classify cash flows related to discontinued operations as one line item within each category of cash flows in our consolidated statements of cash flows.
Earnings per Common Share	Earnings per Common Share— The calculation of earnings per common share is based on the weighted-average number of our common shares outstanding during the applicable period. The calculation for diluted earnings per common share recognizes the effect of all potential dilutive common shares, including warrants, that were outstanding during the respective periods, unless their impact would be antidilutive. The calculation of earnings per common share also considers the effect of participating securities. Stock-based compensation awards that contain nonforfeitable rights to dividends and dividend equivalents, such as our nonvested restricted stock awards granted before 2014 and restricted stock units, are considered participating securities and are included in the computation of earnings per common share pursuant to the two-class method. In applying the two-class method, earnings are allocated to both common stock shares and participating securities based on their respective weighted-average shares outstanding for the period. We use the if-converted method to include our Convertible perpetual preferred stock and convertible senior subordinated notes in our computation of diluted earnings per share. All other potential dilutive shares, including warrants, are included in our weighted-average diluted share count using the treasury stock method.
Treasury Stock	Treasury Stock— Shares of common stock repurchased by us are recorded at cost as treasury stock. When shares are reissued, we use an average cost method to determine cost. The difference between the cost of the shares and the re-issuance price is added to or deducted from Capital in excess of par value . We account for the retirement of treasury stock as a reduction of retained earnings. However, due to our Accumulated deficit , the retirement of treasury stock is currently recorded as a reduction of Capital in excess of par value .
Comprehensive Income	Comprehensive Income— Comprehensive income is comprised of Net income and changes in unrealized gains or losses on available-for-sale securities and is included in the consolidated statements of comprehensive income.
Recent Accounting Pronouncements	Recent Accounting Pronouncements — In May 2014, the FASB updated its revenue recognition standard to clarify the principles for recognizing revenue and eliminate industry-specific guidance. In addition, the updated standard revises current disclosure requirements in an effort to help financial statement users better understand the nature, amount, timing, and uncertainty of revenue that is recognized. This revised standard will be effective for HealthSouth for the annual reporting period beginning on January 1, 2017, including interim periods within that year. Early adoption is not permitted. We continue to review the requirements of this revised standard and any potential impact it may have on our financial position, results of operations, or cash flows. It will require us to reclassify our Provision for doubtful accounts from a component of Net operating revenues to operating expenses. In February 2015, the FASB issued ASU 2015-02, “Consolidations (Topic 810) - Amendments to the Consolidation Analysis,” which provides guidance on evaluating whether a reporting entity should consolidate certain legal entities. Specifically, the amendments modify the evaluation of whether limited partnerships and similar legal entities are variable interest entities (“VIE”). Under this analysis, limited partnerships and other similar entities will be considered a VIE unless the limited partners hold substantive kick-out rights or participating rights. Further, the amendments eliminate the presumption that a general partner should consolidate a limited partnership under the voting interest model, as well as affect the consolidation analysis of reporting entities that are involved with VIEs, particularly those that have fee arrangements and related party relationships. This standard is effective for annual periods beginning after December 15, 2015 and interim periods within those annual periods. Early adoption is permitted, and the reporting entity may apply the amendments using a modified retrospective approach or a full retrospective application. We do not expect the adoption of this authoritative guidance in 2016 to have a material impact on our consolidated financial statements. In April 2015, the FASB issued ASU No. 2015-03, “Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs.” The new guidance requires that debt issuance costs related to a recognized debt liability be presented on the consolidated balance sheet as a direct deduction from the debt liability, similar to the presentation of debt discounts. For public companies, the new guidance is effective for fiscal years beginning after December 15, 2015 and interim periods within those fiscal years. Early adoption is permitted for financial statements that have not been previously issued and the new guidance should be applied on a retrospective basis. We elected to early adopt this new guidance effective as of December 31, 2015 and have applied these changes retrospectively to all periods presented. The adoption of this guidance did not have material effect on our consolidated financial position, results of operations, or cash flows. See Note 8, Long-Term Debt , and Note 12, Fair Value Measurements. In July 2015, the FASB updated its revenue recognition standard to defer its effective date by one year. The FASB decided, based on its outreach to various stakeholders and the forthcoming amendments to the new revenue standard, that a deferral is necessary to provide adequate time to effectively implement the new revenue standard. This revised standard will be effective for our annual reporting period beginning on January 1, 2018, including interim periods within that year. Early adoption is permitted but not earlier than the original effective date. In August 2015, the FASB issued ASU No. 2015-15, “Interest-Imputation of Interest (Subtopic 835-30): Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements,” to provide authoritative guidance related to line-of-credit arrangements, which were not addressed in ASU No. 2015-03. An entity may defer and present debt issuance costs related to line-of-credit arrangements as an asset. We elected to early adopt this new guidance effective as of December 31, 2015 and have applied these changes retrospectively to all periods presented. The adoption of this guidance did not have a material effect on our consolidated financial position, results of operations, or cash flows. See Note 8, Long-Term Debt , and Note 12, Fair Value Measurements. In September 2015, the FASB issued ASU 2015-16 “Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments.” This standard eliminates the requirement for an acquirer in a business combination to account for measurement-period adjustments retrospectively. The new standard requires an acquirer to recognize measurement-period adjustments during the period in which it determines the amount of the adjustment. In addition, it requires the acquirer to record, in the same period’s financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the provisional amounts as if the accounting had been completed at the acquisition date. This standard is effective prospectively for annual periods beginning after December 15, 2015 and interim periods within those annual periods. Early application is permitted. We do not expect the adoption of this authoritative guidance in 2016 to have a material impact on our consolidated financial statements. In November 2015, the FASB issued ASU No. 2015-17, “Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes,” to simplify the presentation of deferred taxes in the consolidated balance sheet. Under this amendment, entities will no longer be required to separate deferred income tax liabilities and assets into current and noncurrent amounts. Rather, the amendment requires deferred tax liabilities and assets be classified as noncurrent in a consolidated balance sheet. For public companies, the revised standard is effective for annual periods beginning after December 15, 2016 and interim periods within those annual periods. Early adoption is permitted with retrospective application optional. We elected to early adopt this new guidance effective as of December 31, 2015. Prior periods were not retrospectively adjusted for this change in accounting principle. The adoption of this guidance did not have material effect on our consolidated financial position, results of operations, or cash flows. See Note 15, Income Taxes. In January 2016, the FASB issued ASU No. 2016-01, “Financial Instruments - Overall (Topic 825): Recognition and Measurement of Financial Assets and Financial Liabilities.” This standard revises the classification and measurement of investments in certain equity investments and the presentation of certain fair value changes for certain financial liabilities measured at fair value. This revised standard requires the change in fair value of many equity investments to be recognized in net income. This revised standard is effective for interim and annual periods beginning after December 15, 2017, with early adoption permitted. We continue to review the requirements of this revised standard and any potential impact it may have on our financial position, results of operations, or cash flows. We do not believe any other recently issued, but not yet effective, accounting standards will have a material effect on our consolidated financial position, results of operations, or cash flows.

Cash and Marketable Securities

Cash and Marketable Securities (Tables)	12 Months Ended
	Dec. 31, 2015
Cash and Cash Equivalents [Abstract]
Schedule of Investment Components	The components of our investments as of December 31, 2014 are as follows (in millions): Cash & Cash Equivalents Restricted Cash Restricted Marketable Securities Total Cash $ 66.7 $ 45.6 $ — $ 112.3 Equity securities — — 50.5 50.5 Total $ 66.7 $ 45.6 $ 50.5 $ 162.8 The components of our investments as of December 31, 2015 are as follows (in millions): Cash & Cash Equivalents Restricted Cash Restricted Marketable Securities Total Cash $ 61.6 $ 45.9 $ — $ 107.5 Equity securities — — 56.2 56.2 Total $ 61.6 $ 45.9 $ 56.2 $ 163.7
Schedule of Restricted Cash	As of December 31, 2015 and 2014 , Restricted cash consisted of the following (in millions): As of December 31, 2015 2014 Affiliate cash $ 20.3 $ 13.1 Self-insured captive funds 25.6 32.4 Paid-loss deposit funds — 0.1 Total restricted cash $ 45.9 $ 45.6
Available-for-sale Securities Cost to Fair Value Reconciliation	A summary of our restricted marketable securities as of December 31, 2015 is as follows (in millions): Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Equity securities $ 58.3 $ 0.3 $ (2.4 ) $ 56.2 A summary of our restricted marketable securities as of December 31, 2014 is as follows (in millions): Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Equity securities $ 51.3 $ 0.5 $ (1.3 ) $ 50.5
Investment information related to restricted marketable securities	Investing information related to our restricted marketable securities is as follows (in millions): For the Year Ended December 31, 2015 2014 2013 Proceeds from sales of restricted available-for-sale securities $ — $ — $ 16.6 Proceeds from sales of nonrestricted available-for-sale securities $ 12.8 $ 2.7 $ — Gross realized gains $ 1.2 $ 0.5 $ 1.0 Gross realized losses $ — $ (0.1 ) $ (0.1 )

Summary of Significant Accoun30

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2015
Concentration of Net Operating Revenues by Payor [Line Items]
Concentration of Net Operating Revenues by Payor	We derived consolidated Net operating revenues from the following payor sources: For the Year Ended December 31, 2015 2014 2013 Medicare 74.9 % 74.1 % 74.5 % Managed care and other discount plans, including Medicare Advantage 17.7 % 18.6 % 18.5 % Medicaid 3.0 % 1.8 % 1.2 % Other third-party payors 1.7 % 1.8 % 1.8 % Workers' compensation 0.9 % 1.2 % 1.2 % Patients 0.6 % 1.0 % 1.1 % Other income 1.2 % 1.5 % 1.7 % Total 100.0 % 100.0 % 100.0 %
Concentration of Net Patient Service Accounts Receivable by Payor Class	The concentration of net patient service accounts receivable by payor class, as a percentage of total net patient service accounts receivable, is as follows: As of December 31, 2015 2014 Medicare 70.5 % 72.2 % Managed care and other discount plans, including Medicare Advantage 19.7 % 18.5 % Medicaid 2.9 % 1.8 % Other third-party payors 4.1 % 3.8 % Workers' compensation 1.9 % 1.9 % Patients 0.9 % 1.8 % Total 100.0 % 100.0 %
Useful Lives of Property and Equipment	Useful lives are generally as follows: Years Buildings 10 to 30 Leasehold improvements 2 to 15 Vehicles 5 Furniture, fixtures, and equipment 3 to 10 Assets under capital lease obligations: Real estate 15 to 20 Vehicles 3 to 4 Equipment 3 to 5
Estimated Useful Lives and Amortization Basis of Other Intangible Assets	The range of estimated useful lives and the amortization basis for our intangible assets, excluding goodwill, are generally as follows: Estimated Useful Life and Amortization Basis Certificates of need 10 to 30 years using straight-line basis Licenses 10 to 20 years using straight-line basis Noncompete agreements 1 to 18 years using straight-line basis Trade names: Encompass indefinite-lived asset All other 1 to 20 years using straight-line basis Internal-use software 3 to 7 years using straight-line basis Market access assets 20 years using accelerated basis
Inpatient Rehabilitation Hospital [Member]
Concentration of Net Operating Revenues by Payor [Line Items]
Concentration of Net Operating Revenues by Payor	Our inpatient rehabilitation segment derived its Net operating revenues from the following payor sources: As of December 31, 2015 2014 2013 Medicare 73.2 % 73.9 % 74.2 % Managed care and other discount plans, including Medicare Advantage 19.0 % 18.8 % 18.7 % Medicaid 2.5 % 1.8 % 1.2 % Other third-party payors 2.0 % 1.8 % 1.8 % Workers’ compensation 1.1 % 1.2 % 1.3 % Patients 0.7 % 1.0 % 1.1 % Other income 1.5 % 1.5 % 1.7 % Total 100.0 % 100.0 % 100.0 %
Home Health and Hospice [Member]
Concentration of Net Operating Revenues by Payor [Line Items]
Concentration of Net Operating Revenues by Payor	Our home health and hospice segment derived its Net operating revenues from the following payor sources: As of December 31, 2015 2014 2013 Medicare 83.7 % 96.9 % 95.8 % Managed care and other discount plans, including Medicare Advantage 10.7 % 1.8 % 2.5 % Medicaid 5.5 % — % — % Other third-party payors — % 1.0 % 1.4 % Workers’ compensation — % 0.3 % 0.3 % Patients 0.1 % — % — % Total 100.0 % 100.0 % 100.0 %

Accounts Receivable (Tables)

Accounts Receivable (Tables)	12 Months Ended
	Dec. 31, 2015
Receivables [Abstract]
Schedule of Accounts Receivable	Accounts receivable consists of the following (in millions): As of December 31, 2015 2014 Current: Patient accounts receivable, net of allowance for doubtful accounts of $39.3 million in 2015; $22.2 million in 2014 $ 403.3 $ 309.3 Other accounts receivable 7.2 13.9 410.5 323.2 Noncurrent patient accounts receivable, net of allowance for doubtful accounts of $32.3 million in 2015; $20.8 million in 2014 96.6 51.4 Accounts receivable, net $ 507.1 $ 374.6
Schedule of Activity Related to Allowance for Doubtful Accounts	The following is the activity related to our allowance for doubtful accounts (in millions): For the Year Ended December 31, Balance at Beginning of Period Additions and Charges to Expense Deductions and Accounts Written Off Balance at End of Period 2015 $ 43.0 $ 47.2 $ (18.6 ) $ 71.6 2014 $ 33.1 $ 31.6 $ (21.7 ) $ 43.0 2013 $ 28.7 $ 26.0 $ (21.6 ) $ 33.1

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Components of Property and Equipment	Property and equipment consists of the following (in millions): As of December 31, 2015 2014 Land $ 113.3 $ 108.1 Buildings 1,521.1 1,214.4 Leasehold improvements 96.2 79.1 Vehicles 10.0 9.3 Furniture, fixtures, and equipment 392.7 364.2 2,133.3 1,775.1 Less: Accumulated depreciation and amortization (874.3 ) (784.0 ) 1,259.0 991.1 Construction in progress 51.1 28.6 Property and equipment, net $ 1,310.1 $ 1,019.7
Fully Depreciated Assets and Assets Under Capital Lease Obligations	Information related to fully depreciated assets and assets under capital lease obligations is as follows (in millions): As of December 31, 2015 2014 Fully depreciated assets $ 252.4 $ 240.9 Assets under capital lease obligations: Buildings $ 333.9 $ 124.4 Vehicles 6.5 5.2 Equipment 0.3 0.2 340.7 129.8 Less: Accumulated amortization (66.6 ) (55.2 ) Assets under capital lease obligations, net $ 274.1 $ 74.6
Depreciation Expense, Amortization Expense Relating to Assets Under Capital Lease Obligations, Interest Capitalized, and Rent Expense Under Operating Leases	The amount of depreciation expense, amortization expense relating to assets under capital lease obligations, interest capitalized, and rent expense under operating leases is as follows (in millions): For the Year Ended December 31, 2015 2014 2013 Depreciation expense $ 91.0 $ 79.9 $ 67.9 Amortization expense $ 12.7 $ 7.5 $ 9.5 Interest capitalized $ 1.3 $ 1.5 $ 1.9 Rent expense: Minimum rent payments $ 48.8 $ 37.3 $ 40.3 Contingent and other rents 21.6 18.2 20.3 Other 3.8 3.9 4.2 Total rent expense $ 74.2 $ 59.4 $ 64.8
Schedule of Accrued Straight-Line Rent	The excess of cumulative rent expense (recognized on a straight-line basis) over cumulative rent payments made on leases with fixed escalation terms is recognized as straight-line rental accrual and is included in Other long-term liabilities in the accompanying consolidated balance sheets, as follows (in millions): As of December 31, 2015 2014 Straight-line rental accrual $ 11.8 $ 14.6
Schedule of Future Minimum Lease Payments	Future minimum lease payments at December 31, 2015 , for those leases having an initial or remaining noncancelable lease term in excess of one year, are as follows (in millions): Year Ending December 31, Operating Leases Capital Lease Obligations Total 2016 $ 59.2 $ 32.8 $ 92.0 2017 52.1 34.1 86.2 2018 46.0 33.4 79.4 2019 41.2 30.3 71.5 2020 32.9 27.8 60.7 2021 and thereafter 156.2 384.7 540.9 $ 387.6 543.1 $ 930.7 Less: Interest portion (254.9 ) Obligations under capital leases $ 288.2

Goodwill and Other Intangible33

Goodwill and Other Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Changes in the Carrying Amount of Goodwill	The following table shows changes in the carrying amount of Goodwill for the years ended December 31, 2015 , 2014 , and 2013 (in millions): Amount Goodwill as of December 31, 2012 $ 437.3 Acquisition 13.7 Conversion of 100% owned hospital into a joint venture 6.2 Divestiture of skilled nursing facility beds (0.3 ) Goodwill as of December 31, 2013 456.9 Acquisitions 593.1 Consolidation of joint venture formerly accounted for under the equity method of accounting 34.0 Goodwill as of December 31, 2014 1,084.0 Acquisitions 806.1 Goodwill as of December 31, 2015 $ 1,890.1
Schedule of Intangible Assets by Major Class	The following table provides information regarding our other intangible assets (in millions): Gross Carrying Amount Accumulated Amortization Net Certificates of need: 2015 $ 93.9 $ (6.9 ) $ 87.0 2014 27.9 (4.0 ) 23.9 Licenses: 2015 $ 138.9 $ (53.7 ) $ 85.2 2014 110.8 (46.3 ) 64.5 Noncompete agreements: 2015 $ 58.0 $ (37.0 ) $ 21.0 2014 46.2 (29.4 ) 16.8 Trade name - Encompass: 2015 $ 135.2 $ — $ 135.2 2014 135.2 — 135.2 Trade names - all other: 2015 $ 32.9 $ (11.5 ) $ 21.4 2014 19.9 (10.1 ) 9.8 Internal-use software: 2015 $ 155.7 $ (90.5 ) $ 65.2 2014 125.3 (74.5 ) 50.8 Market access assets: 2015 $ 13.2 $ (8.8 ) $ 4.4 2014 13.2 (8.1 ) 5.1 Total intangible assets: 2015 $ 627.8 $ (208.4 ) $ 419.4 2014 478.5 (172.4 ) 306.1
Schedule of Amortization Expense, Intangible Assets	Amortization expense for other intangible assets is as follows (in millions): For the Year Ended December 31, 2015 2014 2013 Amortization expense $ 36.0 $ 20.3 $ 17.3
Schedule of Future Estimated Amortization Expense, Intangible Assets	Total estimated amortization expense for our other intangible assets for the next five years is as follows (in millions): Year Ending December 31, Estimated Amortization Expense 2016 $ 45.4 2017 38.7 2018 30.3 2019 26.8 2020 23.3

Investments in and Advances t34

Investments in and Advances to Nonconsolidated Affiliates (Tables)	12 Months Ended
	Dec. 31, 2015
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures [Abstract]
Schedule of Aggregate Equity and Cost Method Investments	Our investments, which are included in Other long-term assets in our consolidated balance sheets, consist of the following (in millions): As of December 31, 2015 2014 Equity method investments: Capital contributions $ 0.9 $ 0.8 Cumulative share of income 88.0 77.3 Cumulative share of distributions (77.5 ) (69.9 ) 11.4 8.2 Cost method investments: Capital contributions, net of distributions and impairments 0.3 1.2 Total investments in and advances to nonconsolidated affiliates $ 11.7 $ 9.4
Schedule of Combined Assets, Liabilities, and Equity of Equity Method Affiliates	The following summarizes the combined assets, liabilities, and equity and the combined results of operations of our equity method affiliates (on a 100% basis, in millions): As of December 31, 2015 2014 Assets— Current $ 7.8 $ 9.6 Noncurrent 20.5 13.1 Total assets $ 28.3 $ 22.7 Liabilities and equity— Current liabilities $ 1.4 $ 0.7 Noncurrent liabilities 0.1 0.1 Partners’ capital and shareholders’ equity— HealthSouth 11.4 8.2 Outside partners 15.4 13.7 Total liabilities and equity $ 28.3 $ 22.7
Schedule of Combined Results of Operations of Equity Method Affiliates	Condensed statements of operations (in millions): For the Year Ended December 31, 2015 2014 2013 Net operating revenues $ 36.5 $ 50.2 $ 74.3 Operating expenses (15.0 ) (25.9 ) (43.6 ) Income from continuing operations, net of tax 18.9 30.9 24.6 Net income 18.9 30.9 24.6

Long-term Debt (Tables)

Long-term Debt (Tables)	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Schedule of Outstanding Long-term Debt	Our long-term debt outstanding consists of the following (in millions): As of December 31, 2015 2014 Credit Agreement— Advances under revolving credit facility $ 130.0 $ 325.0 Term loan facilities 443.3 447.5 Bonds payable— 8.125% Senior Notes due 2020 — 282.7 7.75% Senior Notes due 2022 174.3 223.7 5.125% Senior Notes due 2023 294.6 — 5.75% Senior Notes due 2024 1,192.6 447.4 5.75% Senior Notes due 2025 343.4 — 2.00% Convertible Senior Subordinated Notes due 2043 265.9 256.7 Other notes payable 39.2 41.5 Capital lease obligations 288.2 86.7 3,171.5 2,111.2 Less: Current portion (36.8 ) (20.8 ) Long-term debt, net of current portion $ 3,134.7 $ 2,090.4
Schedule of Debt Maturities	The following chart shows scheduled principal payments due on long-term debt for the next five years and thereafter (in millions): Year Ending December 31, Face Amount Net Amount 2016 $ 37.0 $ 37.0 2017 36.1 36.1 2018 36.3 36.3 2019 39.5 39.4 2020 814.2 758.4 Thereafter 2,285.4 2,264.3 Total $ 3,248.5 $ 3,171.5
Schedule of Redemption Prices for 2022 Senior Notes	We may redeem the 2022 Notes, in whole or in part, at any time on or after September 15, 2015, at the redemption prices set forth below: Period Redemption Price* 2015 103.875 % 2016 102.583 % 2017 101.292 % 2018 and thereafter 100.000 % * Expressed in percentage of principal amount
Schedule of Redemption Prices for 2023 Senior Notes	We may redeem the 2023 Notes, in whole or in part, at any time on or after March 15, 2018 at the redemption prices set forth below: Period Redemption Price* 2018 103.844 % 2019 102.563 % 2020 101.281 % 2021 and thereafter 100.000 %
Schedule of Redemption Prices for 2024 Senior Notes	We may redeem the 2024 Notes, in whole or in part, at any time on or after November 1, 2017, at the redemption prices set forth below: Period Redemption Price* 2017 102.875 % 2018 101.917 % 2019 100.958 % 2020 and thereafter 100.000 %
Schedule of Redemption Prices for 2025 Senior Notes	We may redeem the 2025 Notes, in whole or in part, at any time on or after September 15, 2020, at the redemption prices set forth below: Period Redemption Price* 2020 102.875 % 2021 101.917 % 2022 100.958 % 2023 and thereafter 100.000 % * Expressed in percentage of principal amount
Schedule of Other Notes Payable	Our notes payable consist of the following (in millions): As of December 31, 2015 2014 Interest Rates Sale/leaseback transactions involving real estate accounted for as financings $ 28.0 $ 28.0 8.1% to 11.2% Acquisition of an inpatient rehabilitation unit 1.3 2.9 7.8% Construction of a new hospital 9.6 10.3 LIBOR + 2.5%; Other 0.3 0.3 6.8% Other notes payable $ 39.2 $ 41.5

Self-Insured Risks Self-Insured

Self-Insured Risks Self-Insured Risks (Tables)	12 Months Ended
	Dec. 31, 2015
Self-Insured Risks [Abstract]
Self-Insurance Reserves	The following table presents the changes in our self-insurance reserves for the years ended December 31, 2015 , 2014 , and 2013 (in millions): 2015 2014 2013 Balance at beginning of period, gross $ 134.3 $ 140.3 $ 148.3 Less: Reinsurance receivables (26.0 ) (32.6 ) (29.4 ) Balance at beginning of period, net 108.3 107.7 118.9 Increase for the provision of current year claims 37.1 34.7 34.4 Decrease for the provision of prior year claims (4.6 ) (3.5 ) (5.9 ) Decrease related to change in statistical confidence level — — (6.7 ) Expenses related to discontinued operations (0.5 ) (0.3 ) (1.8 ) Payments related to current year claims (4.7 ) (4.4 ) (3.9 ) Payments related to prior year claims (22.5 ) (25.9 ) (27.3 ) Acquisitions 2.4 — — Balance at end of period, net 115.5 108.3 107.7 Add: Reinsurance receivables 26.6 26.0 32.6 Balance at end of period, gross $ 142.1 $ 134.3 $ 140.3

Convertible Perpetual Preferr37

Convertible Perpetual Preferred Stock (Tables)	12 Months Ended
	Dec. 31, 2015
Convertible Perpetual Preferred Stock [Abstract]
Summary of Activity, Convertible Perpetual Preferred Stock	The following is a summary of the activity related to our Convertible perpetual preferred stock from December 31, 2012 to December 31, 2015 (in millions, except share data): Number of Shares Outstanding Amount Balance as of December 31, 2012 353,355 $ 342.2 Repurchase of preferred stock (257,110 ) (249.0 ) Balance as of December 31, 2013 and 2014 96,245 93.2 Conversion of preferred stock (96,245 ) (93.2 ) Balance as of December 31, 2015 — $ —
Summary Allocation of Consideration Exchanged, Convertible Perpetual Preferred Stock	The allocation of the consideration exchanged for repurchases of preferred stock is as follows (in millions): For the Year Ended December 31, 2013 Carrying value of shares repurchased $ 249.0 Cumulative dividends included as part of repurchase price 2.2 Excess exchanged in transaction 71.6 $ 322.8

Redeemable Noncontrolling Int38

Redeemable Noncontrolling Interests (Tables)	12 Months Ended
	Dec. 31, 2015
Redeemable Noncontrolling Interest [Line Items]
Redeemable Noncontrolling Interest	The following is a summary of the activity related to our Redeemable noncontrolling interests (in millions): For the Year Ended December 31, 2015 2014 2013 Balance at beginning of period $ 84.7 $ 13.5 $ 7.2 Acquisition of Encompass — 64.5 — Net income attributable to noncontrolling interests 13.8 6.6 5.8 Distributions (7.3 ) (8.5 ) (4.9 ) Contribution to joint venture — 4.3 7.1 Change in fair value 29.9 4.3 (1.7 ) Balance at end of period $ 121.1 $ 84.7 $ 13.5
Reconciliation of Noncontrolling Interests	The following table reconciles the net income attributable to nonredeemable Noncontrolling interests , as recorded in the shareholders’ equity section of the consolidated balance sheets, and the net income attributable to Redeemable noncontrolling interests , as recorded in the mezzanine section of the consolidated balance sheets, to the Net income attributable to noncontrolling interests presented on the consolidated statements of operations (in millions): For the Year Ended December 31, 2015 2014 2013 Net income attributable to nonredeemable noncontrolling interests $ 55.9 $ 53.1 $ 52.0 Net income attributable to redeemable noncontrolling interests 13.8 6.6 5.8 Net income attributable to noncontrolling interests $ 69.7 $ 59.7 $ 57.8

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	Our financial assets and liabilities that are measured at fair value on a recurring basis are as follows (in millions): Fair Value Measurements at Reporting Date Using As of December 31, 2015 Fair Value Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Valuation Technique (1) Prepaid expenses and other current assets: Current portion of restricted marketable securities $ 16.1 $ — $ 16.1 $ — M Other long-term assets: Restricted marketable securities 40.1 — 40.1 — M Redeemable noncontrolling interests 121.1 — — 121.1 I As of December 31, 2014 Prepaid expenses and other current assets: Current portion of restricted marketable securities $ 4.6 $ — $ 4.6 $ — M Other long-term assets: Option to purchase SCA stock 9.9 — — 9.9 M Restricted marketable securities 45.9 — 45.9 — M Redeemable noncontrolling interests 84.7 — — 84.7 I (1) The three valuation techniques are: market approach (M), cost approach (C), and income approach (I).
Schedule of Carrying Amounts and Estimated Fair Values, Financial Instruments	The carrying amounts and estimated fair values for our other financial instruments are presented in the following table (in millions): As of December 31, 2015 As of December 31, 2014 Carrying Amount Estimated Fair Value Carrying Amount Estimated Fair Value Long-term debt: Advances under revolving credit facility $ 130.0 $ 130.0 $ 325.0 $ 325.0 Term loan facilities 443.3 445.0 447.5 450.0 8.125% Senior Notes due 2020 — — 282.7 302.5 7.75% Senior Notes due 2022 174.3 183.7 223.7 240.7 5.125% Senior Notes due 2023 294.6 288.0 — — 5.75% Senior Notes due 2024 1,192.6 1,146.0 447.4 471.4 5.75% Senior Notes due 2025 343.4 332.5 — — 2.00% Convertible Senior Subordinated Notes due 2043 265.9 345.0 256.7 358.4 Other notes payable 39.2 39.2 41.5 41.5 Financial commitments: Letters of credit — 34.2 — 31.8

Share-Based Payments (Tables)

Share-Based Payments (Tables)	12 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Weighted-Average Assumptions Used to Determine Fair Value of Stock Options	The fair values of the options granted during the years ended December 31, 2015 , 2014 , and 2013 have been estimated at the grant date using the Black-Scholes option-pricing model with the following weighted-average assumptions: For the Year Ended December 31, 2015 2014 2013 Expected volatility 39.5 % 40.3 % 41.8 % Risk-free interest rate 1.9 % 2.2 % 1.4 % Expected life (years) 7.7 7.2 7.2 Dividend yield 2.1 % 2.1 % 0.0 %
Schedule of Stock Option Activity	A summary of our stock option activity and related information is as follows: Shares (In Thousands) Weighted- Average Exercise Price per Share Weighted- Average Remaining Life (Years) Aggregate Intrinsic Value (In Millions) Outstanding, December 31, 2014 2,207 $ 20.85 Granted 108 43.14 Exercised (257 ) 26.06 Forfeitures (2 ) 24.85 Expirations — — Outstanding, December 31, 2015 2,056 21.37 4.1 $ 28.5 Exercisable, December 31, 2015 1,811 19.47 3.5 27.8
Schedule of Restricted Stock Activity	A summary of our issued restricted stock awards is as follows (share information in thousands): Shares Weighted-Average Grant Date Fair Value Nonvested shares at December 31, 2014 1,197 $ 23.31 Granted 689 27.86 Vested (1,005 ) 22.18 Forfeited (39 ) 30.03 Nonvested shares at December 31, 2015 842 28.05

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit)	The significant components of the Provision for income tax expense related to continuing operations are as follows (in millions): For the Year Ended December 31, 2015 2014 2013 Current: Federal $ 2.6 $ 2.5 $ 0.9 State and other 12.2 10.8 5.4 Total current expense 14.8 13.3 6.3 Deferred: Federal 113.9 95.3 11.3 State and other 13.2 2.1 (4.9 ) Total deferred expense 127.1 97.4 6.4 Total income tax expense related to continuing operations $ 141.9 $ 110.7 $ 12.7
Schedule of Effective Income Tax Rate Reconciliation	A reconciliation of differences between the federal income tax at statutory rates and our actual income tax expense on our income from continuing operations, which include federal, state, and other income taxes, is presented below: For the Year Ended December 31, 2015 2014 2013 Tax expense at statutory rate 35.0 % 35.0 % 35.0 % Increase (decrease) in tax rate resulting from: State and other income taxes, net of federal tax benefit 3.6 % 4.3 % 4.0 % Increase (decrease) in valuation allowance 1.2 % (1.9 )% (2.3 )% Settlement of tax claims 0.1 % — % (28.7 )% Noncontrolling interests (5.3 )% (5.1 )% (5.1 )% Acquisition of additional equity interest in Fairlawn — % (3.6 )% — % Other, net 1.3 % (0.1 )% 0.3 % Income tax expense 35.9 % 28.6 % 3.2 %
Schedule of Components of Deferred Tax Assets and Liabilities	The significant components of HealthSouth’s deferred tax assets and liabilities are presented in the following table (in millions): As of December 31, 2015 2014 Deferred income tax assets: Net operating loss $ 161.1 $ 301.3 Property, net 48.2 40.7 Insurance reserve 26.0 25.6 Stock-based compensation 23.4 23.7 Allowance for doubtful accounts 24.5 18.0 Alternative minimum tax 10.6 10.5 Carrying value of partnerships 22.1 23.8 Other accruals 25.7 20.6 Tax credits 14.0 9.9 Noncontrolling interest 10.6 — Other 0.8 1.6 Total deferred income tax assets 367.0 475.7 Less: Valuation allowance (27.6 ) (23.0 ) Net deferred income tax assets 339.4 452.7 Deferred income tax liabilities: Intangibles (112.8 ) (97.5 ) Convertible debt interest (35.3 ) (31.7 ) Other (0.5 ) (5.7 ) Total deferred income tax liabilities (148.6 ) (134.9 ) Net deferred income tax assets 190.8 317.8 Less: Current deferred tax assets — 188.4 Noncurrent deferred tax assets $ 190.8 $ 129.4
Schedule of Unrecognized Tax Benefits Rollforward	A reconciliation of the beginning and ending liability for unrecognized tax benefits is as follows (in millions): Gross Unrecognized Income Tax Benefits Accrued Interest and Penalties January 1, 2013 $ 78.0 $ — Gross amount of increases in unrecognized tax benefits related to prior periods 46.7 0.3 Gross amount of decreases in unrecognized tax benefits related to prior periods (1.9 ) — Decreases in unrecognized tax benefits relating to settlements with taxing authorities (121.7 ) — December 31, 2013 1.1 0.3 Gross amount of increases in unrecognized tax benefits related to prior periods 0.7 0.1 Gross amount of decreases in unrecognized tax benefits related to prior periods (0.9 ) (0.4 ) December 31, 2014 0.9 — Gross amount of increases in unrecognized tax benefits related to prior periods 1.7 — Gross amount of increases in unrecognized tax benefits related to current period 0.3 — December 31, 2015 $ 2.9 $ —

Earnings Per Common Share (Tabl

Earnings Per Common Share (Tables)	12 Months Ended
	Dec. 31, 2015
Earnings Per Share [Abstract]
Computation of Basic and Diluted Earnings per Common Share	The following table sets forth the computation of basic and diluted earnings per common share (in millions, except per share amounts): For the Year Ended December 31, 2015 2014 2013 Basic: Numerator: Income from continuing operations $ 253.7 $ 276.2 $ 382.5 Less: Net income attributable to noncontrolling interests included in continuing operations (69.7 ) (59.7 ) (57.8 ) Less: Income allocated to participating securities (1.0 ) (2.3 ) (3.4 ) Less: Convertible perpetual preferred stock dividends (1.6 ) (6.3 ) (21.0 ) Less: Repurchase of convertible perpetual preferred stock — — (71.6 ) Income from continuing operations attributable to HealthSouth common shareholders 181.4 207.9 228.7 (Loss) income from discontinued operations, net of tax, attributable to HealthSouth common shareholders (0.9 ) 5.5 (1.1 ) Less: Income from discontinued operations allocated to participating securities — (0.1 ) — Net income attributable to HealthSouth common shareholders $ 180.5 $ 213.3 $ 227.6 Denominator: Basic weighted average common shares outstanding 89.4 86.8 88.1 Basic earnings per share attributable to HealthSouth common shareholders: Continuing operations $ 2.03 $ 2.40 $ 2.59 Discontinued operations (0.01 ) 0.06 (0.01 ) Net income $ 2.02 $ 2.46 $ 2.58 Diluted: Numerator: Income from continuing operations $ 253.7 $ 276.2 $ 382.5 Less: Net income attributable to noncontrolling interests included in continuing operations (69.7 ) (59.7 ) (57.8 ) Add: Interest on convertible debt, net of tax 9.4 9.0 1.0 Income from continuing operations attributable to HealthSouth common shareholders 193.4 225.5 325.7 (Loss) income from discontinued operations, net of tax, attributable to HealthSouth common shareholders (0.9 ) 5.5 (1.1 ) Net income attributable to HealthSouth common shareholders $ 192.5 $ 231.0 $ 324.6 Denominator: Diluted weighted average common shares outstanding 101.0 100.7 102.1 Diluted earnings per share attributable to HealthSouth common shareholders: Continuing operations $ 1.92 $ 2.24 $ 2.59 Discontinued operations (0.01 ) 0.05 (0.01 ) Net income $ 1.91 $ 2.29 $ 2.58
Reconciliation of Weighted Average Number of Shares Outstanding	The following table sets forth the reconciliation between basic weighted average common shares outstanding and diluted weighted average common shares outstanding (in millions): For the Year Ended December 31, 2015 2014 2013 Basic weighted average common shares outstanding 89.4 86.8 88.1 Convertible perpetual preferred stock 1.0 3.2 10.5 Convertible senior subordinated notes 8.3 8.2 1.0 Restricted stock awards, dilutive stock options, and restricted stock units 2.3 2.5 2.5 Diluted weighted average common shares outstanding 101.0 100.7 102.1
Schedule of Warrants	The following table summarizes information relating to these warrants and their activity during 2013 and through their expiration date (number of warrants in millions): Number of Warrants Weighted Average Exercise Price Common stock warrants outstanding as of December 31, 2012 10.0 $ 32.50 Cashless exercise (4.8 ) 32.50 Cash exercise (2.3 ) 32.50 Common stock warrants outstanding as of December 31, 2013 2.9 32.50 Cashless exercise (1.8 ) 32.16 Cash exercise (1.0 ) 32.16 Expired (0.1 ) 32.16 Common stock warrants outstanding as of January 16, 2014 —

Segment Reporting Segment Rep43

Segment Reporting Segment Reporting (Tables)	12 Months Ended
	Dec. 31, 2015
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Selected financial information for our reportable segments is as follows (in millions): Inpatient Rehabilitation Home Health and Hospice For the Year Ended December 31, For the Year Ended December 31, 2015 2014 2013 2015 2014 2013 Net operating revenues $ 2,653.1 $ 2,377.3 $ 2,244.4 $ 509.8 $ 28.6 $ 28.8 Less: Provision for doubtful accounts (44.7 ) (31.2 ) (25.6 ) (2.5 ) (0.4 ) (0.4 ) Net operating revenues less provision for doubtful accounts 2,608.4 2,346.1 2,218.8 507.3 28.2 28.4 Operating expenses: Inpatient rehabilitation: Salaries and benefits 1,310.6 1,141.0 1,069.7 — — — Other operating expenses 387.7 342.5 314.7 — — — Supplies 120.9 111.5 105.2 — — — Occupancy costs 46.2 41.2 46.5 — — — Home health and hospice: Cost of services sold (excluding depreciation and amortization) — — — 244.8 17.0 16.7 Support and overhead costs — — — 172.7 6.9 6.6 1,865.4 1,636.2 1,536.1 417.5 23.9 23.3 Other income (2.3 ) (4.0 ) (4.5 ) — — — Equity in net income of nonconsolidated affiliates (8.6 ) (10.7 ) (11.2 ) (0.1 ) — — Noncontrolling interests 62.9 59.3 57.2 6.8 0.4 0.6 Segment Adjusted EBITDA $ 691.0 $ 665.3 $ 641.2 $ 83.1 $ 3.9 $ 4.5 Capital expenditures $ 151.7 $ 187.9 $ 216.5 $ 5.8 $ — $ —
Reconciliation of Assets from Segment to Consolidated [Table Text Block]	As of December 31, 2015 As of December 31, 2014 Total assets for reportable segments $ 4,677.4 $ 3,452.6 Reclassification of noncurrent deferred income tax liabilities to net noncurrent deferred income tax assets (71.3 ) (64.3 ) Total consolidated assets $ 4,606.1 $ 3,388.3 Inpatient Rehabilitation Home Health and Hospice HealthSouth Consolidated As of December 31, 2015 Total assets $ 3,589.0 $ 1,088.4 $ 4,606.1 Investments in and advances to nonconsolidated affiliates 9.3 2.4 11.7 As of December 31, 2014 Total assets $ 2,576.3 $ 876.3 $ 3,388.3 Investments in and advances to nonconsolidated affiliates 9.4 — 9.4
Reconciliation of Segment Adjusted EBITDA to Income from Continuing Operations Before Income Tax Expense [Table Text Block]	Segment reconciliations (in millions): For the Year Ended December 31, 2015 2014 2013 Total segment Adjusted EBITDA $ 774.1 $ 669.2 $ 645.7 General and administrative expenses (133.3 ) (124.8 ) (119.1 ) Depreciation and amortization (139.7 ) (107.7 ) (94.7 ) Loss on disposal or impairment of assets (2.6 ) (6.7 ) (5.9 ) Government, class action, and related settlements (7.5 ) 1.7 23.5 Professional fees - accounting, tax, and legal (3.0 ) (9.3 ) (9.5 ) Loss on early extinguishment of debt (22.4 ) (13.2 ) (2.4 ) Interest expense and amortization of debt discounts and fees (142.9 ) (109.2 ) (100.4 ) Gain on consolidation of former equity method hospital — 27.2 — Net income attributable to noncontrolling interests 69.7 59.7 57.8 Gain related to SCA equity interest 3.2 — — Other — — 0.2 Income from continuing operations before income tax expense $ 395.6 $ 386.9 $ 395.2
Reconciliation of Revenue from Segments to Consolidated [Table Text Block]	Additional detail regarding the revenues of our operating segments by service line follows (in millions): For the Year Ended December 31, 2015 2014 2013 Inpatient rehabilitation: Inpatient $ 2,547.2 $ 2,272.5 $ 2,130.8 Outpatient and other 105.9 104.8 113.6 Total inpatient rehabilitation 2,653.1 2,377.3 2,244.4 Home health and hospice: Home health 478.1 28.6 28.8 Hospice 31.7 — — Total home health and hospice 509.8 28.6 28.8 Total net operating revenues $ 3,162.9 $ 2,405.9 $ 2,273.2

Quarterly Data (Unaudited) (Tab

Quarterly Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Quarterly Data (Unaudited) Table	2014 First Second Third Fourth Total (In Millions, Except Per Share Data) Net operating revenues $ 591.2 $ 604.4 $ 596.9 $ 613.4 $ 2,405.9 Operating earnings (a) 105.8 115.4 100.7 96.5 418.4 Provision for income tax expense 32.8 36.5 22.1 19.3 110.7 Income from continuing operations 61.6 94.1 65.7 54.8 276.2 (Loss) income from discontinued operations, net of tax (0.1 ) 3.8 (0.9 ) 2.7 5.5 Net income 61.5 97.9 64.8 57.5 281.7 Less: Net income attributable to noncontrolling interests (14.8 ) (14.8 ) (14.7 ) (15.4 ) (59.7 ) Net income attributable to HealthSouth $ 46.7 $ 83.1 $ 50.1 $ 42.1 $ 222.0 Earnings per common share: Basic earnings per share attributable to HealthSouth common shareholders: (b) Continuing operations $ 0.51 $ 0.89 $ 0.56 $ 0.43 $ 2.40 Discontinued operations — 0.04 (0.01 ) 0.03 0.06 Net income $ 0.51 $ 0.93 $ 0.55 $ 0.46 $ 2.46 Diluted earnings per share attributable to HealthSouth common shareholders: Continuing operations $ 0.48 $ 0.81 $ 0.53 $ 0.41 $ 2.24 Discontinued operations — 0.04 (0.01 ) 0.03 0.05 Net income $ 0.48 $ 0.85 $ 0.52 $ 0.44 $ 2.29 (a) We define operating earnings as income from continuing operations attributable to HealthSouth before (1) loss on early extinguishment of debt; (2) interest expense and amortization of debt discounts and fees; (3) other income; and (4) income tax expense or benefit. (b) Per share amounts may not sum due to the weighted average common shares outstanding during each quarter compared to the weighted average common shares outstanding during the entire year. 2015 First Second Third Fourth Total (In Millions, Except Per Share Data) Net operating revenues $ 740.6 $ 764.4 $ 778.6 $ 879.3 $ 3,162.9 Operating earnings (a) 105.6 123.4 121.2 135.5 485.7 Provision for income tax expense 30.3 32.2 35.9 43.5 141.9 Income from continuing operations 59.3 61.8 67.5 65.1 253.7 (Loss) income from discontinued operations, net of tax (0.3 ) (1.6 ) 0.3 0.7 (0.9 ) Net income 59.0 60.2 67.8 65.8 252.8 Less: Net income attributable to noncontrolling interests (16.5 ) (17.3 ) (17.1 ) (18.8 ) (69.7 ) Net income attributable to HealthSouth $ 42.5 $ 42.9 $ 50.7 $ 47.0 $ 183.1 Earnings per common share: Basic earnings per share attributable to HealthSouth common shareholders: (b) Continuing operations $ 0.47 $ 0.49 $ 0.56 $ 0.51 $ 2.03 Discontinued operations — (0.02 ) — 0.01 (0.01 ) Net income $ 0.47 $ 0.47 $ 0.56 $ 0.52 $ 2.02 Diluted earnings per share attributable to HealthSouth common shareholders: (b) Continuing operations $ 0.44 $ 0.47 $ 0.52 $ 0.48 $ 1.92 Discontinued operations — (0.02 ) — 0.01 (0.01 ) Net income $ 0.44 $ 0.45 $ 0.52 $ 0.49 $ 1.91 (a) We define operating earnings as income from continuing operations attributable to HealthSouth before (1) loss on early extinguishment of debt; (2) interest expense and amortization of debt discounts and fees; (3) other income; and (4) income tax expense. (b) Per share amounts may not sum due to the weighted average common shares outstanding during each quarter compared to the weighted average common shares outstanding during the entire year. 2014 First Second Third Fourth Total (In Millions, Except Per Share Data) Net operating revenues $ 591.2 $ 604.4 $ 596.9 $ 613.4 $ 2,405.9 Operating earnings (a) 105.8 115.4 100.7 96.5 418.4 Provision for income tax expense 32.8 36.5 22.1 19.3 110.7 Income from continuing operations 61.6 94.1 65.7 54.8 276.2 (Loss) income from discontinued operations, net of tax (0.1 ) 3.8 (0.9 ) 2.7 5.5 Net income 61.5 97.9 64.8 57.5 281.7 Less: Net income attributable to noncontrolling interests (14.8 ) (14.8 ) (14.7 ) (15.4 ) (59.7 ) Net income attributable to HealthSouth $ 46.7 $ 83.1 $ 50.1 $ 42.1 $ 222.0 Earnings per common share: Basic earnings per share attributable to HealthSouth common shareholders: (b) Continuing operations $ 0.51 $ 0.89 $ 0.56 $ 0.43 $ 2.40 Discontinued operations — 0.04 (0.01 ) 0.03 0.06 Net income $ 0.51 $ 0.93 $ 0.55 $ 0.46 $ 2.46 Diluted earnings per share attributable to HealthSouth common shareholders: Continuing operations $ 0.48 $ 0.81 $ 0.53 $ 0.41 $ 2.24 Discontinued operations — 0.04 (0.01 ) 0.03 0.05 Net income $ 0.48 $ 0.85 $ 0.52 $ 0.44 $ 2.29

Condensed Consolidating Finan45

Condensed Consolidating Financial Information (Tables)	12 Months Ended
	Dec. 31, 2015
Condensed Consolidating Financial Information [Abstract]
Condensed Consolidating Statement of Operations	For the Year Ended December 31, 2015 HealthSouth Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries HealthSouth Consolidated (In Millions) Net operating revenues $ 19.4 $ 1,927.0 $ 1,320.0 $ (103.5 ) $ 3,162.9 Less: Provision for doubtful accounts — (34.6 ) (12.6 ) — (47.2 ) Net operating revenues less provision for doubtful accounts 19.4 1,892.4 1,307.4 (103.5 ) 3,115.7 Operating expenses: Salaries and benefits 49.4 893.2 745.3 (17.1 ) 1,670.8 Other operating expenses 31.3 274.7 167.4 (41.3 ) 432.1 Occupancy costs 4.0 69.4 25.6 (45.1 ) 53.9 Supplies — 85.2 43.5 — 128.7 General and administrative expenses 128.3 — 5.0 — 133.3 Depreciation and amortization 9.9 84.3 45.5 — 139.7 Government, class action, and related settlements 7.5 — — — 7.5 Professional fees—accounting, tax, and legal 3.0 — — — 3.0 Total operating expenses 233.4 1,406.8 1,032.3 (103.5 ) 2,569.0 Loss on early extinguishment of debt 22.4 — — — 22.4 Interest expense and amortization of debt discounts and fees 130.0 11.9 12.4 (11.4 ) 142.9 Other income (13.6 ) (0.2 ) (3.1 ) 11.4 (5.5 ) Equity in net income of nonconsolidated affiliates — (8.5 ) (0.2 ) — (8.7 ) Equity in net income of consolidated affiliates (322.7 ) (34.5 ) — 357.2 — Management fees (119.7 ) 91.6 28.1 — — Income from continuing operations before income tax (benefit) expense 89.6 425.3 237.9 (357.2 ) 395.6 Provision for income tax (benefit) expense (94.6 ) 169.7 66.8 — 141.9 Income from continuing operations 184.2 255.6 171.1 (357.2 ) 253.7 (Loss) income from discontinued operations, net of tax (1.1 ) — 0.2 — (0.9 ) Net income 183.1 255.6 171.3 (357.2 ) 252.8 Less: Net income attributable to noncontrolling interests — — (69.7 ) — (69.7 ) Net income attributable to HealthSouth $ 183.1 $ 255.6 $ 101.6 $ (357.2 ) $ 183.1 Comprehensive income $ 182.4 $ 255.6 $ 171.3 $ (357.2 ) $ 252.1 Comprehensive income attributable to HealthSouth $ 182.4 $ 255.6 $ 101.6 $ (357.2 ) $ 182.4 For the Year Ended December 31, 2014 HealthSouth Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries HealthSouth Consolidated (In Millions) Net operating revenues $ 16.1 $ 1,719.1 $ 761.1 $ (90.4 ) $ 2,405.9 Less: Provision for doubtful accounts — (22.3 ) (9.3 ) — (31.6 ) Net operating revenues less provision for doubtful accounts 16.1 1,696.8 751.8 (90.4 ) 2,374.3 Operating expenses: Salaries and benefits 22.3 795.7 358.8 (15.1 ) 1,161.7 Other operating expenses 21.6 246.7 120.1 (36.8 ) 351.6 Occupancy costs 4.2 58.2 17.7 (38.5 ) 41.6 Supplies — 78.6 33.3 — 111.9 General and administrative expenses 124.8 — — — 124.8 Depreciation and amortization 9.7 71.9 26.1 — 107.7 Government, class action, and related settlements (1.7 ) — — — (1.7 ) Professional fees—accounting, tax, and legal 9.3 — — — 9.3 Total operating expenses 190.2 1,251.1 556.0 (90.4 ) 1,906.9 Loss on early extinguishment of debt 13.2 — — — 13.2 Interest expense and amortization of debt discounts and fees 99.8 7.8 2.8 (1.2 ) 109.2 Other income (0.7 ) (28.5 ) (3.2 ) 1.2 (31.2 ) Equity in net income of nonconsolidated affiliates — (10.7 ) — — (10.7 ) Equity in net income of consolidated affiliates (314.0 ) (30.6 ) — 344.6 — Management fees (107.9 ) 82.2 25.7 — — Income from continuing operations before income tax (benefit) expense 135.5 425.5 170.5 (344.6 ) 386.9 Provision for income tax (benefit) expense (80.8 ) 148.0 43.5 — 110.7 Income from continuing operations 216.3 277.5 127.0 (344.6 ) 276.2 Income (loss) from discontinued operations, net of tax 5.7 — (0.2 ) — 5.5 Net income 222.0 277.5 126.8 (344.6 ) 281.7 Less: Net income attributable to noncontrolling interests — — (59.7 ) — (59.7 ) Net income attributable to HealthSouth $ 222.0 $ 277.5 $ 67.1 $ (344.6 ) $ 222.0 Comprehensive income $ 221.6 $ 277.5 $ 126.8 $ (344.6 ) $ 281.3 Comprehensive income attributable to HealthSouth $ 221.6 $ 277.5 $ 67.1 $ (344.6 ) $ 221.6 For the Year Ended December 31, 2013 HealthSouth Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries HealthSouth Consolidated (In Millions) Net operating revenues $ 12.2 $ 1,622.4 $ 709.8 $ (71.2 ) $ 2,273.2 Less: Provision for doubtful accounts — (18.3 ) (7.7 ) — (26.0 ) Net operating revenues less provision for doubtful accounts 12.2 1,604.1 702.1 (71.2 ) 2,247.2 Operating expenses: Salaries and benefits 12.1 757.7 334.4 (14.5 ) 1,089.7 Other operating expenses 10.8 238.5 107.5 (33.8 ) 323.0 Occupancy costs 4.1 48.3 17.5 (22.9 ) 47.0 Supplies — 73.8 31.6 — 105.4 General and administrative expenses 119.1 — — — 119.1 Depreciation and amortization 8.8 65.1 20.8 — 94.7 Government, class action, and related settlements (23.5 ) — — — (23.5 ) Professional fees—accounting, tax, and legal 9.5 — — — 9.5 Total operating expenses 140.9 1,183.4 511.8 (71.2 ) 1,764.9 Loss on early extinguishment of debt 2.4 — — — 2.4 Interest expense and amortization of debt discounts and fees 90.4 8.1 3.1 (1.2 ) 100.4 Other income (1.0 ) (1.2 ) (3.5 ) 1.2 (4.5 ) Equity in net income of nonconsolidated affiliates (3.6 ) (7.5 ) (0.1 ) — (11.2 ) Equity in net income of consolidated affiliates (268.0 ) (20.6 ) — 288.6 — Management fees (102.3 ) 78.6 23.7 — — Income from continuing operations before income tax (benefit) expense 153.4 363.3 167.1 (288.6 ) 395.2 Provision for income tax (benefit) expense (169.0 ) 134.4 47.3 — 12.7 Income from continuing operations 322.4 228.9 119.8 (288.6 ) 382.5 Income (loss) from discontinued operations, net of tax 1.2 (0.8 ) (1.5 ) — (1.1 ) Net income 323.6 228.1 118.3 (288.6 ) 381.4 Less: Net income attributable to noncontrolling interests — — (57.8 ) — (57.8 ) Net income attributable to HealthSouth $ 323.6 $ 228.1 $ 60.5 $ (288.6 ) $ 323.6 Comprehensive income $ 322.1 $ 228.1 $ 118.3 $ (288.6 ) $ 379.9 Comprehensive income attributable to HealthSouth $ 322.1 $ 228.1 $ 60.5 $ (288.6 ) $ 322.1
Condensed Consolidating Balance Sheet	As of December 31, 2015 HealthSouth Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries HealthSouth Consolidated (In Millions) Assets Current assets: Cash and cash equivalents $ 41.2 $ 1.3 $ 19.1 $ — $ 61.6 Restricted cash — — 45.9 — 45.9 Accounts receivable, net — 267.2 143.3 — 410.5 Prepaid expenses and other current assets 29.3 22.7 47.5 (18.8 ) 80.7 Total current assets 70.5 291.2 255.8 (18.8 ) 598.7 Property and equipment, net 14.5 965.7 329.9 — 1,310.1 Goodwill — 863.2 1,026.9 — 1,890.1 Intangible assets, net 8.8 123.2 287.4 — 419.4 Deferred income tax assets 176.2 64.1 — (49.5 ) 190.8 Other long-term assets 48.6 75.3 73.1 — 197.0 Intercompany notes receivable 546.6 — — (546.6 ) — Intercompany receivable and investments in consolidated affiliates 2,779.7 — — (2,779.7 ) — Total assets $ 3,644.9 $ 2,382.7 $ 1,973.1 $ (3,394.6 ) $ 4,606.1 Liabilities and Shareholders’ Equity Current liabilities: Current portion of long-term debt $ 40.0 $ 6.8 $ 7.5 $ (17.5 ) $ 36.8 Accounts payable 5.8 35.2 20.6 — 61.6 Accrued payroll 27.7 50.7 47.8 — 126.2 Accrued interest payable 26.5 2.9 0.3 — 29.7 Other current liabilities 68.0 19.0 86.4 (1.3 ) 172.1 Total current liabilities 168.0 114.6 162.6 (18.8 ) 426.4 Long-term debt, net of current portion 2,821.9 255.6 57.2 — 3,134.7 Intercompany notes payable — — 546.6 (546.6 ) — Self-insured risks 19.8 — 81.8 — 101.6 Other long-term liabilities 23.8 12.4 55.9 (49.1 ) 43.0 Intercompany payable — 141.7 179.1 (320.8 ) — 3,033.5 524.3 1,083.2 (935.3 ) 3,705.7 Commitments and contingencies Redeemable noncontrolling interests — — 121.1 — 121.1 Shareholders’ equity: HealthSouth shareholders’ equity 611.4 1,858.4 600.9 (2,459.3 ) 611.4 Noncontrolling interests — — 167.9 — 167.9 Total shareholders’ equity 611.4 1,858.4 768.8 (2,459.3 ) 779.3 Total liabilities and shareholders’ equity $ 3,644.9 $ 2,382.7 $ 1,973.1 $ (3,394.6 ) $ 4,606.1 As of December 31, 2014 HealthSouth Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries HealthSouth Consolidated (In Millions) Assets Current assets: Cash and cash equivalents $ 41.9 $ 1.5 $ 23.3 $ — $ 66.7 Restricted cash — — 45.6 — 45.6 Accounts receivable, net — 202.6 120.6 — 323.2 Deferred income tax assets 125.0 39.8 23.6 — 188.4 Prepaid expenses and other current assets 30.9 15.4 35.2 (18.8 ) 62.7 Total current assets 197.8 259.3 248.3 (18.8 ) 686.6 Property and equipment, net 16.1 752.0 251.6 — 1,019.7 Goodwill — 279.6 804.4 — 1,084.0 Intangible assets, net 11.3 50.6 244.2 — 306.1 Deferred income tax assets 163.3 17.5 — (51.4 ) 129.4 Other long-term assets 55.8 42.5 64.2 — 162.5 Intercompany notes receivable 385.2 — — (385.2 ) — Intercompany receivable and investments in consolidated affiliates 1,898.7 — — (1,898.7 ) — Total assets $ 2,728.2 $ 1,401.5 $ 1,612.7 $ (2,354.1 ) $ 3,388.3 Liabilities and Shareholders’ Equity Current liabilities: Current portion of long-term debt $ 27.9 $ 4.2 $ 6.2 $ (17.5 ) $ 20.8 Accounts payable 9.3 29.5 14.6 — 53.4 Accrued payroll 17.5 55.6 50.2 — 123.3 Accrued interest payable 19.2 1.8 0.2 — 21.2 Other current liabilities 70.4 15.2 61.3 (1.3 ) 145.6 Total current liabilities 144.3 106.3 132.5 (18.8 ) 364.3 Long-term debt, net of current portion 1,973.4 83.9 33.1 — 2,090.4 Intercompany notes payable — — 385.2 (385.2 ) — Self-insured risks 22.9 — 75.8 — 98.7 Other long-term liabilities 21.2 12.7 55.0 (51.4 ) 37.5 Intercompany payable — 381.0 173.2 (554.2 ) — 2,161.8 583.9 854.8 (1,009.6 ) 2,590.9 Commitments and contingencies Convertible perpetual preferred stock 93.2 — — — 93.2 Redeemable noncontrolling interests — — 84.7 — 84.7 Shareholders’ equity: HealthSouth shareholders’ equity 473.2 817.6 526.9 (1,344.5 ) 473.2 Noncontrolling interests — — 146.3 — 146.3 Total shareholders’ equity 473.2 817.6 673.2 (1,344.5 ) 619.5 Total liabilities and shareholders’ equity $ 2,728.2 $ 1,401.5 $ 1,612.7 $ (2,354.1 ) $ 3,388.3
Condensed Consolidating Statement of Cash Flows	For the Year Ended December 31, 2015 HealthSouth Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries HealthSouth Consolidated (In Millions) Net cash provided by operating activities $ 29.6 $ 222.6 $ 232.2 $ 0.4 $ 484.8 Cash flows from investing activities: Acquisition of businesses, net of cash acquired (954.6 ) — (30.5 ) — (985.1 ) Purchases of property and equipment (15.9 ) (46.1 ) (66.4 ) — (128.4 ) Capitalized software costs (24.5 ) (0.4 ) (3.2 ) — (28.1 ) Proceeds from sale of restricted investments — — 0.2 — 0.2 Proceeds from sale of marketable securities 12.8 — — — 12.8 Purchases of restricted investments — — (7.1 ) — (7.1 ) Net change in restricted cash — — 2.7 — 2.7 Funding of intercompany note receivable (2.0 ) — — 2.0 — Proceeds from repayment of intercompany note receivable 24.0 — — (24.0 ) — Other (0.5 ) 2.3 0.9 — 2.7 Net cash provided by investing activities of discontinued operations 0.5 — — — 0.5 Net cash used in investing activities (960.2 ) (44.2 ) (103.4 ) (22.0 ) (1,129.8 ) Cash flows from financing activities: Principal borrowings on term loan facilities 250.0 — 2.0 (2.0 ) 250.0 Proceeds from bond issuance 1,400.0 — — — 1,400.0 Principal payments on debt, including pre-payments (595.0 ) (1.6 ) (0.8 ) — (597.4 ) Principal payments on intercompany note payable — — (24.0 ) 24.0 — Borrowings on revolving credit facility 540.0 — — — 540.0 Payments on revolving credit facility (735.0 ) — — — (735.0 ) Debt amendment and issuance costs (31.9 ) — — — (31.9 ) Principal payments under capital lease obligations (0.3 ) (4.5 ) (6.2 ) — (11.0 ) Repurchases of common stock, including fees and expenses (45.3 ) — — — (45.3 ) Dividends paid on common stock (77.2 ) — — — (77.2 ) Dividends paid on convertible perpetual preferred stock (3.1 ) — — — (3.1 ) Distributions paid to noncontrolling interests of consolidated affiliates — — (54.4 ) — (54.4 ) Other 2.2 1.5 1.5 — 5.2 Change in intercompany advances 225.5 (174.0 ) (51.1 ) (0.4 ) — Net cash provided by (used in) financing activities 929.9 (178.6 ) (133.0 ) 21.6 639.9 Decrease in cash and cash equivalents (0.7 ) (0.2 ) (4.2 ) — (5.1 ) Cash and cash equivalents at beginning of year 41.9 1.5 23.3 — 66.7 Cash and cash equivalents at end of year $ 41.2 $ 1.3 $ 19.1 $ — $ 61.6 Supplemental schedule of noncash investing activity: Conversion of preferred stock to common stock $ 93.2 $ — $ — $ — $ 93.2 Intercompany note activity (183.5 ) — 183.5 — — For the Year Ended December 31, 2014 HealthSouth Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries HealthSouth Consolidated (In Millions) Net cash provided by operating activities $ 21.9 $ 260.1 $ 162.9 $ — $ 444.9 Cash flows from investing activities: Acquisition of businesses, net of cash acquired (674.6 ) — (20.2 ) — (694.8 ) Purchases of property and equipment (15.6 ) (124.0 ) (31.3 ) — (170.9 ) Capitalized software costs (8.6 ) (1.4 ) (7.0 ) — (17.0 ) Proceeds from sale of restricted investments — — 0.3 — 0.3 Purchases of restricted investments — — (3.5 ) — (3.5 ) Net change in restricted cash 1.0 — 5.8 — 6.8 Other — (0.7 ) 2.9 — 2.2 Net cash used in investing activities (697.8 ) (126.1 ) (53.0 ) — (876.9 ) Cash flows from financing activities: Principal borrowings on term loan facilities 450.0 — — — 450.0 Proceeds from bond issuance 175.0 — — — 175.0 Principal payments on debt, including pre-payments (298.0 ) (1.5 ) (3.1 ) — (302.6 ) Borrowings on revolving credit facility 440.0 — — — 440.0 Payments on revolving credit facility (160.0 ) — — — (160.0 ) Principal payments under capital lease obligations (0.3 ) (2.5 ) (3.3 ) — (6.1 ) Debt amendment and issuance costs (6.5 ) — — — (6.5 ) Repurchases of common stock, including fees and expenses (43.1 ) — — — (43.1 ) Dividends paid on common stock (65.8 ) — — — (65.8 ) Dividends paid on convertible perpetual preferred stock (6.3 ) — — — (6.3 ) Distributions paid to noncontrolling interests of consolidated affiliates — — (54.1 ) — (54.1 ) Proceeds from exercising stock warrants 6.3 — — — 6.3 Other 7.4 — — — 7.4 Change in intercompany advances 158.6 (130.8 ) (27.8 ) — — Net cash provided by (used in) financing activities 657.3 (134.8 ) (88.3 ) — 434.2 (Decrease) increase in cash and cash equivalents (18.6 ) (0.8 ) 21.6 — 2.2 Cash and cash equivalents at beginning of year 60.5 2.3 1.7 — 64.5 Cash and cash equivalents at end of year $ 41.9 $ 1.5 $ 23.3 $ — $ 66.7 Supplemental schedule of noncash financing activities: Equity rollover from Encompass management $ — $ — $ 64.5 $ — $ 64.5 For the Year Ended December 31, 2013 HealthSouth Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries HealthSouth Consolidated (In Millions) Net cash provided by operating activities $ 113.2 $ 235.7 $ 121.4 $ — $ 470.3 Cash flows from investing activities: Acquisition of businesses, net of cash acquired — (28.9 ) — — (28.9 ) Purchases of property and equipment (2.8 ) (167.9 ) (24.5 ) — (195.2 ) Capitalized software costs (6.0 ) (11.1 ) (4.2 ) — (21.3 ) Proceeds from sale of restricted investments — — 16.9 — 16.9 Proceeds from sale of Digital Hospital 10.8 — — — 10.8 Purchases of restricted investments — — (9.2 ) — (9.2 ) Net change in restricted cash (0.2 ) — (2.9 ) — (3.1 ) Other — 0.9 (0.4 ) — 0.5 Net cash provided by investing activities of discontinued operations — 3.1 0.2 — 3.3 Net cash provided by (used in) investing activities 1.8 (203.9 ) (24.1 ) — (226.2 ) Cash flows from financing activities: Principal payments on debt, including pre-payments (59.5 ) (1.3 ) (1.7 ) — (62.5 ) Principal borrowings on notes — — 15.2 — 15.2 Borrowings on revolving credit facility 197.0 — — — 197.0 Payments on revolving credit facility (152.0 ) — — — (152.0 ) Principal payments under capital lease obligations (0.3 ) (6.3 ) (3.5 ) — (10.1 ) Debt amendment and issuance costs (2.6 ) — — — (2.6 ) Repurchases of common stock, including fees and expenses (234.1 ) — — — (234.1 ) Dividends paid on common stock (15.7 ) — — — (15.7 ) Dividends paid on convertible perpetual preferred stock (23.0 ) — — — (23.0 ) Distributions paid to noncontrolling interests of consolidated affiliates — — (46.3 ) — (46.3 ) Proceeds from exercising stock warrants 15.3 — — — 15.3 Other 4.8 — 1.6 — 6.4 Change in intercompany advances 84.3 (22.2 ) (62.1 ) — — Net cash used in financing activities (185.8 ) (29.8 ) (96.8 ) — (312.4 ) (Decrease) increase in cash and cash equivalents (70.8 ) 2.0 0.5 — (68.3 ) Cash and cash equivalents at beginning of year 131.3 0.3 1.2 — 132.8 Cash and cash equivalents at end of year $ 60.5 $ 2.3 $ 1.7 $ — $ 64.5 Supplemental schedule of noncash financing activities: Convertible debt issued $ 320.0 $ — $ — $ — $ 320.0 Repurchase of preferred stock (320.0 ) — — — (320.0 )

Business Combinations (Tables)

Business Combinations (Tables)	12 Months Ended
	Dec. 31, 2015
Business Combinations [Abstract]
Schedule of Assets Acquired and Liabilities Assumed at the Acquisition Date	The preliminary fair value of the assets acquired and liabilities assumed at the acquisition date were as follows (in millions): Cash and cash equivalents $ 42.6 Accounts receivable 25.7 Prepaid expenses and other current assets 2.8 Property and equipment 220.6 Identifiable intangible assets: Noncompete agreements (useful lives of 1 to 2 years) 9.7 Trade names (useful lives of 20 years) 8.9 Certificates of need (useful lives of 20 years) 36.6 Licenses (useful lives of 20 years) 11.4 Goodwill 642.6 Other long-term assets 0.9 Total assets acquired 1,001.8 Liabilities assumed: Current portion of long-term debt 4.1 Accounts payable 1.7 Accrued payroll 3.7 Other current liabilities 10.8 Long-term debt, net of current portion 205.8 Deferred tax liabilities 3.9 Total liabilities assumed 230.0 Noncontrolling interests 0.4 Net assets acquired $ 771.4 The fair value of the assets acquired and liabilities assumed at the acquisition date for Encompass were as follows (in millions): Cash and cash equivalents $ 20.9 Accounts receivable 37.6 Prepaid expenses and other current assets 8.6 Property and equipment 9.6 Identifiable intangible assets: Noncompete agreements (useful life of 2 to 5 years) 5.6 Trade name (indefinite life) 135.2 Licenses (useful life of 10 years) 58.2 Internal-use software (useful life of 3 years) 3.2 Goodwill 592.5 Other long-term assets 2.1 Total assets acquired 873.5 Current portion of long-term debt 2.0 Accounts payable 0.9 Accrued payroll 25.8 Other current liabilities 18.5 Long-term debt, net of current portion 2.0 Deferred tax liabilities 64.3 Total liabilities assumed 113.5 Redeemable noncontrolling interests 64.5 Net assets acquired $ 695.5 The fair value of the assets acquired and liabilities assumed at the acquisition dates for the other acquisitions completed in 2014 were as follows (in millions): Total current assets $ 12.1 Property and equipment, net 36.9 Identifiable intangible assets: Noncompete agreements (useful lives of 2 to 3 years) 0.4 Trade names (useful lives of 20 years) 2.9 Certificates of need (useful lives of 20 years) 10.8 Licenses (useful lives of 20 years) 2.1 Goodwill 34.6 Total assets acquired 99.8 Total current liabilities assumed (7.8 ) Total long-term liabilities assumed (13.4 ) Net assets acquired $ 78.6 The preliminary fair value of the assets acquired and liabilities assumed at the acquisition date were as follows (in millions): Cash and cash equivalents $ 0.4 Accounts receivable 10.5 Prepaid expenses and other current assets 2.4 Property and equipment 0.7 Identifiable intangible assets: Noncompete agreements (useful lives of 3 years) 0.8 Trade name (useful life of 5 years) 2.8 Certificates of need (useful lives of 10 years) 15.6 Licenses (useful lives of 10 years) 13.0 Internal use software 0.4 Goodwill 142.5 Investment in nonconsolidated subsidiaries 2.2 Total assets acquired 191.3 Liabilities assumed: Current portion of long-term debt 0.1 Accounts payable 2.4 Accrued payroll 2.4 Other current liabilities 2.8 Long-term debt, net of current portion 0.2 Deferred tax liabilties 9.4 Total liabilities assumed 17.3 Noncontrolling interests 4.3 Net assets acquired $ 169.7 The fair value of the assets acquired and liabilities assumed at the acquisition dates for the other home health and hospice transactions completed in 2015 were as follows (in millions): Property and equipment $ 0.1 Identifiable intangible assets: Noncompete agreements (useful lives of 2 to 5 years) 1.3 Trade names (useful lives of 1 year) 0.5 Certificates of need (useful lives of 10 years) 4.9 Licenses (useful lives of 10 years) 3.6 Goodwill 20.3 Total assets acquired 30.7 Total liabilities assumed (0.2 ) Net assets acquired $ 30.5 The fair value of the assets acquired and liabilities assumed at the acquisition dates for the other inpatient rehabilitation transactions completed in 2015 were as follows (in millions): Total current assets $ 10.1 Property and equipment 42.7 Identifiable intangible assets: Noncompete agreements (useful lives of 2 to 3 years) 0.1 Trade names (useful lives of 20 years) 0.8 Certificates of need (useful lives of 20 years) 8.8 Licenses (useful lives of 20 years) 0.2 Goodwill 0.7 Total assets acquired 63.4 Total liabilities assumed (2.7 ) Net assets acquired $ 60.7
Schedule of Noncash or Part Noncash Acquisitions	Information regarding the net cash paid for the other home health and hospice acquisitions during each period presented is as follows (in millions): For the Year Ended December 31, 2015 2014 2013 Fair value of assets acquired $ 10.4 $ — $ — Goodwill 20.3 — — Fair value of liabilities assumed (0.2 ) — — Net cash paid for acquisitions $ 30.5 $ — $ — Information regarding the net cash paid for the acquisition of Encompass is as follows (in millions): Fair value of assets acquired, net of $20.9 million of cash acquired $ 260.1 Goodwill 592.5 Fair value of liabilities assumed (113.5 ) Redeemable noncontrolling interests (64.5 ) Net cash paid for acquisition $ 674.6 Information regarding the net cash paid for all other acquisitions during each period presented is as follows (in millions): For the Year Ended December 31, 2014 2013 Fair value of assets acquired, net of $5.1 million of cash acquired in 2014 $ 60.1 $ 15.6 Goodwill 34.6 13.7 Fair value of liabilities assumed (21.2 ) (0.4 ) Fair value of noncontrolling interest owned by joint venture partner (18.3 ) — Fair value of equity interest prior to acquisition (35.0 ) — Net cash paid for acquisitions $ 20.2 $ 28.9 Information regarding the net cash paid for the acquisition of Reliant is as follows (in millions): Fair value of assets acquired, net of $42.6 million of cash acquired $ 316.6 Goodwill 642.6 Fair value of liabilities assumed (230.0 ) Noncontrolling interests (0.4 ) Net cash paid for acquisition $ 728.8 Information regarding the net cash paid for other inpatient rehabilitation acquisitions during each period presented is as follows (in millions): For the Year Ended December 31, 2015 2014 2013 Fair value of assets acquired $ 62.8 $ 60.1 $ 15.6 Goodwill 0.7 34.6 13.7 Fair value of liabilities assumed (2.7 ) (21.2 ) (0.4 ) Fair value of noncontrolling interest owned by joint venture partner (4.2 ) (18.3 ) — Fair value of equity interest prior to acquisition — (35.0 ) — Net cash paid for acquisitions $ 56.6 $ 20.2 $ 28.9 Information regarding the net cash paid for the acquisition of CareSouth is as follows (in millions): Fair value of assets acquired, net of $0.4 million of cash acquired $ 48.4 Goodwill 142.5 Fair value of liabilities assumed (17.3 ) Fair value of noncontrolling interest owned by joint venture partner (4.3 ) Net cash paid for acquisitions $ 169.3
Summary of Actual and Pro Forma Results of Operations for Acquisitions	The following table summarizes the results of operations of the above 2014 transactions from their respective dates of acquisition included in our consolidated results of operations and the unaudited pro forma results of operations of the combined entity had the date of the acquisitions been January 1, 2013 (in millions): Net Operating Revenues Net Income Attributable to HealthSouth Acquired entities only: Actual from acquisition date to December 31, 2014* $ 27.2 $ 4.0 Combined entity: Supplemental pro forma from 1/01/2014-12/31/2014 (unaudited) 2,799.8 237.5 Combined entity: Supplemental pro forma from 1/01/2013-12/31/2013 (unaudited) 2,627.6 311.3 * Encompass - Actual amounts are zero due to the acquisition of Encompass on December 31, 2014. Fairlawn - includes operating results from June 1, 2014 through December 31, 2014 Quillen - includes operating results from November 1, 2014 through December 31, 2014 The following table summarizes the results of operations of the above mentioned transactions from their respective dates of acquisition included in our consolidated results of operations and the unaudited pro forma results of operations of the combined entity had the date of the acquisitions been January 1, 2014 (in millions): Net Operating Revenues Net Income Attributable to HealthSouth Acquired entities only: Actual from acquisition date to December 31, 2015:* Reliant $ 63.7 $ 11.2 All Other Inpatient 54.7 1.7 CareSouth 19.2 2.5 All Other Home Health and Hospice 17.8 1.2 Combined entity: Supplemental pro forma from 1/01/2015-12/31/2015 (unaudited) 3,479.9 234.0 Combined entity: Supplemental pro forma from 1/01/2014-12/31/2014 (unaudited) 2,851.0 276.9 * Savannah - includes operating results from April 1, 2015 through December 31, 2015 Cardinal Hill - includes operating results from May 1, 2015 through December 31, 2015 Integrity - includes operating results from March 3, 2015 through December 31, 2015 Harvey - includes operating results from April 15, 2015 through December 31, 2015 Heritage - includes operating results from May 1, 2015 through December 31, 2015 Alliance - includes operating results from June 4, 2015 through December 31, 2015 Southern Utah - includes operating results from July 1, 2015 through December 31, 2015 ORS - includes operating results from July 13, 2015 through December 31, 2015 Reliant - includes operating results from October 1, 2015 through December 31, 2015 CareSouth - includes operating results from November 2, 2015 through December 31, 201

Cash and Marketable Securitie47

Cash and Marketable Securities - Tables 1 & 2 (Details) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Components of Investments
Cash and cash equivalents	$ 61.6	$ 66.7	$ 64.5	$ 132.8
Restricted Cash	45.9	45.6
Restricted Marketable Securities	56.2	50.5
Total	163.7	162.8
Cash [Member]
Components of Investments
Cash and cash equivalents	61.6	66.7
Restricted Cash	45.9	45.6
Restricted Marketable Securities	0	0
Total	107.5	112.3
Equity Securities [Member]
Components of Investments
Cash and cash equivalents	0	0
Restricted Cash	0	0
Restricted Marketable Securities	56.2	50.5
Total	$ 56.2	$ 50.5

Cash and Marketable Securitie48

Cash and Marketable Securities - Table 3 (Details) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Restricted Cash
Restricted Cash	$ 45.9	$ 45.6
Affiliate cash [Member]
Restricted Cash
Restricted Cash	20.3	13.1
Self-insured captive funds [Member]
Restricted Cash
Restricted Cash	25.6	32.4
Paid-loss deposit funds [Member]
Restricted Cash
Restricted Cash	$ 0	$ 0.1

Summary of Significant Accoun49

Summary of Significant Accounting Policies - Table 1 (Details)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Concentration of Net Operating Revenues by Payor [Abstract]
Medicare	74.90%	74.10%	74.50%
Managed care and other discount plans, including Medicare Advantage	17.70%	18.60%	18.50%
Medicaid	3.00%	1.80%	1.20%
Other third-party payors	1.70%	1.80%	1.80%
Workers' compensation	0.90%	1.20%	1.20%
Patients	0.60%	1.00%	1.10%
Other income	1.20%	1.50%	1.70%
Total	100.00%	100.00%	100.00%

Cash and Marketable Securitie50

Cash and Marketable Securities - Tables 4 & 5 (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Summary of Restricted Marketable Securities
Restricted marketable securities, cost	$ 58.3	$ 51.3
Restricted marketable securities, gross unrealized gains	0.3	0.5
Restricted marketable securities, gross unrealized losses	(2.4)	(1.3)
Restricted marketable securities, fair value	$ 56.2	$ 50.5

Summary of Significant Accoun51

Summary of Significant Accounting Policies Summary of Significant Accounting Policies - Table 2 (Details)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Concentration of Net Operating Revenues by Payor [Line Items]
Medicare	74.90%	74.10%	74.50%
Managed care and other discount plans, including Medicare Advantage	17.70%	18.60%	18.50%
Medicaid	3.00%	1.80%	1.20%
Other third-party payors	1.70%	1.80%	1.80%
Workers' compensation	0.90%	1.20%	1.20%
Patients	0.60%	1.00%	1.10%
Other income	1.20%	1.50%	1.70%
Total	100.00%	100.00%	100.00%
Inpatient Rehabilitation Hospital [Member]
Concentration of Net Operating Revenues by Payor [Line Items]
Medicare	73.20%	73.90%	74.20%
Managed care and other discount plans, including Medicare Advantage	19.00%	18.80%	18.70%
Medicaid	2.50%	1.80%	1.20%
Other third-party payors	2.00%	1.80%	1.80%
Workers' compensation	1.10%	1.20%	1.30%
Patients	0.70%	1.00%	1.10%
Other income	1.50%	1.50%	1.70%
Total	100.00%	100.00%	100.00%

Cash and Marketable Securitie52

Cash and Marketable Securities - Table 6 (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Restricted Marketable Securities [Member]
Investment information related to restricted marketable securities
Proceeds from sales of restricted available-for-sale securities	$ 0	$ 0	$ 16.6
Gross realized gains	1.2	0.5	1
Gross realized losses	0	(0.1)	(0.1)
Nonrestricted Marketable Securities [Member]
Investment information related to restricted marketable securities
Proceeds from sales of restricted available-for-sale securities	$ 12.8	$ 2.7	$ 0

Summary of Significant Accoun53

Summary of Significant Accounting Policies Summary of Significant Accounting Policies Table 3 (Details)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Concentration of Net Operating Revenues by Payor [Line Items]
Medicare	74.90%	74.10%	74.50%
Managed care and other discount plans, including Medicare Advantage	17.70%	18.60%	18.50%
Medicaid	3.00%	1.80%	1.20%
Other third-party payors	1.70%	1.80%	1.80%
Workers' compensation	0.90%	1.20%	1.20%
Patients	0.60%	1.00%	1.10%
Total	100.00%	100.00%	100.00%
Home Health and Hospice [Member]
Concentration of Net Operating Revenues by Payor [Line Items]
Medicare	83.70%	96.90%	95.80%
Managed care and other discount plans, including Medicare Advantage	10.70%	1.80%	2.50%
Medicaid	5.50%	0.00%	0.00%
Other third-party payors	0.00%	1.00%	1.40%
Workers' compensation	0.00%	0.30%	0.30%
Patients	0.10%	0.00%	0.00%
Total	100.00%	100.00%	100.00%

Cash and Marketable Securitie54

Cash and Marketable Securities - Textual (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Cash and Marketable Securities (Textual) [Abstract]
Restricted marketable securities included in other long-term assets	$ 40.1	$ 45.9
Impairment charges related to restricted marketable securities	$ 0	$ 0	$ 0

Summary of Significant Accoun55

Summary of Significant Accounting Policies - Table 4 (Details)	Dec. 31, 2015	Dec. 31, 2014
Concentration Of Net Patient Service Accounts Receivable By Payor Class [Abstract]
Medicare	70.50%	72.20%
Managed care and other discount plans, including Medicare Advantage	19.70%	18.50%
Medicaid	2.90%	1.80%
Other third-party payors	4.10%	3.80%
Workers' compensation	1.90%	1.90%
Patients	0.90%	1.80%
Total	100.00%	100.00%

Summary of Significant Accoun56

Summary of Significant Accounting Policies - Table 5 (Details)	12 Months Ended
	Dec. 31, 2015
Buildings [Member] | Maximum [Member]
Useful lives of assets
Useful Life	30 years
Buildings [Member] | Minimum [Member]
Useful lives of assets
Useful Life	10 years
Leasehold improvements [Member] | Maximum [Member]
Useful lives of assets
Useful Life	15 years
Leasehold improvements [Member] | Minimum [Member]
Useful lives of assets
Useful Life	2 years
Vehicles [Member]
Useful lives of assets
Useful Life	5 years
Furniture and Fixtures [Member] | Maximum [Member]
Useful lives of assets
Useful Life	10 years
Furniture and Fixtures [Member] | Minimum [Member]
Useful lives of assets
Useful Life	3 years
Real Estate, Asset under capital lease obligation [Member] | Maximum [Member]
Useful lives of assets
Useful Life	20 years
Real Estate, Asset under capital lease obligation [Member] | Minimum [Member]
Useful lives of assets
Useful Life	15 years
Vehicles, Asset under capital lease obligation [Member] | Maximum [Member]
Useful lives of assets
Useful Life	4 years
Vehicles, Asset under capital lease obligation [Member] | Minimum [Member]
Useful lives of assets
Useful Life	3 years
Equipment, Asset under capital lease obligation [Member] | Maximum [Member]
Useful lives of assets
Useful Life	5 years
Equipment, Asset under capital lease obligation [Member] | Minimum [Member]
Useful lives of assets
Useful Life	3 years

Summary of Significant Accoun57

Summary of Significant Accounting Policies - Table 6 (Details)	12 Months Ended
	Dec. 31, 2015
Certificate of Need [Member]
Estimated Useful Lives and Amortization Basis of Other Intangible Assets
Finite-Lived Intangible Assets, Amortization Method	straight-line
Certificate of Need [Member] | Maximum [Member]
Estimated Useful Lives and Amortization Basis of Other Intangible Assets
Finite-Lived Intangible Assets, Useful Life	30 years
Certificate of Need [Member] | Minimum [Member]
Estimated Useful Lives and Amortization Basis of Other Intangible Assets
Finite-Lived Intangible Assets, Useful Life	10 years
Licenses [Member]
Estimated Useful Lives and Amortization Basis of Other Intangible Assets
Finite-Lived Intangible Assets, Amortization Method	straight-line
Licenses [Member] | Maximum [Member]
Estimated Useful Lives and Amortization Basis of Other Intangible Assets
Finite-Lived Intangible Assets, Useful Life	20 years
Licenses [Member] | Minimum [Member]
Estimated Useful Lives and Amortization Basis of Other Intangible Assets
Finite-Lived Intangible Assets, Useful Life	10 years
Noncompete Agreements [Member]
Estimated Useful Lives and Amortization Basis of Other Intangible Assets
Finite-Lived Intangible Assets, Amortization Method	straight-line
Noncompete Agreements [Member] | Maximum [Member]
Estimated Useful Lives and Amortization Basis of Other Intangible Assets
Finite-Lived Intangible Assets, Useful Life	18 years
Noncompete Agreements [Member] | Minimum [Member]
Estimated Useful Lives and Amortization Basis of Other Intangible Assets
Finite-Lived Intangible Assets, Useful Life	1 year
Trade Names [Member]
Estimated Useful Lives and Amortization Basis of Other Intangible Assets
Finite-Lived Intangible Assets, Amortization Method	straight-line
Trade Names [Member] | Maximum [Member]
Estimated Useful Lives and Amortization Basis of Other Intangible Assets
Finite-Lived Intangible Assets, Useful Life	20 years
Trade Names [Member] | Minimum [Member]
Estimated Useful Lives and Amortization Basis of Other Intangible Assets
Finite-Lived Intangible Assets, Useful Life	1 year
Internal Use Software [Member]
Estimated Useful Lives and Amortization Basis of Other Intangible Assets
Finite-Lived Intangible Assets, Amortization Method	straight-line
Internal Use Software [Member] | Maximum [Member]
Estimated Useful Lives and Amortization Basis of Other Intangible Assets
Finite-Lived Intangible Assets, Useful Life	7 years
Internal Use Software [Member] | Minimum [Member]
Estimated Useful Lives and Amortization Basis of Other Intangible Assets
Finite-Lived Intangible Assets, Useful Life	3 years
Market access assets [Member]
Estimated Useful Lives and Amortization Basis of Other Intangible Assets
Finite-Lived Intangible Assets, Amortization Method	accelerated
Finite-Lived Intangible Assets, Useful Life	20 years

Summary of Significant Accoun58

Summary of Significant Accounting Policies - Textual (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]
Use of Estimates, Policy [Policy Text Block]	180 days
Summary of Significant Accounting Policies (Textual) [Abstract]
Number of States in which Entity Operates	34
Compliance Threshold Percentage Under The Medicare, Medicaid, and SCHIP Extension Act of 2007	60.00%
Reduction in Net Operating Revenue, Post-Payment Claims	$ (0.6)	$ 0.4
Medicare Denials, Percentage Collected After Appeal	71.00%
Medicare Denials, Percentage Collected After Appeal, Including Administrative Law Judge Hearings	70.00%
Minimum amount of loss contingency accrual to consider the associated estimated legal fees as accrued	$ 5
Advertising expenses, included in Other operating expenses	$ 7.3	$ 5.3	$ 5.2
Market access assets [Member]
Summary of Significant Accounting Policies (Textual) [Abstract]
Market Access Assets, Useful Life	20 years
Finite-Lived Intangible Assets, Amortization Method	accelerated
RAC Audits [Member]
Summary of Significant Accounting Policies (Textual) [Abstract]
Percentage of average annual patient discharges requested for review, less than	1.00%

Accounts Receivable - Table 1 (

Accounts Receivable - Table 1 (Details) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Schedule of Accounts Receivable, Net, Current
Patient accounts receivable, net of allowance for doubtful accounts of $39.3 million in 2015; $22.2 million in 2014	$ 403.3	$ 309.3
Other accounts receivable	7.2	13.9
Accounts receivable, net, current	410.5	323.2
Noncurrent patient accounts receivable, net of allowance for doubtful accounts of $32.3 million in 2015; $20.8 million in 2014	96.6	51.4
Accounts receivable, net	507.1	374.6
Allowance for Doubtful Accounts [Abstract]
Allowance for doubtful accounts receivable, current	39.3	22.2
Allowance for doubtful accounts receivable, noncurrent	$ 32.3	$ 20.8

Accounts Receivable - Table 2 (

Accounts Receivable - Table 2 (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Schedule of Activity Related to our Allowance for Doubtful Accounts
Balance at Beginning of Period	$ 43	$ 33.1	$ 28.7
Additions and Charges to Expense	47.2	31.6	26
Deductions and Accounts Written off	(18.6)	(21.7)	(21.6)
Balance at End of Period	$ 71.6	$ 43	$ 33.1

Accounts Receivable - Textual (

Accounts Receivable - Textual (Details)	Dec. 31, 2015	Dec. 31, 2014
Accounts Receivable (Textual) (Abstract)
Allowance for Doubtful Accounts as a Percentage of Total Patient Accounts Receivable	12.50%	10.70%

Property and Equipment - Table

Property and Equipment - Table 1 (Details) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Components of Property and Equipment
Land	$ 113.3	$ 108.1
Buildings	1,521.1	1,214.4
Leasehold Improvements	96.2	79.1
Vehicles	10	9.3
Furniture, Fixtures, and Equipment	392.7	364.2
Property and Equipment, Gross	2,133.3	1,775.1
Less: Accumulated depreciation and amortization	(874.3)	(784)
Property and Equipment, Net Excluding CIP	1,259	991.1
Construction in progress	51.1	28.6
Property and Equipment, net	$ 1,310.1	$ 1,019.7

Property and Equipment - Tabl63

Property and Equipment - Table 2 (Details) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Fully Depreciated Assets and Assets Under Capital Lease Obligations
Fully depreciated assets	$ 252.4	$ 240.9
Assets under capital lease obligations:
Capital Leased Assets, Gross	340.7	129.8
Accumumlated Amortization	(66.6)	(55.2)
Assets Under Capital Lease Obligations, Net	274.1	74.6
Building [Member]
Assets under capital lease obligations:
Capital Leased Assets, Gross	333.9	124.4
Vehicles [Member]
Assets under capital lease obligations:
Capital Leased Assets, Gross	6.5	5.2
Equipment [Member]
Assets under capital lease obligations:
Capital Leased Assets, Gross	$ 0.3	$ 0.2

Property and Equipment - Tabl64

Property and Equipment - Table 3 (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Summary of Depreciation Expense, Amortization Expense Relating to Assets Under Capital Lease Obligations, Interest Capitalized, and Rent Expense Under Operating Leases
Depreciation expense	$ 91	$ 79.9	$ 67.9
Amortization expense	12.7	7.5	9.5
Interest capitalized	1.3	1.5	1.9
Rent expense:
Minimum rent payments	48.8	37.3	40.3
Contingent and other rents	21.6	18.2	20.3
Other	3.8	3.9	4.2
Total rent expense	$ 74.2	$ 59.4	$ 64.8

Property and Equipment - Tabl65

Property and Equipment - Table 4 (Details) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Schedule of Accrued Straight-line Rent
Straight-line rental accrual	$ 11.8	$ 14.6

Property and Equipment - Tabl66

Property and Equipment - Table 5 (Details) $ in Millions	Dec. 31, 2015USD ($)
Schedule of Future Minimum Lease Payments
Operating Leases, 2016	$ 59.2
Operating Leases, 2017	52.1
Operating Leases, 2018	46
Operating Leases, 2019	41.2
Operating Leases, 2020	32.9
Operating Leases, 2021 and thereafter	156.2
Operating Leases, Total	387.6
Capital Lease Obligations, 2016	32.8
Capital Lease Obligations, 2017	34.1
Capital Lease Obligations, 2018	33.4
Capital Lease Obligations, 2019	30.3
Capital Lease Obligations, 2020	27.8
Capital Lease Obligations, 2021 and thereafter	384.7
Capital Lease Obligations, Total	543.1
Less: Interest portion	(254.9)
Obligations under capital leases	288.2
Operating & Capital Lease Obligations, 2016	92
Operating & Capital Lease Obligations, 2017	86.2
Operating & Capital Lease Obligations, 2018	79.4
Operating & Capital Lease Obligations, 2019	71.5
Operating & Capital Lease Obligations, 2020	60.7
Operating & Capital Lease Obligations, 2021 and thereafter	540.9
Operating & Capital Lease Obligations, Total	$ 930.7

Property and Equipment - Textua

Property and Equipment - Textual (Details) $ in Millions	3 Months Ended	12 Months Ended
	Sep. 30, 2013USD ($)	Dec. 31, 2015USD ($)yr	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)	Mar. 31, 2008
Property and Equipment (Textual) [Abstract]
Percentage of property and equipment, net pledged to lenders under credit agreement		75.00%
Operating Lease Term, Minimum | yr		3
Operating Lease Term, Maximum | yr		15
Rental Income from Subleases		$ 5	$ 5.1	$ 4.9
Total Expected Future Minimum Sublease Rental Income		13.5
Percentage of Net Profit Due Company from Hospital Building Sale					40.00%
Proceeds from sale of Digital Hospital	$ 10.8	$ 0	$ 0	$ 10.8
Number of sale/leaseback transactions		2
Sale/Leaseback Transactions, Future Minimum Payments, 2016		$ 2.7
Sale/Leaseback Transactions, Future Minimum Payments, 2017		2.7
Sale/Leaseback Transactions, Future Minimum Payments, 2018		2.7
Sale/Leaseback Transactions, Future Minimum Payments, 2019		2.7
Sale/Leaseback Transactions, Future Minimum Payments, 2020		2.7
Sale/Leaseback Transactions, Future Minimum Payments, 2021 & Thereafter		$ 8.3

Goodwill and Other Intangible68

Goodwill and Other Intangible Assets - Table 1 (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Schedule of Changes in the Carrying Amount of Goodwill
Goodwill, Beginning Balance	$ 1,084	$ 456.9	$ 437.3
Goodwill, Acquired During Period	806.1	593.1	13.7
Goodwill, Written off Related to Sale of Business Unit			(0.3)
Goodwill, Ending Balance	$ 1,890.1	1,084	456.9
Consolidation of Joint Venture [Member]
Schedule of Changes in the Carrying Amount of Goodwill
Goodwill, Period Increase		$ 34
Conversion of wholly owned subsidiary to joint venture [Member]
Schedule of Changes in the Carrying Amount of Goodwill
Goodwill, Period Increase			$ 6.2

Goodwill and Other Intangible69

Goodwill and Other Intangible Assets - Table 2 (Details) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Schedule of Intangible Assets by Major Class
Gross Carrying Amount	$ 627.8	$ 478.5
Accumulated Amortization	(208.4)	(172.4)
Net	419.4	306.1
Certificate of Need [Member]
Schedule of Intangible Assets by Major Class
Gross Carrying Amount	93.9	27.9
Accumulated Amortization	(6.9)	(4)
Net	87	23.9
Licenses [Member]
Schedule of Intangible Assets by Major Class
Gross Carrying Amount	138.9	110.8
Accumulated Amortization	(53.7)	(46.3)
Net	85.2	64.5
Noncompete Agreements [Member]
Schedule of Intangible Assets by Major Class
Gross Carrying Amount	58	46.2
Accumulated Amortization	(37)	(29.4)
Net	21	16.8
Trade Name - Encompass [Member]
Schedule of Intangible Assets by Major Class
Gross Carrying Amount	135.2	135.2
Accumulated Amortization	0	0
Net	135.2	135.2
Trade Names - All other [Member]
Schedule of Intangible Assets by Major Class
Gross Carrying Amount	32.9	19.9
Accumulated Amortization	(11.5)	(10.1)
Net	21.4	9.8
Software [Member]
Schedule of Intangible Assets by Major Class
Gross Carrying Amount	155.7	125.3
Accumulated Amortization	(90.5)	(74.5)
Net	65.2	50.8
Market access assets [Member]
Schedule of Intangible Assets by Major Class
Gross Carrying Amount	13.2	13.2
Accumulated Amortization	(8.8)	(8.1)
Net	$ 4.4	$ 5.1

Goodwill and Other Intangible70

Goodwill and Other Intangible Assets - Table 3 (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Schedule of Amortization Expense, Intangible Assets
Amortization expense	$ 36	$ 20.3	$ 17.3

Goodwill and Other Intangible71

Goodwill and Other Intangible Assets - Table 4 (Details) $ in Millions	Dec. 31, 2015USD ($)
Schedule of Future Estimated Amortization Expense, Other Intangible Assets
Year Ending December 31, 2016	$ 45.4
Year Ending December 31, 2017	38.7
Year Ending December 31, 2018	30.3
Year Ending December 31, 2019	26.8
Year Ending December 31, 2020	$ 23.3

Goodwill and Other Intangible72

Goodwill and Other Intangible Assets - Textuals (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]
Affiliates Ownership Percentage, Jonesboro			100.00%
Divested Skilled Nursing Facility Beds			41
Goodwill, Impairment Loss	$ 0	$ 0	$ 0
Goodwill, Impaired, Accumulated Impairment Loss	$ 0

Investments in and Advances t73

Investments in and Advances to Nonconsolidated Affiliates -Table 1 (Details) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Equity method investments:
Capital contributions	$ 0.9	$ 0.8
Cumulative share of income	88	77.3
Cumulative share of distributions	(77.5)	(69.9)
Equity Method Investments	11.4	8.2
Cost method investments:
Capital contributions, net of distributions and impairments	0.3	1.2
Total Investments in and advances to nonconsolidated affiliates	$ 11.7	$ 9.4

Investments in and Advances t74

Investments in and Advances to Nonconsolidated Affiliates - Tables 2 & 3 (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Assets-
Current	$ 7.8	$ 9.6
Noncurrent	20.5	13.1
Total assets	28.3	22.7
Liabilities and equity-
Current liabilities	1.4	0.7
Noncurrent liabilities	0.1	0.1
Partners' capital and shareholders' equity-
HealthSouth	11.4	8.2
Outside partners	15.4	13.7
Total liabilities and equity	28.3	22.7
Combined Statements of Operations of Equity Method Affiliates
Net operating revenues	36.5	50.2	$ 74.3
Operating expenses	(15)	(25.9)	(43.6)
Income from continuing operations, net of tax	18.9	30.9	24.6
Net income	$ 18.9	$ 30.9	$ 24.6

Investments in and Advances t75

Investments in and Advances to Nonconsolidated Affiliates - Textual (Details) - facilities	Dec. 31, 2015	Dec. 31, 2013
Investments in and Advances to Nonconsolidated Affiliates (Textual) [Abstract]
Number of Partially-Owned Subsidiaries	7
Number of General or Limited Partnerships, Limited Liability Companies, or Joint Ventures	6
Affiliates Ownership Percentage		100.00%
Minimum [Member]
Investments in and Advances to Nonconsolidated Affiliates (Textual) [Abstract]
Affiliates Ownership Percentage	1.00%
Maximum [Member]
Investments in and Advances to Nonconsolidated Affiliates (Textual) [Abstract]
Affiliates Ownership Percentage	60.00%

Long-term Debt - Table 1 (Detai

Long-term Debt - Table 1 (Details) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Schedule of Outstanding Long-term Debt
Advances Under Revolving Credit Facility	$ 130	$ 325
Term loan facilities	443.3	447.5
Other Notes Payable	39.2	41.5
Capital Lease Obligations	288.2	86.7
Debt and Capital Lease Obligations	3,171.5	2,111.2
Long-term Debt and Capital Lease Obligations, Current	(36.8)	(20.8)
Long-term debt, net of current portion	3,134.7	2,090.4
8.125% Senior Notes Due 2020 [Member]
Schedule of Outstanding Long-term Debt
Senior Notes	0	282.7
7.75% Senior Notes Due 2022 [Member]
Schedule of Outstanding Long-term Debt
Senior Notes	174.3	223.7
5.125% Senior Notes Due 2023 [Member]
Schedule of Outstanding Long-term Debt
Senior Notes	294.6	0
5.75% Senior Notes Due 2024 [Member]
Schedule of Outstanding Long-term Debt
Senior Notes	1,192.6	447.4
5.75% Senior Notes Due 2025 [Member]
Schedule of Outstanding Long-term Debt
Senior Notes	343.4	0
2.00% Convertible Senior Subordinated Notes due 2043 [Member]
Schedule of Outstanding Long-term Debt
Convertible Subordinated Debt	$ 265.9	$ 256.7

Long-term Debt - Table 2 (Detai

Long-term Debt - Table 2 (Details) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Long-term Debt by Maturity
Debt and Capital Lease Obligations	$ 3,171.5	$ 2,111.2
Face Amount [Member]
Long-term Debt by Maturity
2,016	37
2,017	36.1
2,018	36.3
2,019	39.5
2,020	814.2
Thereafter	2,285.4
Debt and Capital Lease Obligations	3,248.5
Net Amount [Member]
Long-term Debt by Maturity
2,016	37
2,017	36.1
2,018	36.3
2,019	39.4
2,020	758.4
Thereafter	2,264.3
Debt and Capital Lease Obligations	$ 3,171.5

Long-term Debt - Tables 3, 4, &

Long-term Debt - Tables 3, 4, & 5 (Details)	Dec. 31, 2015	Nov. 30, 2015	Sep. 30, 2015	Apr. 10, 2015	Mar. 31, 2015	Dec. 31, 2014
7.75% Senior Notes Due 2022 [Member]
Redemption Price, Senior Notes, Percentage of Principal [Abstract]
Senior Notes, Redemption Price, Percentage of Principal		103.875%				103.00%
7.75% Senior Notes Due 2022 [Member] | Senior Notes, Redemption Price, Period One [Member]
Redemption Price, Senior Notes, Percentage of Principal [Abstract]
Senior Notes, Redemption Price, Percentage of Principal	103.875%
7.75% Senior Notes Due 2022 [Member] | Senior Notes, Redemption Price, Period Two [Member]
Redemption Price, Senior Notes, Percentage of Principal [Abstract]
Senior Notes, Redemption Price, Percentage of Principal	102.583%
7.75% Senior Notes Due 2022 [Member] | Senior Notes, Redemption Price, Period Three [Member]
Redemption Price, Senior Notes, Percentage of Principal [Abstract]
Senior Notes, Redemption Price, Percentage of Principal	101.292%
7.75% Senior Notes Due 2022 [Member] | Senior Notes, Redemption Price, Period Four [Member]
Redemption Price, Senior Notes, Percentage of Principal [Abstract]
Senior Notes, Redemption Price, Percentage of Principal	100.00%
5.125% Senior Notes Due 2023 [Member] | Senior Notes, Redemption Price, Period One [Member]
Redemption Price, Senior Notes, Percentage of Principal [Abstract]
Senior Notes, Redemption Price, Percentage of Principal					103.844%
5.125% Senior Notes Due 2023 [Member] | Senior Notes, Redemption Price, Period Two [Member]
Redemption Price, Senior Notes, Percentage of Principal [Abstract]
Senior Notes, Redemption Price, Percentage of Principal					102.563%
5.125% Senior Notes Due 2023 [Member] | Senior Notes, Redemption Price, Period Three [Member]
Redemption Price, Senior Notes, Percentage of Principal [Abstract]
Senior Notes, Redemption Price, Percentage of Principal					101.281%
5.125% Senior Notes Due 2023 [Member] | Senior Notes, Redemption Price, Period Four [Member]
Redemption Price, Senior Notes, Percentage of Principal [Abstract]
Senior Notes, Redemption Price, Percentage of Principal					100.00%
5.75% Senior Notes Due 2024 [Member] | Senior Notes, Redemption Price, Period One [Member]
Redemption Price, Senior Notes, Percentage of Principal [Abstract]
Senior Notes, Redemption Price, Percentage of Principal	102.875%
5.75% Senior Notes Due 2024 [Member] | Senior Notes, Redemption Price, Period Two [Member]
Redemption Price, Senior Notes, Percentage of Principal [Abstract]
Senior Notes, Redemption Price, Percentage of Principal	101.917%
5.75% Senior Notes Due 2024 [Member] | Senior Notes, Redemption Price, Period Three [Member]
Redemption Price, Senior Notes, Percentage of Principal [Abstract]
Senior Notes, Redemption Price, Percentage of Principal	100.958%
5.75% Senior Notes Due 2024 [Member] | Senior Notes, Redemption Price, Period Four [Member]
Redemption Price, Senior Notes, Percentage of Principal [Abstract]
Senior Notes, Redemption Price, Percentage of Principal	100.00%
5.75% Senior Notes Due 2025 [Member] | Senior Notes, Redemption Price, Period One [Member]
Redemption Price, Senior Notes, Percentage of Principal [Abstract]
Senior Notes, Redemption Price, Percentage of Principal			102.875%
5.75% Senior Notes Due 2025 [Member] | Senior Notes, Redemption Price, Period Two [Member]
Redemption Price, Senior Notes, Percentage of Principal [Abstract]
Senior Notes, Redemption Price, Percentage of Principal			101.917%
5.75% Senior Notes Due 2025 [Member] | Senior Notes, Redemption Price, Period Three [Member]
Redemption Price, Senior Notes, Percentage of Principal [Abstract]
Senior Notes, Redemption Price, Percentage of Principal			100.958%
5.75% Senior Notes Due 2025 [Member] | Senior Notes, Redemption Price, Period Four [Member]
Redemption Price, Senior Notes, Percentage of Principal [Abstract]
Senior Notes, Redemption Price, Percentage of Principal			100.00%
8.125% Senior Notes Due 2020 [Member]
Redemption Price, Senior Notes, Percentage of Principal [Abstract]
Senior Notes, Redemption Price, Percentage of Principal				104.063%

Long-term Debt - Table 6 (Detai

Long-term Debt - Table 6 (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Notes Payable [Abstract]
Sale Leaseback Transaction, Amount Due under Financing Arrangement	$ 28	$ 28
Long-term debt	1.3	2.9
Construction Payable	9.6	10.3
Other Notes Payable, Other	0.3	0.3
Other Notes Payable	$ 39.2	$ 41.5
Other Notes Payable, Other [Member]
Notes Payable [Abstract]
Debt Instruments, Effective Interest Rate	6.80%
7.8% Other Notes Payable [Member] | Acquisition, Note Payable [Member]
Notes Payable [Abstract]
Debt Instruments, Effective Interest Rate	7.80%	7.80%
2.7% Other Notes Payable [Member] | Construction, Note Payable [Member]
Notes Payable [Abstract]
Debt Instruments, Effective Interest Rate	2.70%
Debt Instrument, Description of Variable Rate Basis	LIBOR + 2.5%
Minimum [Member] | 8.1% Other Notes Payable [Member] | Sale/Leaseback Transactions [Member]
Notes Payable [Abstract]
Debt Instruments, Effective Interest Rate	8.10%	8.10%
Minimum [Member] | 5.7% Other Notes Payable [Member] | Other Notes Payable, Other [Member]
Notes Payable [Abstract]
Debt Instruments, Effective Interest Rate	5.70%	5.70%
Maximum [Member] | 11.2% Other Notes Payable [Member] | Sale/Leaseback Transactions [Member]
Notes Payable [Abstract]
Debt Instruments, Effective Interest Rate	11.20%	11.20%
Maximum [Member] | 6.8% Other Notes Payable [Member] | Other Notes Payable, Other [Member]
Notes Payable [Abstract]
Debt Instruments, Effective Interest Rate	6.80%	6.80%

Long-term Debt - Textual (Detai

Long-term Debt - Textual (Details) $ / shares in Units, $ in Millions	Mar. 24, 2016USD ($)	Nov. 30, 2015USD ($)	Apr. 10, 2015USD ($)	Oct. 01, 2014USD ($)	Jan. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Nov. 30, 2013shares	Dec. 31, 2015USD ($)$ / shares	Jun. 30, 2015USD ($)	Mar. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)shares	Dec. 31, 2012USD ($)	Sep. 30, 2012USD ($)	Dec. 31, 2010	Dec. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2014USD ($)shares	Dec. 31, 2013USD ($)	Dec. 31, 2011USD ($)	Jul. 01, 2017	Feb. 23, 2016USD ($)	Sep. 30, 2015USD ($)	Sep. 01, 2015USD ($)	Aug. 31, 2015USD ($)	Jul. 29, 2015USD ($)	Jul. 28, 2015	Jun. 24, 2015USD ($)	Jun. 23, 2015USD ($)	Jan. 29, 2015USD ($)	Sep. 30, 2014USD ($)	Sep. 22, 2014	Sep. 18, 2014USD ($)	Nov. 29, 2013	Nov. 18, 2013USD ($)$ / shares	Jun. 11, 2013USD ($)	Oct. 09, 2012	Sep. 11, 2012USD ($)	Mar. 07, 2011USD ($)	Oct. 07, 2010USD ($)	Dec. 01, 2009USD ($)
Long Term Debt (Textual) [ Abstract]
Senior Notes, Face Amount																																					$ 275		$ 525
Senior secured leverage ratio maximum								1.75								1.75
Term loan facility, draw				$ 75
Repayments of Long-term Debt																$ 597.4	$ 302.6	$ 62.5
Loss on early extinguishment of debt								$ 2.4	$ 18.8	$ 1.2						22.4	13.2	$ 2.4
Term Loan Payable						$ 447.5		$ 443.3			$ 447.5					443.3	447.5
Senior Notes Issuance, Proceeds Used For Debt Reduction													$ 64.5
Revolver, Amounts Drawn																$ 130	$ 325
Revolver, Interest Rate at Period End						2.00%		2.30%			2.00%					2.30%	2.00%
Letters of Credit, Amount Outstanding						$ 31.8		$ 34.2			$ 31.8					$ 34.2	$ 31.8
Senior Notes, Repurchase Price, Change in Control								101.00%								101.00%
Convertible Perpetual Preferred Stock, Dividend Rate							6.50%									6.50%
Debt Issuance Cost																	20.4
Capital expenditures, permitted																											$ 350	$ 200
Financial Covenants Leverage Ratio, Maximum								4.50								4.50									4.50	4.25
2014 Credit Agreement [Member]
Long Term Debt (Textual) [ Abstract]
Term Loan Facility, Maximum Borrowing Capacity						$ 450		$ 450			$ 450					$ 450	$ 450
Senior secured leverage ratio maximum						4.25		1.75			4.25					1.75	4.25														1.75
Percentage Owed, Principal Outstanding, Term Loan								1.25%								1.25%
Revolving Credit Facility, Maximum Borrowing Capacity						$ 600		$ 600			$ 600					$ 600	$ 600
Letter of Credit, Subfacility, Maximum Borrowing Capacity						260		260			$ 260					260	260
Term Loan and Revolver, Basis Spread on Variable Rate											0.50%
Term Loan and Revolver, Commitment Fee Percentage											0.375%
Credit Agreement, Restriction																200
2013 Credit Agreement [Member]
Long Term Debt (Textual) [ Abstract]
Revolving Credit Facility, Maximum Borrowing Capacity																																			$ 600
Letter of Credit, Subfacility, Maximum Borrowing Capacity																																			$ 260
Revolving Credit Facility [Member]
Long Term Debt (Textual) [ Abstract]
Senior Notes Issuance, Proceeds Used For Debt Reduction														$ 195
Revolver, Amounts Drawn											$ 325
Term Loan Facilities [Member]
Long Term Debt (Textual) [ Abstract]
Term Loan Facility, Maximum Borrowing Capacity																									$ 500
Term loan facility, draw						375					375						375					$ 125
Senior Notes Issuance, Proceeds Used For Debt Reduction					$ 250
Term loan facility, Unused Borrowing Capacity, Amount																							$ 250
7.25% Senior Notes Due 2018 [Member]
Long Term Debt (Textual) [ Abstract]
Senior Notes, Face Amount																																						$ 60	$ 275
Senior Notes, Issue Price																																						103.25%
Repayments of Long-term Debt				$ 281								$ 30.2
Senior Notes, Redemption Price, Expressed as Percentage of Principal				103.625%
Senior Notes Issuance, Proceeds Used For Debt Reduction													33.5
Debt Instrument, Maturity Date															Oct. 1, 2018
Debt Instruments, Effective Interest Rate																																							7.50%
Senior Notes, Frequency of Periodic Payment															semiannually in arrears on April 1 and October 1 of each year.
Senior Notes, Principal Extinguished				$ 271.4
7.25% and 7.75% Senior Notes due 2018 and 2022, Respectively [Member]
Long Term Debt (Textual) [ Abstract]
Senior Notes, Face Amount																																						$ 120
Senior Notes, Proceeds Received From Issuance																																						122
Repayments of Long-term Debt												60	1.9
Senior Notes, Repurchase Amount, Any Twelve-Month Period																																	10.00%
Senior Notes, Redemption Price, Expressed as Percentage of Principal																																	103.00%			103.00%
Total outstanding principal amount of Senior Notes to be retired												58.1
Senior Notes Issuance, Proceeds Used For Debt Reduction													64.5						$ 45
8.125% Senior Notes Due 2020 [Member]
Long Term Debt (Textual) [ Abstract]
Senior Notes, Face Amount																																								$ 290
Senior Notes, Issue Price																																								98.327%
Repayments of Long-term Debt			$ 302
Senior Notes, Redemption Price, Expressed as Percentage of Principal			104.063%
Senior Notes, Stated Interest Rate																																								8.70%
Senior Notes, Principal Extinguished			$ 290
Senior Notes, Amount Outstanding						282.7		0			$ 282.7					0	$ 282.7
7.75% Senior Notes Due 2022 [Member]
Long Term Debt (Textual) [ Abstract]
Senior Notes, Face Amount																																						$ 60	$ 250
Senior Notes, Issue Price																																						103.50%
Repayments of Long-term Debt		$ 52				$ 26						$ 27.9
Senior Notes, Repurchase Amount, Any Twelve-Month Period						10.00%					10.00%						10.00%
Senior Notes, Redemption Price, Expressed as Percentage of Principal		103.875%				103.00%					103.00%						103.00%
Senior Notes Issuance, Proceeds Used For Debt Reduction													$ 31
Debt Instrument, Maturity Date															Sep. 15, 2022
Senior Notes, Stated Interest Rate																																							7.75%
Debt Instruments, Effective Interest Rate																																							7.90%
Senior Notes, Frequency of Periodic Payment															semiannually in arrears on March 15 and September 15 of each year.
Senior Notes, Principal Extinguished		$ 50
Senior Notes, Amount Outstanding						$ 223.7		174.3			$ 223.7					174.3	$ 223.7
Extinguishment of Debt, Amount		$ 50				25.1
5.75% Senior Notes Due 2024 [Member]
Long Term Debt (Textual) [ Abstract]
Senior Notes, Face Amount					$ 400																			$ 350					$ 400	$ 175		$ 175
Senior Notes, Issue Price					102.00%																			100.50%					102.00%	103.625%		103.625%					100.00%
Senior Notes, Proceeds From Private Offering																								$ 351						$ 182
Senior Notes, Proceeds Received From Issuance																													$ 406			$ 182					$ 270
Senior Notes Issuance, Proceeds Used For Debt Reduction					$ 250
Debt Instrument, Maturity Date													Nov. 1, 2024
Senior Notes, Stated Interest Rate																																					5.75%
Debt Instruments, Effective Interest Rate																																					5.80%
Senior Notes, Frequency of Periodic Payment													semiannually in arrears on May 1 and November 1 of each year.
Senior Notes, Amount Outstanding						447.4		1,192.6			447.4					1,192.6	447.4
5.75% Senior Notes Due 2025 [Member]
Long Term Debt (Textual) [ Abstract]
Senior Notes, Face Amount																						$ 350	$ 350
Senior Notes, Issue Price																						100.00%	100.00%
Senior Notes, Proceeds From Private Offering																						$ 344	$ 344
Senior Notes, Stated Interest Rate										5.75%
Senior Notes, Amount Outstanding						0		343.4			0					343.4	0
5.125% Senior Notes Due 2023 [Member]
Long Term Debt (Textual) [ Abstract]
Senior Notes, Face Amount										$ 300
Senior Notes, Issue Price										100.00%
Senior Notes, Proceeds Received From Issuance										$ 295
Senior Notes, Stated Interest Rate										5.125%
Senior Notes, Amount Outstanding						0		$ 294.6			0					$ 294.6	0
2.00% Convertible Senior Subordinated Notes due 2043 [Member]
Long Term Debt (Textual) [ Abstract]
Senior Notes, Face Amount						$ 320					$ 320						$ 320																	$ 320
Debt Instrument, Maturity Date							Dec. 1, 2043
Senior Notes, Stated Interest Rate																																		2.00%
Debt Instruments, Effective Interest Rate																																		6.00%
Senior Notes, Frequency of Periodic Payment							semiannually in arrears in cash on June 1 and December 1 of each year
Long-term Debt, Contingent Payment of Principal or Interest							Beginning with the six-month period starting December 1, 2018, contingent interest is payable, in addition to regular interest, if the trading price of the Convertible Notes for each of the five trading days ending two trading days prior to any six-month contingent interest period is equal to or greater than $1,200. The amount of contingent interest payable per $1,000 principal amount of the Convertible Notes in respect of any contingent interest period is equal to 0.25% of the average trading price of the Convertible Notes during the specified measurement period.
Debt Instrument, Convertible, Terms of Conversion							25.2194 shares per $1,000 principal amount									26.2583 for each $1,000 principal amount
Debt Instrument, Convertible, Conversion Price | $ / shares								$ 38.08								$ 38.08																		$ 39.652
Debt Instrument, Convertible, Redemption Percentage							120.00%
Debt Instrument, Convertible, Threshold Trading Days												20
Debt Instrument, Convertible, Threshold Consecutive Trading Days												30 days
Debt Instrument, Redemption Price, Percentage							100.00%
Convertible Debt, Repurchase Price, Fundamental Change																																		100.00%
Capital Lease Obligations [Member] | Minimum [Member]
Long Term Debt (Textual) [ Abstract]
Debt Instruments, Effective Interest Rate								2.00%								2.00%
Capital Lease Obligations [Member] | Maximum [Member]
Long Term Debt (Textual) [ Abstract]
Debt Instruments, Effective Interest Rate								11.00%								11.00%
Convertible Preferred Stock [Member]
Long Term Debt (Textual) [ Abstract]
Temporary Equity, Repurchased during Period, Shares | shares							257,110					257,110				(96,245)	257,110
London Interbank Offered Rate (LIBOR) [Member] | 2014 Credit Agreement [Member]
Long Term Debt (Textual) [ Abstract]
Term Loan and Revolver, Basis Spread on Variable Rate																2.00%
Subsequent Event [Member] | 7.75% Senior Notes Due 2022 [Member]
Long Term Debt (Textual) [ Abstract]
Senior Notes, Redemption Price, Expressed as Percentage of Principal																					103.875%
Senior Notes, Portion of Principal Extinguished, Commitment																					$ 50
Scenario, Forecast [Member]
Long Term Debt (Textual) [ Abstract]
Repayments of Long-term Debt	$ 52
Loss on early extinguishment of debt	$ 2
Financial Covenants Leverage Ratio, Maximum																				4.25

Self-Insured Risks - Table 1 (D

Self-Insured Risks - Table 1 (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Insurance Reserves [Line Items]
Self-Insurance Reserves, Balance at Beginning of Period, Gross		$ 134.3	$ 140.3	$ 148.3
Reinsurance Receivables		(26)	(32.6)	(29.4)
Self-Insurance Reserves, Balance at Beginning of Period, Net		108.3	107.7	118.9
Self-Insurance Reserves, Balance at End of Period, Net	$ 107.7	115.5	108.3	107.7
Reinsurance Receivables	32.6	26.6	26	32.6
Self-Insurance Reserves, Balance at End of Period, Gross	140.3	142.1	134.3	140.3
Provision, Current Year Claims [Member]
Insurance Reserves [Line Items]
Increase (Decrease) in Self-Insurance Reserve		37.1	34.7	34.4
Provision, Prior Year Claims [Member]
Insurance Reserves [Line Items]
Increase (Decrease) in Self-Insurance Reserve		(4.6)	(3.5)	(5.9)
Statistical Confidence Level [Member]
Insurance Reserves [Line Items]
Increase (Decrease) in Self-Insurance Reserve	$ (6.7)	0	0	(6.7)
Discontinued Operations, Insurance Reserve [Member]
Insurance Reserves [Line Items]
Increase (Decrease) in Self-Insurance Reserve		(0.5)	(0.3)	(1.8)
Payments, Current Year Claims [Member]
Insurance Reserves [Line Items]
Increase (Decrease) in Self-Insurance Reserve		(4.7)	(4.4)	(3.9)
Payments, Prior Year Claims [Member]
Insurance Reserves [Line Items]
Increase (Decrease) in Self-Insurance Reserve		(22.5)	(25.9)	(27.3)
Acquisitions [Member]
Insurance Reserves [Line Items]
Increase (Decrease) in Self-Insurance Reserve		$ 2.4	$ 0	$ 0

Self-Insured Risks - Textual (D

Self-Insured Risks - Textual (Details) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 31, 2013USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)	Sep. 30, 2013
Insurance Reserves [Line Items]
Maximum Self-Insured Risk		$ 25
Self-Insurance Reserves, Current		$ 40.5	$ 35.6
Number of Individual Claims Covered by Self-Insured Risk Reserves		1,100	1,100
Statistical Confidence Level [Member]
Insurance Reserves [Line Items]
Statistical Confidence Level			50.00%		70.00%
Increase (Decrease) in Self Insurance Reserve	$ (6.7)	$ 0	$ 0	$ (6.7)

Convertible Perpetual Preferr83

Convertible Perpetual Preferred Stock - Table 1 (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended	12 Months Ended
	Nov. 30, 2013	Dec. 31, 2013	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Temporary Equity [Abstract]
Temporary Equity, Carrying Amount, Attributable to Parent, Beginning			$ 93.2
Temporary Equity, Carrying Amount, Attributable to Parent, Ending			$ 0	$ 93.2
Convertible Preferred Stock [Member]
Temporary Equity [Abstract]
Temporary Equity, Shares Outstanding, Beginning Balance			96,245	96,245	353,355
Temporary Equity, Repurchased during Period, Shares	(257,110)	(257,110)	96,245	(257,110)
Temporary Equity, Shares Outstanding, Ending Balance		96,245	0	96,245	96,245
Temporary Equity, Carrying Amount, Attributable to Parent, Beginning			$ 93.2	$ 93.2	$ 342.2
Temporary Equity, Carrying Amount, Period Increase (Decrease)			93.2	(249)	(249)
Temporary Equity, Carrying Amount, Attributable to Parent, Ending		$ 93.2	$ 0	$ 93.2	$ 93.2

Convertible Perpetual Preferr84

Convertible Perpetual Preferred Stock - Table 2 (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Temporary Equity [Abstract]
Excess exchanged in transaction	$ 0	$ 0	$ 71.6
Convertible Preferred Stock [Member]
Temporary Equity [Abstract]
Carrying value of shares repurchased	$ (93.2)	$ 249	249
Cumulative dividends included as part of purchase price			2.2
Excess exchanged in transaction			71.6
Temporary Equity, Consideration Exchanged for Repurchase			$ 322.8

Convertible Perpetual Preferr85

Convertible Perpetual Preferred Stock - Textual (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended	3 Months Ended	12 Months Ended
	Nov. 30, 2013	Dec. 31, 2013	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Apr. 23, 2015	Apr. 22, 2015	Nov. 18, 2013	Dec. 31, 2012	Sep. 11, 2012	Oct. 07, 2010	Mar. 07, 2006
Convertible Perpetual Preferred Stock, Shares Issued			0	96,245								400,000
Convertible Perpetual Preferred Stock, Liquidation Preference			$ 0	$ 1,000
Convertible Perpetual Preferred Stock, Dividend Rate	6.50%		6.50%
Convertible Perpetual Preferred Stock, Terms of Conversion			We may at any time cause the shares of preferred stock to be automatically converted into shares of our common stock at the conversion rate then in effect if the closing sale price of our common stock for 20 trading days within a period of 30 consecutive trading days ending on the trading day before the date we give the notice of forced conversion exceeds 150% of the conversion price of the preferred stock. If we are subject to a fundamental change, as defined in the certificate of designation of the preferred stock, each holder of shares of preferred stock has the right, subject to certain limitations, to require us to purchase with cash any or all of its shares of preferred stock at a purchase price equal to 100% of the accreted liquidation preference, plus any accrued and unpaid dividends to the date of purchase. In addition, if holders of the preferred stock elect to convert shares of preferred stock in connection with certain fundamental changes, we will in certain circumstances increase the conversion rate for such shares of preferred stock.
Convertible Perpetual Preferred Stock, Conversion Price												$ 30.50
Common stock, par value			$ 0.01	$ 0.01
Convertible Perpetual Preferred Stock, Shares Issued Upon Conversion												32.7869
Debt Instrument, Principal Amount										$ 275	$ 525
Preferred Stock Dividends, Dividends Declared			$ 1.6	$ 6.3	$ 21
Convertible Preferred Stock [Member]
Convertible Perpetual Preferred Stock, Liquidation Preference							$ 1,000
Temporary Equity, Repurchased during Period, Shares	257,110	257,110	(96,245)	257,110
Preferred Stock, Par or Stated Value Per Share							$ 0.10
Temporary Equity, Consideration Exchanged for Repurchase					$ 322.8
Temporary Equity, Shares Outstanding		96,245	0	96,245	96,245	96,245			353,355
Temporary Equity, Carrying Amount, Period Increase (Decrease)			$ 93.2	$ (249)	$ (249)
Capital in Excess of Par Value, Reduction					73.8
Cumulative dividends included as part of purchase price					2.2
Preferred Stock Dividends, Dividends Declared			1.6	6.3	$ 21
Convertible Perpetual Preferred Stock, Accrued Dividends			1.6
Common Stock [Member]
Convertible Perpetual Preferred Stock, Conversion Price						$ 33.9905
Common stock, par value						$ 0.01
Convertible Perpetual Preferred Stock, Shares Issued Upon Conversion						3,271,415
Convertible Perpetual Preferred Stock, Accrued Dividends			$ 21.3	18.6
2.00% Convertible Senior Subordinated Notes due 2043 [Member]
Debt Instrument, Principal Amount				$ 320				$ 320

Redeemable Noncontrolling Int86

Redeemable Noncontrolling Interests - Table 1 (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Redeemable Noncontrolling Interest [Line Items]
Balance at beginning of period	$ 84.7
Net Income attributable to noncontrolling interest	13.8	$ 6.6	$ 5.8
Distributions declared	(49)	(44.9)	(40.4)
Balance at end of period	121.1	84.7
Altoona and Jonesboro [Member]
Redeemable Noncontrolling Interest [Line Items]
Balance at beginning of period		13.5
Net Income attributable to noncontrolling interest	13.8	6.6	5.8
Distributions declared	(7.3)	(8.5)	(4.9)
Contribution to joint venture	0	4.3	7.1
Change in fair value		4.3	(1.7)
Balance at end of period	121.1		13.5
Altoona [Member]
Redeemable Noncontrolling Interest [Line Items]
Balance at beginning of period		13.5	7.2
Balance at end of period			13.5
Altoona, Jonesboro, and Encompass [Member]
Redeemable Noncontrolling Interest [Line Items]
Balance at beginning of period	84.7
Change in fair value	29.9
Balance at end of period		84.7
Encompass [Member]
Redeemable Noncontrolling Interest [Line Items]
Redeemable noncontrolling interests, Increase from acquisition	$ 0	$ 64.5	$ 0

Redeemable Noncontrolling Int87

Redeemable Noncontrolling Interests - Table 2 (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Redeemable Noncontrolling Interest [Line Items]
Net income attributable to nonredeemable noncontrolling interest									$ 55.9	$ 53.1	$ 52
Net income attributable to redeemable noncontrolling interest									13.8	6.6	5.8
Net income attributable to noncontrolling interests	$ 18.8	$ 17.1	$ 17.3	$ 16.5	$ 15.4	$ 14.7	$ 14.8	$ 14.8	$ 69.7	$ 59.7	$ 57.8

Fair Value Measurements - Table

Fair Value Measurements - Table 1 (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Derivative Asset, Noncurrent		$ 9.9
Redeemable Noncontrolling Interest, Equity, Fair Value	$ 121.1	84.7
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Redeemable Noncontrolling Interest, Equity, Fair Value	0	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Redeemable Noncontrolling Interest, Equity, Fair Value	0	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Redeemable Noncontrolling Interest, Equity, Fair Value	$ 121.1	84.7
Other Long-Term Assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Derivative Asset, Noncurrent		9.9
Other Long-Term Assets [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Derivative Asset, Noncurrent		0
Other Long-Term Assets [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Derivative Asset, Noncurrent		0
Other Long-Term Assets [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Derivative Asset, Noncurrent		$ 9.9
Noncontrolling Interests
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Fair Value, Valuation Techniques	I	I
Restricted Marketable Securities [Member] | Prepaid Expenses and Other Current Assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Available-for-sale Securities, Fair Value	$ 16.1	$ 4.6
Fair Value, Valuation Techniques	M	M
Restricted Marketable Securities [Member] | Prepaid Expenses and Other Current Assets [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Available-for-sale Securities, Fair Value	$ 0	$ 0
Restricted Marketable Securities [Member] | Prepaid Expenses and Other Current Assets [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Available-for-sale Securities, Fair Value	16.1	4.6
Restricted Marketable Securities [Member] | Prepaid Expenses and Other Current Assets [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Available-for-sale Securities, Fair Value	0	0
Restricted Marketable Securities [Member] | Other Long-Term Assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Available-for-sale Securities, Fair Value	$ 40.1	$ 45.9
Fair Value, Valuation Techniques	M	M
Restricted Marketable Securities [Member] | Other Long-Term Assets [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Available-for-sale Securities, Fair Value	$ 0	$ 0
Restricted Marketable Securities [Member] | Other Long-Term Assets [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Available-for-sale Securities, Fair Value	40.1	45.9
Restricted Marketable Securities [Member] | Other Long-Term Assets [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Available-for-sale Securities, Fair Value	$ 0	$ 0
Surgical Care Affiliates [Member] | Other Long-Term Assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Fair Value, Valuation Techniques		M

Fair Value Measurements - Tab89

Fair Value Measurements - Table 2 (Details) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Carrying Amounts and Estimated Fair Values, Financial Instruments [Abstract]
Advances Under Revolving Credit Facility	$ 130	$ 325
Term loan facilities	443.3	447.5
Other Notes Payable	39.2	41.5
Letters of Credit, Fair Value	34.2	31.8
Revolving Credit Facility [Member] | Carrying Amount [Member]
Carrying Amounts and Estimated Fair Values, Financial Instruments [Abstract]
Advances Under Revolving Credit Facility	130	325
Revolving Credit Facility [Member] | Estimated Fair Value [Member]
Carrying Amounts and Estimated Fair Values, Financial Instruments [Abstract]
Advances Under Revolving Credit Facility, Fair Value	130	325
Term Loan Facilities [Member] | Carrying Amount [Member]
Carrying Amounts and Estimated Fair Values, Financial Instruments [Abstract]
Term loan facilities	443.3	447.5
Term Loan Facilities [Member] | Estimated Fair Value [Member]
Carrying Amounts and Estimated Fair Values, Financial Instruments [Abstract]
Term loan facilities, fair value	445	450
8.125% Senior Notes Due 2020 [Member]
Carrying Amounts and Estimated Fair Values, Financial Instruments [Abstract]
Senior Notes	0	282.7
8.125% Senior Notes Due 2020 [Member] | Carrying Amount [Member]
Carrying Amounts and Estimated Fair Values, Financial Instruments [Abstract]
Senior Notes	0	282.7
8.125% Senior Notes Due 2020 [Member] | Estimated Fair Value [Member]
Carrying Amounts and Estimated Fair Values, Financial Instruments [Abstract]
Senior Notes, Fair Value	0	302.5
7.75% Senior Notes Due 2022 [Member]
Carrying Amounts and Estimated Fair Values, Financial Instruments [Abstract]
Senior Notes	174.3	223.7
7.75% Senior Notes Due 2022 [Member] | Carrying Amount [Member]
Carrying Amounts and Estimated Fair Values, Financial Instruments [Abstract]
Senior Notes	174.3	223.7
7.75% Senior Notes Due 2022 [Member] | Estimated Fair Value [Member]
Carrying Amounts and Estimated Fair Values, Financial Instruments [Abstract]
Senior Notes, Fair Value	183.7	240.7
5.125% Senior Notes Due 2023 [Member]
Carrying Amounts and Estimated Fair Values, Financial Instruments [Abstract]
Senior Notes	294.6	0
5.125% Senior Notes Due 2023 [Member] | Carrying Amount [Member]
Carrying Amounts and Estimated Fair Values, Financial Instruments [Abstract]
Senior Notes	294.6	0
5.125% Senior Notes Due 2023 [Member] | Estimated Fair Value [Member]
Carrying Amounts and Estimated Fair Values, Financial Instruments [Abstract]
Senior Notes, Fair Value	288	0
5.75% Senior Notes Due 2024 [Member]
Carrying Amounts and Estimated Fair Values, Financial Instruments [Abstract]
Senior Notes	1,192.6	447.4
5.75% Senior Notes Due 2024 [Member] | Carrying Amount [Member]
Carrying Amounts and Estimated Fair Values, Financial Instruments [Abstract]
Senior Notes	1,192.6	447.4
5.75% Senior Notes Due 2024 [Member] | Estimated Fair Value [Member]
Carrying Amounts and Estimated Fair Values, Financial Instruments [Abstract]
Senior Notes, Fair Value	1,146	471.4
5.75% Senior Notes Due 2025 [Member]
Carrying Amounts and Estimated Fair Values, Financial Instruments [Abstract]
Senior Notes	343.4	0
5.75% Senior Notes Due 2025 [Member] | Carrying Amount [Member]
Carrying Amounts and Estimated Fair Values, Financial Instruments [Abstract]
Senior Notes	343.4	0
5.75% Senior Notes Due 2025 [Member] | Estimated Fair Value [Member]
Carrying Amounts and Estimated Fair Values, Financial Instruments [Abstract]
Senior Notes, Fair Value	332.5	0
2.00% Convertible Senior Subordinated Notes due 2043 [Member]
Carrying Amounts and Estimated Fair Values, Financial Instruments [Abstract]
Convertible Subordinated Debt	265.9	256.7
2.00% Convertible Senior Subordinated Notes due 2043 [Member] | Carrying Amount [Member]
Carrying Amounts and Estimated Fair Values, Financial Instruments [Abstract]
Convertible Subordinated Debt	265.9	256.7
2.00% Convertible Senior Subordinated Notes due 2043 [Member] | Estimated Fair Value [Member]
Carrying Amounts and Estimated Fair Values, Financial Instruments [Abstract]
Convertible Debt, Fair Value	345	358.4
Other Notes Payable [Member] | Carrying Amount [Member]
Carrying Amounts and Estimated Fair Values, Financial Instruments [Abstract]
Other Notes Payable	39.2	41.5
Other Notes Payable [Member] | Estimated Fair Value [Member]
Carrying Amounts and Estimated Fair Values, Financial Instruments [Abstract]
Other Notes Payable, Fair Value	39.2	41.5
Letters of Credit [Member] | Carrying Amount [Member]
Carrying Amounts and Estimated Fair Values, Financial Instruments [Abstract]
Letters of Credit	0	0
Letters of Credit [Member] | Estimated Fair Value [Member]
Carrying Amounts and Estimated Fair Values, Financial Instruments [Abstract]
Letters of Credit, Fair Value	$ 34.2	$ 31.8

Fair Value Measurements - Textu

Fair Value Measurements - Textual (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Apr. 13, 2015	Apr. 01, 2015	Dec. 31, 2007
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain	$ 0	$ 27.2	$ 0
Option Contract, Annual Premium						15.00%
Option Contract, Exercisable					30.00%	30.00%
Derivative Asset, Noncurrent		9.9
Derivative, Gain on Derivative	2	9.9
Available-for-sale Securities, Gross Realized Gains (Losses), Sale Proceeds	1.2
Fair Value, Measurements, Nonrecurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Gains or losses in assets disclosed at fair value	0
Fairlawn Rehabilitation Hospital [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain	$ 0	$ 27.2	$ 0
Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Option Contract, Equity Opportunity						5.00%
Surgical Care Affiliates [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Share Price				$ 35.43
Option Contract, Shares Received				326,242

Share-Based Payments - Table 1

Share-Based Payments - Table 1 (Details)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Schedule of Weighted Average Assumptions Used to Determine Fair Value of Stock Options
Expected volatility	39.50%	40.30%	41.80%
Risk-free interest rate	1.90%	2.20%	1.40%
Expected life (years)	7 years 8 months 12 days	7 years 2 months	7 years 2 months
Dividend yield	2.10%	2.10%	0.00%

Share-Based Payments - Table 2

Share-Based Payments - Table 2 (Details) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2015USD ($)$ / sharesshares
Summary of stock option activity and related information
Outstanding, December 31, 2014, Shares | shares	2,207
Outstanding, December 31, 2014, Weighted-Average Exercise Price Per Share | $ / shares	$ 20.85
Granted, Shares | shares	108
Granted, Weighted-Average Exercise Price Per Share | $ / shares	$ 43.14
Exercised, Shares | shares	(257)
Exercised, Weighted-Average Exercise Price Per Share | $ / shares	$ 26.06
Forfeitures, Shares | shares	(2)
Forfeiture, Weighted Average Exercise price Per Share | $ / shares	$ 24.85
Expirations, Shares | shares	0
Expirations, Weighted-Average Exercise Price Per Share | $ / shares	$ 0
Outstanding, December 31, 2015, Shares | shares	2,056
Outstanding, December 31, 2015, Weighted-Average Exercise Price Per Share | $ / shares	$ 21.37
Outstanding, December 31, 2015, Remaining Life	4 years 1 month 6 days
Outstanding, December 31, 2015, Aggregate Intrinsic Value | $	$ 28.5
Exercisable, December 31, 2015, Shares | shares	1,811
Exercisable, December 31, 2015, Weighted-Average Exercise Price Per Share | $ / shares	$ 19.47
Exercisable, December 31, 2015, Remaining Life	3 years 6 months
Exercisable, December 31, 2015, Aggregate Intrinsic Value | $	$ 27.8

Share-Based Payments - Table 3

Share-Based Payments - Table 3 (Details) - Restricted Stock [Member] - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]
Nonvested shares, Beginning Balance, Shares	1,197
Nonvested shares, Beginning Balance, Weighted-Average Grant Date Fair Value	$ 23.31
Granted, Shares	689
Granted, Weighted-Average Grant Date Fair Value	$ 27.86	$ 23.94	$ 23.55
Vested, Shares	(1,005)
Vested, Weighted-Average Grant Date Fair Value	$ 22.18
Forfeited, Shares	(39)
Forfeited, Weighted-Average Grant Date Fair Value	$ 30.03
Nonvested shares, Ending Balance, Shares	842	1,197
Nonvested shares, Ending Balance, Weighted-Average Grant Date Fair Value	$ 28.05	$ 23.31

Share-Based Payments - Textual

Share-Based Payments - Textual (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation (Textual) [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value	$ 2.3	$ 7.4	$ 8.2
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate	39.50%	40.30%	41.80%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	1.90%	2.20%	1.40%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	7 years 8 months 12 days	7 years 2 months	7 years 2 months
2008 Amended and Restated Equity Incentive Plan [Member]
Share-based Compensation (Textual) [Abstract]
Share-based Compensation Plan, Shares Authorized	9,000,000	9,000,000	9,000,000
Stock Options [Member]
Share-based Compensation (Textual) [Abstract]
Share-based Compensation, Options, Grants in Period, Weighted-Average Fair Value	$ 15.11	$ 11.41	$ 10.96
Share-based Compensation Expense	$ 1.6	$ 1.9	$ 2.1
Share-based Compensation, Unrecognized Expense	$ 1.8
Share-based Compensation, Unrecognized Expense, Time Period Expected to be Recognized	21 months
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value	$ 4.2	2.4	1.9
Stock Appreciation Rights (SARs) [Member]
Share-based Compensation (Textual) [Abstract]
Share-based Compensation, Options, Grants in Period, Weighted-Average Fair Value	$ 64.09
Share-based Compensation Expense	$ 3.5
Share-based Compensation, Unrecognized Expense	$ 12.2
Share-based Compensation, Unrecognized Expense, Time Period Expected to be Recognized	6 years 3 months
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted	122,976
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	129,124
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate	30.70%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	2.10%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	6 years 3 months 18 days
Share-based Compensation Plan, Number of Shares Available for Grant	252,100
Restricted Stock [Member]
Share-based Compensation (Textual) [Abstract]
Share-based Compensation Expense	$ 19.5	$ 20.8	$ 21.6
Share-based Compensation, Unrecognized Expense	$ 16.2
Share-based Compensation, Unrecognized Expense, Time Period Expected to be Recognized	21 months
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	842,000	1,197,000
Share-based Compensation, Restricted Stock Awards, Grants in Period, Weighted Average Fair Value	$ 27.86	$ 23.94	$ 23.55
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Total Fair Value	$ 41	$ 25.9	$ 15.7
Restricted Stock Units (RSUs) [Member]
Share-based Compensation (Textual) [Abstract]
Share-based Compensation Expense	1.3	$ 1.2	$ 1.2
Share-based Compensation, Unrecognized Expense	$ 0
Share-based Compensation Plan, Restricted Stock Units, Issued in Period	30,744	36,350	51,180
Share-based Compensation Plan, Restricted Stock Units, Issued in Period, Weighted Average Grant Date Fair Value	$ 42.46	$ 33.02	$ 22.47
Share-based Compensation Plan, Restricted Stock Units As Dividend Equivalents, Issued in Period	7,645	8,149	1,831
Share-based Compensation Plan, Number of Shares Available for Grant	391,855

Employee Benefit Plans - Textua

Employee Benefit Plans - Textual (Details) $ in Millions	12 Months Ended
	Dec. 31, 2015USD ($)yr	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)
Employee Benefit Plans [Abstract]
Company Healthcare Plans, Total Costs Net of Employee Contributions	$ 109.3	$ 85.2	$ 73.4
Retirement Investment Plan, Maximum Employee Contribution	100.00%
Retirement Investment Plan, Company Match	50% of the first 6% of each participant’s elective deferrals
Retirement Investment Plan, Age Requirement	21
Retirement Investment Plan, Company Match, Vesting Percentage	100.00%
Retirement Investment Plan, Company Match, Vesting Period | yr	3
Retirement Investment Plan, Company Match, Total Costs	$ 15	13.9	13.2
Retirement Investment Plan, Company Match, Funded by Plan Forfeiture Account	0.9	0.5	0.5
Senior Management Bonus Program, Total Costs	$ 9.1	$ 9	$ 11.5

Income Taxes - Table 1 (Details

Income Taxes - Table 1 (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Current:
Federal									$ 2.6	$ 2.5	$ 0.9
State and local									12.2	10.8	5.4
Total current expense									14.8	13.3	6.3
Deferred:
Federal									113.9	95.3	11.3
State and local									13.2	2.1	(4.9)
Total deferred expense									127.1	97.4	6.4
Total income tax expense related to continuing operations	$ 43.5	$ 35.9	$ 32.2	$ 30.3	$ 19.3	$ 22.1	$ 36.5	$ 32.8	$ 141.9	$ 110.7	$ 12.7

Income Taxes - Table 2 (Details

Income Taxes - Table 2 (Details)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Effective Income Tax Rate Reconciliation
Tax expense at statutory rate	35.00%	35.00%	35.00%
Increase (decrease) in tax rate resulting from:
State and other income taxes, net of federal tax benefit	3.60%	4.30%	4.00%
Increase (decrease) in valuation allowance	1.20%	(1.90%)	(2.30%)
Settlement of tax claims	0.10%	0.00%	(28.70%)
Noncontrolling interests	(5.30%)	(5.10%)	(5.10%)
Acquisition of additional equity interest in Fairlawn	0.00%	(3.60%)	0.00%
Other, net	1.30%	(0.10%)	0.30%
Income tax expense	35.90%	28.60%	3.20%

Income Taxes - Tables 3 & 4 (De

Income Taxes - Tables 3 & 4 (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Components of Deferred Tax Assets [Abstract]
Net Operating Loss	$ 161.1	$ 301.3
Property, net	48.2	40.7
Insurance Reserve	26	25.6
Stock-based compensation	23.4	23.7
Allowance for doubtful accounts	24.5	18
Alternative minimum tax	10.6	10.5
Carrying value of partnerships	22.1	23.8
Other accruals	25.7	20.6
Tax credits	14	9.9
Noncontrolling interest	10.6	0
Other	0.8	1.6
Total deferred income tax assets	367	475.7
Less: Valuation allowance	(27.6)	(23)
Net deferred income tax assets	339.4	452.7
Components of Deferred Tax Liabilities [Abstract]
Intangibles	(112.8)	(97.5)
Convertible debt interest	(35.3)	(31.7)
Other	(0.5)	(5.7)
Total deferred income tax liabilities	(148.6)	(134.9)
Net deferred income tax assets	190.8	317.8
Less: Current deferred tax assets	0	188.4
Noncurrent deferred tax assets	190.8	129.4
Gross Unrecognized Income Tax Benefits
Gross unrecognized income tax benefits, Beginning Balance	0.9	1.1	$ 78
Gross amount of increases in unrecognized tax benefits related to prior periods	1.7	0.7	46.7
Gross amount of decreases in unrecognized tax benefits related to prior periods		(0.9)	(1.9)
Decreases in unrecognized tax benefits relating to settlements with taxing authorities			(121.7)
Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions	0.3
Gross unrecognized income tax benefits, Ending Balance	2.9	0.9	1.1
Unrecognized Tax Benefits, Accrued Interest and Penalties
Unrecognized Tax Benefits, Accrued interest and penalties, Beginning Balance	0	0.3	0
Gross amount of increases in unrecognized tax benefits related to prior periods	0	0.1	0.3
Gross amount of decreases in unrecognized tax benefits related to prior periods		(0.4)	0
Decreases in unrecognized tax benefits relating to settlements with taxing authorities			0
Unrecognized Tax Benefits, Accrued interest and penalties, Ending Balance	0	$ 0	$ 0.3
Gross amount of increases in unrecognized tax benefits related to current period	$ 0

Income Taxes - Textual (Details

Income Taxes - Textual (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Jun. 30, 2013	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Valuation Allowance [Line Items]
Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions		$ 0.3
Noncontrolling interest		10.6	$ 0
Income Tax Effects Allocated Directly to Equity		(11.7)	(1.8)	$ 2.9
Income Taxes (Textual) [Abstract]
Increase Net Operating Loss Carryforward, Gross	$ 283
Net Operating Loss Carryforwards		161.1	301.3
Gross Operating Loss Carryforwards		261.6
Excess Tax Benefit from Share-based Compensation		14.6
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount		4.6	(7.7)	(9.1)
Valuation Allowance		27.6	23
Gross Unrecognized Tax Benefits		2.9	0.9	1.1	$ 78
Unrecognized Tax Benefits, Accrued Interest		0	0	0.3	0
Unrecognized Tax Benefits that Would Impact Effective Tax Rate		2.9	$ 0.9	$ 0.4	$ 76
Federal [Member]
Income Taxes (Textual) [Abstract]
Income Tax Benefit Resulting From Tax Settlement	$ 115
Net Operating Loss Carryforwards		91.6
Tax Credit Carryforward, Amount		14
State [Member]
Income Taxes (Textual) [Abstract]
Net Operating Loss Carryforwards		69.5
Minimum [Member]
Valuation Allowance [Line Items]
Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit		0.5
Maximum [Member]
Valuation Allowance [Line Items]
Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit		$ 2.9

Earnings Per Common Share - Tab

Earnings Per Common Share - Table 1 (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Numerator:
Income from continuing operations	$ 65.1	$ 67.5	$ 61.8	$ 59.3	$ 54.8	$ 65.7	$ 94.1	$ 61.6	$ 253.7	$ 276.2	$ 382.5
Less: Net income attributable to noncontrolling interests included in continuing operations									(69.7)	(59.7)	(57.8)
Less: Income allocated to participating securities									(1)	(2.3)	(3.4)
Less: Convertible perpetual preferred stock dividends									(1.6)	(6.3)	(21)
Less: Repurchase of convertible perpetual preferred stock									0	0	(71.6)
Income from continuing operations attributable to HealthSouth common shareholders									181.4	207.9	228.7
(Loss) income from discontinued operations, net of tax, attributable to HealthSouth common shareholders									(0.9)	5.5	(1.1)
Less: Income from discontinued operations allocated to participating securities									0	(0.1)	0
Net income attributable to HealthSouth common shareholders									$ 180.5	$ 213.3	$ 227.6
Denominator:
Basic weighted average common shares outstanding									89.4	86.8	88.1
Basic earnings per share attributable to HealthSouth common shareholders
Continuing operations	$ 0.51	$ 0.56	$ 0.49	$ 0.47	$ 0.43	$ 0.56	$ 0.89	$ 0.51	$ 2.03	$ 2.40	$ 2.59
Discontinued operations	$ 0.01	$ 0	$ (0.02)	$ 0	$ 0.03	$ (0.01)	$ 0.04	$ 0	(0.01)	0.06	(0.01)
Net income									$ 2.02	$ 2.46	$ 2.58
Numerator:
Income from continuing operations	$ 65.1	$ 67.5	$ 61.8	$ 59.3	$ 54.8	$ 65.7	$ 94.1	$ 61.6	$ 253.7	$ 276.2	$ 382.5
Less: Net income attributable to noncontrolling interests included in continuing operations									(69.7)	(59.7)	(57.8)
Add: Interest on convertible debt, net of tax									9.4	9	1
Income from continuing operations attributable to HealthSouth common shareholders									193.4	225.5	325.7
(Loss) income from discontinued operations, net of tax, attributable to HealthSouth common shareholders									(0.9)	5.5	(1.1)
Net income attributable to HealthSouth common stockholders									$ 192.5	$ 231	$ 324.6
Denominator:
Diluted weighted average common shares outstanding									101	100.7	102.1
Diluted earnings per share attributable to HealthSouth common shareholders:
Continuing operations	$ 0.48	$ 0.52	$ 0.47	$ 0.44	$ 0.41	$ 0.53	$ 0.81	$ 0.48	$ 1.92	$ 2.24	$ 2.59
Discontinued operations	0.01	0	(0.02)	0	0.03	(0.01)	0.04	0	(0.01)	0.05	(0.01)
Net income	$ 0.49	$ 0.52	$ 0.45	$ 0.44	$ 0.44	$ 0.52	$ 0.85	$ 0.48	$ 1.91	$ 2.29	$ 2.58

Earnings per Common Share - 101

Earnings per Common Share - Table 2 (Details) - shares shares in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Earnings Per Share [Abstract]
Basic weighted average common shares outstanding	89.4	86.8	88.1
Convertible perpetual preferred stock	1	3.2	10.5
Convertible senior subordinated notes	8.3	8.2	1
Restricted stock awards, dilutive stock options, and restricted stock units	2.3	2.5	2.5
Diluted weighted average common shares outstanding	101	100.7	102.1

Earnings per Common Share - 102

Earnings per Common Share - Table 3 (Details) - $ / shares shares in Millions	1 Months Ended	12 Months Ended
	Jan. 16, 2014	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2012	Sep. 30, 2009
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Outstanding, Beginning Balance		10
Warrants expired	(0.1)
Stock Warrants Issued, Exercise Price	$ 32.16		$ 32.50	$ 32.50	$ 41.40
Class of Warrant or Right, Outstanding, Ending Balance	0
Cashless exercise [Member]
Class of Warrant or Right [Line Items]
Warrants exercised	(1.8)	(4.8)
Stock Warrants Issued, Exercise Price	$ 32.16	$ 32.50
Cash exercise [Member]
Class of Warrant or Right [Line Items]
Warrants exercised	(1)	(2.3)
Stock Warrants Issued, Exercise Price	$ 32.16	$ 32.50

Earnings Per Common Share - Tex

Earnings Per Common Share - Textual (Details) $ / shares in Units, $ in Millions	Jul. 17, 2014$ / shares	Jan. 31, 2016$ / shares	Oct. 31, 2015$ / shares	Jul. 31, 2015$ / shares	Jan. 31, 2014$ / shares	Jan. 16, 2014USD ($)$ / sharesshares	Jul. 31, 2013$ / shares	Mar. 31, 2013USD ($)$ / sharesshares	Dec. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2014USD ($)$ / sharesshares	Dec. 31, 2013USD ($)$ / sharesshares	Feb. 14, 2014USD ($)	Feb. 28, 2013USD ($)	Dec. 31, 2012$ / sharesshares	Oct. 31, 2011USD ($)	Sep. 30, 2009yr$ / sharesshares	Oct. 31, 2006$ / sharesshares	Jan. 31, 2004shares
Earnings Per Common Share (Textual) [Abstract]
Antidilutive Securities Excluded from Computation of Earnings Per Share									100,000	100,000
Payments for Repurchase of Common Stock | $									$ 45.3	$ 43.1	$ 234.1
Common Stock, Dividends, Per Share, Declared | $ / shares	$ 0.21			$ 0.23			$ 0.18		$ 0.88	$ 0.78	$ 0.36
Class of Warrant or Right, Outstanding						0				2,900,000				10,000,000				10,000,000
Stock Warrants Issued, Potential Number of Common Stock Shares																	2,000,000
Stock Warrants Issued, Exercise Price | $ / shares						$ 32.16				$ 32.50				$ 32.50		$ 41.40
Common Stock, Dividends, Per Share, Cash Paid | $ / shares					$ 0.18
Stock Warrants Issued, Exercise Rate						0.2021
Proceeds from exercising stock warrants | $						$ 6.3			$ 0	$ 6.3	$ 15.3
Common Stock Shares Issued Under Consolidated Securities Action Settlement																5,000,000
Common Stock Warrants Issued Under Consolidated Securities Action Settlement																8,200,000
Stock Warrants Issued, Term | yr																7
Convertible Debenture [Member]
Earnings Per Common Share (Textual) [Abstract]
Debt Instrument, Interest Rate, Stated Percentage																		3.25%
Common Stock [Member]
Earnings Per Common Share (Textual) [Abstract]
Stock Repurchase Program, Authorized Amount | $										$ 200		$ 250	$ 350		$ 125
Repurchase of common stock, Shares								9,100,000	1,300,000	1,300,000
Treasury Stock Acquired, Average Cost Per Share | $ / shares								$ 25.50
Repurchase of Common Stock | $								$ 234.1
Payments for Repurchase of Common Stock | $									$ 45.3	$ 43.1
Dividends Payable, Current | $									$ 21.3	$ 18.6
Stock Warrants Issued, Exercise Price | $ / shares																	$ 32.50
Common Stock, Dividends, Per Share, Cash Paid | $ / shares			$ 0.23
Stock warrants exercised, Shares						200,000					500,000
Subsequent Event [Member] | Common Stock [Member]
Earnings Per Common Share (Textual) [Abstract]
Common Stock, Dividends, Per Share, Cash Paid | $ / shares		$ 0.23

Contingencies and Other Comm104

Contingencies and Other Commitments - Textual (Details)	12 Months Ended
	Dec. 31, 2004USD ($)	Dec. 31, 1995	Dec. 31, 2015USD ($)	Feb. 28, 2015	Apr. 24, 2014	Mar. 04, 2013
Loss Contingencies [Line Items]
Compliance Threshold Under Health Care Act			60.00%
Purchase Obligations, Due Within One Year			$ 33,300,000
Purchase Obligations, Due within Two Years			28,200,000
Purchase Obligations, Due Within Three Years			21,100,000
Purchase Obligations, Due Within Four Years			12,600,000
Purchase Obligations, Due Within Five Years			11,900,000
Purchase Obligations, Due After Five Years			$ 7,200,000
Litigation, General Medicine [Member]
Loss Contingencies [Line Items]
Long-term Purchase Commitment, Time Period		3 years
Consent Judgment Awarded to Plaintiff	$ 376,000,000
Loss Contingency, Litigation Settlement, Consideration	$ 300,000
HHS-OIG Investigation [Member]
Loss Contingencies [Line Items]
Number of hospitals that received subpoenas					7	4
Number of patient medical records requested for each hospital in subpoenas						100
Number of hospitals that received supplemental subpoenas					2
Number of additional patient medical records requested				70
Compliance Threshold Under Health Care Act			60.00%

Segment Reporting Segment Re105

Segment Reporting Segment Reporting - Table 1 (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Segment Reporting Information [Line Items]
Net operating revenues	$ 879.3	$ 778.6	$ 764.4	$ 740.6	$ 613.4	$ 596.9	$ 604.4	$ 591.2	$ 3,162.9	$ 2,405.9	$ 2,273.2
Less: Provision for doubtful accounts									(47.2)	(31.6)	(26)
Net operating revenues less provision for doubtful accounts									3,115.7	2,374.3	2,247.2
Costs and Expenses [Abstract]
Salaries and benefits									1,670.8	1,161.7	1,089.7
Other operating expenses									432.1	351.6	323
Supplies									128.7	111.9	105.4
Occupancy costs									53.9	41.6	47
Total segment level operating expenses									2,569	1,906.9	1,764.9
Other income									(5.5)	(31.2)	(4.5)
Equity in net income of nonconsolidated affiliates									(8.7)	(10.7)	(11.2)
Noncontrolling interest	$ (18.8)	$ (17.1)	$ (17.3)	$ (16.5)	$ (15.4)	$ (14.7)	$ (14.8)	$ (14.8)	(69.7)	(59.7)	(57.8)
Inpatient Rehabilitation Hospital [Member]
Segment Reporting Information [Line Items]
Net operating revenues									2,653.1	2,377.3	2,244.4
Less: Provision for doubtful accounts									44.7	31.2	25.6
Net operating revenues less provision for doubtful accounts									2,608.4	2,346.1	2,218.8
Costs and Expenses [Abstract]
Salaries and benefits									1,310.6	1,141	1,069.7
Other operating expenses									387.7	342.5	314.7
Supplies									120.9	111.5	105.2
Occupancy costs									46.2	41.2	46.5
Cost of services sold (excluding depreciation and amortization)									0	0	0
Support and overhead costs									0	0	0
Total segment level operating expenses									1,865.4	1,636.2	1,536.1
Other income									2.3	4	4.5
Equity in net income of nonconsolidated affiliates									8.6	10.7	11.2
Noncontrolling interest									(62.9)	(59.3)	(57.2)
Segment Adjusted EBITDA									691	665.3	641.2
Capital Expenditures									151.7	187.9	216.5
Home Health and Hospice [Member]
Segment Reporting Information [Line Items]
Net operating revenues									509.8	28.6	28.8
Less: Provision for doubtful accounts									2.5	0.4	0.4
Net operating revenues less provision for doubtful accounts									507.3	28.2	28.4
Costs and Expenses [Abstract]
Salaries and benefits									0	0	0
Other operating expenses									0	0	0
Supplies									0	0	0
Occupancy costs									0	0	0
Cost of services sold (excluding depreciation and amortization)									244.8	17	16.7
Support and overhead costs									172.7	6.9	6.6
Total segment level operating expenses									417.5	23.9	23.3
Other income									0	0	0
Equity in net income of nonconsolidated affiliates									0.1	0	0
Noncontrolling interest									(6.8)	(0.4)	(0.6)
Segment Adjusted EBITDA									83.1	3.9	4.5
Capital Expenditures									$ 5.8	$ 0	$ 0

Segment Reporting Segment Re106

Segment Reporting Segment Reporting - Table 2 (Details) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	$ 4,606.1	$ 3,388.3
Investments in and advances to nonconsolidated affiliates	11.7	9.4
Inpatient Rehabilitation Hospital [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	3,589	2,576.3
Investments in and advances to nonconsolidated affiliates	9.3	9.4
Home Health and Hospice [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	1,088.4	876.3
Investments in and advances to nonconsolidated affiliates	$ 2.4	$ 0

Segment Reporting Segment Re107

Segment Reporting Segment Reporting - Table 3 (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
General and administrative expenses									$ (133.3)	$ (124.8)	$ (119.1)
Depreciation and amortization									(139.7)	(107.7)	(94.7)
Loss on disposal or impairment of assets									(2.6)	(6.7)	(5.9)
Government, class action, and related settlements									(7.5)	1.7	23.5
Professional fees - accounting, tax, and legal									(3)	(9.3)	(9.5)
Loss on early extinguishment of debt	$ (2.4)		$ (18.8)	$ (1.2)					(22.4)	(13.2)	(2.4)
Interest expense and amortization of debt discounts and fees									(142.9)	(109.2)	(100.4)
Gain on consolidation of former equity method hospital									0	27.2	0
Net income attributable to noncontrolling interests	$ 18.8	$ 17.1	$ 17.3	$ 16.5	$ 15.4	$ 14.7	$ 14.8	$ 14.8	69.7	59.7	57.8
Gain related to SCA equity interest									3.2	0	0
Income from continuing operations before income tax expense									395.6	386.9	395.2
Other Expenses									0	0	0.2
Inpatient Rehabilitation Hospital and Home Health and Hospice [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total segment Adjusted EBITDA									774.1	669.2	645.7
Fairlawn Rehabilitation Hospital [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Gain on consolidation of former equity method hospital									$ 0	$ 27.2	$ 0

Segment Reporting Segment Re108

Segment Reporting Segment Reporting - Table 4 (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets for reportable segments	$ 4,606.1	$ 3,388.3
Reclassification of noncurrent deferred income tax liabilities to net noncurrent deferred income tax assets	(71.3)	(64.3)
Total assets	4,606.1	3,388.3
Inpatient Rehabilitation Hospital and Home Health and Hospice [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets for reportable segments	4,677.4	3,452.6
Total assets	$ 4,677.4	$ 3,452.6

Segment Reporting Segment Re109

Segment Reporting Segment Reporting - Table 5 (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Segment Reporting, Revenue Reconciling Item [Line Items]
Net operating revenues	$ 879.3	$ 778.6	$ 764.4	$ 740.6	$ 613.4	$ 596.9	$ 604.4	$ 591.2	$ 3,162.9	$ 2,405.9	$ 2,273.2
Inpatient Rehabilitation Hospital [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Net operating revenues									2,653.1	2,377.3	2,244.4
Inpatient [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Net operating revenues									2,547.2	2,272.5	2,130.8
Outpatient and other [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Net operating revenues									105.9	104.8	113.6
Home Health and Hospice [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Net operating revenues									509.8	28.6	28.8
Home health [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Net operating revenues									478.1	28.6	28.8
Hospice [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Net operating revenues									$ 31.7	$ 0	$ 0

Segment Reporting Segment Re110

Segment Reporting Segment Reporting - Textuals (Details)	Dec. 31, 2015facilities	Dec. 31, 2014
Segment Reporting Information [Line Items]
Number of Home Health Locations Before Encompass Acquisition		25
Number of States in which Entity Operates	34
Inpatient Rehabilitation Hospital [Member]
Segment Reporting Information [Line Items]
Number of States in which Entity Operates	29
Number of inpatient rehabilitation hospitals	121
Number of Joint Venture Hospitals Accounted for Using the Equity Method	1
Number of inpatient rehabilitation units under management contracts	3
Home Health and Hospice [Member]
Segment Reporting Information [Line Items]
Number of States in which Entity Operates	23
Number of Hospital Based Home Health and Hospice Agencies	213

Quarterly Data (Unaudited) Tabl

Quarterly Data (Unaudited) Tables 1 - 2 (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Quarterly Financial Data
Net operating revenues	$ 879.3	$ 778.6	$ 764.4	$ 740.6	$ 613.4	$ 596.9	$ 604.4	$ 591.2	$ 3,162.9	$ 2,405.9	$ 2,273.2
Operating earnings	135.5	121.2	123.4	105.6	96.5	100.7	115.4	105.8	485.7	418.4
Provision for income tax expense	43.5	35.9	32.2	30.3	19.3	22.1	36.5	32.8	141.9	110.7	12.7
Income from continuing operations	65.1	67.5	61.8	59.3	54.8	65.7	94.1	61.6	253.7	276.2	382.5
(Loss) income from discontinued operations, net of tax	0.7	0.3	(1.6)	(0.3)	2.7	(0.9)	3.8	(0.1)	(0.9)	5.5	(1.1)
Net income	65.8	67.8	60.2	59	57.5	64.8	97.9	61.5	252.8	281.7	381.4
Less: Net income attributable to noncontrolling interests	(18.8)	(17.1)	(17.3)	(16.5)	(15.4)	(14.7)	(14.8)	(14.8)	(69.7)	(59.7)	(57.8)
Net income attributable to HealthSouth	$ 47	$ 50.7	$ 42.9	$ 42.5	$ 42.1	$ 50.1	$ 83.1	$ 46.7	$ 183.1	$ 222	$ 323.6
Basic earnings (loss) per share attributable to HealthSouth common shareholders:
Continuing operations	$ 0.51	$ 0.56	$ 0.49	$ 0.47	$ 0.43	$ 0.56	$ 0.89	$ 0.51	$ 2.03	$ 2.40	$ 2.59
Discontinued operations	0.01	0	(0.02)	0	0.03	(0.01)	0.04	0	(0.01)	0.06	(0.01)
Net income	0.52	0.56	0.47	0.47	0.46	0.55	0.93	0.51	2.02	2.46	2.58
Diluted earnings (loss) per share attributable to HealthSouth common shareholders:
Continuing operations	0.48	0.52	0.47	0.44	0.41	0.53	0.81	0.48	1.92	2.24	2.59
Discontinued operations	0.01	0	(0.02)	0	0.03	(0.01)	0.04	0	(0.01)	0.05	(0.01)
Net income	$ 0.49	$ 0.52	$ 0.45	$ 0.44	$ 0.44	$ 0.52	$ 0.85	$ 0.48	$ 1.91	$ 2.29	$ 2.58

Condensed Consolidating Fina112

Condensed Consolidating Financial Information Tables 1 - 5 (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Condensed Consolidating Statements of Operations
Net operating revenues	$ 879.3	$ 778.6	$ 764.4	$ 740.6	$ 613.4	$ 596.9	$ 604.4	$ 591.2	$ 3,162.9	$ 2,405.9	$ 2,273.2
Less: Provision for doubtful accounts									(47.2)	(31.6)	(26)
Net operating revenues less provision for doubtful accounts									3,115.7	2,374.3	2,247.2
Operating expenses:
Salaries and benefits									1,670.8	1,161.7	1,089.7
Other operating expenses									432.1	351.6	323
Occupancy costs									53.9	41.6	47
Supplies									128.7	111.9	105.4
General and administrative expenses									133.3	124.8	119.1
Depreciation and amortization									139.7	107.7	94.7
Government, class action, and related settlements									7.5	(1.7)	(23.5)
Professional fees-accounting, tax, and legal									3	9.3	9.5
Total operating expenses									2,569	1,906.9	1,764.9
Loss on early extinguishment of debt	2.4		18.8	1.2					22.4	13.2	2.4
Interest expense and amortization of debt discounts and fees									142.9	109.2	100.4
Other income									(5.5)	(31.2)	(4.5)
Equity in net income of nonconsolidated affiliates									(8.7)	(10.7)	(11.2)
Equity in net income of consolidated affiliates									0	0	0
Management fees									0	0	0
Income from continuing operations before income tax expense									395.6	386.9	395.2
Provision for income tax expense	43.5	35.9	32.2	30.3	19.3	22.1	36.5	32.8	141.9	110.7	12.7
Income from continuing operations	65.1	67.5	61.8	59.3	54.8	65.7	94.1	61.6	253.7	276.2	382.5
Income (loss) from discontinued operations, net of tax	0.7	0.3	(1.6)	(0.3)	2.7	(0.9)	3.8	(0.1)	(0.9)	5.5	(1.1)
Net income	65.8	67.8	60.2	59	57.5	64.8	97.9	61.5	252.8	281.7	381.4
Less: Net income attributable to noncontrolling interests	(18.8)	(17.1)	(17.3)	(16.5)	(15.4)	(14.7)	(14.8)	(14.8)	(69.7)	(59.7)	(57.8)
Net income attributable to HealthSouth	47	$ 50.7	$ 42.9	$ 42.5	42.1	$ 50.1	$ 83.1	$ 46.7	183.1	222	323.6
Comprehensive income									252.1	281.3	379.9
Comprehensive income attributable to HealthSouth									182.4	221.6	322.1
Current assets:
Cash and cash equivalents	61.6				66.7				61.6	66.7	64.5	$ 132.8
Restricted Cash	45.9				45.6				45.9	45.6
Accounts receivable, net	410.5				323.2				410.5	323.2
Deferred income tax assets	0				188.4				0	188.4
Prepaid expenses and other current assets	80.7				62.7				80.7	62.7
Total current assets	598.7				686.6				598.7	686.6
Property and equipment, net	1,310.1				1,019.7				1,310.1	1,019.7
Goodwill	1,890.1				1,084				1,890.1	1,084	456.9	437.3
Intangible assets, net	419.4				306.1				419.4	306.1
Deferred income tax assets	190.8				129.4				190.8	129.4
Other long-term assets	197				162.5				197	162.5
Intercompany notes receivable	0				0				0	0
Intercompany receivable and investments in consolidated affiliates	0				0				0	0
Total assets	4,606.1				3,388.3				4,606.1	3,388.3
Current liabilities:
Current portion of long-term debt	36.8				20.8				36.8	20.8
Accounts payable	61.6				53.4				61.6	53.4
Accrued payroll	126.2				123.3				126.2	123.3
Accrued interest payable	29.7				21.2				29.7	21.2
Other current liabilities	172.1				145.6				172.1	145.6
Total current liabilities	426.4				364.3				426.4	364.3
Long-term debt, net of current portion	3,134.7				2,090.4				3,134.7	2,090.4
Intercompany notes payable	0				0				0	0
Self-insured risks	101.6				98.7				101.6	98.7
Other long-term liabilities	43				37.5				43	37.5
Intercompany payable	0				0				0	0
Total liabilities	$ 3,705.7				$ 2,590.9				$ 3,705.7	$ 2,590.9
Commitments and contingencies
Temporary Equity, Carrying Amount, Attributable to Parent	$ 0				$ 93.2				$ 0	$ 93.2
Redeemable noncontrolling interests	121.1				84.7				121.1	84.7
Shareholders' equity
HealthSouth shareholders' equity	611.4				473.2				611.4	473.2
Noncontrolling interests	167.9				146.3				167.9	146.3
Total shareholders' equity	779.3				619.5				779.3	619.5	468.7	403.5
Total liabilities and shareholders' equity	4,606.1				3,388.3				4,606.1	3,388.3
HealthSouth Corporation
Condensed Consolidating Statements of Operations
Net operating revenues									19.4	16.1	12.2
Less: Provision for doubtful accounts									0	0	0
Net operating revenues less provision for doubtful accounts									19.4	16.1	12.2
Operating expenses:
Salaries and benefits									49.4	22.3	12.1
Other operating expenses									31.3	21.6	10.8
Occupancy costs									4	4.2	4.1
Supplies									0	0	0
General and administrative expenses									128.3	124.8	119.1
Depreciation and amortization									9.9	9.7	8.8
Government, class action, and related settlements									7.5	(1.7)	(23.5)
Professional fees-accounting, tax, and legal									3	9.3	9.5
Total operating expenses									233.4	190.2	140.9
Loss on early extinguishment of debt									22.4	13.2	2.4
Interest expense and amortization of debt discounts and fees									130	99.8	90.4
Other income									(13.6)	(0.7)	(1)
Equity in net income of nonconsolidated affiliates									0	0	(3.6)
Equity in net income of consolidated affiliates									(322.7)	(314)	(268)
Management fees									(119.7)	(107.9)	(102.3)
Income from continuing operations before income tax expense									89.6	135.5	153.4
Provision for income tax expense									(94.6)	(80.8)	(169)
Income from continuing operations									184.2	216.3	322.4
Income (loss) from discontinued operations, net of tax									(1.1)	5.7	1.2
Net income									183.1	222	323.6
Less: Net income attributable to noncontrolling interests									0	0	0
Net income attributable to HealthSouth									183.1	222	323.6
Comprehensive income									182.4	221.6	322.1
Comprehensive income attributable to HealthSouth									182.4	221.6	322.1
Current assets:
Cash and cash equivalents	41.2				41.9				41.2	41.9	60.5	131.3
Restricted Cash	0				0				0	0
Accounts receivable, net	0				0				0	0
Deferred income tax assets					125					125
Prepaid expenses and other current assets	29.3				30.9				29.3	30.9
Total current assets	70.5				197.8				70.5	197.8
Property and equipment, net	14.5				16.1				14.5	16.1
Goodwill	0				0				0	0
Intangible assets, net	8.8				11.3				8.8	11.3
Deferred income tax assets	176.2				163.3				176.2	163.3
Other long-term assets	48.6				55.8				48.6	55.8
Intercompany notes receivable	546.6				385.2				546.6	385.2
Intercompany receivable and investments in consolidated affiliates	2,779.7				1,898.7				2,779.7	1,898.7
Total assets	3,644.9				2,728.2				3,644.9	2,728.2
Current liabilities:
Current portion of long-term debt	40				27.9				40	27.9
Accounts payable	5.8				9.3				5.8	9.3
Accrued payroll	27.7				17.5				27.7	17.5
Accrued interest payable	26.5				19.2				26.5	19.2
Other current liabilities	68				70.4				68	70.4
Total current liabilities	168				144.3				168	144.3
Long-term debt, net of current portion	2,821.9				1,973.4				2,821.9	1,973.4
Intercompany notes payable	0				0				0	0
Self-insured risks	19.8				22.9				19.8	22.9
Other long-term liabilities	23.8				21.2				23.8	21.2
Intercompany payable	0				0				0	0
Total liabilities	$ 3,033.5				$ 2,161.8				$ 3,033.5	$ 2,161.8
Commitments and contingencies
Temporary Equity, Carrying Amount, Attributable to Parent					$ 93.2					$ 93.2
Redeemable noncontrolling interests	$ 0				0				$ 0	0
Shareholders' equity
HealthSouth shareholders' equity	611.4				473.2				611.4	473.2
Noncontrolling interests	0				0				0	0
Total shareholders' equity	611.4				473.2				611.4	473.2
Total liabilities and shareholders' equity	3,644.9				2,728.2				3,644.9	2,728.2
Guarantor Subsidiaries
Condensed Consolidating Statements of Operations
Net operating revenues									1,927	1,719.1	1,622.4
Less: Provision for doubtful accounts									(34.6)	(22.3)	(18.3)
Net operating revenues less provision for doubtful accounts									1,892.4	1,696.8	1,604.1
Operating expenses:
Salaries and benefits									893.2	795.7	757.7
Other operating expenses									274.7	246.7	238.5
Occupancy costs									69.4	58.2	48.3
Supplies									85.2	78.6	73.8
General and administrative expenses									0	0	0
Depreciation and amortization									84.3	71.9	65.1
Government, class action, and related settlements									0	0	0
Professional fees-accounting, tax, and legal									0	0	0
Total operating expenses									1,406.8	1,251.1	1,183.4
Loss on early extinguishment of debt									0	0	0
Interest expense and amortization of debt discounts and fees									11.9	7.8	8.1
Other income									(0.2)	(28.5)	(1.2)
Equity in net income of nonconsolidated affiliates									(8.5)	(10.7)	(7.5)
Equity in net income of consolidated affiliates									(34.5)	(30.6)	(20.6)
Management fees									91.6	82.2	78.6
Income from continuing operations before income tax expense									425.3	425.5	363.3
Provision for income tax expense									169.7	148	134.4
Income from continuing operations									255.6	277.5	228.9
Income (loss) from discontinued operations, net of tax									0	0	(0.8)
Net income									255.6	277.5	228.1
Less: Net income attributable to noncontrolling interests									0	0	0
Net income attributable to HealthSouth									255.6	277.5	228.1
Comprehensive income									255.6	277.5	228.1
Comprehensive income attributable to HealthSouth									255.6	277.5	228.1
Current assets:
Cash and cash equivalents	1.3				1.5				1.3	1.5	2.3	0.3
Restricted Cash	0				0				0	0
Accounts receivable, net	267.2				202.6				267.2	202.6
Deferred income tax assets					39.8					39.8
Prepaid expenses and other current assets	22.7				15.4				22.7	15.4
Total current assets	291.2				259.3				291.2	259.3
Property and equipment, net	965.7				752				965.7	752
Goodwill	863.2				279.6				863.2	279.6
Intangible assets, net	123.2				50.6				123.2	50.6
Deferred income tax assets	64.1				17.5				64.1	17.5
Other long-term assets	75.3				42.5				75.3	42.5
Intercompany notes receivable	0				0				0	0
Intercompany receivable and investments in consolidated affiliates	0				0				0	0
Total assets	2,382.7				1,401.5				2,382.7	1,401.5
Current liabilities:
Current portion of long-term debt	6.8				4.2				6.8	4.2
Accounts payable	35.2				29.5				35.2	29.5
Accrued payroll	50.7				55.6				50.7	55.6
Accrued interest payable	2.9				1.8				2.9	1.8
Other current liabilities	19				15.2				19	15.2
Total current liabilities	114.6				106.3				114.6	106.3
Long-term debt, net of current portion	255.6				83.9				255.6	83.9
Intercompany notes payable	0				0				0	0
Self-insured risks	0				0				0	0
Other long-term liabilities	12.4				12.7				12.4	12.7
Intercompany payable	141.7				381				141.7	381
Total liabilities	$ 524.3				$ 583.9				$ 524.3	$ 583.9
Commitments and contingencies
Temporary Equity, Carrying Amount, Attributable to Parent					$ 0					$ 0
Redeemable noncontrolling interests	$ 0				0				$ 0	0
Shareholders' equity
HealthSouth shareholders' equity	1,858.4				817.6				1,858.4	817.6
Noncontrolling interests	0				0				0	0
Total shareholders' equity	1,858.4				817.6				1,858.4	817.6
Total liabilities and shareholders' equity	2,382.7				1,401.5				2,382.7	1,401.5
Non-Guarantor Subsidiaries
Condensed Consolidating Statements of Operations
Net operating revenues									1,320	761.1	709.8
Less: Provision for doubtful accounts									(12.6)	(9.3)	(7.7)
Net operating revenues less provision for doubtful accounts									1,307.4	751.8	702.1
Operating expenses:
Salaries and benefits									745.3	358.8	334.4
Other operating expenses									167.4	120.1	107.5
Occupancy costs									25.6	17.7	17.5
Supplies									43.5	33.3	31.6
General and administrative expenses									5	0	0
Depreciation and amortization									45.5	26.1	20.8
Government, class action, and related settlements									0	0	0
Professional fees-accounting, tax, and legal									0	0	0
Total operating expenses									1,032.3	556	511.8
Loss on early extinguishment of debt									0	0	0
Interest expense and amortization of debt discounts and fees									12.4	2.8	3.1
Other income									(3.1)	(3.2)	(3.5)
Equity in net income of nonconsolidated affiliates									(0.2)	0	(0.1)
Equity in net income of consolidated affiliates									0	0	0
Management fees									28.1	25.7	23.7
Income from continuing operations before income tax expense									237.9	170.5	167.1
Provision for income tax expense									66.8	43.5	47.3
Income from continuing operations									171.1	127	119.8
Income (loss) from discontinued operations, net of tax									0.2	(0.2)	(1.5)
Net income									171.3	126.8	118.3
Less: Net income attributable to noncontrolling interests									(69.7)	(59.7)	(57.8)
Net income attributable to HealthSouth									101.6	67.1	60.5
Comprehensive income									171.3	126.8	118.3
Comprehensive income attributable to HealthSouth									101.6	67.1	60.5
Current assets:
Cash and cash equivalents	19.1				23.3				19.1	23.3	1.7	1.2
Restricted Cash	45.9				45.6				45.9	45.6
Accounts receivable, net	143.3				120.6				143.3	120.6
Deferred income tax assets					23.6					23.6
Prepaid expenses and other current assets	47.5				35.2				47.5	35.2
Total current assets	255.8				248.3				255.8	248.3
Property and equipment, net	329.9				251.6				329.9	251.6
Goodwill	1,026.9				804.4				1,026.9	804.4
Intangible assets, net	287.4				244.2				287.4	244.2
Deferred income tax assets	0				0				0	0
Other long-term assets	73.1				64.2				73.1	64.2
Intercompany notes receivable	0				0				0	0
Intercompany receivable and investments in consolidated affiliates	0				0				0	0
Total assets	1,973.1				1,612.7				1,973.1	1,612.7
Current liabilities:
Current portion of long-term debt	7.5				6.2				7.5	6.2
Accounts payable	20.6				14.6				20.6	14.6
Accrued payroll	47.8				50.2				47.8	50.2
Accrued interest payable	0.3				0.2				0.3	0.2
Other current liabilities	86.4				61.3				86.4	61.3
Total current liabilities	162.6				132.5				162.6	132.5
Long-term debt, net of current portion	57.2				33.1				57.2	33.1
Intercompany notes payable	546.6				385.2				546.6	385.2
Self-insured risks	81.8				75.8				81.8	75.8
Other long-term liabilities	55.9				55				55.9	55
Intercompany payable	179.1				173.2				179.1	173.2
Total liabilities	$ 1,083.2				$ 854.8				$ 1,083.2	$ 854.8
Commitments and contingencies
Temporary Equity, Carrying Amount, Attributable to Parent					$ 0					$ 0
Redeemable noncontrolling interests	$ 121.1				84.7				$ 121.1	84.7
Shareholders' equity
HealthSouth shareholders' equity	600.9				526.9				600.9	526.9
Noncontrolling interests	167.9				146.3				167.9	146.3
Total shareholders' equity	768.8				673.2				768.8	673.2
Total liabilities and shareholders' equity	1,973.1				1,612.7				1,973.1	1,612.7
Eliminating Entries
Condensed Consolidating Statements of Operations
Net operating revenues									(103.5)	(90.4)	(71.2)
Less: Provision for doubtful accounts									0	0	0
Net operating revenues less provision for doubtful accounts									(103.5)	(90.4)	(71.2)
Operating expenses:
Salaries and benefits									(17.1)	(15.1)	(14.5)
Other operating expenses									(41.3)	(36.8)	(33.8)
Occupancy costs									(45.1)	(38.5)	(22.9)
Supplies									0	0	0
General and administrative expenses									0	0	0
Depreciation and amortization									0	0	0
Government, class action, and related settlements									0	0	0
Professional fees-accounting, tax, and legal									0	0	0
Total operating expenses									(103.5)	(90.4)	(71.2)
Loss on early extinguishment of debt									0	0	0
Interest expense and amortization of debt discounts and fees									(11.4)	(1.2)	(1.2)
Other income									11.4	1.2	1.2
Equity in net income of nonconsolidated affiliates									0	0	0
Equity in net income of consolidated affiliates									357.2	344.6	288.6
Management fees									0	0	0
Income from continuing operations before income tax expense									(357.2)	(344.6)	(288.6)
Provision for income tax expense									0	0	0
Income from continuing operations									(357.2)	(344.6)	(288.6)
Income (loss) from discontinued operations, net of tax									0	0	0
Net income									(357.2)	(344.6)	(288.6)
Less: Net income attributable to noncontrolling interests									0	0	0
Net income attributable to HealthSouth									(357.2)	(344.6)	(288.6)
Comprehensive income									(357.2)	(344.6)	(288.6)
Comprehensive income attributable to HealthSouth									(357.2)	(344.6)	(288.6)
Current assets:
Cash and cash equivalents	0				0				0	0	$ 0	$ 0
Restricted Cash	0				0				0	0
Accounts receivable, net	0				0				0	0
Deferred income tax assets					0					0
Prepaid expenses and other current assets	(18.8)				(18.8)				(18.8)	(18.8)
Total current assets	(18.8)				(18.8)				(18.8)	(18.8)
Property and equipment, net	0				0				0	0
Goodwill	0				0				0	0
Intangible assets, net	0				0				0	0
Deferred income tax assets	(49.5)				(51.4)				(49.5)	(51.4)
Other long-term assets	0				0				0	0
Intercompany notes receivable	(546.6)				(385.2)				(546.6)	(385.2)
Intercompany receivable and investments in consolidated affiliates	(2,779.7)				(1,898.7)				(2,779.7)	(1,898.7)
Total assets	(3,394.6)				(2,354.1)				(3,394.6)	(2,354.1)
Current liabilities:
Current portion of long-term debt	(17.5)				(17.5)				(17.5)	(17.5)
Accounts payable	0				0				0	0
Accrued payroll	0				0				0	0
Accrued interest payable	0				0				0	0
Other current liabilities	(1.3)				(1.3)				(1.3)	(1.3)
Total current liabilities	(18.8)				(18.8)				(18.8)	(18.8)
Long-term debt, net of current portion	0				0				0	0
Intercompany notes payable	(546.6)				(385.2)				(546.6)	(385.2)
Self-insured risks	0				0				0	0
Other long-term liabilities	(49.1)				(51.4)				(49.1)	(51.4)
Intercompany payable	(320.8)				(554.2)				(320.8)	(554.2)
Total liabilities	$ (935.3)				$ (1,009.6)				$ (935.3)	$ (1,009.6)
Commitments and contingencies
Temporary Equity, Carrying Amount, Attributable to Parent					$ 0					$ 0
Redeemable noncontrolling interests	$ 0				0				$ 0	0
Shareholders' equity
HealthSouth shareholders' equity	(2,459.3)				(1,344.5)				(2,459.3)	(1,344.5)
Noncontrolling interests	0				0				0	0
Total shareholders' equity	(2,459.3)				(1,344.5)				(2,459.3)	(1,344.5)
Total liabilities and shareholders' equity	$ (3,394.6)				$ (2,354.1)				$ (3,394.6)	$ (2,354.1)

Condensed Consolidating Fina113

Condensed Consolidating Financial Information Tables 6 - 8 (Details) $ in Millions	1 Months Ended	3 Months Ended		12 Months Ended
	Jan. 16, 2014USD ($)	Sep. 30, 2013USD ($)	Dec. 31, 2012USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)
Cash flows from investing activities:
Acquisition of businesses, net of cash acquired				$ (985.1)	$ (694.8)	$ (28.9)
Purchases of property and equipment				(128.4)	(170.9)	(195.2)
Capitalized software costs				(28.1)	(17)	(21.3)
Proceeds from sale of restricted investments				0.2	0.3	16.9
Proceeds from sale of marketable securities				12.8	0	0
Proceeds from sale of Digital Hospital		$ 10.8		0	0	10.8
Purchase of restricted investments				(7.1)	(3.5)	(9.2)
Net change in restricted cash				2.7	6.8	(3.1)
Funding of intercompany note receivable				0
Proceeds from repayment of intercompany note receivable				0
Other				2.7	2.2	0.5
Net cash provided by investing activities of discontinued operations				0.5	0	3.3
Net cash used in investing activities				(1,129.8)	(876.9)	(226.2)
Cash flows from financing activities:
Principal borrowings on term loan facilities				250	450	0
Proceeds from bond issuance				1,400	175	0
Principal payments on debt, including pre-payments				(597.4)	(302.6)	(62.5)
Principal borrowings on notes				0	0	15.2
Principal payments on intercompany note payable				0
Borrowings on revolving credit facility				540	440	197
Payments on revolving credit facility				(735)	(160)	(152)
Debt amendment and issuance costs				(31.9)	(6.5)	(2.6)
Principal payments under capital lease obligations				(11)	(6.1)	(10.1)
Repurchase of common stock, including fees and expenses				(45.3)	(43.1)	(234.1)
Net cash provided by operating activities				484.8	444.9	470.3
Dividends paid on common stock				(77.2)	(65.8)	(15.7)
Dividends paid on convertible perpetual preferred stock				(3.1)	(6.3)	(23)
Distributions paid to noncontrolling interests of consolidated affiliates				(54.4)	(54.1)	(46.3)
Proceeds from exercising stock warrants	$ 6.3			0	6.3	15.3
Other				5.2	7.4	6.4
Change in intercompany advances				0	0	0
Net cash provided by (used in) financing activities				639.9	434.2	(312.4)
Increase (decrease) in cash and cash equivalents				(5.1)	2.2	(68.3)
Cash and cash equivalents at end of year			$ 132.8	61.6	66.7	64.5
Supplemental schedule of noncash investing and financing activities: [Abstract]
Conversion of Preferred Stock				93.2
Intercompany note activity				0
Equity rollover from Encompass management				0	64.5	0
Convertible debt issued				0	0	320
Repurchase of preferred stock				$ 0	0	(320)
Condensed Consolidating Financial Information (Textual) (Abstract)
HealthSouth ownership percentage of subsidiary guarantors				100.00%
Senior secured leverage ratio maximum				1.75
Consolidated coverage ratio minimum				2
Deferred income tax assets				$ 190.8	129.4
HealthSouth Corporation
Cash flows from investing activities:
Acquisition of businesses, net of cash acquired				(954.6)	(674.6)	0
Purchases of property and equipment				(15.9)	(15.6)	(2.8)
Capitalized software costs				(24.5)	(8.6)	(6)
Proceeds from sale of restricted investments				0	0	0
Proceeds from sale of marketable securities				12.8
Proceeds from sale of Digital Hospital						10.8
Purchase of restricted investments				0	0	0
Net change in restricted cash				0	1	(0.2)
Funding of intercompany note receivable				(2)
Proceeds from repayment of intercompany note receivable				24
Other				(0.5)	0	0
Net cash provided by investing activities of discontinued operations				0.5		0
Net cash used in investing activities				(960.2)	(697.8)	1.8
Cash flows from financing activities:
Principal borrowings on term loan facilities				250	450
Proceeds from bond issuance				1,400	175
Principal payments on debt, including pre-payments				(595)	(298)	(59.5)
Principal borrowings on notes						0
Principal payments on intercompany note payable				0
Borrowings on revolving credit facility				540	440	197
Payments on revolving credit facility				(735)	(160)	(152)
Debt amendment and issuance costs				(31.9)	(6.5)	(2.6)
Principal payments under capital lease obligations				(0.3)	(0.3)	(0.3)
Repurchase of common stock, including fees and expenses				(45.3)	(43.1)	(234.1)
Net cash provided by operating activities				29.6	21.9	113.2
Dividends paid on common stock				(77.2)	(65.8)	(15.7)
Dividends paid on convertible perpetual preferred stock				(3.1)	(6.3)	(23)
Distributions paid to noncontrolling interests of consolidated affiliates				0	0	0
Proceeds from exercising stock warrants					6.3	15.3
Other				2.2	7.4	4.8
Change in intercompany advances				(225.5)	(158.6)	(84.3)
Net cash provided by (used in) financing activities				929.9	657.3	(185.8)
Increase (decrease) in cash and cash equivalents				(0.7)	(18.6)	(70.8)
Cash and cash equivalents at end of year			131.3	41.2	41.9	60.5
Supplemental schedule of noncash investing and financing activities: [Abstract]
Conversion of Preferred Stock				93.2
Intercompany note activity				(183.5)
Equity rollover from Encompass management					0
Convertible debt issued						320
Repurchase of preferred stock						320
Condensed Consolidating Financial Information (Textual) (Abstract)
Deferred income tax assets				176.2	163.3
Guarantor Subsidiaries
Cash flows from investing activities:
Acquisition of businesses, net of cash acquired				0	0	(28.9)
Purchases of property and equipment				(46.1)	(124)	(167.9)
Capitalized software costs				(0.4)	(1.4)	(11.1)
Proceeds from sale of restricted investments				0	0	0
Proceeds from sale of marketable securities				0
Proceeds from sale of Digital Hospital						0
Purchase of restricted investments				0	0	0
Net change in restricted cash				0	0	0
Funding of intercompany note receivable				0
Proceeds from repayment of intercompany note receivable				0
Other				2.3	(0.7)	0.9
Net cash provided by investing activities of discontinued operations				0		3.1
Net cash used in investing activities				(44.2)	(126.1)	(203.9)
Cash flows from financing activities:
Principal borrowings on term loan facilities				0	0
Proceeds from bond issuance				0	0
Principal payments on debt, including pre-payments				(1.6)	(1.5)	(1.3)
Principal borrowings on notes						0
Principal payments on intercompany note payable				0
Borrowings on revolving credit facility				0	0	0
Payments on revolving credit facility				0	0	0
Debt amendment and issuance costs				0	0	0
Principal payments under capital lease obligations				(4.5)	(2.5)	(6.3)
Repurchase of common stock, including fees and expenses				0	0	0
Net cash provided by operating activities				222.6	260.1	235.7
Dividends paid on common stock				0	0	0
Dividends paid on convertible perpetual preferred stock				0	0	0
Distributions paid to noncontrolling interests of consolidated affiliates				0	0	0
Proceeds from exercising stock warrants					0	0
Other				1.5	0	0
Change in intercompany advances				174	130.8	22.2
Net cash provided by (used in) financing activities				(178.6)	(134.8)	(29.8)
Increase (decrease) in cash and cash equivalents				(0.2)	(0.8)	2
Cash and cash equivalents at end of year			0.3	1.3	1.5	2.3
Supplemental schedule of noncash investing and financing activities: [Abstract]
Conversion of Preferred Stock				0
Intercompany note activity				0
Equity rollover from Encompass management					0
Convertible debt issued						0
Repurchase of preferred stock						0
Condensed Consolidating Financial Information (Textual) (Abstract)
Deferred income tax assets				64.1	17.5
Non-Guarantor Subsidiaries
Cash flows from investing activities:
Acquisition of businesses, net of cash acquired				(30.5)	(20.2)	0
Purchases of property and equipment				(66.4)	(31.3)	(24.5)
Capitalized software costs				(3.2)	(7)	(4.2)
Proceeds from sale of restricted investments				0.2	0.3	16.9
Proceeds from sale of marketable securities				0
Proceeds from sale of Digital Hospital						0
Purchase of restricted investments				(7.1)	(3.5)	(9.2)
Net change in restricted cash				2.7	5.8	(2.9)
Funding of intercompany note receivable				0
Proceeds from repayment of intercompany note receivable				0
Other				0.9	2.9	(0.4)
Net cash provided by investing activities of discontinued operations				0		0.2
Net cash used in investing activities				(103.4)	(53)	(24.1)
Cash flows from financing activities:
Principal borrowings on term loan facilities				2	0
Proceeds from bond issuance				0	0
Principal payments on debt, including pre-payments				(0.8)	(3.1)	(1.7)
Principal borrowings on notes						15.2
Principal payments on intercompany note payable				(24)
Borrowings on revolving credit facility				0	0	0
Payments on revolving credit facility				0	0	0
Debt amendment and issuance costs				0	0	0
Principal payments under capital lease obligations				(6.2)	(3.3)	(3.5)
Repurchase of common stock, including fees and expenses				0	0	0
Net cash provided by operating activities				232.2	162.9	121.4
Dividends paid on common stock				0	0	0
Dividends paid on convertible perpetual preferred stock				0	0	0
Distributions paid to noncontrolling interests of consolidated affiliates				(54.4)	(54.1)	(46.3)
Proceeds from exercising stock warrants					0	0
Other				1.5	0	1.6
Change in intercompany advances				51.1	27.8	62.1
Net cash provided by (used in) financing activities				(133)	(88.3)	(96.8)
Increase (decrease) in cash and cash equivalents				(4.2)	21.6	0.5
Cash and cash equivalents at end of year			1.2	19.1	23.3	1.7
Supplemental schedule of noncash investing and financing activities: [Abstract]
Conversion of Preferred Stock				0
Intercompany note activity				183.5
Equity rollover from Encompass management					64.5
Convertible debt issued						0
Repurchase of preferred stock						0
Condensed Consolidating Financial Information (Textual) (Abstract)
Deferred income tax assets				0	0
Eliminating Entries
Cash flows from investing activities:
Acquisition of businesses, net of cash acquired				0	0	0
Purchases of property and equipment				0	0	0
Capitalized software costs				0	0	0
Proceeds from sale of restricted investments				0	0	0
Proceeds from sale of marketable securities				0
Proceeds from sale of Digital Hospital						0
Purchase of restricted investments				0	0	0
Net change in restricted cash				0	0	0
Funding of intercompany note receivable				2
Proceeds from repayment of intercompany note receivable				(24)
Other				0	0	0
Net cash provided by investing activities of discontinued operations				0		0
Net cash used in investing activities				(22)	0	0
Cash flows from financing activities:
Principal borrowings on term loan facilities				(2)	0
Proceeds from bond issuance				0	0
Principal payments on debt, including pre-payments				0	0	0
Principal borrowings on notes						0
Principal payments on intercompany note payable				24
Borrowings on revolving credit facility				0	0	0
Payments on revolving credit facility				0	0	0
Debt amendment and issuance costs				0	0	0
Principal payments under capital lease obligations				0	0	0
Repurchase of common stock, including fees and expenses				0	0	0
Net cash provided by operating activities				0.4	0	0
Dividends paid on common stock				0	0	0
Dividends paid on convertible perpetual preferred stock				0	0	0
Distributions paid to noncontrolling interests of consolidated affiliates				0	0	0
Proceeds from exercising stock warrants					0	0
Other				0	0	0
Change in intercompany advances				0.4	0	0
Net cash provided by (used in) financing activities				21.6	0	0
Increase (decrease) in cash and cash equivalents				0	0	0
Cash and cash equivalents at end of year			$ 0	0	0	0
Supplemental schedule of noncash investing and financing activities: [Abstract]
Conversion of Preferred Stock				0
Intercompany note activity				0
Equity rollover from Encompass management					0
Convertible debt issued						0
Repurchase of preferred stock						$ 0
Condensed Consolidating Financial Information (Textual) (Abstract)
Deferred income tax assets				$ (49.5)	(51.4)
Scenario, Previously Reported [Member] | Non-Guarantor Subsidiaries
Condensed Consolidating Financial Information (Textual) (Abstract)
Deferred income tax assets					$ 51.4

Business Combinations Business

Business Combinations Business Combinations - Table 1 (Details) - USD ($) $ in Millions	1 Months Ended
	Oct. 31, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Business Acquisition [Line Items]
Cash and cash equivalents	$ 42.6
Accounts receivable, net	25.7
Prepaid expenses and other current assets	2.8
Property and equipment, net	220.6
Goodwill		$ 1,890.1	$ 1,084	$ 456.9	$ 437.3
Long-term debt		$ 1.3	$ 2.9
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net	771.4
Reliant [Member]
Business Acquisition [Line Items]
Goodwill	642.6
Other long-term assets	0.9
Total assets acquired	1,001.8
Current portion of long-term debt	4.1
Accounts payable	1.7
Accrued payroll	3.7
Other current liabilities	10.8
Long-term debt	205.8
Deferred tax liabilities	3.9
Total liabilities assumed	230
Noncontrolling Interest, Acquired	0.4
Fair value of noncontrolling interest owned by joint venture partner	(0.4)
Noncompete Agreements [Member]
Business Acquisition [Line Items]
Identifiable intangible assets, Finite life	9.7
Trade Names [Member]
Business Acquisition [Line Items]
Identifiable intangible assets, Finite life	8.9
Certificate of Need [Member]
Business Acquisition [Line Items]
Identifiable intangible assets, Finite life	36.6
License [Member]
Business Acquisition [Line Items]
Identifiable intangible assets, Finite life	$ 11.4

Business Combinations Busine115

Business Combinations Business Combinations - Table 2 (Details) - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Oct. 31, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Business Acquisition [Line Items]
Goodwill, Acquired During Period		$ 806.1	$ 593.1	$ 13.7
Payments to Acquire Businesses, Net of Cash Acquired		$ 985.1	$ 694.8	$ 28.9
Reliant [Member]
Business Acquisition [Line Items]
Fair value of assets acquired	$ 316.6
Goodwill, Acquired During Period	642.6
Noncash or Part Noncash Acquisition, Value of Liabilities Assumed	(230)
Fair value of noncontrolling interest owned by joint venture partner	(0.4)
Payments to Acquire Businesses, Net of Cash Acquired	$ 728.8

Business Combinations Busine116

Business Combinations Business Combinations - Table 3 (Details) - USD ($) $ in Millions	Dec. 31, 2015	Oct. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Business Acquisition [Line Items]
Property and equipment, net		$ 220.6
Goodwill	$ 1,890.1		$ 1,084	$ 456.9	$ 437.3
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net		771.4
Inpatient Rehabilitation Hospital [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets	10.1
Property and equipment, net	42.7
Goodwill	0.7
Total assets acquired	63.4
Total liabilities assumed	2.7
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net	60.7
Noncompete Agreements [Member]
Business Acquisition [Line Items]
Identifiable intangible assets, Finite life		9.7
Noncompete Agreements [Member] | Inpatient Rehabilitation Hospital [Member]
Business Acquisition [Line Items]
Identifiable intangible assets, Finite life	0.1
Trade Names [Member]
Business Acquisition [Line Items]
Identifiable intangible assets, Finite life		8.9
Trade Names [Member] | Inpatient Rehabilitation Hospital [Member]
Business Acquisition [Line Items]
Identifiable intangible assets, Finite life	0.8
Certificate of Need [Member]
Business Acquisition [Line Items]
Identifiable intangible assets, Finite life		36.6
Certificate of Need [Member] | Inpatient Rehabilitation Hospital [Member]
Business Acquisition [Line Items]
Identifiable intangible assets, Finite life	8.8
License [Member]
Business Acquisition [Line Items]
Identifiable intangible assets, Finite life		$ 11.4
License [Member] | Inpatient Rehabilitation Hospital [Member]
Business Acquisition [Line Items]
Identifiable intangible assets, Finite life	$ 0.2

Business Combinations Busine117

Business Combinations Business Combinations - Table 4 (Details) - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Apr. 30, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Business Acquisition [Line Items]
Goodwill, Acquired During Period		$ 806.1	$ 593.1	$ 13.7
Payments to Acquire Businesses, Net of Cash Acquired		985.1	694.8	28.9
Inpatient Rehabilitation Hospital [Member]
Business Acquisition [Line Items]
Fair value of assets acquired		62.8	60.1	15.6
Goodwill, Acquired During Period	$ 0.7	0.7	34.6	13.7
Noncash or Part Noncash Acquisition, Value of Liabilities Assumed		(2.7)	(21.2)	(0.4)
Fair value of noncontrolling interest owned by joint venture partner		(4.2)	(18.3)	0
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value		0	(35)	0
Payments to Acquire Businesses, Net of Cash Acquired		$ 56.6	$ 20.2	$ 28.9

Business Combinations Busine118

Business Combinations Business Combinations - Table 5 (Details) - USD ($) $ in Millions	Dec. 31, 2015	Nov. 30, 2015	Oct. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Business Acquisition [Line Items]
Cash and cash equivalents			$ 42.6
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables			25.7
Prepaid expenses and other current assets			2.8
Property and equipment, net			220.6
Goodwill	$ 1,890.1			$ 1,084	$ 456.9	$ 437.3
Long-term debt	$ 1.3			$ 2.9
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net			771.4
CareSouth [Member]
Business Acquisition [Line Items]
Cash and cash equivalents		$ 0.4
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables		10.5
Prepaid expenses and other current assets		2.4
Property and equipment, net		0.7
Goodwill		142.5
Investment in noconsolidated affiliates, acquired		2.2
Total assets acquired		191.3
Current portion of long-term debt		0.1
Accounts payable		2.4
Accrued payroll		2.4
Other current liabilities		2.8
Long-term debt		0.2
Deferred tax liabilities		9.4
Total liabilities assumed		17.3
Noncontrolling Interest, Acquired		4.3
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net		169.7
Noncompete Agreements [Member]
Business Acquisition [Line Items]
Identifiable intangible assets, Finite life			9.7
Noncompete Agreements [Member] | CareSouth [Member]
Business Acquisition [Line Items]
Identifiable intangible assets, Finite life		0.8
Trade Names [Member]
Business Acquisition [Line Items]
Identifiable intangible assets, Finite life			8.9
Trade Names [Member] | CareSouth [Member]
Business Acquisition [Line Items]
Identifiable intangible assets, Finite life		2.8
Certificate of Need [Member]
Business Acquisition [Line Items]
Identifiable intangible assets, Finite life			36.6
Certificate of Need [Member] | CareSouth [Member]
Business Acquisition [Line Items]
Identifiable intangible assets, Finite life		15.6
License [Member]
Business Acquisition [Line Items]
Identifiable intangible assets, Finite life			$ 11.4
License [Member] | CareSouth [Member]
Business Acquisition [Line Items]
Identifiable intangible assets, Finite life		13
Internal Use Software [Member] | CareSouth [Member]
Business Acquisition [Line Items]
Identifiable intangible assets, Finite life		$ 0.4

Business Combinations Busine119

Business Combinations Business Combinations - Table 6 (Details) - USD ($) $ in Millions	Nov. 30, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Business Acquisition [Line Items]
Goodwill, Acquired During Period		$ 806.1	$ 593.1	$ 13.7
Payments to Acquire Businesses, Net of Cash Acquired		$ 985.1	$ 694.8	$ 28.9
CareSouth [Member]
Business Acquisition [Line Items]
Fair value of assets acquired	$ 48.4
Goodwill, Acquired During Period	142.5
Noncash or Part Noncash Acquisition, Value of Liabilities Assumed	(17.3)
Fair value of noncontrolling interest owned by joint venture partner	(4.3)
Payments to Acquire Businesses, Net of Cash Acquired	$ 169.3

Business Combinations Busine120

Business Combinations Business Combinations - Table 7 (Details) - USD ($) $ in Millions	Dec. 31, 2015	Oct. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Business Acquisition [Line Items]
Property and equipment, net		$ 220.6
Goodwill	$ 1,890.1		$ 1,084	$ 456.9	$ 437.3
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net		771.4
Home Health and Hospice [Member]
Business Acquisition [Line Items]
Property and equipment, net	0.1
Goodwill	20.3
Total assets acquired	30.7
Total liabilities assumed	(0.2)
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net	30.5
Noncompete Agreements [Member]
Business Acquisition [Line Items]
Identifiable intangible assets, Finite life		9.7
Noncompete Agreements [Member] | Home Health and Hospice [Member]
Business Acquisition [Line Items]
Identifiable intangible assets, Finite life	1.3
Trade Names [Member]
Business Acquisition [Line Items]
Identifiable intangible assets, Finite life		8.9
Trade Names [Member] | Home Health and Hospice [Member]
Business Acquisition [Line Items]
Identifiable intangible assets, Finite life	0.5
Certificate of Need [Member]
Business Acquisition [Line Items]
Identifiable intangible assets, Finite life		36.6
Certificate of Need [Member] | Home Health and Hospice [Member]
Business Acquisition [Line Items]
Identifiable intangible assets, Finite life	4.9
License [Member]
Business Acquisition [Line Items]
Identifiable intangible assets, Finite life		$ 11.4
License [Member] | Home Health and Hospice [Member]
Business Acquisition [Line Items]
Identifiable intangible assets, Finite life	$ 3.6

Business Combinations Busine121

Business Combinations Business Combinations - Table 8 (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Business Acquisition [Line Items]
Goodwill, Acquired During Period	$ 806.1	$ 593.1	$ 13.7
Payments to Acquire Businesses, Net of Cash Acquired	985.1	694.8	28.9
Home Health and Hospice [Member]
Business Acquisition [Line Items]
Fair value of assets acquired	10.4	0	0
Goodwill, Acquired During Period	20.3	0	0
Noncash or Part Noncash Acquisition, Value of Liabilities Assumed	(0.2)	0	0
Payments to Acquire Businesses, Net of Cash Acquired	$ 30.5	$ 0	$ 0

Business Combinations Busine122

Business Combinations Business Combinations - Table 9 (Details) - USD ($) $ in Millions	2 Months Ended	3 Months Ended	7 Months Ended	9 Months Ended	10 Months Ended	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Business Acquisition [Line Items]
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual			$ 27.2
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual			$ 4
Business Acquisition, Pro Forma Revenue							$ 2,799.8	$ 2,627.6
Business Acquisition, Pro Forma Net Income (Loss)							237.5	$ 311.3
Reliant [Member]
Business Acquisition [Line Items]
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual		$ 63.7
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual		$ 11.2
Inpatient Rehabilitation Hospital [Member]
Business Acquisition [Line Items]
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual				$ 54.7
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual				$ 1.7
CareSouth [Member]
Business Acquisition [Line Items]
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual	$ 19.2
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual	$ 2.5
Home Health and Hospice [Member]
Business Acquisition [Line Items]
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual					$ 17.8
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual					$ 1.2
2015 Acquisitions [Member]
Business Acquisition [Line Items]
Business Acquisition, Pro Forma Revenue						$ 3,479.9	2,851
Business Acquisition, Pro Forma Net Income (Loss)						$ 234	$ 276.9

Business Combinations Busine123

Business Combinations Business Combinations - Table 10 (Details) - USD ($) $ in Millions	Dec. 31, 2015	Oct. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Business Acquisition [Line Items]
Cash and cash equivalents		$ 42.6
Accounts receivable, net		25.7
Prepaid expenses and other current assets		2.8
Property and equipment, net		220.6
Goodwill	$ 1,890.1		$ 1,084	$ 456.9	$ 437.3
Long-term debt	1.3		2.9
Redeemable noncontrolling interests	$ 121.1		84.7
Noncompete Agreements [Member]
Business Acquisition [Line Items]
Identifiable intangible assets, Finite life		9.7
Trade Names [Member]
Business Acquisition [Line Items]
Identifiable intangible assets, Finite life		8.9
License [Member]
Business Acquisition [Line Items]
Identifiable intangible assets, Finite life		$ 11.4
Encompass [Member]
Business Acquisition [Line Items]
Cash and cash equivalents			20.9
Accounts receivable, net			37.6
Prepaid expenses and other current assets			8.6
Property and equipment, net			9.6
Goodwill			592.5
Other long-term assets			2.1
Total assets acquired			873.5
Current portion of long-term debt			2
Accounts payable			0.9
Accrued payroll			25.8
Other current liabilities			18.5
Long-term debt			2
Deferred tax liabilities			64.3
Total liabilities assumed			113.5
Redeemable noncontrolling interests			64.5
Net assets acquired			695.5
Encompass [Member] | Noncompete Agreements [Member]
Business Acquisition [Line Items]
Identifiable intangible assets, Finite life			5.6
Encompass [Member] | License [Member]
Business Acquisition [Line Items]
Identifiable intangible assets, Finite life			58.2
Encompass [Member] | Software Development [Member]
Business Acquisition [Line Items]
Identifiable intangible assets, Finite life			3.2
Encompass [Member] | Trade Names [Member]
Business Acquisition [Line Items]
Indentifiable intangible assets, Indefinite life			$ 135.2

Business Combinations Busine124

Business Combinations Business Combinations - Table 11 (Details) - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Net Cash Paid For All Acquisitions During Each Period Presented
Goodwill		$ 806.1	$ 593.1	$ 13.7
Net cash paid for acquisitions		985.1	694.8	$ 28.9
Encompass [Member]
Business Acquisition [Line Items]
Cash Acquired from Acquisition		$ 20.9
Net Cash Paid For All Acquisitions During Each Period Presented
Fair value of assets acquired			260.1
Goodwill	$ 34		592.5
Fair value of liabilities assumed			113.5
Redeemable noncontrolling interests			(64.5)
Net cash paid for acquisitions			$ 674.6

Business Combinations - Table 1

Business Combinations - Table 12 (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Oct. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Business Acquisition [Line Items]
Property and equipment, net		$ 220.6
Goodwill	$ 1,890.1		$ 1,084	$ 456.9	$ 437.3
Noncompete Agreements [Member]
Business Acquisition [Line Items]
Identifiable intangible assets, Finite life		9.7
Trade Names [Member]
Business Acquisition [Line Items]
Identifiable intangible assets, Finite life		8.9
Certificate of Need [Member]
Business Acquisition [Line Items]
Identifiable intangible assets, Finite life		36.6
License [Member]
Business Acquisition [Line Items]
Identifiable intangible assets, Finite life		$ 11.4
Inpatient [Member] | Noncompete Agreements [Member] | Minimum [Member]
Useful Lives of Acquired Finite-Lived Intangible Assets [Abstract]
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life	2 years
Inpatient [Member] | Noncompete Agreements [Member] | Maximum [Member]
Useful Lives of Acquired Finite-Lived Intangible Assets [Abstract]
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life	3 years
Inpatient [Member] | Trade Names [Member]
Useful Lives of Acquired Finite-Lived Intangible Assets [Abstract]
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life	20 years
Inpatient [Member] | Certificate of Need [Member]
Useful Lives of Acquired Finite-Lived Intangible Assets [Abstract]
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life	20 years
Inpatient [Member] | License [Member]
Useful Lives of Acquired Finite-Lived Intangible Assets [Abstract]
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life	20 years
Series of Individually Immaterial Business Acquisitions [Member]
Business Acquisition [Line Items]
Total current assets			12.1
Property and equipment, net			36.9
Goodwill			34.6
Total assets acquired			99.8
Total current liabilities assumed			7.8
Total long-term liabilities			13.4
Net assets acquired			78.6
Series of Individually Immaterial Business Acquisitions [Member] | Noncompete Agreements [Member]
Business Acquisition [Line Items]
Identifiable intangible assets, Finite life			0.4
Series of Individually Immaterial Business Acquisitions [Member] | Trade Names [Member]
Business Acquisition [Line Items]
Identifiable intangible assets, Finite life			2.9
Series of Individually Immaterial Business Acquisitions [Member] | Certificate of Need [Member]
Business Acquisition [Line Items]
Identifiable intangible assets, Finite life			10.8
Series of Individually Immaterial Business Acquisitions [Member] | License [Member]
Business Acquisition [Line Items]
Identifiable intangible assets, Finite life			$ 2.1

Business Combinations - Tabl126

Business Combinations - Table 13 (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Net Cash Paid For All Acquisitions During Each Period Presented
Goodwill	$ 806.1	$ 593.1	$ 13.7
Net cash paid for acquisitions	985.1	694.8	28.9
Series of Individually Immaterial Business Acquisitions [Member]
Business Acquisition [Line Items]
Cash Acquired from Acquisition	$ 5.1
Net Cash Paid For All Acquisitions During Each Period Presented
Fair value of assets acquired		60.1	15.6
Goodwill		34.6	13.7
Fair value of liabilities assumed		21.2	0.4
Fair value of noncontrolling interest owned by joint venture partner		(18.3)	0
Fair value of equity interest prior to acquisition		35	0
Net cash paid for acquisitions		$ 20.2	$ 28.9

Business Combinations - Tabl127

Business Combinations - Table 14 (Details) - USD ($) $ in Millions	7 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Summary of Actual and Pro Forma Results of Operations for Acquisitions
Acquired entity only: Actual from acquisition date to December 31, 2015, Net Operating Revenues	$ 27.2
Acquired entity only: Actual from acquisition date to December 31, 2015, Net Income Attributable to HealthSouth	$ 4
Combined entity: Supplemental pro forma (unaudited), Net Operating Revenues		$ 2,799.8	$ 2,627.6
Combined entity: Supplemental pro forma (unaudited), Net Income Attributable to HealthSouth		$ 237.5	$ 311.3

Business Combinations - Textual

Business Combinations - Textual (Details) $ in Millions

Nov. 30, 2015USD ($)facilities

Oct. 31, 2015USD ($)

Apr. 30, 2015USD ($)

Jun. 30, 2014USD ($)

Nov. 30, 2013USD ($)

Apr. 30, 2013USD ($)

Dec. 31, 2015USD ($)

Dec. 31, 2014USD ($)

Dec. 31, 2013USD ($)

Oct. 01, 2015USD ($)

May. 31, 2015

Nov. 30, 2014USD ($)

Jun. 29, 2014USD ($)

Mar. 31, 2014

Business Acquisition [Line Items]

Number of States in which Entity Operates

34

Redeemable noncontrolling interests

$ 121.1

$ 84.7

Goodwill, Acquired During Period

806.1

593.1

$ 13.7

Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain

$ 0

$ 27.2

$ 0

Income Tax Rate, Percent

35.00%

35.00%

35.00%

CareSouth [Member]

Business Acquisition [Line Items]

Business Acquisition, Goodwill, Expected Tax Deductible Amount, Percent

0.00%

Goodwill, Acquired During Period

$ 142.5

Reliant [Member]

Business Acquisition [Line Items]

Number of Locations of an Acquired Entity

11

Business Acquisition, Goodwill, Expected Tax Deductible Amount, Percent

100.00%

Number of Hospital Beds Acquired

902

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Capital Lease Obligation

$ 210

Goodwill, Acquired During Period

$ 642.6

Fairlawn Rehabilitation Hospital [Member]

Business Acquisition [Line Items]

Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain

$ 0

$ 27.2

$ 0

Business Acquisition, Goodwill, Expected Tax Deductible Amount

$ 0

Quillen Rehabilitation Hospital [Member]

Business Acquisition [Line Items]

Noncontrolling Interest, Ownership Percentage by Parent

50.00%

Number of Hospital Beds Acquired

26

Goodwill, Acquired During Period

$ 0.6

Business Acquisition, Goodwill, Expected Tax Deductible Amount

$ 0

Walton Rehabilitation Hospital [Member]

Business Acquisition [Line Items]

Number of Hospital Beds Acquired

58

Goodwill, Acquired During Period

$ 13.7

Business Acquisition, Goodwill, Expected Tax Deductible Amount

$ 13.7

Encompass [Member]

Business Acquisition [Line Items]

Number of Locations of an Entity

135

Number of States in which Entity Operates

12

Redeemable noncontrolling interests

$ 64.5

Subsidiary's common stock held by subsidiary 's management, Percent

16.70%

Business Acquisition, Goodwill, Expected Tax Deductible Amount, Percent

0.00%

Affiliates Ownership Percentage, Percentage Increase

30.00%

Noncontrolling Interest, Ownership Percentage by Parent

80.00%

50.00%

Goodwill, Acquired During Period

$ 34

$ 592.5

Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain

$ 27.2

Inpatient Rehabilitation Hospital [Member]

Business Acquisition [Line Items]

Noncontrolling Interest, Ownership Percentage by Parent

83.00%

Number of Hospital Beds Acquired

50

158

Goodwill, Acquired During Period

$ 0.7

$ 0.7

$ 34.6

$ 13.7

Number of Beds Acquired, Skilled Nursing Facility

74

Home health [Member]

Business Acquisition [Line Items]

Number of Joint Venture Hospitals Accounted for Using the Equity Method | facilities

2

Home health [Member] | CareSouth [Member]

Business Acquisition [Line Items]

Number of Locations of an Acquired Entity

44

Hospice [Member] | CareSouth [Member]

Business Acquisition [Line Items]

Number of Locations of an Acquired Entity

3

Trade Names [Member] | Home health [Member]

Business Acquisition [Line Items]

Acquired Finite-lived Intangible Asset, Weighted Average Useful Life

1 year

Trade Names [Member] | CareSouth [Member]

Business Acquisition [Line Items]

Acquired Finite-lived Intangible Asset, Weighted Average Useful Life

5 years

Trade Names [Member] | Reliant [Member]

Business Acquisition [Line Items]

Acquired Finite-lived Intangible Asset, Weighted Average Useful Life

20 years

Noncompete Agreements [Member] | CareSouth [Member]

Business Acquisition [Line Items]

Acquired Finite-lived Intangible Asset, Weighted Average Useful Life

3 years

Certificate of Need [Member] | Home health [Member]

Business Acquisition [Line Items]

Acquired Finite-lived Intangible Asset, Weighted Average Useful Life

10 years

Certificate of Need [Member] | CareSouth [Member]

Business Acquisition [Line Items]

Acquired Finite-lived Intangible Asset, Weighted Average Useful Life

10 years

Certificate of Need [Member] | Reliant [Member]

Business Acquisition [Line Items]

Acquired Finite-lived Intangible Asset, Weighted Average Useful Life

20 years

License [Member] | Home health [Member]

Business Acquisition [Line Items]

Acquired Finite-lived Intangible Asset, Weighted Average Useful Life

10 years

License [Member] | CareSouth [Member]

Business Acquisition [Line Items]

Acquired Finite-lived Intangible Asset, Weighted Average Useful Life

10 years

License [Member] | Reliant [Member]

Business Acquisition [Line Items]

Acquired Finite-lived Intangible Asset, Weighted Average Useful Life

20 years

Maximum [Member] | Noncompete Agreements [Member] | Home health [Member]

Business Acquisition [Line Items]

Acquired Finite-lived Intangible Asset, Weighted Average Useful Life

5 years

Maximum [Member] | Noncompete Agreements [Member] | Reliant [Member]

Business Acquisition [Line Items]

Acquired Finite-lived Intangible Asset, Weighted Average Useful Life

2 years

Minimum [Member] | Noncompete Agreements [Member] | Home health [Member]

Business Acquisition [Line Items]

Acquired Finite-lived Intangible Asset, Weighted Average Useful Life

2 years

Minimum [Member] | Noncompete Agreements [Member] | Reliant [Member]

Business Acquisition [Line Items]

Acquired Finite-lived Intangible Asset, Weighted Average Useful Life

1 year